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Abstract 
Microsatellites are short repetitive DNA sequences, which are liable to replication 
errors. Microsatellite instability (MSI) is controlled by the mismatch repair system, and 
accumulation of microsatellite mutations is used as a diagnostic criterion for tumours 
where this repair system is compromised, such as those which develop in Lynch 
Syndrome (HNPCC) patients. Currently, the Amsterdam II screening criteria and revised 
Bethesda Guidelines are used to identify tumours for MSI testing using both 
immunohistochemistry and fragment analysis tests. However, because Lynch Syndrome 
patients are being missed, testing for all colorectal and endometrial cancers is now being 
recommended. Faster and cheaper MSI testing methods are therefore desirable. Although 
PCR and sequencing error compromise sequence based typing of the repeats currently 
used for diagnosis, some short mononucleotide repeats have been identified which show 
low level instability, suggesting that sequence typing of short repeats may be possible. 
Here, I investigate the utility of high throughput sequencing (HTS) as the basis for MSI 
testing. 
As an initial assessment of the method, I used the MiSeq platform to type 22 
previously published short mononucleotide repeats in 4 microsatellite unstable (MSI-H) 
tumours, and showed that MSI could be detected above background noise in 7-12bp 
repeats. To identify the most variable short repeat markers for MSI testing, I then  
analysed MSI in whole genome sequence data from The Cancer Genome Atlas network, 
and identified a panel of 120 7-12bp informative mononucleotide repeats which were 
subsequently evaluated on a panel of 5 MSI-H tumours and controls. The most 
informative 20 markers were further tested on a panel of 58 colorectal tumours to define 
thresholds for instability calling. Using a panel of eighteen 8-12bp mononucleotides it 
was possible to distinguish between MSI-H and microsatellite stable (MSS) tumours with 
a sensitivity and specificity of 100%.  
Flanking SNPs were also evaluated and identified an excess of allelic bias among 
MSI-H tumours compared to MSS tumours, a feature that could be integrated into the 
MSI test. Finally, short mononucleotide repeats with flanking SNPs were assessed for 
their potential to identify clonal variation in MSI-H tumours. Using a multiple biopsy 
approach evidence of different sub-clones was found in three MSI-H tumours, suggesting 
that these markers could be used for analysis of clonal variation and evolution. 
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Chapter 1. Introduction 
1.1. The global burden of cancer 
Cancer is a leading cause of death worldwide. In 2012 there were estimated to be 
8.2 million deaths caused by cancer around the world (Ferlay et al., 2015). In the USA, 
cancer is currently the second largest cause of death and it is estimated that it will become 
the most common cause of death over the next few years (Siegel et al., 2015). The world’s 
cancer burden is expected to increase over the next few years. In 2012 there was estimated 
to be 14.1 million new cases of cancer, and estimated projections for 2025 total 20-24 
million new cases of cancer (Ferlay et al., 2015, Gulland, 2014). It is therefore important 
to prioritise the treatment and prevention of cancer. Factors which it is believed will 
contribute to a future rise in cancer burden include life style changes, increased life 
expectancy, and an increase in the world’s population.  
Lung cancer is the most common form of cancer with an estimated 1.8 million 
new cases and ~1.6 million deaths worldwide in 2012 (Ferlay et al., 2015). This accounts 
for 13% of new cancer cases (Gulland, 2014). The number of lung cancer cases show a 
large positive correlation with the prevalence of tobacco smoking (Bray et al., 2012). In 
countries with a high human development index (HDI) the lung cancer rates in men are 
decreasing while there is an increase in the lung cancer rates in women (Bray et al., 2012, 
Siegel et al., 2015), reflecting the changes in smoking habits of men and women (Bray et 
al., 2012). Lung cancer is the most common form of cancer in countries with a high or 
medium HDI and is set to rise steeply in low HDI countries with rising use of tobacco 
(Bray et al., 2012).    
Breast cancer is the second most common cancer with an estimated 1.7 million 
new cases in 2012 and ~522,000 deaths worldwide (Ferlay et al., 2015). This constitutes 
11.9% of new cancer cases in 2012 (Gulland, 2014).  
The third most common cancer type in 2012 was colorectal cancer with ~1.4 
million new cases and ~694,000 deaths (Ferlay et al., 2015). Colorectal cancers therefore 
constitute 9.7% of the world’s cancer burden (Gulland, 2014). There is an increasing rate 
of colorectal cancers in high and middle HDI areas (Bray et al., 2012). The reason for this 
is that many types of colorectal cancer can largely be attributed to lifestyle factors. For 
example, there is an increased risk of colorectal cancer associated with alcohol 
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consumption, smoking, obesity, diabetes, the consumption of large amounts of meat, and 
little physical activity (Huxley et al., 2009).  
The fourth most common form of cancer in 2012 was prostate cancer which 
accounted for around 7.9% of new cancer cases (1.1 million) and ~307,000 deaths 
worldwide (Ferlay et al., 2015, Gulland, 2014).  
Colorectal cancers are among the types associated with high socio-economic 
development; 40% of the global incidence of this cancer can be found in regions with a 
very high HDI, which only contain 15% of the world’s population (Bray et al., 2012). In 
the future, it is likely that reduction in infection related cancers as a result of development 
in less developed countries will be offset by an increase cancers associated with a Western 
life style and increased life expectancy (Bray et al., 2012, Pourhoseingholi et al., 2015). 
1.2. Colorectal cancer  
There are different types of colorectal cancer (CRC) which are traditionally 
divided into two groups, those with chromosome instability and those with mismatch 
repair gene defects (Umar, 2004). Chromosome instability is the most common cause of 
colon cancer accounting for approximately 85% of CRCs (Sinicrope and Sargent, 2012). 
These cancers are characterized by the gain or loss of chromosomes and chromosome 
parts, the amplification of genes, and chromosome translocations (Grady, 2004). 
Chromosome instability can occur due to defects that affect the mitotic checkpoint (Pino 
and Chung, 2010). The mitotic checkpoint ensures that all chromatids are aligned 
properly before anaphase commences. A failure of this can lead to unequal chromosome 
segregation. Another cause of chromosome instability is abnormal centrosome function, 
which can also lead to unequal chromosome segregation (Pino and Chung, 2010). Other 
mechanisms that can cause chromosome instability include telomere dysfunction which 
can lead to chromosomes breaking and fusing during mitosis, and problems with the 
mitotic cell cycle arrest response which can lead to DNA damage not being repaired (Pino 
and Chung, 2010). 
The other 15% of CRCs have mismatch repair gene defects and are characterized 
by microsatellite instability (MSI) (Grady, 2004), which can be defined as somatic 
changes in the length of microsatellites. Microsatellites are repetitive regions of DNA 
which are scattered throughout the genome. Because of their repetitive nature, 
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polymerases are more likely to cause slippage in the form of insertions and deletions 
while replicating microsatellites compared to other regions of DNA. Defects in mismatch 
repair genes cause MSI because errors during DNA replication are not rectified by the 
cell’s compromised mismatch repair system. The DNA mismatch repair system is also a 
part of the mechanism which causes cell death when the mutation burden becomes too 
high (Boland, 2007). This function is also lost with a compromised mismatch repair 
system. A compromised mismatch repair system can, through these two mechanisms, lead 
to a high mutation burden which can cause cancer. MSI will cause tumorigenesis through 
mutations in genes which contain coding microsatellites (Grady, 2004). Two examples of 
such genes are TGFBR2 and BAX (Grady, 2004).  
Based on microsatellite status, colorectal tumours can be divided into 3 the 
categories; tumours with high levels of microsatellite instability (MSI-H), tumours with 
low levels of microsatellite instability (MSI-L), and tumours which are microsatellite 
stable (MSS). Tumours with mismatch repair defects have high levels of microsatellite 
instability and are categorised as MSI-H tumours. MSS tumours are usually tumours 
associated with chromosome instability. MSI-L tumours also appear to arise as a result 
of chromosome instability (Pawlik et al., 2004). The MSI-L category has been widely 
used, but there is debate over whether there is a qualitative difference between MSI-L and 
MSS tumours and if MSI-L tumours can be considered a discrete group (Tomlinson et 
al., 2002).    
A recent molecular classification has identified four molecular sub groups 
(Guinney et al., 2015).  The distinction of tumours with a breakdown in mismatch repair 
is still evident; they demonstrated marked inter connectivity across 6 different 
classification systems and distilled the groups into four consensus molecular subtypes: 
CMS1 Microsatellite instability, immune (14%) 
CMS2 Canonical (37%) 
CMS3 Metabolic (13%) 
CMS4 Mesenchymal (23%) 
Tumours which could not be classified into one of these groups were deemed to 
represent a transitional phenotype or intratumoural heterogeneity. The focus of this thesis, 
in this new classification, is on CMS1. 
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1.2.1. Lynch Syndrome 
Lynch syndrome, formerly known as hereditary non-polyposis colorectal cancer 
(HNPCC), is a hereditary form of autosomal dominant colon cancer which results from 
inherited mismatch repair gene defects and is characterized by high levels of 
microsatellite instability (Schofield et al., 2009). Lynch Syndrome constitutes 20% of 
MSI-H CRCs (Sinicrope and Sargent, 2012). Mutations in the MLH1, MSH2, MSH6, 
PMS2 and PMS1 genes can cause Lynch Syndrome (Silva et al., 2009). A deletion in the 
EPCAM gene upstream of MSH2 can cause the knockout of MSH2 and has also been 
shown to be a pathogenic mutation in some Lynch Syndrome patients (Kempers et al., 
2011). Patients with Lynch Syndrome develop their first cancer early, on average in their 
mid forties, unlike patients with sporadic MSI-H cancers where the average age is over 
seventy (Boland, 2007). In addition to an increased risk of CRC, Lynch Syndrome is 
associated with an elevated risk of endometrial cancer (Aarnio et al., 1999, Hendriks et 
al., 2004), bladder cancer (van der Post et al., 2010), and tumours of the small intestine, 
ovary, urinary tract, stomach, biliary tract, pancreas, brain, and sebaceous glands 
(Balmana et al., 2010). The risk of developing CRC by the age of 70 years has been 
estimated at 66% for men, and for women the risk of developing a colorectal or 
endometrial cancer is estimated at 73% (Stoffel et al., 2009). 
1.2.2. Sporadic microsatellite unstable tumours 
Sporadic MSI-H tumours are usually caused by the epigenetic silencing of MLH1 
caused by promoter methylation (Boland, 2007, Sinicrope and Sargent, 2012). Whereas 
Lynch Syndrome tumours have been thought to arise from adenomas, sporadic MSI-H 
CRCs arise from serrated polyps (McGivern et al., 2004). More recently, the sessile 
serrated adenoma with its indistinct edges, mucus cap and characteristic “saw tooth” 
histology has become the primary suspect for the high prevalence of ascending colon 
“interval cancers” arising between frequent screening colonoscopies (Crockett et al., 
2015). 
Approximately 80% of MSI-H tumours are sporadic tumours. Sporadic MSI-H 
tumours, in addition to having on average a later age of onset compared to Lynch 
Syndrome tumours, also have a predisposition for the proximal colon and are more 
common in women than men (Jass, 2004). 
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1.3. Mismatch repair system in human cells 
During DNA replication, DNA polymerases make replication errors at a rate of 
one error per 104-105 nucleotides (Iyer et al., 2006). The human DNA polymerases, 
polymerase δ and polymerase ε which perform the bulk of our DNA replication have 
proofreading exonuclease activity (Korona et al., 2011). The proofreading ability of these 
polymerases means that post-editing, the number of replication errors is further reduced 
to an error rate of one error per ~107 nucleotides (Iyer et al., 2006, Kunkel, 2004). In 
addition, the cells mismatch repair system corrects replication errors further reducing the 
error rate to one in ~109-1010 (Hsieh and Yamane, 2008). 
The mismatch repair complex consists of the protein complexes MutSα, MutSβ 
and MutLα. MutSα is a heterodimer made up of MSH2 and MSH6, and this heterodimer 
repairs base mismatches including indels up to ~10 nucleotides in length (Iyer et al., 
2006). MutSβ is a heterodimer made up of MSH2 and MSH3, which repairs indels of 2bp 
to ~10bp in length (Iyer et al., 2006). The MutS heterodimers form a clamp that moves 
along the DNA double helix examining around ~700bp for mismatches at a time before 
dissociating (Martin-Lopez and Fishel, 2013). When a MutSα or MutSβ protein identifies 
a mismatch they undergo a conformation change (Qiu et al., 2012). MutSα or MutSβ then 
recruits and mediates the binding of MutLα (Iyer et al., 2006, Qiu et al., 2012). The MutLα 
heterodimer is composed of the proteins MLH1 and PMS2. The function of MutLα is to 
assist the mismatch repair by interacting with either MutSα or MutSβ (Hsieh and Yamane, 
2008).   
Before a mismatch can be corrected, the strand with the mistake needs to be 
identified. The mechanisms that allows the recognition of the newly synthesised nascent 
strand by the mismatch repair complex is uncertain in eukaryotes (Lujan et al., 2013). In 
prokaryotes, the nascent strand is recognised by the mismatch repair system due to the 
lack of methylation on that strand (Pukkila et al., 1983). An endonuclease MutH incises 
the unmethylated strand creating a break, which initiates the removal of bases from the 
break to and including the mismatch (Kunkel and Erie, 2005). For prokaryotes, there is a 
delay between the synthesis of a new DNA strand and the methylation of that strand 
(Lyons and Schendel, 1984). This gives the mismatch repair system the opportunity to 
locate replication mistakes while the lack of methylation functions as a marker to identify 
the nascent strand. In Eukaryotes methylation is not used as a strand specific marker, but 
single strand breaks are sufficient to direct the mismatch repair system to hydrolyse the 
6 
 
strand with the break (Iyer et al., 2006). It is therefore possible that strand discontinuities 
that have occurred during DNA replication could be used by the mismatch repair system 
to identify the newly synthesised strand. For the lagging strand, it is believed that DNA 
discontinuities between Okazaki fragment may be used  by the mismatch repair system 
to identify the newly replicated DNA strand (Nick McElhinny et al., 2010). For the 
leading strand, other mechanisms must be involved in marking the nascent strand. During 
DNA replication in eukaryotes, including humans, a ribonucleotide is erroneously 
incorporated on average every 1250 bases by DNA polymerase ε which catalyses leading 
strand replication (Dalgaard, 2012). Erroneously incorporated ribonucleotides are 
removed by ribonucleotide excision repair, which is initiated by the enzyme RNase H2 
creating a nick in the newly replicated strand (Lujan et al., 2013). The strand breaks 
created by RNase H2 are one likely mechanism by which the mismatch repair system is 
directed to the nascent strand (Lujan et al., 2013).  
Exonuclease I (EXO1) interacts with MSH2, MSH3 and MLH1, and performs the 
hydrolysis of the nascent strand from a strand break to ~ 150bp beyond the mismatch 
(Kunkel and Erie, 2005). Strand breaks used to initiate the process can be located either 
5’ or 3’ to the mismatch. EXO1 is essential for both 5’ and 3’ directed mismatch repair 
(Constantin et al., 2005). EXO1 is a 5’- 3’ endonuclease and therefore the endonuclease 
activity of MutLα is thought to play an essential role 3’-5’ directed mismatch repair 
(Martin-Lopez and Fishel, 2013). DNA polymerase δ resynthesizes the part of the nascent 
strand that has been removed by Exonuclease I, repairing the DNA mismatch (Iyer et al., 
2006).  
Figure 1.1 gives simplified representation of the mismatch repair system. 
 
7 
 
 
Figure 1.1: A simplified diagram of mismatch repair. 
Knockout of mismatch repair function means that DNA replication errors in the 
form of base pair mismatches and indels up to 10bp are not repaired and can therefore 
accumulate. Microsatellite DNA is especially prone to replication mistakes in the form of 
insertions and deletions (Rose and Falush, 1998). Insertions and deletions in 
microsatellites are therefore used as an indicator of mismatch repair deficiency in 
tumours.    
1.4. Mismatch repair and microsatellite instability 
Microsatellites are repetitive sequences with repeat units of 1 - 6bp. 
Microsatellites are known to be unstable during meiotic and mitotic replication in 
eukaryotes and prokaryotes (Strauss, 1999). Factors which affect the susceptibility of 
microsatellites to slippage events include the length of the microsatellite, repeat unit 
length, base composition, and the sequence surrounding a microsatellite (Chung et al., 
2010). Microsatellite instability is a failure to correct DNA replication errors as a result 
of defects in mismatch repair (MMR) genes. Testing for MSI in tumours is therefore used 
to identify MMR gene defects. Traditionally mononucleotide and dinucleotide repeats 
have been used in MSI tests (Boland et al., 1998, Umar, 2004). Tri-, tetra-, and 
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pentanucleotide repeats are less desirable in an MSI test because they show a low 
mutability in MSI-H tumours (Umar et al., 2004). Also, one cause of tetra nucleotide 
repeat instability, also know as Elevated Microsatellite Alterations at Selected 
Tetranucleotide repeats (EMAST), is believed to be a consequence of inflammation, and 
research suggests that this instability is reversible in tumours (Devaraj et al., 2010, 
Haugen et al., 2008). 
1.5. Markers used for determining the MSI status of tumours 
BAT26 is a quasimonomorphic microsatellite which is used as a marker for 
determining the MSI status of colorectal tumours. Bocker et al. (1997), Hoang et al. 
(1997), and Zhou et al. (1998) gave strong evidence that BAT26 could be used to classify 
the MSI status of tumours on its own without the use of normal DNA (Salahshor et al., 
1999). There has, however, been some controversy about this over the years. Bubb et al. 
(1996) identified tumours with other unstable microsatellites where BAT26 was 
unaffected (Salahshor et al., 1999). Tumours which test positive for only BAT26 have 
also been observed (Salahshor et al., 1999). More recently, it has been suggested that 
tumours classed as MSI-H in the absence of BAT26 mutations may be falsely classified 
and are actually MSI-L or MSS. However, in MSI diagnostic testing, such confusion is 
avoided as several microsatellites are used. A reference panel of two mononucleotide 
microsatellites (BAT25 and BAT26), and three dinucleotide microsatellites (D5S346, 
D2S123, and D17S250) were proposed as consensus sequences for MSI testing at a 
National Cancer Institute workshop in 1997 (Boland et al., 1998).  
In 2002 an international consensus recommended that dinucleotide repeats be 
replaced by mononucleotide repeats (Buhard et al., 2006). Since then there has not been 
an updated consensus over which new microsatellite markers to use. Buhard et al. (2006) 
suggested using the markers BAT26, BAT25, NR-27, NR-24, and NR-21 because these 
are quasimonomorphic in the Caucasian population. Using quasimonomorphic markers 
has the advantage that a comparison with a patients normal DNA is not needed. Buhard 
et al. (2006) have previously shown that a test they have compiled using these five 
mononucleotide repeats was 100% sensitive and specific. Buhard et al. (2006) show that 
using a cut off of 3 out of 5 markers with an abnormal length is a good test for a 
compromised mismatch repair system in CRCs worldwide, with few exceptions. The 
exceptions consist of Sub-Saharan African populations (the Biaka Pygmies and San 
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populations) where these markers are polymorphic, therefore 3 out of 5 markers with 
abnormal length does not necessarily indicate a MSI-H tumour. For these populations this 
test would require comparing normal DNA and the tumour DNA. In the Caucasian and 
Asian patients, 2 out of 5 unstable markers was a sufficient cut-off for calling a tumour 
MSI-H without any tumour being misclassified due to polymorphisms (Buhard et al., 
2006).   
The Northern Genetics Service in Newcastle Upon Tyne, England uses the 
following mononucleotide microsatellites: BAT25, BAT26, NR-21, NR-24 and MONO-
27. If two or more of these microsatellite markers are unstable, then the cancer is 
classified as MSI-H. If the tumour has been classified as having MSI then the Northern 
Genetics Service will also test for the BRAFV600E mutation.    
1.6. BRAF and KRAS mutations in CRCs 
Other mutations frequently occurring in CRCs include mutations in the two genes 
BRAF and KRAS. These mutations are important to consider as they impact the prognosis 
of CRCs. In CRCs, activating mutations in the proto-oncogene BRAF are clustered in 
exon 15 creating the BRAF V600E amino acid substitution (Sinicrope and Sargent, 2012). 
The BRAF V600E mutation is found in sporadic MSI-H CRCs, but rarely in familial MSI-
H CRCs caused by Lynch Syndrome. It can therefore be used to help distinguish 
hereditary from sporadic cancer (Schofield et al., 2009). The BRAF V600E mutation is 
associated with a worse prognosis for microsatellite stable CRCs, but it is still associated 
with a good prognosis in MSI-H CRCs (Samowitz et al., 2005).    
KRAS is a component of the EGFR signalling pathway which regulates cell 
migration and proliferation among other cellular processes, and activating mutations in 
KRAS are found in 30-45% of CRCs (Heinemann et al., 2009, Kikuchi et al., 2009). An 
activating KRAS mutation leads to resistance to drugs like cetuximab and panitumumab, 
which are used in EGFR monoclonal inhibitory antibody chemotherapy (Heinemann et 
al., 2009). This is because EGFR monoclonal inhibitory antibody chemotherapy targets 
the EGFR signalling pathway upstream of KRAS (Heinemann et al., 2009). This targeting 
mechanism fails when KRAS has an activating mutation and therefore will reactivate the 
signalling pathway preventing effective treatment. Activating KRAS mutations occur 
mainly in codons 12 and 13, with up to 90% of these mutations found in these two codons 
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(Heinemann et al., 2009). These mutations are important to test for as they determine if 
EGFR monoclonal inhibitory antibody chemotherapy will be an effective treatment.       
1.7. MSI as an indicator of prognosis 
The literature generally agrees that MSI-H is a predictor of a better prognosis in 
CRCs compared to MSS (Popat et al., 2005, Sinicrope and Sargent, 2012). This is true 
for both sporadic and inherited CRCs. Popat et al. (2005) analysed the survival benefits 
of MSI in several different papers and concluded that MSI-H colorectal tumours had on 
average a 15% better overall survival rate. Figure 1.2 from the study of Popat et al. (2005) 
shows the correlation between MSI-H and survival benefit. 
 
Figure 1.2: Forest plot of hazard ratios for overall survival of patients with MSI-H CRCs from different 
studies. These studies include patients with colorectal cancer stages 1, 2, 3, and 4. The forest plot has been 
taken from Popat et al, 2005 and shows that MSI CRCs have a hazard ratio of 0.65 compared to 
microsatellite stable CRCs which is a 0.35 reduction in hazard ratio. * Patients with stage 2 CRC. ** 
Patients with stage 1 CRC.  
Although the literature is in overall agreement that MSI-H is associated with 
improved prognosis in CRCs there are exceptions. For example,  the study by Salahshor 
et al. (1999) did not find a significant correlation between MSI-H colorectal tumours and 
better prognosis. They concluded that “MSI status is not an independent prognostic 
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factor”, and the authors theorised that other studies may be finding a false correlation due 
to not taking into account the correlation between MSI and Dukes’ stage. However the 
study had a very low number of positive controls (n=22) and their figures do show a weak 
trend towards better survival for the patients with MSI-H tumour even if it is not 
statistically significant. It could also be argued that if MSI-H tumours tend to have a lower 
tumour stage than MSS tumours, then this could be a characteristic of MSI-H tumours 
and Dukes’ stage should not be corrected for. More recent studies, such as Popat et al. 
(2005) have also tried correcting for the stages of CRCs and found that this still results in 
improved prognosis in the presence of MSI-H. Despite MSI-H being a good predictor of 
prognosis MSI testing is only routinely used to identify patients with Lynch Syndrome 
(Sinicrope and Sargent, 2012). 
1.8. Chemotherapy response in MSI-H tumours 
MSI-H CRCs, whether sporadic or inherited, respond similarly to many different 
drugs. This will be due to the mismatch repair system being knocked out in both cancer 
types. In the literature there is wide support for the theory that the drug 5-fluorouracil (5-
FU) does not provide benefit to patients with MSI-H CRCs (Popat et al., 2005, Sargent 
et al., 2010). There is, however, some controversy over the effect 5-FU on CRCs with a 
compromised mismatch repair system. Hutchins et al. (2011) found that there was a 
benefit of using 5-FU which was independent of mismatch repair status, in their analysis 
of 2 year cancer recurrence rates using data from the Quick and Simple and Reliable 
(QUASAR) trial. There is also evidence that the HSP110ΔE9 mutation in the HSP110 
gene makes patients susceptible to the benefits of 5-FU. This mutation occurs as a result 
of a compromised mismatch repair system in around 53% of MSI-H CRCs (Dorard et al., 
2011). MSI-H tumours with a high expression of HSP110ΔE9 mRNA appear to respond 
well to 5-FU (Dorard et al., 2011). The drug irinotecan shows promise as an MSI-H 
cancer drug. Data from preclinical studies suggest that it could be more effective for MSI-
H CRC compared to MSS CRCs (Sinicrope and Sargent, 2012). MRE11A mutations, 
which are found in 70-85% of cancers with MSI-H, may be the reason for the 
susceptibility of these cancers to irinotecan (Sinicrope and Sargent, 2012). However, 
irinotecan requires further study (Sinicrope and Sargent, 2012). Although there is 
currently not much information about the drug oxaliplatin used on its own, evidence 
suggests that this drug works just as well for both CRCs with mismatch repair gene 
defects and those without (Sinicrope and Sargent, 2012). Another drug that may confer 
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survival benefit to patients with MSI-H colorectal cancers is the drug bevacizumab 
(Pogue-Geile et al., 2013). This drug does not appear to give any survival benefit to 
patients with MSS tumours. There are also other drugs which appear to work well for 
MSS CRCs but don't work well for MSI-H CRCs. For example, evidence suggests that 
the drugs cisplatin and carboplatin do not work well on cancers with a compromised 
mismatch repair system (Sinicrope and Sargent, 2012).  
There are a lot of drugs being tested that might prove effective against MSI-H 
CRCs (Sinicrope and Sargent, 2012). As the knowledge about this type of cancer grows, 
more effective treatments will be devised. For example evidence suggests that immune 
system activity can be seen as a positive indicator of prognosis (Galluzzi et al., 2012). 
Immune system activity could also possibly be used to predict patient’s responses to 
different drugs (Galluzzi et al., 2012). The highly active immune response seen in MSI-
H CRCs could be taken advantage of in this way to improve patient outcome. MSI-H 
CRCs have a pronounced immune response in the form of tumor-infiltrating T cells 
(Schwitalle et al., 2008). This immune response is most likely a response to carboxy-
terminal frameshift peptides produced by these cancers (Schwitalle et al., 2008).  
In 2015 a major study of the drug pembrolizumab showed startling benefits in 
MMR deficient colorectal cancer with a highly significant beneficial effect in cases of 
metastatic disease when compared to MMR proficient tumours (Le et al., 2015). In this 
study 40% of the patients with a MMR colorectal cancer had an immune related objective 
response and the progression free survival rate at 20 weeks was 78% for the patients with 
a MMR colorectal cancer. If the benefits of pembrolizumab are confirmed, MMR 
functional testing of all colorectal cancers is likely to become mandatory. 
1.9. Economic evaluation of testing for mismatch repair defects in all 
colorectal tumours 
Identifying patients with Lynch Syndrome is important because they have a high 
risk of developing second primary tumours and many of their relatives are also likely to 
be affected (Hampel et al., 2008, Barrow et al., 2013). These patients would therefore 
benefit from regular follow up. If tumours are detected earlier this has a significant 
improved prognosis for the patients. Regular colonoscopies will also save lives through 
identifying pre-cancerous polyps, which can be removed (Barrow et al., 2013). It has been 
estimated that more than 60% of Lynch Syndrome cancer deaths could be saved with the 
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proper follow up (Hampel et al., 2008). In addition to early tumour identification, 
identification of Lynch Syndrome enables prophylactic medication (like aspirin) to be 
used. Burn et al. (2011) showed that taking 600mg of aspirin a day for > 2 years gave a 
~60% reduction in Lynch Syndrome cancer rates. A combination of aspirin and regular 
colonoscopies could prove to be quite an effective treatment for Lynch Syndrome cancers, 
but the majority of sufferers remain undiagnosed until disease presents in either 
themselves or a close family member. The challenge is identifying Lynch Syndrome 
patients so that they can receive the right follow up and preventative treatment. 
Patients who present with a colorectal cancer are usually only screened for Lynch 
Syndrome in NHS England if they have a family history of cancer (Vasen et al., 2010). 
Many other Western European countries also use this approach (Vasen et al., 2010). A 
strategy of screening all colorectal cancers for MSI, then Lynch Syndrome, could be used 
to detect many of the patients and families with Lynch Syndrome that currently go 
undetected. The main reason why not all CRCs are screened for Lynch Syndrome is the 
costs this would incur. Identifying instances of sporadic MSI-H CRCs is also important 
because, as mentioned earlier, the cancer causing mechanism present in these cancers 
differs from MSS CRCs. This also means that sporadic MSI-H CRCs have a different 
prognosis to MSS CRCs and also respond differently to chemotherapy. It may be 
beneficial to identify these patients so they can receive a personalised treatment. Here the 
cost of tests is also an issue. Because MSI tests are expensive it would, with the current 
methods, be very expensive to test all CRCs in order to identify MSI-H cancers though 
this would be cost effective according to the recent major health economic assessment 
(Snowsill et al., 2015). Testing of cases where the cancer occurs in patients under 50 years 
is now becoming routine in the NHS in England but relies on the labour intensive 
immunohistochemistry. 
The knockout of mismatch repair genes can be screened for using an MSI test or 
by performing immunohistochemistry staining. In an MSI test, somatic changes in 
microsatellite lengths can be used to infer mismatch repair defects, and this is the basis 
of the fragment analysis based MSI test currently in use. In an immunohistochemistry  
test the mismatch repair genes are evaluated by looking at the expression of the MLH1, 
MSH2, MSH6, and PMS2 proteins. BRAF V600E mutation screening of MSI-H tumours 
can be used to narrow down which patients may have Lynch Syndrome and save 
screening costs because the BRAF mutation rarely occurs in Lynch Syndrome patients 
but is very common in sporadic MSI-H colorectal cancers (Jin et al., 2013). For example 
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the study by Domingo et al. (2004) analysed 206 sporadic MSI-H tumours and 111 Lynch 
Syndrome tumours and found that 40% of the sporadic tumours had a BRAF V600E 
mutation while none of the Lynch Syndrome tumours had the mutation. 
The financial costs of screening all colorectal cancers for mismatch repair defects 
and Lynch Syndrome using current methods would be high, but the money that could be 
saved through the early identification of cancers is also high. The average cost of a MSI 
test in England is £202 (Snowsill et al., 2014). The average costs of an 
immunohistochemistry test and a BRAF test are £238 and £118 respectively (Snowsill et 
al., 2014). Snowsill et al. (2014) based these prices on numbers reported directly from 
laboratories for costs of NHS England provided tests, and where possible these prices 
also include the cost of administration, equipment wear and tear costs, training time and 
the costs of repeated tests. Whyte et al. (2012) report that the lifetime costs for treating 
colorectal cancer are dependent on the stage the cancer has reached. For a Dukes stage A 
cancer the lifetime treatment costs are estimated at £12455, while for a Dukes stage B,C 
and D colorectal cancer the lifetime treatment cost are £17137, £23502, and £25703 
respectively (Whyte et al., 2012). This highlights the importance of discovering cancers 
early from an economic perspective. Identifying Lynch Syndrome patients and following 
them up by regular monitoring not only saves lives, but will also decrease the treatment 
costs of those patients as cancers are identified earlier, or prevented through prophylactic 
use of drugs such as Aspirin. 
1.10. The history of Lynch Syndrome identification 
1.10.1. The discovery of Lynch Syndrome 
Dr. Aldred Warthin published the first study on this hereditary disorder in 1913 
after becoming intrigued by the number of bowel and endometrial cancers in one family, 
designated family G (1985). Warthin concluded that there was an inherited increased 
susceptibility to cancer in this family, but at the time the tumour causing mechanism was 
unknown. At the time there was scepticism that there could be a hereditary component to 
cancer. The significance of this new hereditary form of cancer was not fully understood 
until Henry T. Lynch documented the cancer syndrome in more detail including family 
G, and it was established that the disease followed a Mendelian pattern of inheritance 
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(Lynch, 1985, Lynch and Smyrk, 1996). As a result of the work conducted by Henry T. 
Lynch the term Lynch Syndrome was proposed by Boland and has gained widespread 
acceptance. The connection between Lynch Syndrome/HNPCC and mismatch repair gene 
mutations was not discovered until 1993 (Fishel et al., 1993, Leach et al., 1993).   
1.10.2. The Amsterdam criteria for Lynch Syndrome identification 
The first screening criteria developed for Lynch Syndrome identification, the 
Amsterdam criteria, were developed in 1991 (Boland et al., 1998, Umar, 2006), and had 
an estimated sensitivity of 60% and specificity of 70% (Lipton et al., 2004). They were 
primarily established to provide uniformity across studies to aid linkage studies in 
HNPCC (Vasen et al., 1999). The Amsterdam criteria were criticized when used in 
clinical practice for a lack of sensitivity as they assessed only colorectal cancers, resulting 
in the exclusion of patients who presented with other cancer types associated with Lynch 
Syndrome (Vasen et al., 1999). As a result, the criteria were updated so as to include 
cancers of the large bowel, endometrium, small bowel, ureter, and renal pelvis 
(Amsterdam II criteria, see Table 1). 
 
Table 1.1: Amsterdam II Criteria 
1.10.3. The Bethesda Guidelines for Lynch Syndrome identification 
The link between microsatellite instability and Lynch Syndrome was not 
discovered until 1993 (Aaltonen et al., 1993, Ionov et al., 1993, Peltomaki et al., 1993, 
Thibodeau et al., 1993). This, and subsequent research, led to the idea that MSI testing 
could be used to more accurately identify which patients had Lynch Syndrome. The 
Bethesda Guidelines, which are used to identify cancers to be tested for MSI, were 
All of the Following Must Apply for a Putative Diagnosis of HNPCC to be Made in a Family
There are at least three relatives with an HNPCC‐associated cancer (large bowel, 
endometrium, small bowel, ureter, or renal pelvis, though not including stomach, ovary, 
brain, bladder, or skin)
One affected person is a first‐degree relative of the other two 
At least one person was diagnosed before the age of 50 years
At least two successive generations are affected 
Familial adenomatous polyposis has been excluded Tumors have been verified by 
pathologic examination
This table was modified from Lipton et al, (2004)
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originally released in 1996 and resulted from the “The Intersection of Pathology and 
Genetics in the Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndrome" 
workshop (Boland et al., 1998). According to Terdiman et al. (2001) the first version of 
the Bethesda Guidelines had a sensitivity and specificity of 96% and 27% respectively. 
In 2002 the Bethesda Guidelines were updated to reflect the target audience of clinicians 
and pathologists, and so the guidelines could easily be disseminated to the public (revised 
Bethesda Guidelines, see Table 2) (Umar et al., 2004, Umar, 2006). There was also more 
emphasis placed on the testing of relatives because of a fear that the importance of this 
was not being recognized (Umar et al., 2004). 
 
Table 1.2: Revised Bethesda Criteria 
1.10.4. MSI testing using fragment analysis 
The National Cancer Institute Workshop on MSI in 1997 proposed a consensus 
panel of 5 markers for MSI testing which included 2 mononucleotide repeats and 3 
dinucleotide repeats (Boland et al., 1998, Umar, 2004). Tumours were classified as MSI-
H if instability was detected in two or more markers, MSI-L if instability was only present 
in 1 marker. If all five markers were found to be stable, the tumour could be classed as 
MSS. Prior to this there had been no agreement on which microsatellites to use in an MSI 
test.  
Tumours from individuals should be tested for MSI in the following situations:
1. Colorectal cancer diagnosed in a patient who is less than 50 years of age.
2. Presence of synchronous, metachronous colorectal, or other HNPCC associated 
tumors,1 regardless of age.
3. Colorectal cancer with the MSI‐H histology2 diagnosed in a patient who is less than 60 
years of age.
4. Colorectal cancer diagnosed in one or more first‐degree relatives with an HNPCC‐
related tumor, with one of the cancers being diagnosed under age 50 years.
5. Colorectal cancer diagnosed in two or more first‐ or second‐degree relatives with 
HNPCC‐related tumors, regardless of age.
1Hereditary nonpolypos is  colorectal  cancer (HNPCC)‐related tumors  include  colorectal , endometria l , 
stomach, ovarian, pancreas , ureter and renal  pelvis , bi l iary tract, and brain (usual ly gl ioblastoma  as  
seen in Turcot syndrome) tumors , sebaceous  gland adenomas  and keratoacanthomas  in Muir–Torre  
syndrome, and carcinoma  of the  smal l  bowel .
2Presence  of tumor infi l trating l ymphocytes , Crohn’s ‐l i ke  l ymphocytic reaction, mucinous/s ignet‐ring 
di fferentiation, or medul lary growth pattern.
This  table  was  modified from (Umar 2006)
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In 2002 an international consensus recommended that five mononucleotide 
repeats be used instead of a panel of mononucleotide and dinucleotide repeats (Buhard et 
al., 2006). The change was proposed to improve the sensitivity of the panel. It was feared 
that the original panel would miss-classify MSI-H tumours and overestimate the number 
of MSI-L tumours due to the low sensitivity of the dinucleotide repeats (Umar et al., 
2004). Swapping the 3 dinucleotide repeats for mononucleotide repeats was done both 
the increase the sensitivity of the panel and because the use of 5 quasimonomorphic 
markers would allow tests to be performed in the absence matched normal tissue (Umar 
et al., 2004). See Figure 1.3 for an example of a MSI test using a panel of 5 
mononucleotide repeats.  
 
Figure 1.3: Standard MSI test with a panel of 5 mononucleotide repeats: This figure shows an example of 
a standard MSI test where tumour and matched normal have analyzed. The Promega MSI Analysis System, 
Version 1.2 kit was used to amplify the markers NR-21, BAT26, BAT25, NR-24, and MONO-27. 
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1.11. Drawbacks of the Amsterdam II criteria and revised Bethesda 
Guidelines 
While the Amsterdam II criteria and revised Bethesda Guidelines are effective at 
identifying patients for further screening for Lynch Syndrome, a large number of Lynch 
Syndrome patients are being missed by the current approach. Perez-Carbonell et al. 
(2012) screened 2093 colorectal cancer patients for Lynch Syndrome, and found that 
14.3% of the Lynch Syndrome patients did not meet the revised Bethesda Guidelines. 
These Lynch Syndrome patients would not have been discovered if the revised Bethesda 
Guidelines had been used to identify which patients should receive molecular testing. 
Another study by Canard et al. (2012) tested 1040 colorectal cancer and identified 25 
patients with Lynch Syndrome. Out of these 25 patients 11 would have been missed if the 
Amsterdam II criteria were used, and 3 would have been missed using the Bethesda 
Guidelines.  
Similarly, identifying patients with Lynch Syndrome based on the Bethesda 
guidelines has been reported to miss around 28% of cases (Hampel et al., 2008). Other 
studies have also shown that the Amsterdam criteria fail to identify a large number of 
patients with Lynch Syndrome (Boland et al., 1998, Hampel et al., 2008) and give false 
positives when faced with other familial cancers (Boland, 2007). Hampel et al. (2008) 
conclude that in the future as family sizes decrease, using family based methods for 
detecting Lynch Syndrome will get harder. Testing all CRCs for Lynch Syndrome is 
therefore important, as it will save many lives. As mentioned before, MSI testing is 
expensive  (Umar, 2004). Current international testing varies, but due to the costs of tests, 
most places rely on the Bethesda guidelines and Amsterdam criteria to find high risk 
patients and only test these. Because the Bethesda guidelines and Amsterdam criteria fail 
to identify a significant number of Lynch Syndrome patients (Canard et al., 2012, Mills 
et al., 2014, Perez-Carbonell et al., 2012). This has led to suggestions that all CRC and 
endometrial tumours should receive molecular testing (Vasen et al., 2013, Canard et al., 
2012, Mills et al., 2014, Julie et al., 2008). 
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1.12. The drawback of using immunohistochemistry and MSI testing to 
identify loss of MMR function 
Both the MSI test and immunohistochemistry require expert interpretation as the 
stutter peaks of an MSI test and the staining patterns of an immunohistochemistry test can 
both be tricky to interpret in some cases. One example of this is shown in a study where 
7 pathologists evaluated 100 cases using immunohistochemistry (Overbeek et al., 2008). 
Only in 82% of cases did 5 or more pathologists reach the same conclusion, but the 2 
experienced pathologists identified all MSI-H tumours correctly. This example shows 
that highly trained personnel are vital for immunohistochemistry interpretations. Without 
highly trained personnel mistakes can be made.  
 A recent US based analysis of results from a biannual proficiency test for MSI 
testing, involving between 42 - 104 laboratories from 2005-2012, established that the 
average correct classification rate of samples by participating labs was 95.4% (Boyle et 
al., 2014). The standards of the MSI tests between different laboratories is currently high, 
but there is some variation which could indicate that moving to a more automated MSI 
test where simpler interpretation is required could be an improvement.  
1.13. Testing for MSI using next generation sequencing 
The advent of high throughput sequencing technologies has enabled the potential 
for sequence based MSI classification to be investigated at the genome level. The 
potential utility of a next generation sequence based approach was established by a study 
from The Cancer Genome Atlas (TCGA) project. They analysed the exomes of 224 
matched CRC / normal pairs looking at 6-10bp mononucleotide repeats, and established 
that MSI could be detected using next generation sequencing. (Cancer Genome Atlas 
Network, 2012). This result was later confirmed in gastric cancers and gastric cancer cell 
lines where mononucleotide repeat sizes >4bp were analysed (Yoon et al., 2013). Since 
then, software has been developed to analyse whole genome, exome, whole 
transcriptome, and capture panel data (Lu et al., 2013, Niu et al., 2014, Salipante et al., 
2014). 
Currently, such genome-wide approaches are not cost effective, but suggest that 
systematic assessment of shorter repeats for sequence-based MSI detection is warranted. 
Sequence based MSI typing could be advantageous in terms of cost, with high throughput 
20 
 
enabling the sequencing of many tumours simultaneously, and ease of interpretation 
through automation. However, long microsatellites are not amenable to sequence 
analysis, and although some short (6-14bp) mononucleotide repeats have been identified 
which exhibit instability, the frequencies of instability are highly variable (Sammalkorpi 
et al., 2007, Vilkki et al., 2002, Woerner et al., 2003, Zhang et al., 2001). A panel of short 
repeats that are highly variable in MSI-H tumours and amenable to sequencing could, 
however, prove effective in an MSI test.   
Personalised oncology will in the future be used to prescribe the best treatment 
for each individual’s cancer (Sinicrope and Sargent, 2012). Personalised oncology 
involves prescribing chemotherapy based on a tumours molecular signature. As 
mentioned previously, MSI-H and MSS tumours respond differently to different drugs 
such as 5-fluorouracil, irinotecan, bevacizumab and pembrocizumab. Future CRC 
treatment strategies could therefore take into a tumour’s MSI status in addition to other 
tumour biomarkers to enable the prescription of a more personalised treatment.     
The advent of future technologies targeted to the market of personalised medicine, 
such as point of care devices would enable a test to be performed cheaply with a fast 
turnaround time. One company currently developing a point of care device aimed at 
cancer diagnostics, among other things, is the Newcastle Upon Tyne, UK based company 
QuantuMDx. The QuantuMDx Q-POC platform, which is currently under development, 
should be capable of detecting 64 genetic features per disposable cassette at a price of 
~£20 (Burn, 2013). It is estimated that genetic tests using the Q-POC will take as little as 
15 minutes or less (Burn, 2013). QuantuMDx’s device has four main components; a tissue 
lysis chamber, a DNA extraction cassette containing a proprietary sorbent filter that 
allows DNA to pass through while binding cellular material such as proteins and lipids, 
a microfluidic based PCR cassette, and a silicon nanowire field effect transistor which 
can be used as a nanosensor for detecting base incorporation in a sequencing by synthesis 
reaction. The Q-POC device being developed by the company QuantuMDx, should lend 
itself to short amplicon sequencing based assays which are both cheap and quick. 
Developing an MSI assay compatible with QuantuMDx’s device could enable a 
sequencing based MSI test that is fast and affordable, which would bring us one step 
further towards the goal of testing all CRCs and endometrial cancers for MSI without 
adding an extra financial burden on health systems. On the Q-POC platform, MSI testing 
could be performed in conjunction with testing for other cancer biomarkers such as BRAF 
and KRAS mutations. A deposable cassette that allows the testing of many different cancer 
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biomarkers, including microsatellite instability, would eliminate the need for multiple 
separate diagnostic tests.  
1.14. Project aims and outline of results chapters  
The primary aim of this project has been to identify markers for a sequencing 
based MSI test, and test these on CRCs to create a panel of markers that can differentiate 
between MSI-H and MSS CRCs and is compatible with the QuantuMDx Q-POC 
technology. To address this aim, mononucleotide repeats obtained from the literature 
were analysed to assess the suitability of using short repeats and Illumina sequencing to 
detect MSI. Whole genome analysis of MSI-H CRCs was performed to identify highly 
unstable mononucleotide repeats, which could be used as markers in a sequencing based 
MSI test. 120 of the identified mononucleotide repeats were analysed on a small panel of 
tumours to confirm that these repeats could be used as markers for identifying MSI. 
Finally, a larger panel of colorectal tumours were analysed using 20 of the most 
informative repeats to find out if a small number of repeats, which are highly susceptible 
to deletions in MSI-H tumours, could be used to differentiate between MSI-H and MSS 
tumours. Short mononucleotide repeats may also be good for assessing clonality in MSI-
H tumours so a subsidiary aim was to test this hypothesis on tumours where multiple 
biopsies had been procured.  
In the first results chapter (Chapter 3) I evaluate the feasibility of using Illumina 
sequencing of short mononucleotide repeats for differentiating between MSI-H and MSS 
tumours. The amount of noise in the form of sequencing and PCR error produced from 
sequencing different lengths of mononucleotide repeats is also evaluated, to assess if real 
mutations can be detected over background noise levels. 
In the second results chapter (Chapter 4) I evaluate the ability of different variant 
callers to identify indels in mononucleotide repeats, and whole genome sequences of 
MSI-H CRCs are analysed to determine the distribution of variant reads in 7-12bp 
mononucleotide repeats, and identify candidate markers for an MSI test.  
In the third results chapter (Chapter 5) I select the most variable markers with 
neighbouring SNPs, identified in the whole genome analysis, and test their levels of 
instability in a small panel of tumours to enable the selection of the most variable repeat 
for use in a future sequencing based MSI test. In this chapter the results of an analysis of 
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allelic bias in microsatellite unstable repeats is also presented, which aims to evaluate if 
this can be used to differentiate between real mutations and sequencing/PCR error. 
In the fourth results chapter (Chapter 6) I use previously tested markers with 
neighbouring SNPs to analyse MSI-H tumour biopsies for clonal variations across 
different tumour regions.  
In the fifth results chapter (Chapter 7) I evaluate 20 of the most variable short 
mononucleotide repeats identified previously, on a panel of over 50 CRC to determine 
thresholds for calling instability, and evaluate if the panel can correctly classify all MSI-
H and MSS tumours. This chapter also contains my contributions towards the 
development of a potential platform for a sequencing based MSI test; the QuantuMDx Q-
POC. 
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Chapter 2. Methods 
2.1. Clinical work 
2.1.1. Ethical approval 
Tissue and blood samples from patients enrolled in the CAPP2 study were 
obtained after ethical review (REC reference MREC/98/3/24). The CAPP2 patents were 
anonymised for the purpose of this work, but by using the CAPP patient U numbers 
included in this thesis the samples can be linked back to the patient details by someone 
with authorised access to the CAPP study files. 
Blood samples were collected as part of the DISC study: Diet related biomarkers 
of colorectal cancer risk. These samples were covered by ethics ref. 09/H0907/77 granted 
by the Newcastle and North Tyneside 2 REC. The blood samples were anonymised prior 
to use in this work. 
All other human tissue samples collected and used as part of this PhD project were 
covered by ethical approval as part of the study “The use of rapid DNA extraction and 
genetic testing on silicone nanowires to screen for microsatellite instability in tumour 
tissue as a matter of routine” (IRAS project ID: 99148, REC reference: 13/LO/1514). All 
tissue samples were anonymised for the purpose of this PhD project, but patient data could 
be retrieved by someone with the proper authorised access. 
2.1.2. Tissue collection 
2.1.2.1. Lynch Syndrome patient samples 
For patients enrolled in the CAPP2 study, tumour, blood and normal mucosa 
samples were collected previously by the CAPP study team. Criteria for inclusion in the 
CAPP2 study included a diagnosis of Lynch Syndrome, an intact colon or only a 
segmental resection. Exclusion criteria for participation in the CAPP2 study included 
medical contraindications for aspirin, and patients already on NSAIDs or steroids. 
Tumour and normal mucosa samples were supplied as Formalin-fixed, paraffin-
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embedded (FFPE) tissue in the form of wax curls (A list of tumour samples can be found 
in Appendix Table 9.2. DNA from blood samples had previously been extracted by the 
CAPP study group. 
2.1.2.2. Normal control blood samples 
Blood to be used as normal controls was supplied by the DISC study group. 
2.1.2.3. Samples MSI tested by the Northern Genetics Service 
 DNA and wax curls were obtained from tumours previously tested for MSI by 
the Northern Genetics Service, Newcastle Hospitals NHS Foundation Trust using the 
Promega MSI Analysis System, Version 1.2 kit (Promega, Madison, WI, United States 
of America). 
2.1.2.4. Tumour sampling techniques for the clonality analysis 
Tumour and tissue samples for clonality analyses were obtained from the 
Pathology Department, Newcastle Hospitals NHS Foundation Trust. Biopsies were taken 
from fresh colorectal tumours shortly after resection by Dr Stephanie Needham 
(Pathology department, Newcastle Hospitals NHS Foundation Trust). Biopsies were 
taken from each tumour at intervals using the hours of a clock face as a reference point. 
The side of the tumour closest to the antimesenteric border was defined as 12 o’clock. In 
some of the tumours it was impractical to use the antimesenteric border as 12 o’clock, for 
example because the tumours had grown across the antimesenteric border. In these cases 
the proximal orientation of the tumour was defined as 12 o’clock. Where possible four 
scalpel biopsies of external tumour tissue were taken from the 3, 6, 9 and 12 o’clock 
positions round the tumour followed by four fine needle aspiration biopsies taken from 
the 3, 6, 9 and 12 o’clock positions from deeper within the tumours using BD Microlance 
21-gage needles (BD, New Jersey, United States of America). If the tumour was too small 
for this sampling technique then not all 8 biopsies were collected. Normal mucosa was 
sampled using a scalpel 7-10cm away from the tumour to ensure the normal mucosa 
biopsies were not contaminated by any tumour tissue. 
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2.2. DNA extraction 
2.2.1. DNA extraction from FFPE tissues using the Promega DNA 
ReliaPrep™ FFPE gDNA Miniprep System kit 
DNA extractions from wax embedded tissue were performed using the 
ReliaPrep™ FFPE gDNA Miniprep System kit (Promega, Madison, WI, United States of 
America) according to the manufacturer’s protocol, with the exception of a prolonged 
deparaffination step. Briefly, samples were deparaffinised using mineral oil incubated at 
80oC for ~1 hour. Following cooling, proteinase K digestion was performed at 56oC for 
an hour then 80oC for an hour, RNase was added to the samples, and then the DNA was 
purified using spin columns. Elution volumes used consisted of either 30μl or 40μl. 
2.2.2. DNA extraction from FFPE tissues using the BiOstic® FFPE Tissue 
DNA Isolation Kit 
DNA extractions from wax embedded tissue were performed using the BiOstic® 
FFPE Tissue DNA Isolation Kit (Mo Bio, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Elution volumes of 50μl -100μl were used. 
2.2.3. DNA extraction from fresh tissue 
DNA was extracted from fresh and fresh frozen tissue using the ReliaPrep™ 
gDNA Tissue Miniprep System kit (Promega, Madison, WI, United States of America) 
according to the manufacturer’s protocol. Elution volumes consisted of 50μl -80μl. 
2.2.4. DNA extraction from blood 
DNA was extracted from blood using a QIAamp DNA Investigator Kit (Qiagen, 
Venlo, Netherlands) according to the manufacturer’s protocol. The volume of blood used 
was 85μl. DNA was eluted using 65μl of deionised water (dH2O).   
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2.2.5. DNA extraction using QuantuMDx’s DNA extraction cassette 
Experiments on both blood and wax embedded tissue have been performed using 
QuantuMDx’s DNA extraction cassette. The extraction of DNA from samples consisted 
of a lysis step, activating the sorbent filter in the DNA extraction cassette with prep buffer, 
and DNA extraction by passing the lysis mixture through the activated sorbent filter.  
Lysis of whole blood consisted of adding 5μl of whole blood to 95μl of proprietary 
lysis solutions and incubating this at 60oC for 2 hours. For FFPE tissues the wax removal 
and tissue lysis was performed using reagents taken from the ReliaPrep™ FFPE gDNA 
Miniprep System kit as detailed in section 2.2.1. The DNA extraction program consisted 
of first wetting the filter with ~200μl of the proprietary prep buffer to activate the filter. 
After a 5 minute activation time the sample was loaded onto the filter at a speed of 
100μl/min. Then the cassette was refilled with prep buffer. This second lot of buffer was 
run through the cassette to elute the DNA at a speed of 50μl/min. Small pauses can be 
programmed in at intervals determined by the user so that the DNA can be collected in 
elute fractions of varying volumes. The filter retains the cellular components that are 
passed through it, with the exception of DNA, which is passed out through the collection 
channel together with the buffer. A photo showing the layout of the DNA extraction 
cassette can be found in Figure 2.1. The sample and buffer are pushed through the DNA 
extraction cassette using the syringes of QuantuMDx’s prototype machine (the 
MiniChemLab) (see Figure 2.2). 
 
Figure 2.1: QuantuMDx’s prototype DNA extraction cassette. 
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Figure 2.2: The QuantuMDx prototype (The MiniChemLab) with the cassette manifold (right corner) and 
the syringe pumps (left corner). 
2.3. Polymerase chain reaction 
2.3.1. PCR using QuantuMDx’s PCR cassette 
PCR cassette experiments were performed using the first generation of 
QuantuMDx PCR cassettes produced by MiniFab (MiniFab, Melbourne, Australia). 
Cassettes were run both with and without a surfactant coating the PCR channels. A 
surfactant coating was applied by soaking the PCR channels with solutions of 0.1mg/ml 
BSA and/or 2.5% PVP for between 10min to 3hours. PCR reactions were carried out 
using reagents from the HotStarTaq Plus kit (Qiagen, Venlo, Netherlands) and 
Deoxynucleotide (dNTP) Solution Mix (New England BioLabs, Ipswich, Massachusetts, 
USA). PCR reactions were made up of 1x reaction buffer, 0.2mM dNTP mix, 0.1-
0.125U/μl polymerase, 1uM forward primer, 1uM reverse primer, DNA (master mix 
concentrations of 0.4ng/μl -1ng/μl gDNA or PCR product), and 0%-2.5% PVP. To 
activate the HotStartTaq the PCR mix was heated to 95oC for 5min on a MultiGene II 
Thermocycler (Labnet International Inc, Edison, USA) prior to loading onto a PCR 
cassette. PCR mix volumes of 50-100μl were pumped through PCR cassettes at flow rates 
of either 10μl/min or 5μl/min. The PCR channel of QuantuMDx’s cassettes provide 30 
PCR cycles. All PCR reactions performed were two-step PCR reactions with denaturation 
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temperatures varying between 90-95oC and an annealing temperature of 56oC. See Figure 
2.3 for a diagram of QuantuMDx’s PCR cassette and testbed used for running the 
cassettes.   
 
Figure 2.3: QuantuMDx’s first generation cassette PCR using a prototype machine developed by MiniFab. 
Panel A: The testing platform for QuantuMDx’s first generation PCR cassettes. Panel B: Simplified 
diagram showing how the PCR cassette works when it is placed on the heaters of QuantuMDx’s prototype. 
Panel C: A used PCR cassette.  
2.3.2. Tube based PCR 
2.3.2.1. Positive and negative controls for PCR reactions performed on QuantuMDx’s 
PCR cassettes 
Negative controls for PCR consisted of adding an aliquot of the PCR mix prior to 
the addition of DNA, in a 0.2ml PCR tube, and adding dH2O to dilute the master mix 
components to the correct concentrations. Positive controls for the cassette PCRs 
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consisted of placing an aliquot of the PCR mix with DNA in a 0.2ml PCR tube. Both 
positive and negative controls were run on a MultiGene II Thermocycler using the 
program found in Table 2.1. 
 
Table 2.1: Thermocycler program used to amplify positive and negative controls for the PCR cassette 
experiments. 
2.3.2.2. Amplicon production for sequencing based MSI detection 
PCR reactions for the purpose of creating amplicons for sequencing on the 
Illumina MiSeq were created using the high fidelity Herculase II Fusion DNA polymerase 
(Agilent, Santa Clara, CA, USA). PCR reactions were carried out in a total volume of 
25μl consisting of 17.25μl H2O, 5μl 5x Reaction buffer, 0.25μl dNTP mix, 0.25μl 
polymerase, 0.63μl (10uM) forward primer, 0.63μl (10uM) reverse primer, 1μl DNA (10-
40ng depending on DNA quality). PCR amplification was carried out on a Bio-Rad T100 
Thermal Cycler (Bio-Rad, Hercules, CA, USA) according to the program found in Table 
2.2. 
 
Table 2.2: Primary PCR thermocycler program to produce amplicons for sequencing based MSI detection. 
* Number of Cycles used for DNA obtained from FFPE tissues. ** Number of cycles used for DNA 
obtained from fresh or fresh frozen tissue. 
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2.4. DNA quantification 
2.4.1. Nanodrop assay 
For quantification of DNA concentration, 1.5μl of DNA sample was loaded onto 
a Nanodrop ND-2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), which had been pre blanked with the same DNA suspension buffer 
used to elute the DNA samples being measured.  Purity of DNA was measured by taking 
the A260/280 ratio. 
2.4.2. Picogreen assay 
Double stranded DNA concentration was measured using the Quant-iT™ 
PicoGreen® dsDNA Assay Kit (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) according to manufacturer’s recommendations. Briefly, a 1x PicoGreen working 
solution was prepared by diluting the 200x stock Invitrogen Quant-iT™ PicoGreen® 
solution in 1x Tris-EDTA (TE) buffer. Samples were measured in triplicate where 
possible and the standard curve was prepared in duplicate on each plate. Each reaction 
volume totalled 100μl. Absorbance readings were taken using a Fluoroskan Ascent FL 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA). The Fluoroskan Ascent FL 
program included shaking the plate before absorbance readings were taken. The averages 
of the standard curves were plotted in Microsoft Excel and the linear regression equation 
obtained from this curve was used to convert the absorbance readings of the samples into 
DNA concentrations. 
2.4.3. Qubit DNA quantification 
DNA quantification using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) was performed using the Invitrogen dsDNA HS Assay 
Kit and Invitrogen dsDNA BR Assay Kit (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) according to manufacturer’s instructions. 
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2.4.4. Bioanalyser 
All Bioanalyser experiments were performed using the Agilent 2100 Bioanalyzer 
(Agilent, Santa Clara, CA, USA). Bioanalyzer High Sensitivity Assays were performed 
according to the instructions in the Agilent High Sensitivity DNA Kit Quick Start Guide. 
2.4.5. QIAxcel 
The QIAxcel was used to quantify amplicons generated for the second and third 
MiSeq sequencing runs. Capillary Gel electrophoresis was performed on a QIAxcel 
System (Qiagen, Venlo, Netherlands) using a QIAxcel DNA Screening Kit (2400) 
(Qiagen, Venlo, Netherlands) according to manufacturer’s protocol. 
2.5. PCR product visualisation 
2.5.1. Gel preparation and electrophoresis 
Gels consisted of 2% Invitrogen E-Gels (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) or Gels made up by dissolving 1.5g SeaKem® LE Agarose (Lonza, 
Basel, Switzerland) in 100ml of 1% tris-acetate-EDTA (TBE) using a microwave oven. 
For TBE gels, 10µl of GelRed Nucleic Acid Gel Stain 10,000x (Biotium Inc, Hayward, 
CA, USA) was added to allow the visualisation of gels. Samples and ladders were mixed 
with BlueJuice™ Gel Loading Buffer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) at a concentration of 1x prior to loading onto a Gel. The ladders 
were either Quick-Load® 2-Log DNA Ladder (0.1-10.0 kb) (New England BioLabs Inc, 
Ipswich, Massachusetts, USA) or Invitrogen 1kb Plus DNA Ladder (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). TBE gels were run at 95 volts until separation 
of DNA fragments was achieved, and E-Gels were run for 26 minutes on an E-Gel iBase 
Power System (Thermo Fisher Scientific, Waltham, Massachusetts, USA) before 
visualisation using a UVP GelDoc-It 310 Imaging System (UVP, Upland CA, USA). 
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2.6. DNA purification 
2.6.1. AMPure magnetic bead purification of PCR product  
Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA) PCR product 
purification was performed manually in accordance with the recommendations found in 
the Nextera XT DNA Sample Preparation Guide (revision C). Ampure cleanup was used 
to purify pooled PCR product to be used as input for the Nextera XT library prep, and as 
part of the Nextera XT library prep procedure.  
2.7. Sequencing and fragment analysis 
2.7.1. MSI testing using fragment analysis 
Amplification of MSI markers was performed using a MSI Analysis System, 
Version 1.2 kit (Promega, Madison, WI, United States of America). The PCR 
amplification mix was produced according to the manufacturer’s specifications. The PCR 
reactions were run on a SensoQuest Labcycler Thermocycler (SensoQuest GmbH, 
Göttingen, Germany) using the program found in Table 2.3). 
 
Table 2.3: Thermocycler program used for the amplification of MSI markers from the Promega MSI 
Analysis System kit. 
Fragment analysis was performed on an ABI PRISM 3130xl Genetic Analyzer 
(Life Technologies, Carlsbad, CA, United States of America) using 11μl Hi-Di 
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formamide, 1μl ILS 600, and 2μl PCR product per well. The MSI analysis was carried 
out using the GeneMapper Software (Life Technologies, Carlsbad, CA, United States of 
America). The interpretation of all fragment analysis traces were checked by Ottie 
O’Brien (Northern Genetics Service, Newcastle Hospitals NHS Foundation Trust). 
2.7.2. Next generation sequencing on the Illumina MiSeq platform 
Amplicons to be sequenced on the Illumina MiSeq platform (Illumina, San Diego, 
CA, United States of America) were generated using the PCR protocol listed in section 
2.3.2.2. For the first MiSeq run, amplicons were run on a TBE gel to confirm that 
amplicons had the desired length. A selection of 5-7 amplicons of varying band intensities 
from each gel were quantified using a Qubit 2.0. The concentrations of the remaining 
amplicons were estimated based on the band intensities seen on the gel images by 
comparing them to the bands of known concentration. For subsequent MiSeq runs all 
amplicons were quantified on a QIAxcel System. For each sample, amplicons were 
pooled at a roughly equal concentration prior to PCR cleanup using Agencourt AMPure 
XP. After AMPure clean up all amplicon pools were quantified using a Qubit 2.0 
Fluorometer and diluted to a concentration of ~0.2ng/μl, which is the recommended input 
DNA concentration for the Illumina Nextera XT kit. 
2.7.2.1. Nextera XT adapter and barcoding 
Library prep was performed using the Nextera XT DNA Library Prep kit 
(Illumina, San Diego, CA, United States of America). Briefly, sequencing adaptors were 
added using an enzymatic tagmentation step followed by a PCR reaction to add sample 
specific indexes. Following PCR cleanup, a magnetic bead based normalisation step was 
used to bring all samples to the same concentrations prior to pooling all samples ready 
for sequencing. 
The library prep was performed according to the manufacturers protocol (Nextera 
XT DNA Sample Preparation Guide, revision C) with the exception of the following: The 
PCR plates and seals consisted of 96-Well PCR Plates, Non-Skirted Cuttable (Starlab, 
Milton Keynes, UK) and Aluminium StarSeal (Starlab, Milton Keynes, UK). A magnetic 
ring plate was used instead of the recommended magnetic plate. For the first MiSeq run 
a Vortex Mixer – WIZARD (VELP Scientifica, Usmate Velate MB, Italy) set to a speed 
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of 1700rpm was used instead of the recommended plate shaker. For the first MiSeq run 
the Bioanalyser was used to check samples after the AMPure cleanup step. For 
subsequent MiSeq runs the QIAxcel was used instead of the Bioanalyser. 
2.7.2.2. MiSeq sequencing 
Amplicons prepared for sequencing using the Nextera XT Library Prep kit were 
sequenced on the Illumina MiSeq platform using a MiSeq Reagent kit V2 (500 cycles) 
(Illumina, San Diego, CA, United States of America) for the first MiSeq run, and a MiSeq 
Reagent kit V3 (600 cycles) (Illumina, San Diego, CA, United States of America) for 
subsequent MiSeq runs. For the first MiSeq run, the sequenced library was made up of 
24μl PAL (Pooled Amplicon Library), 546μl HT1, and 30μl 12.5pM PhiX creating a 
12.5pM library with a 5% PhiX spike-in. For subsequent MiSeq runs the sequenced 
library consisted of 35μl PAL (Pooled Amplicon Library), 535μl HT1, and 30μl 20pM 
PhiX creating a 20pM library with a 5% PhiX spike-in. 
Sequencing was performed using targeted resequencing and the PCR amplicon 
workflow with paired end read sequencing (251 cycles for both read 1 and read 2) and 
adaptor trimming. Sequencing was performed on the Illumina MiSeq to an average read 
depth of >10000 per amplicon. 
2.8. Informatics  
2.8.1. Literature review and homopolymer selection  
To identify short homopolymers previously shown to be unstable in CRCs, a 
systematic literature review was carried out using PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), Google Scholar (http://scholar.google.co.uk) 
and the Selective Targets in Human MSI-H Tumorigenesis Database (SelTarBase, 
http://www.seltarbase.org). 6bp -16bp homopolymers were identified for potential 
inclusion in this study. Repeats were checked for common polymorphisms and 
neighbouring SNPs using the UCSC Genome Browser (Kent et al., 2002) and dbSNP 
(build 173) (Sherry et al., 2001). Repeats containing a known repeat length polymorphism 
were excluded from the study with the exception of polymorphisms where no frequency 
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data was available. These were not excluded because the polymorphisms were assumed 
to be very rare or not validated. To facilitate the investigation of allelic bias of MSI, 
homopolymers within 80bp of SNPs with a minor allele frequency between 0.05 – 0.95 
were selected where possible. 
2.8.2. Primer design 
Primers were designed using Primer3 (Rozen and Skaletsky, 2000) or manually if 
Primer3 returned no suitable oligos. Primers designed manually had a Tm of 57oC-60oC. 
The Tm was calculated as follows: Tm = 4×(G+C)+2×(A+T). Primers were designed to 
create amplicons of ~300-350bp. All primers were checked for common SNPs using SNP 
Check (https://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm), off target binding 
using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) or BLAT (Kent, 2002), and 
appropriate melting temperatures and absence of secondary structures using OligoCalc 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) or Primer3. The primers 
were produced by either Metabion (Metabion International AG, Steinkirchen, Germany) 
or Biobasic (Bio Basic Inc., Markham, Canada) and purified by desalting. A list of all 
primers can be found in Table 9.1 in the Appendix. 
2.8.3. Sequence data files 
The sequence data analysed in this thesis consisted of amplicon sequence data, 
whole genome sequences, and one exome sequence. 
Amplicon sequence data were generated on the Illumina MiSeq as described in 
section 2.7.2. The data were retrieved from the MiSeq in the form of FASTQ files. 
Whole genome sequences consisting of MSI-H colorectal cancers, matched 
normals, and MSS cancers were obtained from The Cancer Genome Atlas (TCGA) group  
in the form of BAM files (Data access request [#17798-1] approved by the TCGA Data 
Access Committee). The samples used consisted of 12 MSI-H tumours, 12 MSS tumours 
and matched normal tissue for 11 of the MSI-H tumours (see Appendix Table 9.3 for 
details of the samples used). The whole genome sequences generated by the TCGA had 
a ~3-4 fold sequence coverage for each sample (Cancer Genome Atlas Network, 2012). 
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FASTQ files for one exome sequence were provided by Dr Mauro Santibaez-
Koref, (Institute of Genetic Medicine, Newcastle University). This sequence data were 
derived from the normal tissue of a patient unaffected by Lynch Syndrome. 
2.8.4. Producing scripts 
The text editor GNU nano 2.0.9 (Allegretta) was used to write and edit the shell 
and Perl scripts used to perform the work detailed in this thesis.  
2.8.5. Visualization of sequence alignments 
The Integrative Genomics Viewer (IGV) (Robinson et al., 2011) was used to 
visualise the aligned reads from BAM files. 
2.8.6. DNA sequence analysis pipeline 
2.8.6.1. Sequence alignment 
BAM files, obtained from The Cancer Genome Atlas group, were converted to 
FASTQ files using bam2fastq (version 1.1.0) (bam2fastq software 
[http://gsl.hudsonalpha.org/information/software/bam2fastq]).  
For sequence alignment the Burrows–Wheeler Aligner (BWA) (version 0.6.2) (Li 
and Durbin, 2009) was used. Input files consisted of FASTQ files and output files 
consisted of SAM files. Reads were aligned to the human genome sequence build 
GRCh37/hg19. 
The conversion of SAM files to BAM files as well as indexing and sorting of 
BAM files was achieved using Samtools (version 0.1.18) (Li et al., 2009). Samtools was 
also used to create the pileup file needed for variant calling with VarScan. 
Prior to indel calling using GATK duplicate sequences were removed from sorted 
and indexed BAM files using Picard (version 1.75) (PICARD 
[http://picard.sourceforge.net]). 
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2.8.6.2. Variant calling 
The pileup2indel function from VarScan (version 2.2.2) (Koboldt et al., 2009) 
was used with default parameters. Variant calling was performed using the pileup file 
created by Samtools as an input file.  
Dindel (version 1.01) (Albers et al., 2011) was run using default parameters. The 
sorted and indexed BAM file, processed by Samtools, was used as the input file. 
Prior to variant calling from the whole genome sequences using GATK, sorted 
and indexed BAM files with duplicates removed were merged into a multisample BAM 
file using GATK (version 2.2.9) and realignment around indels was performed. This 
multisample BAM file was then used as the input file for variant calling with GATK. For 
the Variant caller comparison a sorted and indexed BAM file, processed by Samtools, 
was used as the input file for GATK. 
The GATK UnifiedGenotyper (version 2.2.9) was first tried using default 
parameters, however due to the low complexity of the data, maxGaussians had to be 
lowered to 4 for the indel error model. The SNP error model was run with a maxGaussians 
value of 6 as recommended. For the indel caller comparison, the GATK 
HomopolymerRun annotation was used to allow the identification of variants in 
homopolymers. For the analysis of colorectal cancer whole genome sequences, the 
GATK UnifiedGenotyper was used to produce a raw variant call file annotated using the 
TandemRepeatAnnotator annotation for the ease of identifying indels in mononucleotide 
repeats. All homopolymers with known polymorphisms as of dbSNP (version 137, hg19) 
were also annotated. 
An in-house variant caller, Concordant Overlapping Paired Reads Caller 
(COPReC), was designed and run by Dr Mauro Santibanez-Koref (Institute of Genetic 
Medicine, Newcastle University). COPReC only reports indels in concordant overlapping 
reads. This caller uses SAM files as input files. The output from this variant caller consists 
of a table for each homopolymer and SNP combination, which contains the paired end 
read counts for each recorded homopolymer length, and the base at the SNP site for each 
read that contains both homopolymer and SNP. COPReC was used to analyse all of the 
amplicon sequence data.   
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2.8.6.2.a Scripts for the variant calling pipelines  
Shell scripts for Varscan, Dindel and GATK can be found on the supplementary 
CD (see the folder “Variant Calling/Indel Caller Comparison”).   
Shell scripts for the GATK pipeline used for analysing whole genome sequences 
can be found in the folder “Variant Calling/TCGA Analysis” on the accompanying CD. 
2.8.7. Data manipulation and analysis using in house Perl scripts 
The following Perl scripts were written to parse data, and/or analyse read 
frequencies and indel size distributions (for details, see text in the result sections). All 
scripts are included as Supplementary Information in the folder “Sequence Analysis” on 
the accompanying CD. 
2.8.7.1. Comparison of the variant callers Dindel and GATK  
Dindel_GATK_compare.pl: Counts and lists the indels in homopolymers >7bp 
that the Dindel and GATK VCF files have in common, as well as counting and listing the 
indels that are unique to a VCF file using the chromosome and position data to determine 
if two indels are the same. 
2.8.7.2. Analysis of indel frequencies in MSI-H samples and controls using whole 
genome sequence data 
Perl_SelectVariants_RPA_RU.pl: Extracts all indels in homopolymers of 7-
12bp from a VCF file created by the GATK UnifiedGenotyper and annotated using 
GATK’s TandemRepeatAnnotator.  
TCGA_AnnotationSelector.pl: Filters out unnecessary annotations from the file 
generated by Perl_SelectVariants_RPA_RU.pl, creating a smaller output file containing 
the variants of interest and useful annotations. 
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REF_ALT_AnnotationSelector.pl: Calculates the number of reference and 
variant reads in each sample for each homopolymer. This script uses the output of 
TCGA_AnnotationSelector.pl as an input file. 
The output from REF_ALT_AnnotationSelector.pl was opened in Microsoft 
Excel where reference and variant reads for each sample group (MSI-H samples, MSS 
samples and matched normal for the MSI-H samples) were added up and the percentage 
of reference and variant reads for each group was calculated. All reads from each group 
were combined before analysis because of the low pass nature of the sequence data. The 
percentage of variant reads was rounded up to the nearest 5% prior to plotting graphs 
showing the number of homopolymers with different variant read frequencies. Separate 
graphs were produced for each homopolymer length, and G/C and A/T homopolymers 
were also analysed separately. All repeats with common polymorphisms (dbSNP version 
173) were removed prior to any analysis and the creation of graphs. 
2.8.7.3. Analysis of indel sizes in different homopolymer lengths using whole genome 
sequence data  
TCGA_AnnotationSelector_ForIndividIndelPercentages.pl: Using the output 
of Perl_SelectVariants_RPA_RU.pl as an input file, selects useful annotations and adds 
a read count of zero for samples that have no reads spanning a homopolymer. 
REF_ALT_AnnotationSelector_Percentages.pl: Using the output of 
TCGA_AnnotationSelector_ForIndividIndelPercentages.pl as an input file, calculates the 
number of reference alleles and number of reads corresponding to each indel size for each 
sample group (MSI-H samples, MSS samples and matched normal for the MSI-H 
samples). Then calculates the percentages of reads corresponding to each indel size. 
IndelGaps_AnnotationSelector.pl: Adds the size of each indel to the end of the 
lines in the file produced by REF_ALT_AnnotationSelector_Percentages.pl. 
IndelSizeSelector.pl: Extracts homopolymers of user specified length from the 
file generated by IndelGaps_AnnotationSelector.pl, so that different lengths of 
homopolymer can be analysed separately. 
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HomopolymerCount.pl: Counts the number of homopolymers with indels of 
each size so this can easily be plotted in Microsoft Excel. Separate counts are done for 
A/T homopolymers and G/C homopolymer. The script uses the output of 
IndelSizeSelector.pl as input. 
HomopolymerCount_percent.pl: A variation of HomopolymerCount.pl, which 
allows thresholds to be set so that only indels with a frequency that passes the threshold 
will be counted. The script in Supplementary Information currently has a threshold set to 
10%. This script uses the output of IndelSizeSelector.pl as input. 
2.8.7.4. Annotating neighbouring SNPs 
AnnotateCloseSNPs.pl: Using  a tab delimited text file as input, annotates any 
SNPs from dbSNP (version 137, hg19) (Sherry et al., 2001) within 30bp of the start of 
repeats. 
2.8.7.5. Analysis of allelic bias 
AlleleicBias_IndividualIndels.pl: Using output from COPReC, identifies 
repeats that are heterozygous for a neighbouring SNP and calculates the percentage of 
reads corresponding to each variant repeat length, and reference repeat length, for both 
alleles. Repeats are defined as heterozygous if there are ≥100 paired end reads spanning 
both SNP and repeat for each allele, and one allele does not have less than 10% of the 
total read count. 
ChangeIndelOrder_AllelicBias.pl: Uses the output from 
AlleleicBias_IndividualIndels.pl to print out a table containing the fractions of variant 
and reference reads in descending order of repeat length for each homopolymer to allow 
for the easy creation of graphs in Microsoft Excel. 
41 
 
2.9. Statistical analyses 
2.9.1. Fisher’s exact tests 
The following Perl scripts were written to parse data, and perform two-tailed 
Fisher’s exact tests (for details, see text in the result sections). All scripts are included in 
Supplementary Information on the accompanying CD in the folder “Fisher’s Exact Test”. 
FisherTest_AllDeletions.pl: Using output generated by COPReC, this script 
identifies repeats that are heterozygous for a neighbouring SNP and performs a two-tailed 
Fisher’s exact test to determine if the fraction of deletions are significantly different 
between the two alleles. Repeats are defined as heterozygous if there are ≥100 paired end 
reads spanning both SNP and repeat for each allele, and one allele does not have less than 
10% of the total read count. This script calculates the number of reads that contain a 
deletion and the number of reads that do not contain a deletion for each allele, and then 
uses these values to perform a Fisher’s exact test. The Fisher’s exact test calculations 
were performed using an external module integrated into the Perl script (Pedersen T., 
https://metacpan.org/pod/Text::NSP::Measures::2D::Fisher::twotailed).  
FisherTest_IndividualIndels.pl: Using output generated by COPReC, this script 
identifies repeats that are heterozygous for a neighbouring SNP and performs a two-tailed 
Fisher’s exact test to determine if the fraction individual indels is significantly different 
between the two alleles. Repeats are defined as heterozygous if there are ≥100 paired end 
reads spanning both SNP and repeat for each allele, and one allele does not have less than 
10% of the total read count. For each allele this script categorises reads as; reads 
containing the indel size under investigation, or reads that do not contain the indel size 
under investigation. Next, this script calculates the number of reads in each category for 
both alleles and uses this as the input in the Fisher’s exact test 2 x 2 contingency table. 
The two-tailed Fisher’s exact test calculations were performed using an external open 
source module integrated into the Perl script (Pedersen T., 
https://metacpan.org/pod/Text::NSP::Measures::2D::Fisher::twotailed). 
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2.9.2. Match probability calculations  
A match probability calculation was used to determine if there had been a sample 
mix-up for the U303 tumour sample. For the calculations the NorthGene (NorthGene Ltd, 
Newcastle upon Tyne, UK) Caucasian allele database and an Fst of 2% were used. Below 
are the calculations for size bias, which take into account that the database used is only 
an estimation of the allele frequencies in the population. 
Heterozygotes:           Homozygotes:    
ሺࡺ	ൈ	࡭࢒࢒ࢋ࢒ࢋ	ࡲ࢘ࢋ࢛ࢗࢋ࢔ࢉ࢟ሻା૛
ࡺା૝          
ሺࡺ	ൈ	࡭࢒࢒ࢋ࢒ࢋ	ࡲ࢘ࢋ࢛ࢗࢋ࢔ࢉ࢟ሻା૝
ࡺା૝   
 
N=Size of allele database 
Next, the match probability frequencies were calculated using the equations bellow. 
Heterozygotes:         Homozygotes:    
૛ሺࣂାሺ૚ିࣂሻ	ࢌ࢖ሻሺࣂାሺ૚ିࣂሻࢌࢗ
ሺ૚ାࣂሻሺ૚ା૛ࣂሻ        
ሺ૛ࣂାሺ૚ିࣂሻࢌ࢖ሻሺ૜ࣂାሺ૚ିࣂሻࢌࢗ
ሺ૚ାࣂሻሺ૚ା૛ࣂሻ   
 
θ=0.02 (the Fst value) 
fp= the size bias for allele 1 
fq= the size bias for allele 2 
 
The match probability frequencies for all markers were multiplied together. 1 divided by 
the product of the match probability frequencies generates the final match probability 
figure. The chance of obtaining a match if the sample originated from someone other than, 
and unrelated to, the person being tested is 1 in whatever the final match probability figure 
is. If there are no mismatches between tissues and the match probability figure is over 1 
billion, then it can be concluded that both samples belong to the same person. 
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2.9.3. Optimising thresholds for differentiating between MSI-H and MSS 
samples 
Different deletion frequencies of between 0 and 1 at increments of 0.001 were 
used as potential thresholds. Initially, the deletion frequency that gave the lowest number 
of errors was identified and used as the threshold. If the lowest number of errors could be 
obtained at more than one deletion frequency, then the lowest of these deletion 
frequencies was used as the threshold. Frequency of errors was calculated using the 
following equation: 
FPR × Nbr MSS + FNR × Nbr MSI-H = Number of errors 
FPR= false positive rate 
FNR= false negative rate 
Nbr MSS= number of MSS tumours 
Nbr MSI-H = number of MS-H tumours 
 
The false positive rate was defined as the fraction of repeats with a deletion 
frequency of or above the threshold in the MSS samples, and the false negative rate was 
defined as the number of repeats with a deletion frequency below the threshold in MSI-
H samples. 
The weighting of different errors was also used to adjust the thresholds. A false 
positive error was weighted as 1.5x and 2x worse than a false negative error. This was 
achieved by multiplying the number of false positives by the weighting before adding up 
false positives and false negatives. The deletion frequency with the lowest number was 
used as the threshold. If the lowest number could be found at several different deletion 
frequencies, then the lowest of these deletion frequencies was used as the threshold. The 
weighting of false positive errors needed to achieve a deletion frequency threshold where 
there would be no false positive errors was also identified. The equation used can be found 
below: 
WFP × FPR × Nbr MSS + FNR × Nbr MSI-H = Weighted errors 
FPR= false positive rate 
FNR= false negative rate 
Nbr MSS= number of MSS tumours 
Nbr MSI-H = number of MS-H tumours 
WFP = weighting of false positive errors 
 
 
44 
 
For each homopolymer size there would be a different deletion frequency that 
gave the lowest number of errors or weighted errors. For each set of deletion frequencies, 
the number of repeats classed as unstable for each tumour was calculated and plotted. 
Each set of deletion frequencies was also used to predict how many errors there would be 
for each repeat size given a panel of tumours, which conform to a division of 85% MSS 
tumours and 15% MSI-H tumours. This was achieved by multiplying the false positive 
rate by 85 to obtain the percentage of false positive errors and multiplying the false 
negative rate by 15 to obtain the percentage of false negative errors for a panel of tumours 
consisting of 85% MSS tumours and 15% MSI-H tumours.  
All graphs and calculations in the section were drawn using Microsoft Excel.  
2.9.4. Binomial classification  
Area under the receiver operating characteristic curve (AUC) calculations, and the 
sensitivity and specificity curves were produced by Dr Mauro Santibanez-Koref (Institute 
of Genetic Medicine, Newcastle University) using the statistical computing environment 
R (R Core Team). 
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Chapter 3. Assessing next generation sequencing of 
known short homopolymers in microsatellite unstable 
tumours 
3.1. Introduction and Aims 
3.1.1. Introduction 
3.1.1.1. MSI in long and short homopolymers  
Currently, fragment analysis is used for MSI testing. Fragment analysis is a 
capillary electrophoresis based method, which allows the measurement of DNA fragment 
lengths. The markers that are most frequently used for MSI testing by fragment analysis 
today are BAT26 (A)26, BAT25 (A)25, MONO-27 (A)27, NR-21 (A)21, and NR-24 (A)24 
(Boyle et al., 2014). Mononucleotide repeats of these lengths have the advantage that they 
are highly susceptible to slippage in tumours with mismatch repair defects (Umar et al., 
2004). This means that a panel of as little as five markers is enough for an MSI test. For 
example using the mononucleotide repeats BAT-25, BAT-26, NR-21, NR-24 and NR- 27 
with two unstable markers as the criteria for classifying a sample as MSI-H, Goel et al. 
(2010) achieved a sensitivity of 95.6% and a positive predictive value of 100% for a panel 
of 114 mismatch repair deficient tumours and 99 mismatch repair proficient tumours. 
Suraweera et al. (2002) have achieved a 100% sensitivity and specificity using the same 
panel of repeats on a different panel of tumours. On the other hand, the drawback of using 
microsatellites of these lengths is that they are also highly unstable in vitro (Fazekas et 
al., 2010). Due to the lengths of these mononucleotide repeats, commercially available 
polymerases are unable to faultlessly replicate them. The result of this is seen as a stutter 
pattern on the fragment analysis traces, even in repeats amplified from MSS tumours. For 
this reason, the repeat lengths used in MSI tests today would not be ideal for a sequencing 
based assay.  
In the late 1990s and early 2000s there was evidence that short mononucleotide 
repeats were susceptible to MSI, but at a much lower frequency than the longer repeats 
used in current fragment analysis tests (Vilkki et al., 2002). Although short repeats could 
be used in an MSI test, there is data available which indicates that repeat length affects 
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stability and error rate. This should be considered when selecting mononucleotide repeats 
for an MSI test.  
The susceptibility of different homopolymer lengths to MSI has been studied 
previously, which gives some indication of which repeat lengths to would be appropriate 
for a next generation sequencing based MSI test. Microsatellites as short as 7-13bp have 
been reported as being susceptible to MSI (Sammalkorpi et al., 2007, Vilkki et al., 2002, 
Woerner et al., 2003). Vilkki et al. (2002) screened fourteen intronic homopolymers of 
6bp-9bp in up to 93 MSI-H tumours and identified instability in six of these markers. 
These markers consisted of one 7bp repeat showing instability in two tumours (2/93), two 
8bp repeats showing instability in 2 tumours (2/81) and 5 tumours (5/93) respectively, 
and three 9bp repeats showing instability in 4 tumours (4/84), 5 tumours (5/88) and 4 
tumours (4/93) respectively. They also screened eight coding homopolymers and found 
instability in one 9bp repeat for 22.9% of the MSI-H tumours analysed. Woerner et al. 
(2003) analysed 181 homopolymers of lengths 4bp-13bp in colorectal cancers and found 
15 repeats with instability in over 40% of the MSI-H tumours analysed. These repeats 
consisted of two 8bp repeats, two 9bp repeats, six 10bp repeats, four 11bp repeats and 
one 13bp repeat.  
Sammalkorpi et al. (2007) studied 114 intergenic repeats in up to 30 MSI-H 
tumours to assess their instability using Sanger sequencing. The repeats were 6-10bp in 
length. Repeats were classed as unstable if a variant with >10% of the relative fluorescent 
units compared to the wild type allele was detected. Only four out of the twenty-nine 6bp 
repeats showed instability for at least one sample, suggesting that 6bp repeats are not very 
susceptible to MSI. For the 7bp and 8bp repeats thirteen out of twenty-five repeats were 
classed as unstable and eighteen out of twenty-two were classed as unstable respectively. 
On average, the 7bp repeats were unstable in 3% of the samples and the 8bp repeats were 
unstable in 13% of the samples. For the 9bp repeats surveyed, all sixteen showed MSI in 
at least one tumour and on average repeats showed instability in 29% of the samples. Only 
one of the twenty-two 10bp repeats was not unstable in any sample and on average 10bp 
repeats were unstable in 50% of the samples. This data indicates that MSI rates increase 
with the length of the homopolymer and there are large differences in instability rates for 
homopolymers of different lengths.  
Unfortunately, PCR and sequencing error is also expected to increase with 
homopolymer length. Clarke et al. (2001) found that a Thermus aquaticus based 
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polymerase (AmpliTaq) could correctly amplify a mononucleotide repeat of 9bp under 
standard PCR conditions, but for a mononucleotide repeat of 11bp there was a 10% error 
rate measured using sequencing individual clones after subcloning of the PCR product,  
and for a 13bp mononucleotide repeat there was a 66% error rate. Fazekas et al. (2010) 
showed that using the polymerase Herculase II Fusion improved replication of 
mononucleotide repeats to the point where DNA replication was nearly error free after 35 
PCR cycles for homopolymers up to 13bp in length. After 13bp the error rate increases 
with homopolymer length. In theory, therefore, a panel of short homopolymers could be 
used to create a MSI test that is compatible with sequencing. However, because of the 
reduced susceptibility of 7-13bp homopolymers to MSI, a much larger panel of repeats 
would be need in an MSI test.  
Generally, the length of a microsatellite and the susceptibility of a microsatellite 
to MSI are positively correlated (Sinicrope and Sargent, 2012, Vilkki et al., 2002, 
Woerner et al., 2003). On the other hand, the rate of PCR and sequencing error also 
increases with repeat length (Clarke et al., 2001, Fazekas et al., 2010). Because the 
optimal trade off between error rates and susceptibility to MSI has not been determined 
for a sequencing based MSI assay, more empirical data would be required to determine 
the appropriate repeat length and number of markers to use. PCR errors have the potential 
to occur during amplicon generation, library prep (unless a PCR free library prep is used), 
during cluster formation prior to next generation sequencing and during the sequencing 
by synthesis reaction. To develop a high throughput sequencing based MSI test it would, 
therefore, be necessary to investigate rates of instability and rates of error on the chosen 
sequencing platform, to determine both the optimal size and number of repeats to use, 
and also determine criteria for distinguishing between MSI-H and MSS samples. 
3.1.1.2. Next generation sequencing of short homopolymers  
Despite the discovery of homopolymers that were susceptible to MSI and short 
enough to sequence in the late 1990s and early 2000s a sequencing based MSI assay was 
not implemented because the sequencing technology at the time (Sanger sequencing) 
meant that it was impractical and not economically viable compared to fragment analysis. 
One reason for this is the number of amplicons that would need to be created and 
sequenced individually. With recent improvements in sequencing, and huge reduction in 
sequencing costs, it is now possible to consider high throughput screening approaches to 
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test for microsatellite instability. The monomolecular nature of next generation 
sequencing also provides a quantitative approach to measuring insertion and deletion 
(indel) frequencies, which would be useful for creating a sequencing based MSI test.  
The first paper to illustrate the potential use of next generation sequencing for 
detecting MSI was a high throughput sequence analysis of colorectal cancers performed 
by the Cancer Genome Atlas Network (2012). Their main focus was mutation detection 
and classification of subtypes of CRCs. However, they did also analyse MSI using exome 
data. Using their pipeline for variant calling they were initially unable to distinguish 
between MSI-H tumours and controls. These difficulties were due to low mutation 
frequencies being detected in mononucleotide repeats in normal tissue. These mutated 
reads they concluded were most likely derived by errors occurring from PCR 
amplification. They therefore focused their analysis of MSI on a handful of 
mononucleotide repeats in selected genes. Manual inspection of the reads from the MSI-
H tumours showed that some monunucleotide repeats had a higher variant read frequency 
compared to what was seen in the matched normal tissue. A variant read frequency 
difference of 20% between tumour and matched normal was defined as the cut off for 
calling a marker unstable. Using this criteria, mononucleotide repeats in 28 genes were 
analysed manually, the results of which showed, that tumours with MLH1 silencing had 
a 50 fold higher rate of frameshift mutations in these genes compared to tumours with a 
mutation rate of ≤ 12 per 106 bases. This showed, as a proof of principle, that 
microsatellite instability in short repeats was detectable using next generation sequencing. 
Prior to the start of this project, this was the only work that had been conducted on MSI 
using next generation sequencing.  
3.1.1.3. Sequencing platforms 
For any sequencing based MSI test selecting a sequencing technology which can 
cope well with long homopolymers is important. Sequencing using chain termination 
would be more appropriate than a sequencing technology such as 454 sequencing or 
IonTorrent where the number of bases in a homopolymer is inferred by signal intensity. 
SOLiD sequencing was discounted because of the aim to develop an MSI test, which 
would ultimately be compatible with the sequencing technology being developed by the 
company QuantuMDx. QuantuMDx will be using a sequencing by synthesis approach. 
SOLiD sequencing on the other hand, uses a sequencing by ligation approach using di-
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base probes. It would be easier to transfer a test developed using a similar sequencing 
technology to the QuantuMDx platform. Using SOLiD sequencing would also have the 
disadvantage that the sequencing would have to be outsourced.  
Illumina sequencing would be the most appropriate because of its low error rate 
for homopolymers.  Minoche et al. (2011) have reported average error rate for Illumina 
sequencing as 0.002% for 2bp homopolymers, rising to ~2% for 17bp homopolymers. 
Illumina sequencing has also shown promise in the paper by the Cancer Genome Atlas 
Network (2012), and was therefore the first choice for investigating MSI in 
homopolymers. The MiSeq should be an appropriate Illumina platform because it would 
give a sufficient read depth for investigating the suitability of using short homopolymers 
to detect MSI. Another advantage is that there is a MiSeq located at the Centre for Life 
allowing the sequencing to be performed locally hence avoiding the extra cost and delay 
in outsourcing the sequencing. 
3.1.1.4. Allelic distributions of MSI 
A sequence based approach may also enable the allelic origin of instability to be 
investigated through the analysis of single nucleotide polymorphisms (SNPs) located 
close to the repeat. Including these SNPs means that in heterozygous individuals it will 
be possible to identify which allele homopolymer length variants belong to on reads that 
span both SNP and homopolymer. It should therefore be possible to determine if a specific 
indel is more prevalent on one allele than the other. If microsatellite instability is caused 
by random errors in microsatellite replication, which are not corrected by a cells 
compromised MMR system, then instability events are unlikely to affect both alleles of a 
short homopolymer. This is because short homopolymers have a low susceptibility to 
replication errors in vivo and two errors in the same position on both chromosomes are 
therefore less likely to occur. SNPs may therefore be useful as it may provide a method 
by which instability could be distinguished from error, as PCR or sequencing error is 
unlikely to be allele specific because this type of error is likely to occur several times 
during a PCR reaction and both alleles will be susceptible. 
50 
 
3.1.2. Aims 
The initial high throughput genome sequencing of CRC patients had established 
the potential for a sequence based MSI test, and the plummeting cost of sequencing 
suggests that it may be economically viable. Sanger based analyses of individual repeats 
had established that extensive variation in stability and error rates existed. The initial aim 
of this work was to investigate the suitability of the MiSeq platform for MSI detection 
using known variable short repeats. Specifically, this work aimed to:  
 Determine the optimal homopolymer length for use in a sequencing based assay  
 Determine how easy it is to distinguish between MSI-H samples and controls 
using short homopolymers. 
 Evaluate the feasibility of a sequencing based MSI test. 
 Evaluate the feasibility of using SNPs to distinguish between alleles     
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3.2. Results 
3.2.1. Error frequencies for homopolymers in Illumina data 
First, to check that next generation sequencing is capable of accurately sequencing 
short homopolymers, alignment files produced from one control exome were analysed. 
The aim was to examine how sequencing errors and PCR artefacts are influenced by 
homopolymer length. To identify unstable homopolymers of a suitable length for this 
initial assessment the Selective Targets in Human MSI-H Tumorigenesis Database 
(SelTarBase, http://www.seltarbase.org) was screened to identify homopolymers of 
lengths 7-16bp. SelTarBase is a database containing microsatellites that have shown 
instability in MSI-H tumours. The selected 7-16bp homopolymers were checked for 
common polymorphisms using the UCSC Genome Browser (Kent et al., 2002). If no 
polymorphisms were listed then the homopolymers were assumed to be monomorphic. A 
list of the 29 monomorphic homopolymers that were selected is presented in Table 3.1. 
Size bp  Base  Name  Variant Position  Read Depth 
7  C  Axin2  chr17:63532585‐63532591  9 
7  C  XYLT2  chr17:48433967‐48433973  33 
7  C  RFX5  chr1:151318741‐151318747  11 
8  A  ACVR2  chr2:148683686‐148683693  54 
8  C  BAX  chr19:49458971‐49458978  74 
8  C  BRD1  chr22:50193070‐50193077  1 
8  A  CCKBR  chr11:6292451‐6292458  52 
8  A  LARP7  chr4:113570754‐113570761  89 
8  C  LIMK2  chr22:31672777‐31672784  10 
8  C  MAPRE3  chr2:27248517‐27248524  18 
8  C  MYH11  chr16:15802687‐15802694  24 
8  A  MYO1A  chr12:57422573‐57422580  89 
8  A  PA2G4  chr12:56505302‐56505309  152 
9  A  C4orf6  chr4:5527116‐5527125  37 
9  A  CLOCK  chr4:56336954‐56336962  125 
9  A  TTK  chr6:80751897‐80751905  122 
9  C  ELAVL3  chr19:11577605‐11577613  2 
10  A  TGFBR2  chr3:30691872‐30691881  149 
10  A  RFC3  chr13:34398063‐34398072  97 
11  A  ASTE1  chr3:130733047‐130733057  129 
11  A  MRE11A   chr11:94212931‐94212941  92 
11  A  SLC22A9   chr11:63149671‐63149681  134 
11  A  TAF1B   chr2:9989571‐9989581  34 
12  C  MRPL2  chr6:43021977‐43021988  9 
12  A  PCDHGA12   chr5:140812756‐140812805  110 
13  A  LGALS3   chr14:55612007‐55612019  106 
13  A  CCDC88A  chr2:47635524‐47635536  124 
16  A  FLJ20489  chr12:48174352‐48174367  40 
27  A  BAT26  chr2:47641560‐47641586  8 
Table 3.1: Monomorphic homopolymers that were used to investigate levels of sequencing error in Illumina 
sequencing. 
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The Integrated Genome Viewer (IGV) (Robinson et al., 2011) was then used to 
inspect these homopolymers for indels within a single exome sequence from a normal 
control subject. Reads spanning the homopolymers and at least 5bp either side of the 
homopolymer were counted. As the microsatellites are assumed to be monomorphic, any 
deviation from the reference sequence was counted as an error.  
Analysis of the homopolymers showed that PCR/sequencing errors do increase 
with repeat length (see Figure 3.1). This is consistent with what has been reported by 
(Fazekas et al., 2010). For the 7bp – 10bp homopolymers, less than 3% of reads contained 
PCR/sequencing errors (see Figure 3.1). Homopolymers of lengths 11bp – 12bp were 
more prone to PCR and sequencing error, the fraction of reads containing errors being 
around 10% (see Figure 3.1). For the 13bp homopolymers analysed, 16% of the reads 
contained errors. At the time when this analysis was being performed, no studies had been 
published addressing whether it would be possible to distinguish between MSI and 
artefacts with such high background noise. It was therefore deemed a risk to focus on 
repeats of this length and longer. For the 16bp repeat analysed only 65% of the reads 
matched the reference sequence. With such a high error rate it was concluded that it would 
be very hard to detect indels caused by MSI in homopolymers of this size and longer. For 
comparison one of the repeats used in a standard fragment analysis, BAT26 (27bp), was 
also analysed. Only 50% of the reads corresponded to the reference sequence for this long 
repeat. Because the 7bp – 10bp homopolymers had error rates of less than 3%, it was 
concluded that microsatellites of these lengths would be possible to type in a MSI assay 
without much interfering background noise from PCR/Sequencing error. 
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Figure 3.1: Effect of homopolymers size on error rates in Illumina sequencing. This figure shows indel 
frequencies in monomorphic homopolymers. Indel frequencies increase with homopolymer length 
indicating that sequencing/PCR errors increase with homopolymer length.   
3.2.2. Selecting suitable known homopolymers for MSI identification 
Having established that is possible to sequence homopolymers between 7-10bp 
using Illumina sequencing; these lengths were considered the most promising for use in 
an MSI test. Current literature and the MSI database SelTarBase 
(http://www.seltarbase.org) were used to identify short homopolymers (between 7 – 
10bp) that have been reported to be affected by microsatellite instability. To facilitate 
investigation of allelic stability, homopolymers in close proximity to SNPs with a  high 
minor allele frequency were selected where possible, by using the UCSC Genome 
Browser (Kent et al., 2002) and dbSNP (build 173) (Sherry et al., 2001) to identify 
suitable SNPs with a minor allele frequency between 0.05 – 0.95 (a minor allele frequency 
close to 0.5 being preferred). The UCSC Genome Browser and dbSNP (build 173) was 
also used to exclude any homopolymers with SNPs that could cause a length change of 
the repeat. Potential repeat length polymorphisms where no frequency data was available 
were not excluded because they were assumed to be very rare or not validated.  
Subsequent to the analysis three repeats were found to not conform to the criteria for 
selecting monomorphic repeats. The three repeats AL590078, SLC4A3, and AL390295 
all have SNPs with a high minor frequency where the minor allele creates a length change 
in the repeat.  
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Twenty-two homopolymers were identified and primers were produced. These 
included five homopolymers, one of each size from 11-15bp, which were chosen to see 
if data from these repeat sizes might be of interest. In total 17/22 repeats analysed had 
neighbouring SNPs with a minor allele frequency >0.05. Primers were designed to create 
amplicons ~300bp. This was done so amplicons would be compatible with the 
requirements of the Nextera XT sample prep kit (Illumina, San Diego, CA, United States 
of America), and to allow for SNPs and homopolymer to be sequenced together in both 
the forwards and reverse direction (see methods section 2.8.2). Creating amplicons which 
allowed overlapping paired end reads meant that it will be possible to further reduce 
sequencing error by only analysing concordant reads.   
Repeat 
Name 
Repeat 
length  
(bp) 
Repeat 
Unit  
Instability 
in CRC (%) 
(SelTarbase 
release 
201307) 
SNP minor 
allele 
frequency 
and base 
(dbSNP build 
173) 
Repeat length 
polymorphism 
minor allele 
frequency 
(dbSNP build 
173) 
Reference 
Axin2  7  C  14.4  A: 0.174 none  Thorstensen et al. (2005) 
AL590078  8  A  10.7  C: 0.203 0.150  Sammalkorpi et al. (2007) 
MX1  8  C  13  A: 0.260 NFD  Kloor (pers. Comm.) 
HPS1  8  C  28  G: 0.053G: 0.052  none  Alhopuro et al. (2012) 
IL1R2  8  C  32.3  G: 0.227 none  Alhopuro et al. (2008) 
DEPDC2  8  C  35  C: 0.407 none  Alhopuro et al. (2008) 
APBB2  8  C  36.6  G: 0.138 NFD  Alhopuro et al. (2008) 
SLC4A3  8  C  36.7  A: 0.038 0.038  Woerner et al. (2001) 
AC079893  9  A  3.3  T: 0.298 none  Sammalkorpi et al. (2007) 
AL390295  9  A  13.8 
A: 0.222 0.222
0.251   Sammalkorpi et al. (2007) 
AL359238  9  A  44  T: 0.062 none  Sammalkorpi et al. (2007) 
AP003532_2  9  A  46.4  G: 0.111 none  Sammalkorpi et al. (2007) 
TTK  9  A  50.2  A: 0.079 none  Williams et al. (2010) 
C4orf6  9  A  60  A: 0.059G: 0.0192  NFD  Woerner et al. (2001) 
AL954650  9  C  63  T: 0.138 none  Sammalkorpi et al. (2007) 
AL355154  10  A  66.7  T: 0.403 none  Sammalkorpi et al. (2007) 
AVIL  10  A  70.2  A: 0.247 none  Woerner et al. (2010) 
ASTE1  11  A  78  No SNP none  Woerner et al. (2010) 
MRPL2  12  C  91.5  T: 0.245 none  Woerner et al. (2010) 
EGFR  13  A  72.1  No SNP none  Yuan et al. (2009) 
FBXO46  14  A  95.2  A: 0.027 NFD  Woerner et al. (2001) 
FTO  15  A  81.8 
‐: 0.042
C: 0.016  none  Woerner et al. (2001) 
 
Table 3.2: A list of the repeats sequenced in results chapter 3, the MSI rates reported in SelTarBase, and 
the minor allele frequency of neighbouring SNPs. Note: many of the homopolymers are named after the 
gene they are located in. NFD = no frequency data available in dbSNP build 173.  
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3.2.3. Data generation 
Initially, material from 8 Lynch Syndrome patients was assessed to make sure 
there was enough material present to generate 22 amplicons. Samples of FFPE tumour 
material, FFPE normal mucosa, and blood were available for all 8 patients. Blood from 
four age matched normal controls, and FFPE microsatellite stabile (MSS) tumour tissue 
from four age matched and sex matched controls were also obtained. Having these 
controls means that it is possible to identify any artefacts that could be caused by 
imbedding the samples in wax, and it will be possible to control for PCR/sequencing 
artefacts in the tumours using the matched normal tissue. DNA extraction was carried out 
on each sample as described in methods sections 2.2.2 and 2.2.4. The DNA samples 
obtained were quantified and a PCR reaction was performed using FBXO46 to check the 
quality of the DNA. For three out of eight Lynch Syndrome patient samples, at least one 
of the FFPE samples failed to produce any PCR product. High failure rates from PCR 
reactions using DNA derived from FFPE tissues is a well-known problem (Gilbert et al., 
2007). Formalin fixing causes a degradation of DNA. This degradation is dependent on 
factors such as the length of time a tissue sample is retained in formalin  solution, 
temperature and pH during fixation and the age of wax blocks (Gilbert et al., 2007). 
The samples that were used consist of 3 tissues (FFPE tumour sample, FFPE 
normal mucosa, and blood) from 5 Lynch Syndrome patients. Having these 3 matched 
tissue samples from each patient makes it possible to decipher the patient’s genotype and 
compare it to the variants found in the cancer sample. The mutation status of each of the 
5 patients can be found in Table 3.3. 
 
Table 3.3: Germline mutations in the five Lynch Syndrome patients who’s tumours were analysed in this 
study.  
Amplicons were created for each homopolymer (a total of 575 amplicons). The 
PCRs were performed using the Herculase II Fusion polymerase (Agilent, Santa Clara, 
CA, United States of America) as this polymerase had the lowest error rates when 
replicating homopolymers in a study by Fazekas et al. (2010). All products were 
Patient Number Mutation
U096 MLH 1 exon 17, familial splice site mutation (c.1989+1G>A) 
U179
MLH1  exon 18. single base pair deletion in codon 697, this is a frameshift mutation resulting in 61 
novel amino acids at the 3' end of MLH1 protein 
U184 Missense mutation (c.677G>T; p.Arg226Leu) in exon 8 of MLH1.
U303 MLH1 missense T117M in exon 4
U312 MSH2 - deleted exon 8
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generated usinga Bio-Rad T100tm thermal cycler (Bio-Rad, Hercules, CA, United States 
of America) using the same PCR program. PCR amplification for all DNA samples was 
performed on one plate for each amplicon set to minimise any differences in processing 
between samples. Products were visualised on an agarose gel to confirm that amplicons 
had the expected size and to check for miss-priming. If any samples failed PCR 
amplification they were repeated.  As an example, amplicons created for the 
homopolymer FBXO46 can be found in Figure 3.2. Although the normal mucosa sample 
from patient 4 shows weak amplification, all reactions generated the expected amplicon 
of size 303bp. 
 
Figure 3.2: The amplicon set for one of the homopolymers (FBXO46). 1= patient U096, 2= patient U179, 
3=patient U184, 4= patient U303, 5= patient U312. A-D= Normal control MSS Tumour Tissue, E-H= 
Normal control blood, N= Negative (no DNA) control 
Once all amplicons were produced, between 5 and 7 amplicon from each gel 
image were selected for quantification using a Qubit 2.0 fluorometer (Life Technologies, 
Carlsbad, CA, United States of America). Amplicons were chosen so that amplicons with 
a range of different band intensities on the gel were quantified. The concentrations of the 
remaining amplicons were estimated based on the band intensities seen on the gel images 
by comparing them to the bands of known concentration. Amplicons for each sample 
were pooled at a roughly equal concentration. The pooled amplicons were cleaned using 
Agencourt AMPure XP beads (Beckman Coulter, Pasadena, California, United States) 
before being diluted to ~0.2ng/µl, which is the recommended input DNA concentration 
for the Illumina Nextera XT kit. Illumina adapters were added to the amplicons using the 
Nextera XT library prep kit (Illumina, San Diego, CA, United States of America). Agilent 
Bioanalyser high sensitivity chips (Agilent, Santa Clara, CA, United States of America) 
were used to determine the quality of the library before the Nextera XT normalization 
step. Sequencing was then performed on an Illumina MiSeq.  
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For the MiSeq run a MiSeq Reagent Kit (500-cycles) (Illumina, San Diego, CA, 
United States of America) was used. A cluster density of 560000 clusters per mm2 was 
obtained and a Q-score of over 30 was achieved for 64.57% of the bases sequenced (see 
Figure 3.4). A Q-score of 30 is equal to 99.9% probability of a base being called 
accurately. A drop of in Q-score was observed towards the latter cycles (see Figure 3.3). 
This is believed to be due to having reaching the end of many of the amplicons. A total 
of 11,236,567 reads were obtained from this MiSeq run and all samples were represented. 
Despite having the least reads, the U303 tumour sample had an average of 98,500 reads 
per amplicon.  
 
Figure 3.3: The quality score (Q-Score) distribution for each cycle showing a drop in Q-Score towards the 
later cycles of each read. 
 
Figure 3.4: The quality score (Q-Score) distribution for the reads generated on the MiSeq. Blue = bases 
with a Q-Score <30, Green = bases with a Q-Score >30.  
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3.2.4. Variant calling 
To identify variants in next generation sequence data a variant caller was used. 
Variant callers detect differences between a reference sequence and the sequence of a 
sample. Using algorithms the variant caller classes these inconsistencies between the 
reference sequence and a sample as either likely to be real variants or artefacts. Only 
variant that are deemed to be real according to the algorithms of the variant caller are 
reported.  Algorithms differ for different variant callers which can result in discrepancies 
in variant calls. For the purpose of this study it was important to be able to analyse both 
artefacts caused by sequencing and PCR error as well as true indel events. For this reason 
the use of a standard variant caller that filters out artefacts would be inappropriate. To 
circumvent the use of a standard variant caller, a simple in-house caller was created. This 
caller has been named “Concordant Overlapping Paired Reads Caller” (COPReC). 
COPReC only reports indels in concordant overlapping reads, therefore reducing the 
amount of sequencing error. Dr Mauro Santibanez-Koref (Institute of Genetic Medicine, 
Newcastle University) designed COPReC and performed the variant calling for this 
MiSeq run. The output consisted of the length variants observed for each homopolymer 
and how many paired end reads corresponded to each length. COPReC also has the 
advantage to be able to call low frequency indels that may be filtered out by a 
conventional indel caller. All indels are of interest as it will also be important to 
understand the distribution of sequencing and PCR error for different homopolymers. 
3.2.5. Polymorphic homopolymers 
Repeats with length polymorphisms were undesired because they would 
complicate the detection of MSI. Even with matched normal controls for each of the MSI-
H tumours, polymorphisms would make it impossible to measure the frequency of variant 
reads caused by MSI in an individual with a read length polymorphism of corresponding 
length. The reason for this is that PCR amplification from poor quality template DNA can 
be biased so that the allele ratios for heterozygotes are not 50/50. Ascertaining the 
frequency of variant reads that can be attributed to an MSI event would therefore be 
difficult in these circumstances. 
Despite attempts to only select monomorphic homopolymers it was clear from the 
data that two out of the twenty-two sequenced repeats, MX1 and C4orf6, contained read 
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length polymorphisms in at least one of the controls (see Figure 3.5). Polymorphisms for 
these two repeats have been registered on dbSNP, but no frequency data were available 
(see section 3.2.2). Based on that information it was possible that these polymorphisms 
were extremely rare so the repeats were included. However, for the repeats MX1 and 
C4orf6 my data suggests the polymorphisms are not rare (see Figure 3.5). Because length 
polymorphisms will make it harder to detect MSI events, these two repeats were excluded 
from further analysis. 
 
Figure 3.5: Frequency of variant alleles in all samples for markers MX1 and C4orf6. Both homopolymers 
were known to contain polymorphisms of unknown frequency (see Table 3.2). Panel A: the 8bp repeat 
MX1. Panel B: The 9bp repeat C4orf6.  T= Tumour sample, N= Normal Mucosa, B=Blood 
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3.2.6. PCR/Sequencing error in short homopolymers 
Because of the repetitive nature of homopolymers some sequence and PCR error 
was expected. To ascertain the levels of errors produced, mean variant read frequencies 
were calculated for the control samples (see Table 3.4). Variant reads observed in control 
samples were assumed to be derived from PCR errors during sample preparation. The 7bp 
repeat has a mean error frequency of 0.2% and 0.3% for all the controls. The 8bp repeats 
have a mean error frequency of between 2%- 3.7%. The 9bp repeats have a mean error 
frequency of between 0.4% – 7.7%.  The 10bp homopolymers have a mean variant read 
frequency of between 2.7% -8.5%. The longer repeats had even higher error frequencies 
(see Table 3.4). 
  
Table 3.4: Mean error rates consisting of PCR and sequencing error divided into the different control sample 
groups. The longer repeats have a high error rate (highlighted in orange). LS = Lynch Syndrome. 
3.2.7. Levels of instability observed in short homopolymers 
For each indel size the percentage of reads with that indel size were calculated 
and graphs for each homopolymer were plotted. In only one homopolymer, APBB2, there 
was a higher insertion frequency observed in one of the MSI-H samples compared to the 
controls (see Figure 3.6).  
Repeat length (bp) LS Blood LS Normal Tissue Normal Bloods MSS Tumours
$Axin2 7 0.2% 0.3% 0.2% 0.3%
$AL590078 8 1.4% 1.9% 1.7% 0.5%
$APBB2 8 2.2% 2.2% 2.6% 2.0%
$DEPDC2 8 3.7% 3.6% 3.8% 3.7%
$HPS1 8 2.4% 2.4% 2.4% 2.4%
$IL1R2 8 2.4% 3.7% 2.6% 2.6%
$SLC4A3 8 2.6% 2.8% 2.7% 3.5%
$AC079893 9 0.6% 0.8% 0.4% 0.7%
$AL359238 9 1.5% 1.4% 1.4% 1.5%
$AL390295 9 1.5% 1.5% 1.7% 0.8%
$AL954650 9 7.7% 7.4% 5.7% 6.8%
$AP003532_2 9 1.2% 1.1% 1.3% 1.5%
$TTK 9 3.2% 2.8% 3.2% 3.2%
$AL355154 10 3.0% 2.7% 3.2% 3.8%
$AVIL 10 8.1% 8.5% 7.7% 6.8%
$ASTE1 11 18.4% 21.5% 18.0% 19.4%
$MRPL2 12 75.6% 73.2% 76.5% 89.1%
$EGFR 13 42.5% 49.2% 45.0% 42.1%
$FBXO46 14 47.6% 53.9% 45.4% 44.7%
$FTO 15 77.3% 78.6% 71.9% 87.8%
Mean Error Rates
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Figure 3.6: Indel rates in the homopolymer APBB2. The U179 tumour sample has an insertion frequency 
of 5.8%, which is higher than that of any other sample. T= Tumour sample, N= Normal Mucosa, B=Blood 
The only 7bp repeat, Axin2, showed no difference in the frequency of variant 
reads between the control samples and the MSI-H samples (Figure 3.7). For all samples 
the reference reads made up over 99% of the reads covering the Axin2 homopolymer.  
 
Figure 3.7: The frequency of reference reads for the 7bp homopolymer Axin2. T= Tumour sample, N= 
Normal Mucosa, B=Blood 
Because of varying levels of PCR/sequencing error within repeats of the same 
length, it is not easy determining a cut off value for distinguishing between background 
error and MSI events. In this chapter arbitrary thresholds were set for calling repeats 
unstable. Cut off values were not calculated because a low number of repeats and samples 
were used. Calculating cut off values will be covered later in this thesis. 
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For the 8-10bp repeats a deletion was classed as MSI if more than 10% of the 
reads contained that deletion. For the larger homopolymers there was a lot of 
PCR/sequencing error (see Table 3.4). For the longer homopolymers MSI events 
presented as larger deletions compared to the background noise (see Figure 3.8). For the 
11-13bp repeats an event was classed as being caused by MSI if there was a 2bp deletion 
or larger which accounted for ≥ 10% of the reads. The 14-15bp homopolymers were 
classed as unstable if there was a 3bp deletion or larger which contained ≥ 10% of the 
reads for that homopolymer.  
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Figure 3.8: In the larger homopolymers MSI was observed as larger deletions. Panel A: The 11bp repeat 
ASTE1 with a 2bp deletion present in over 10% of the reads for samples U303T, U312T and U179T. Panel 
B: The 13bp repeat EGFR with a 2bp deletion present in over 10% of the reads for samples U303T and 
U179T. Panel C: The 14bp repeat FBXO46 with a 3bp or 4bp deletion present in over 10% of the reads for 
samples U303T, U312T and U179T. T= Tumour sample, N= Normal Mucosa, B=Blood 
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Variant reads containing deletion frequency levels consistent with instability were 
observed for 10 out of the 20 homopolymers in at least one tumour. All 20 homopolymers 
were classed as stable in all of the control samples. The ten homopolymers and deletion 
sizes which best separated the MSI-H samples from the controls can be found in Figure 
3.9. All of the Lynch Syndrome patient tumour samples, with the exception of the tumour 
from patient U184, had at least three unstable homopolymers. In fact based on the data 
obtained for the U184 tumour sample, this sample behaves like a MSS sample. The 
tumour U096 had two unstable 8bp repeats and one unstable 10bp repeat, while there was 
no evidence of instability in the longer 11bp-14bp repeats. The other Lynch Syndrome 
tumours, with the exception of  the U184 tumour sample, all had at least two unstable 
11bp-14bp repeats.
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Figure 3.9: Results for the ten markers with elevated deletion frequencies in Lynch Syndrome tumours. The deletion sizes shown are the best for separating the tumours from the Lynch 
Syndrome patients and the controls. Four out of the five tumours from Lynch Syndrome patients show an increased deletion frequency in at least three homopolymers compared to the 
controls. No MSI events were observed for the tumour from patient U184. T= Tumour sample, N= Normal Mucosa, B=Blood.
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3.2.8. Fragment analysis MSI results 
The five tumours obtained from Lynch Syndrome patients were assumed to be 
MSI-H because of their origin. However the results of the next generation sequencing 
assay provide no evidence for instability in the tumour derived from patient U184 using 
the 20 markers analysed here (see Figure 3.9). Patient U184 has a germline Missense 
mutation in exon 8 of MLH1 (c.677G>T; p.Arg226Leu). It was therefore assumed that a 
tumour derived from this patient would be mismatch repair deficient and MSI-H. 
However, it had not been formally tested prior to this analysis. 
Conventional MSI tests were therefore performed to confirm the MSI status of all 
five Lynch Syndrome tumours. The kit used for the MSI test was the Promega MSI 
Analysis System, Version 1.2 kit (Promega, Madison, WI, United States of America). 
The results of the MSI assay confirmed that the tumours from patients U096, U179, U303, 
and U312 are MSI-H (see Table 3.5). The fragment analysis results for the tumour from 
patient U184 show that this tumour is MSS, indicating that is a sporadic tumour unrelated 
to the Lynch Syndrome associated predisposition. This is consistent with the results 
obtained from the sequencing of short homopolymers (see Figure 3.10). My 
interpretations of the fragment analysis traces was confirmed by Ottie O’Brien (Northern 
Genetics Service, Newcastle Hospitals NHS Foundation Trust). 
   NR‐21  BAT26  BAT25  NR‐24  MONO‐27 
U096 Tumour  unstable  unstable  unstable  unstable  unstable 
U179 Tumour  unstable  unstable  unstable  unstable  unstable 
U184 Tumour  stable  stable  stable  stable  stable 
U303 Tumour  unstable  unstable  unstable  unstable  unstable 
U312 Tumour  unstable  unstable  unstable  unstable  unstable 
Table 3.5: Results from a standard fragment analysis test results for tumours from Lynch Syndrome patients 
U096, U179, U184, U303, and U312. The test was performed using a Promega MSI Analysis System 
Version 1.2 kit. 
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Figure 3.10: Results from a standard fragment analysis test using a Promega MSI Analysis System Version 
1.2 kit. Panel A shows the test results for the U184 normal mucosa sample, and panel B shows the test 
results for the U184 tumour sample. There is no difference in the stutter pattern of the tumour and normal 
mucosa, both of which show a stutter pattern consistent with the absence of MSI. Therefore according to 
these fragment analysis results the U184 tumour sample is microsatellite stable (MSS).  
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3.2.9. Assessing the value of neighbouring SNPs  
The panel of homopolymers was selected to include SNPs with a high minor allele 
frequency in close proximity to each repeat. In heterozygous individuals it is therefore 
possible to distinguish between alleles for repeats where reads span both the repeat and 
the SNP. For homopolymers that show microsatellite instability in at least one of the MSI-
H samples, neighbouring heterozygous SNPs were used to investigate the distribution of 
variant reads between the two alleles. The aim was to determine whether MSI is an allele 
dependent event or if MSI affects both alleles. A SNP was not considered heterozygous 
if one allele had a read count of less than 10% of the total read count. The criteria that 
repeats were not analysed if one allele has less than 10% of the total read count was used 
because such an extreme allele imbalance might indicate sample contamination.  
For four of the homopolymers MSI was observed in at least one individual with a 
heterozygous SNP. In total, there are five instances where MSI is observed in a 
homopolymers with a neighbouring heterozygous SNP (see Figure 3.11 and Figure 3.12). 
In all five of these instances there was evidence of  bias between indel frequencies for the 
two alleles. The bias ranged from one allele showing 4.9 times the frequency of reads on 
one allele compared to the other allele (U179 tumour 1bp deletion, Figure 3.11 panel A) 
up to 8.4 times the frequency of reads on one allele compared to the other allele (U303 
tumour 4bp deletion, Figure 3.12 panel A).  
Some allelic imbalance is also present in the control samples. The U179 blood 
sample and U179 normal tissue have a 1bp deletion with a frequency of 5.63% and 4.17% 
respectively on one allele, and no reads with a 1bp deletion on the other allele for the 
homopolymer AL355154 (see Figure 3.11 panel B). But for neither U179 blood sample 
and U179 normal tissue does the fraction of reads containing an indel exceed 6% of the 
reads on an allele for the 10bp homopolymer AL355154. There is also a low read count 
in both instances with the AL355154 1bp deletion only being observed in 4 reads and 2 
reads for U179 blood an U179 normal tissue respectively. This amount of variant reads 
is not higher than the background PCR and sequencing error rate seen in 10bp repeats 
(see Table 3.4) and the allelic bias is lower than that observed in the MSI-H samples, 
suggesting that it may be caused by PCR error and stochastic events during PCR.  
The data presented so far suggests that MSI may show allelic bias, however more 
data would be required to confirm if MSI is an allelic event. If MSI is an allele dependent 
event where as PCR/Sequencing error effects both alleles, then for instances where a 
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patient is heterozygous for a SNP it should be possible to distinguish variants resulting 
from MSI from variants resulting from PCR/sequencing error when there is a sufficient 
read depth. For low read depths, distinguishing between MSI and sequencing/PCR error 
may be more problematic because a very small number of reads can make a large 
difference between allele frequencies, such as seen for the U179 control samples for the 
AL355154 homopolymer.   
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Figure 3.11: The percentage distribution of reads in three short repeats (9bp-10bp) with a neighbouring 
heterozygous SNPs in MSI-H tumours and matched normal mucosa and blood. These results show that 
there is an allele bias in the MSI-H tumours with one allele showing a higher frequency of a 1bp deletion 
compared to the other allele. 
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Figure 3.12: The percentage of reads corresponding to a 3bp and 4bp event in the presence of a heterozygous 
SNP in two Lynch Syndrome patients. These results show that there is an allele bias in the MSI-H tumours 
with one allele showing a higher frequency of reads corresponding to a 4bp deletion compared to the other 
allele. 
3.2.10. U303 allelic dropout and identity testing 
Due to discrepancies at SNP positions between the genotype of the U303 normal 
mucosa and the other U303 samples (see Figure 3.11 panel C, and Figure 3.12 panel A), 
an identity test was performed for to confirm that the U303 normal mucosa and U303 
blood sample are derived from the same individual. The identity test was performed using 
the Promega PowerPlex 16 kit (Promega, Madison, WI, United States of America). Due 
to the quality of the U303 normal mucosa DNA, the Powerplex 16 markers with alleles 
larger than 330bp did not amplify well. The identity test was therefore carried out using 
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12 out of the original 16 markers. The results of this test show that the U303 normal 
mucosa sample belongs to the same individual as the U303 Blood sample (see Figure 
3.13). A matched probability calculation estimated that the likelihood of the U303 normal 
mucosa originating from someone other than, and unrelated to the individual the U303 
blood sample was derived from is in the order of 1 in 3×1011. The matched probability 
calculation was performed using an FST value of 0.02 and the database size and allele 
frequencies from the NorthGene database (NorthGene Ltd, Newcastle upon Tyne, UK). 
The absence of one allele at the SNP positions for the sample U303 normal tissue is 
therefore most likely caused by allelic dropout caused by low copy number of starting 
material as a result of degraded DNA obtained from FFPE tissue. PCR amplification from 
poor quality template DNA can cause allelic biases with allele dropout (Wang et al., 
2012). The DNA for U303 normal tissue always produced the lowest amount of PCR 
product, which could suggest there was very little starting material for generating 
amplicons around 300bp in size. 
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Figure 3.13: The results of a PowerPlex16 identity test for U303 Blood sample and U303 Normal tissue. 
These results support the hypothesis that both samples belong to the same individual. Panel A: Identity 
markers for the U303 Blood sample. Panel B: Identity markers for the U303 Normal Mucosa 
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3.3. Discussion 
The aim of this initial work was to use short mononucleotide repeats, previously 
shown to exhibit MSI, to assess if microsatellite unstable tumours could be typed using a 
panel of short repeats sequenced using high throughput sequencing. In this chapter, it has 
been shown that it is possible to detect microsatellite instability using Illumina 
sequencing. The use of a sequencing based assay for the detection of MSI has been 
suggested previously. However prior to the start of this PhD project no data has been 
published to show that a panel of short repeats, sequenced by next generation sequencing, 
could be used to differentiate between MSI-H and MSS samples. The work conducted by  
(Cancer Genome Atlas Network, 2012) indicated it may be possible to type MSI using 
next generation sequencing. However investigating MSI was not the main focus of the 
(Cancer Genome Atlas Network, 2012) paper, and due to having trouble identifying 
unstable repeats using a variant caller, no in depth analysis was performed. Using a panel 
of 20 mononucleotide repeats ranging in size from 7bp to 15bp, and using post-hoc 
threshold values, it was possible to distinguish the MSI-H samples from the stable 
samples (see Figure 3.9). The thresholds used for calling a marker unstable were ≥10% 
of reads containing a deletion for 7-10bp repeats, ≥10% of reads containing a ≥2bp 
deletion for 11-13bp repeats, and ≥10% of reads containing a ≥3bp deletion for 14-15bp 
repeats. Furthermore, the single Lynch Syndrome tumour U184, which did not show 
instability was subsequently found to be MSS using a standard fragment analysis test (see 
Figure 3.10). Lynch Syndrome patients can develop MSS tumours (Giuffre et al., 2005). 
It was therefore not wise to assume that all five tumours from Lynch Syndrome patients 
analysed in this chapter would be MSI-H just because the patients had germline mutations 
in mismatch repair genes. 
Other than one insertion in the repeat APBB2 for the U179 tumour sample, there 
were no other insertion events where a substantial difference between MSI-H samples 
and normal controls was observed. There were, however, several different deletion events 
observed in MSI-H samples. This may suggest that deletions are more indicative of MSI 
than insertions. 
Interpretation of the data obtained so far indicates that shorter repeats are less 
susceptible to MSI, and susceptibility increases with repeat length. This is consistent with 
what is reported in the literature (Sammalkorpi et al., 2007, Vilkki et al., 2002, Woerner 
et al., 2003). For the 8bp repeats only two out of the six repeats were unstable in any of 
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the samples. Out of the six 9bp repeats, four showed instability in at least one sample. 
Whereas the unstable 8bp repeats only showed instability in one sample, one of the 9bp 
repeats showed instability in two samples. All of these results indicate that 9bp repeats 
are more prone to MSI than 8bp repeats. Both of the sequenced 10bp repeats showed 
instability. The 10bp repeats Avil and AL355154 were unstable in three and two out of 
the four MSI-H samples respectively. Each of the 11, 12, 13, and 14bp repeat were 
unstable in at least one of the MSI-H samples. Adding further evidence that susceptibility 
to MSI increases with length. However, one of the tumours, U096 tumour, only displayed 
instability in the 8bp and 10bp repeats.  
The results of this analysis suggest that PCR and sequencing error frequencies 
increase with homopolymer length. This is consistent with results by Fazekas et al. 
(2010), There are, however,  also large differences in error rates between repeats of the 
same length. This suggest that sequence context also plays a large role when it comes to 
sequence/PCR error rates. PCR replication of homopolymers is known to be prone to 
replication errors resulting from polymerase slippage (Clarke et al., 2001, Fazekas et al., 
2010, Flores-Renteria and Whipple, 2011). The effect of these errors on Sanger sequence 
data has been well documented (Fazekas et al., 2010, Flores-Renteria and Whipple, 2011). 
The fidelity of different Taq polymerases has also been investigated in attempts to reduce 
replication errors (Fazekas et al., 2010). To investigate the amount of PCR and 
sequencing error that could be expected from next generation sequencing data the 
frequency of variant reads for different homopolymer sizes were evaluated in a control 
exome. Based on this investigation it was concluded that that the levels of PCR and 
sequencing errors would be almost negligible up to repeat lengths of 10bp and it might 
still be possible to gain valuable information about MSI from repeats of up to 14-15bp. 
However the levels of background noise in my sequencing data is higher than seen 
in the control exome that was initially analysed for sequencing error (see Figure 3.1 and 
Table 3.4). The reason for this is likely to be due to the number of PCR cycles used in the 
initial PCR and during the library prep. Because of the low quality of DNA obtained from 
the FFPE samples and the relatively large amplicon sizes used (a requirement of the 
Nextera XT library prep), a large number of PCR cycles were needed to obtain a sufficient 
quantity of DNA for the Nextera XT library prep after PCR clean up. As a consequence 
the levels of PCR error are very high in the 11-15bp repeats and any 1bp deletions caused 
by MSI would be hard to distinguish from this background noise. Interestingly MSI 
appears to be manifest as larger 2-4bp deletions in these long repeats. At the deletion size 
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of 2bp where MSI is observed in the 11-12bp repeats, the background PCR error, 
measured as the frequency of reads in control samples, is low (see Figure 3.8). For the 
13-14bp repeats there is even more PCR error, but the MSI events are still identifiable. 
However as the 11bp and the 12bp repeat both show MSI in three out of the four MSI-H 
samples while the 13bp and 14bp repeat show instability in two and three of the MSI-H 
samples respectively, there does not seem to be much value gained by using repeats longer 
than 11-12bp. For the 15bp repeat there is so much PCR error that only a fraction of the 
reads correspond to the reference sequence in the control samples. Interestingly the FFPE 
derived DNA did not cause any higher level of PCR and sequencing error compared to 
the DNA derived from blood. This suggest that DNA degradation in FFPE tissues does 
not cause indel events in homopolymers. This means that FFPE tissues are suitable 
templates for a sequencing based MSI testing.  
For next generation sequence data there is the added complication of the use of a 
variant caller. In this chapter the problems of using a standard variant caller were avoided 
by developing a simple caller which makes no assumptions of data distributions for 
calling variants (ie. not looking for homozygotes heterozygotes etc.). The caller simply 
reports the number of paired-end reads corresponding to each variant. The only filtering 
which is used is that only matching overlapping paired-end reads are reported. The data 
were then analysed by eye after creating graphs in Microsoft Excel.  
As an additional tool for analysing MSI in short homopolymers, neighbouring 
SNPs were chosen to allow the analysis of individual alleles. However, there were only 
four instances where MSI was observed in a homopolymer with a heterozygous SNP. For 
each of these instances there was a bias between the alleles with one allele having >5x 
the frequency of reads compared to the other allele. This is expected as MSI is sometimes 
seen to affect a single allele, reflecting the origin of the length changes in a homopolymer 
as a one hit event, consistent with MSI being caused by random errors during DNA 
replication which are not rectified as opposed to a targeted event towards some 
microsatellites. These results suggest that SNPs may allow these events to be investigated 
in more detail. If this is the case then SNPs could be used as another tool to differentiate 
between sequencing/PCR error and MSI. This would of course be limited to instances 
where there was a heterozygous SNP. 
Analysing the SNP data revealed a complication with using degraded FFPE 
tissues that were not foreseen. For one of the samples, U303 normal tissue, there was 
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allelic dropout for some of the amplicons. This is most likely due to there being very little 
starting material to produce >300bp amplicons as a result of the DNA from that sample 
being very degraded. One of the challenges of genetic cancer diagnostics is obtaining 
good DNA from tumour specimens preserved by formalin fixation and paraffin 
embedding. As this process leads to the degradation and fragmentation of DNA. DNA 
fragmentation limits the PCR amplicon size that can be used. The degree of DNA 
degradation is dependent on the fixative used and its pH, the duration of fixation and how 
long the fixed specimen is stored and at what temperature (Gilbert et al., 2007). The 
failure rate of MSI tests are often not reported in the literature, but DNA degradation in 
FFPE tumour samples is a known reason for the failure of MSI tests (Snowsill et al., 
2014). In this chapter, the quality of DNA limited the number of MSI-H samples used as 
well as being the suspected cause of allelic dropout in one sample. Because of the library 
prep method chosen, PCR amplicons of >300bp were required. This meant that out of 
samples from eight Lynch Syndrome patients, only samples from five patients were of 
sufficient quality to produce PCR amplicons from both tumour and matched normal 
tissue. As a result the amount of data was limited by the number of samples of sufficient 
quality that were obtained. 
Three repeats containing SNPs with a high minor allele frequency that could cause 
length polymorphisms of the repeats were included by mistake (see section 3.2.2). None 
of these repeats were found to be polymorphic in any of the samples sequenced.  These 
three repeats were not found to be unstable in any of the MSI-H samples and were 
therefore not used in any subsequent analysis. 
3.3.1. Conclusions 
In Conclusion, it is possible to distinguish between the MSI-H and MSS stable 
samples using Illumina sequencing. These results show that creating a next generation 
sequencing MSI assay the using short homopolymers is feasible. Eleven out of the twenty 
homopolymers analysed were unstable in at least one MSI-H sample. For the 9bp 
homopolymers four out of six showed MSI for at least one sample, while both 10bp 
homopolymers showed MSI for at least one sample. These are probably the best lengths 
for an MSI test. However, the 8bp homopolymers that showed MSI had the least noise 
(sequencing/PCR error). 7bp repeats may also be of value because of low background 
error if they have a reasonable susceptibility to MSI. Unfortunately, not enough 7bp 
78 
 
repeats were sequenced to assess their susceptibility to MSI. 11bp and 12bp 
homopolymers were deemed interesting due to the prevalence of 2bp deletions. The 
repeat sizes selected for further study were therefore 7-12bp repeats. The next step will 
be to identify the most unstable 7-12bp repeats for an MSI assay. This will be addressed 
in the next chapter. 
A final MSI test will need robust thresholds for calling instability. In this chapter, 
arbitrary thresholds were set. For a final panel of homopolymers thresholds for defining 
markers as unstable will need to be calculated. Different repeat sizes will require different 
thresholds for the calling of microsatellite instability. It is also possible that individual 
repeats may require individual thresholds because the levels of PCR error vary for repeats 
of the same length. As the level of PCR error increases it will be increasingly difficult to 
differentiate between MSI-H samples and MSS samples. Because both the susceptibility 
of repeats to MSI and PCR error increases with repeat length a compromise between these 
factors has to made when choosing a final panel of repeats. Because only one repeat of 
each size from 11-15bp was sequenced there is very limited data for these repeat sizes. 
However, the results that were obtained suggest that even the 11bp and 12bp repeats are 
highly susceptible to MSI and not much is gained by analysing longer repeats than theses. 
It was therefore concluded that 7-12bp repeats would be the best lengths to use. The SNPs 
evaluated so far (SNPs in MSI-H samples with an unstable homopolymer) show that MSI 
occurred in one allele for those samples. This indicates that the second allele could be 
used as a negative control or a ratio of instability between two alleles could be 
incorporated into an MSI test. The number of markers for a MSI panel would have to be 
chosen taking into account the degree of instability of the markers. The number of 
markers needed for a panel will also depend on how susceptible the markers are to MSI 
events. To date there have been no attempts examine whole genome sequences to identify 
the most unstable short repeats for the use in an MSI test. This is the focus for chapter 4. 
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Chapter 4. Identification and analysis of highly 
variable homopolymers from next generation sequence  
4.1. Introduction and aims 
4.1.1. Introduction 
Changes in microsatellite lengths occur due to strand slippages during DNA 
replication that lead to the template strand and nascent strand aligning out of register 
(Ellegren, 2004). When DNA replication continues with the strands out of register the 
result is an insertion or deletion. Homopolymers are the most unstable repeat type in 
mismatch repair deficient cells (Lang et al., 2013, Yoon et al., 2013, Umar et al., 2004). 
This makes homopolymers the most suitable repeat for a sequencing based MSI test, and 
also makes homopolymers a good choice for studying MSI. In chapter 3 it was shown 
that there is a positive correlation between homopolymer length and instability in MSI-H 
samples. It is also well documented in the literature that in general the length of a repeat 
is positively correlated with mutation rates in MSI-H cancers (Ellegren, 2004, Lang et al., 
2013). However, there are also other factors that also play a role in the mutability of 
repeats such as repeat unit and sequence context. For example, G/C homopolymers have 
a higher mutability than A/T homopolymers (Ellegren, 2004, Sammalkorpi et al., 2007). 
The base composition of the sequence surrounding a microsatellite also plays a large role 
in the susceptibility of a repeat to MSI (Chung et al., 2010). For example, Harfe and Jinks-
Robertson (2000) found that altering the 3 bases on either side of a 10bp homopolymer 
had up to a fourfold effect on the stability of the homopolymer. Another example of 
sequence context having an effect on homopolymer stability is that closely situated 
homopolymers are more mutable than a single homopolymer of the same length (Lang et 
al., 2013, Ma et al., 2012). In chapter 3 it was established that the MiSeq platform is 
appropriate for sequencing homopolymers and detecting microsatellite instability, but the 
frequency of instability was variable among different homopolymers. The optimal 
homopolymer length for an MSI test is still unclear, and it not clear if the repeats that 
have been reported in the literature are the best markers for an MSI test, or how many 
will be needed. In addition, the appropriate thresholds for distinguishing instability and 
error remain to be defined. Analysis of whole genome sequences may be informative 
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because there are many factors that increase the susceptibility of a repeat to MSI and it 
would be advantageous to find the most unstable homopolymers.  
4.1.1.1. MSI within genes and intergenic regions 
Although whole genome sequence data has been generated from CRCs (Cancer 
Genome Atlas Network, 2012), the dynamics of MSI in colorectal cancer has not been 
investigated in detail using whole genome sequence data. Next generation sequencing has 
allowed the identification of a large set of more informative markers for the identification 
of MSI in colorectal cancer. The focus of the literature to date had however been on 
exonic repeats using RNAseq data and exome data (Cancer Genome Atlas Network, 
2012, Lu et al., 2013, Salipante et al., 2014, Terdiman et al., 2001). This limits the number 
of repeats that have been investigated, especially because less than 2% of the genome is 
coding, and homopolymers are under represented in exonic sequences compared to the 
rest of the genome (Borstnik and Pumpernik, 2002). There are also very few G/C 
homopolymers in the genome compared to A/T homopolymers (see Figure 4.1). 
Therefore, G/C homopolymers have not been studied in any great detail in MSI-H CRC 
samples because only investigating G/C homopolymers in coding sequences limits the 
numbers available for study. 
 
Figure 4.1: The frequency of different lengths of A/T and G/C homopolymers in the human genome. ▼G/C 
homopolymers. ● A/T homopolymers. This figure is modified from Dechering et al. (1998). 
In exons a mutation in a repeat is likely to affect the function of the cell, and many 
repeats are therefore highly conserved. Due to most exonic homopolymers being highly 
conserved, a larger number of variable homopolymers are likely to be found in intergenic 
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regions. A few mutations will be more common because they give a replication advantage 
to the tumour cells affected. For example two repeats that show high mutation rates in 
colorectal cancers are a 10bp poly A repeat in the TGFBR2 gene and a 8bp poly A repeat 
in the ACVR2 gene. These two repeats were not included in the initial analysis due to the 
lack of a close SNP with a high minor allele frequency, but they have been analysed in 
other studies. One study looking at colorectal cancer cell lines and xenographs found that 
22 out of 24 of the samples had a bi-allelic inactivation of the ACVR2 gene (Hempen et 
al., 2003). In 21 of the samples with bi-allelic inactivation there was a frameshift causing 
indel in the A8 repeat of ACVR2 exon 10 in at least one of the alleles. All 24 samples 
had an indel in at least one of the alleles of the A10 repeat in TGFBR2 (Hempen et al., 
2003). These mutations in these repeats will be over represented in MSI-H tumours 
because they cause frameshift mutations that inactivate tumour suppressor genes leading 
to increased tumour cell proliferation.  
Most mutations in coding homopolymers will affect the cell in a way that is not 
conducive to tumour cell proliferation and survival, leading to cells with theses mutations 
being selected against. Most highly unstable repeats in coding sequences are therefore 
limited to repeats where mutations do not lead to a survival disadvantage for tumour cells. 
It is therefore likely that there will be many more homopolymers that are highly variable 
in MSI-H tumours in intergenic regions which are not so highly conserved and where 
mutations are less likely to result in a negative selection pressure for cells. Furthermore, 
the sequence context is likely to be much more variable in non-coding regions, and this 
may affect repeat stability. For example, repeats situated within a few base pairs of each 
other are likely to be rare in coding sequences, and closely situated repeats that do not 
lead to a survival disadvantage for cells when mutated are likely to be rarer.  
Because there are many factors that increase or decrease the susceptibility of a 
repeat to MSI it would be advantageous to use whole genome sequences to select the most 
unstable repeats for MSI testing. Having a larger set of unstable homopolymers would 
also allow for homopolymers in close proximity to SNPs with a high minor allele 
frequency to be chosen for further study. This would benefit the analysis of the allelic 
distribution of MSI. Whole genome sequence data for MSI-H and MSS CRCs including 
matching normal tissue was available from The Cancer Genome Atlas Network. This data 
had not previously been mined for unstable homopolymers in CRCs because of problems 
identifying indels in homopolymers using standard variant callers (Cancer Genome Atlas 
Network, 2012). The problems which were encountered included PCR and sequencing 
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error in controls which made it harder to identify differences between controls and MSI-
H samples as well as the challenge of using standard variant callers to identify indels in 
repeats. The low coverage of the whole genome data (~3-4 fold sequence coverage) also 
makes it harder to distinguish PCR and sequencing errors from real mutations. In this 
chapter whole genome sequence data generated by The Cancer Genome Atlas Network 
is utilised to identify differences in homopolymer indel distributions between MSI-H 
tumours, matched normal tissue and MSS tumours. A list of unstable homopolymers is 
generated with information on neighbouring SNPs, which will later be used to identify 
homopolymers which are highly susceptible to MSI for further study. To overcome the 
challenges of using low coverage sequence data the variant calls from all tumour in each 
group were pooled prior to analysis. 
4.1.1.2. Accuracy of indel identification by variant callers 
Despite the availability of low pass whole genome sequence data for repeat 
identification, at the outset of this work there was no consensus as to the most appropriate 
variant caller for indel identification in homopolymers. A potential issue with identifying 
highly unstable homopolymers is that for indels there is still very little consistency 
between different variant callers (Li, 2014, O'Rawe et al., 2013). O'Rawe et al. (2013) 
assessed three different variant calling pipelines (SOAPindel, BWA-GATK, SAMtools) 
and discovered that there was only a 26.8% concordance between the indels being called 
using those pipelines. 28.5% of the indels were unique to GATK, 22.4% unique to 
SOAPindel, and 7.8% unique to SAMtools (O'Rawe et al., 2013). Pabinger et al. (2014) 
compared the number of indel calls made by CRISP, GATK, SAMtools, SNVer and 
VarScan 2, and they called 259, 1959, 234, 332 and 1896 indels respectively, with GATK 
and VarScan having the largest number of indels in common (~57%). More recently, 
Houniet et al. (2015) have evaluated the indel callers Samtools, Dindel and GATK for 
their ability to identify indels in exome sequences. The results of their analysis showed 
that Samtools had a sensitivity of less than 0.05 for identifying indels while GATK had a 
sensitivity of around 0.35 and Dindel had a sensitivity ranging from ~0.17 – ~0.38 
depending on which aligner was used. 
Sequencing and PCR errors are likely to cause problems for indel calling. There 
could be a lot of “noise” in the form of sequencing and PCR error around homopolymers, 
making it important to be able to pick out real indels from the background noise. Most 
83 
 
indel callers have advanced models for dealing with indels in homopolymers caused by 
PCR errors. However there is concern that PCR errors in homopolymers are still not being 
modelled well, with different variant callers calling different indels (Li, 2014). 
Another challenge when it comes to calling indels is obtaining the correct gapped 
alignment around indels. This is especially true for low complexity regions where 
realignment of indels is a large challenge (Li, 2014). As many homopolymers are present 
in low complexity regions, alignment problems can make it harder to differentiate 
between MSI and false positive indels. Li (2014) reported that 50-70% of the 
heterozygous indels detected in their CHM1 cell line sequence data would not exist with 
better realignment. Equally, true indels may be lost after being filtered out by low-
complexity filters. Another alignment problem can be caused because the human genome 
sequence still has gaps where sequence information is missing. Missing paralogous 
sequences can lead to incorrect alignments and the generation of errors (Li, 2014). 
Furthermore, most variant callers are geared towards bi-allelic genomes not 
cancer genomes with multiple alleles. This means that the programs are expecting variants 
in either a heterozygous or a homozygous form. This can lead to allele bias filters 
removing low frequency variants because they do not meet the criteria for being called 
heterozygous. 
Because of the limitations to indel callers mentioned above it will be important to 
assess available callers, select the most appropriate for identifying indels in 
homopolymers from whole genome data, and be aware of any limitations which may 
affect the selection of appropriate homopolymers for an MSI test. In chapter 3, repeats 
were analysed with a simple indel caller, COPReC, that addresses some of these issues, 
however this caller cannot be used on the whole genome sequence data because this caller 
uses overlapping paired end reads. Therefore, for the work conducted in this chapter 
another caller was needed. 
4.1.2. Aims 
At the outset of this work, no genome wide analysis of short homopolymer 
stability in CRCs had been performed, despite the availability of low pass sequence data. 
However, such an analysis would be required to identify the most variable and 
informative markers for use in a sequence based MSI test. The lack of consistency of 
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available variant callers was, however, a barrier to such an analysis. The aims for this 
work in this chapter are to: 
 Assess the three most commonly used variant callers Dindel, GATK and 
VarScan to find the most appropriate for indel discovery in homopolymers.  
 Assess the impact of size and homopolymer sequence upon PCR/sequencing 
error and instability in CRCs 
 Evaluate the indel distribution in 7bp-12bp homopolymers in MSI-H samples 
using whole genome sequence data.  
 Discover homopolymers that are highly variable in MSI-H samples, but not in 
control samples, to enable further assessment of these repeats for inclusion in a 
sequence based MSI test. 
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4.2. Results 
4.2.1. Comparison of variant callers 
To identify an appropriate indel caller for genome wide homopolymer analysis, 
firstly a single control exome sequence was analysed to compare the indel calling of 
Dindel (Albers et al., 2011), GATK (DePristo et al., 2011), and VarScan (Koboldt et al., 
2009). These are 3 of the most commonly used indel callers (Neuman et al., 2013). The  
Illumina reads generated from 1 normal control exome sequence were provided by Dr 
Mauro Santibaez-Koref, (Institute of Genetic Medicine, Newcastle University). The aim 
was to find parameters for indel calling that would allow MSI to be distinguished from 
microsatellite stability. 
For sequence alignment the Burrows–Wheeler Aligner (BWA) (version 0.6.2) (Li 
and Durbin, 2009) was used. Samtools (version 0.1.8) (Li et al., 2009) was used to create 
a sorted bam file and the pileup file needed for variant calling with Varscan. Variant 
calling from the pileup file was achieved using Varscan pilup2indel (version 2.2.2). 
Variant calling was also performed using Dindel (version 1.01) with the sorted bam file 
as input. Prior to indel calling using GATK duplicate sequences were removed from the 
sorted bam file using Picard (version 1.75) (PICARD [http://picard.sourceforge.net]). 
GATK (version 2.2.9) was then used to realign around indels before variant calling was 
performed using GATK’s UnifiedGenotyper (version 2.2.9) and the HomopolymerRun 
tool for annotation. See method sections 2.8.6 for further information about the methods 
used for variant calling.   
The differences in indel calling between Varscan, Dindel and GATK were initially 
assessed by seeing how many indels in homopolymer ≥6bp each program had found 
between positions 1-3395973 on chromosome 1 in the control exome sequence. This was 
achieved by looking through the VCF files and counting the number of homopolymers 
with indels that had been recorded by each program. Using the positional information for 
each homopolymer it was possible to identify which indels had been identified by more 
than one caller. 
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Figure 4.2: Indels called by the variant callers Dindel, VarScan and GATK between positions 1-3395973 
on chromosome 1 for one control exome sequence. 
Only 2 out of the 13 indels called by these three variant callers were found by all 
the variant callers (Figure 4.2). The differences in indel calling between Dindel, GATK, 
and VarScan shows that there is a difference in the algorithms these three programs use 
to call indels. This is consistent with reports in the literature that there are large 
differences in indel calling between different callers (Li, 2014, O'Rawe et al., 2013). This 
also confirms the need to select a caller that is appropriate for calling indels in 
homopolymers.   
Both GATK and Dindel have the option to annotate variants found in 
homopolymer runs. VarScan on the other hand does not contain this option. This means 
that the output (the Variant Call Files or VCF files) from VarScan could not easily be 
filtered for indels in homopolymers. VarScan was therefore not assessed further. To 
extract all relevant annotations in the VCF files generated by GATK and Dindel a Perl 
script was generated (Dindel_GATK_compare.pl) that identifies homopolymers >7bp 
using the homopolymer run annotations in the GATK and Dindel VCF files. This program 
then and counts and lists the indels that two VCF files have in common as well as counting 
and listing the indels that are unique to a VCF file using the chromosome and position 
data to determine if two indels are the same. For both Dindel and GATK variants are left 
aligned in homopolymers, so variants in the same homopolymer will be given the same 
position by both programs. This script was then used to compare the Dindel and GATK 
87 
 
indel calls from the control exome being analysed. The results of this comparison are 
shown in Figure 4.3  
 
Figure 4.3: The number of indels in homopolymers called by Dindel and GATK across one control exome 
sequence. 
There is a large difference in the number of indels in homopolymers >7bp called 
by Dindel and GATK, with Dindel identifying 8127 indels and GATK identifying 3121 
indels. There are also many indels calls that are unique to each program. The overlap of 
indels called by both programs consists of 78% of the indel calls made by GATK and 
30% of the indel calls made by Dindel. Because the differences in indel calling between 
programs are large an attempt was made to distinguish between the two methods in terms 
of their ability to detect indels within homopolymers that are likely to be real. To do this, 
this a set of criteria were defined to distinguish between indels which were likely to be 
false calls, and indels which looked real. This was done to enable the quality of indel calls 
for both programs to be assessed. The criteria used to determine if an indel was likely to 
be real or if it should be disregarded as a false indel can be found in Figure 4.4. The aim 
was to identify the variant caller that misses the least real indels and includes the least 
spurious indels. 
699 57052422
GATK      Dindel 
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Figure 4.4: Flow chart depicting a method for distinguishing between false and real indel calls.  
Using the flow chart shown in Figure 4.4 the first 15 indels were manually 
classified as “real” or “false positive” in each of the following categories: Indels called 
by both GATK and Dindel, Indels unique to GATK, and Indels unique to Dindel. The 
Integrative Genomics Viewer  (IGV) (Robinson et al., 2011) was used to visualise the 
89 
 
aligned reads for each indel in order to determine if the indel conformed to my criteria 
for a real indel. The results of this analysis can be found in Figure 4.5. 
 
Figure 4.5: A comparison between the variant callers GATK and Dindel. Indels that were deemed to be 
accepted if they passed the criteria found in the flow chart in Figure 4.4. The first 15 indels in each of the 
following categories: Indels called by both GATK and Dindel, Indels unique to GATK, and Indels unique 
to Dindel were analysed manually. 
Based on the results shown in Figure 4.5 GATK was deemed to be better than 
Dindel for analysing indels in homopolymers. This is because GATK had a larger number 
of indel calls that passed filter for the variants that were unique to the caller compared to 
Dindel for homopolymers ≤15bp.  60% of the indels unique to GATK pass filter (see 
Figure 4.5 panel E) as opposed to 38.5% for indels unique to Dindel (see Figure 4.5 panel 
D), and this only increases to 76.5% when both used (see Figure 4.5 panel F). So based 
on this limited analysis, GATK is superior for calling indels in homopolymers ≤15bp.  
Dindel had the largest number of indel calls (see figure Figure 4.3), but a higher rate of 
calls that did not pass filter for homopolymers ≤15bp compared to GATK would mean 
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that it would be harder to distinguish between MSI-H and MSS samples as there would 
be more false positive indel calls in both groups. 
Subsequent to the initial analysis of the variant callers and GATK being chosen 
as the most appropriate variant caller for identifying indels in homopolymers, a problem 
with GATKs variant calling was discovered. This problem was a fault in the 
HomopolymerRun annotation, which GATK uses to annotate homopolymer runs. 
Therefore GATK’s TandemRepeatAnnotator was used instead of the HomopolymerRun 
annotator for all subsequent analyses. This is likely to have made GATK even better at 
identifying indels in homopolymers than previously because some homopolymers were 
being missed using the HomopolymerRun annotator. 
4.2.2. Homopolymer analysis of CRCs and controls from TCGA whole genome 
data 
In order to study the indel distribution for different homopolymer lengths in MSI-
H colorectal cancers and compile a list homopolymers susceptible to MSI, analyses of the 
MSI-H tumour whole genome sequences was chosen and compared to matched normal 
and MSS whole genome sequences. The Cancer Genome Atlas Network (TCGA) 
produced the whole genome sequences used in this chapter. These sequences have an 
average ~3-4 fold sequence coverage, which means that it would be beneficial to pool the 
variant calls of all samples of the same type prior to analysing the data instead of 
analysing each sample separately. 
Low depth whole genome sequences consisting of 12 MSI-H tumours, 12 MSS 
tumours and matched normal tissue for 11 of the MSI-H tumours were mined for indels 
in all 7-12bp homopolymers using the Burrows–Wheeler Aligner (BWA) (version 0.6.2), 
Samtools (version 0.1.8), the GATK UnifiedGenotyper (version 2.2.9), and Perl scripts 
(see methods section 2.8.7). First, the BAM files obtained from TCGA were converted to 
fastq files using bam2fastq (version 1.1.0) (bam2fastq software 
[http://gsl.hudsonalpha.org/information/software/bam2fastq]). Then BWA was used to 
covert the fastq files to SAM files, which were then converted to BAM files and sorted 
using Samtools. Picard (version 1.75) was used to exclude sequence duplicates. GATK 
was then used to merge all BAM files creating a multi-sample BAM file and to perform 
a realignment around indels for the multi-sample BAM file. Realignment of all samples 
in a multi-sample BAM file was done to ensure consistent alignment of low pass data 
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from all samples. GATK’s UnifiedGenotyper was used to produce a file containing raw 
variant calls with GATK’s TandemRepeatAnnotater to annotate homopolymers. All 
homopolymers with known polymorphisms as of dbSNP (version 137, hg19) were also 
annotated. The selection of indel calls in 7-12bp homopolymers from the GATK variant 
call file was performed using the Perl script Perl_SelectVariants_RPA_RU.pl (see 
methods section 2.8.7.2). Analysis of read frequencies and indel size distributions were 
done using Perl scripts (see methods sections 2.8.7.2 and 2.8.7.3). Because of the low 
pass nature of the sequence data, all reads from each group (MSI-H samples, MSS 
samples and matched normal for the MSI-H samples) were combined before analysis. 
Any SNPs with a high minor allele frequency from dbSNP (version 137, hg19) (Sherry 
et al., 2001) within 30bp of the start of repeats were annotated using the Perl script 
AnnotateCloseSNPs.pl (see methods section 2.8.7.4). All homopolymers with known 
polymorphisms were excluded.  
218181 variable 7-12bp homopolymers were identified. A/T and G/C 
homopolymer  were analysed separately. 
4.2.3. Indel frequencies in A/T homopolymers from whole genome data 
To investigate the stability of short A/T homopolymers in tumours with mismatch 
repair defects at the genome level, the indel profiles of all A/T 7-12bp repeats called by 
GATK within whole genome sequence data from CRC tumours, after removal of all 
repeats with common polymorphisms (dbSNP version 173) were analysed. 216495 A/T 
homopolymers were identified. For the A/T homopolymers the distribution of variant 
read frequencies in the MSI-H tumours differed from those of the MSS tumours and 
matched normal samples for all homopolymer lengths investigated (see Figure 4.6). The 
distribution of variant read frequencies for the MSS tumours and matched normal samples 
are the similar (see blue and green lines Figure 4.6). Because the distribution of variant 
read frequencies is the same in both the control sample groups, but different in the MSI-
H samples (red line Figure 4.6) it is likely that the difference reflect MSI. 
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Figure 4.6: Frequencies of variant reads in homopolymers for MSI-H tumours, matched normal tissue, and 
MSS tumours. Only homopolymers with no known polymorphisms were included in this analysis. Panels 
A-F: Variant read frequencies in 7bp-12bp A/T homopolymers. 
The variant reads in the MSS tumours and matched normal samples in Figure 4.6 
are presumed to be caused mainly by sequencing and PCR error. For the 7bp-9bp repeats 
the peak of the curve for the MSS samples is at a variant read frequency of zero, which 
means that for a large number of repeats there has been no PCR/sequencing error detected 
(see Figure 4.6 panels A-C). For these repeats the number of homopolymers decreases 
with an increased frequency of variant reads until the graphs level out around at a variant 
read frequency of ~25%. For the 10bp-12bp repeats the peaks of the curve for the MSS 
tumours and matched normal samples is no longer at zero percent (see Figure 4.6 panels 
D-F). There has been a shift in the peak of the curve to 10% for the 10bp and 11bp repeats, 
and to 10%-15% for the 12bp repeats. This shift in the curve is presumed to be caused by 
an increase in PCR/sequencing error for these longer repeats. An increase in PCR error 
with repeat length is consistent with results from chapter 3 and results reported in the 
literature (Clarke et al., 2001, Fazekas et al., 2010, Flores-Renteria and Whipple, 2011). 
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The MSI-H samples had more variant reads than MSS and normal samples (see 
Figure 4.6). The distributions of variant reads vary, and the peak frequency increases 
steadily with homopolymer size. However, the range of the distribution also increases 
with homopolymer length. The peak of the curve for the MSI-H samples is at a higher 
variant read frequency compared to the control samples for all repeat lengths. This will 
be due to the presence of variant reads caused by MSI as well as variant reads caused by 
PCR/sequencing error. It is to be expected that the levels of PCR and sequencing error in 
the MSI-H samples would be equivalent to that observed in the controls for the same 
repeat length. 
The frequency of variant reads in the MSI-H samples increases with repeat length 
(see Figure 4.6). This is consistent with longer repeats being more prone to MSI 
(Sammalkorpi et al., 2007, Vilkki et al., 2002, Woerner et al., 2003). For the 7bp repeats 
the majority of microsatellite unstable repeats have a variant read frequency of between 
10%-25%. This increases with repeat length up to the 12bp repeats where the majority of 
microsatellite unstable repeats have a variant read frequency of between 30%-80%. 
4.2.4. Indel frequencies in G/C homopolymers from whole genome data 
For the G/C homopolymers there are so few homopolymers of each repeat length 
that it is more difficult to discern patterns in the data than it was for the A/T 
homopolymers. In total 1686 G/C homopolymers were identified after the removal of all 
repeats with common sequence length variants using dbSNP version 173. The distribution 
of variant reads for the MSS tumours and matched normal samples are the same in the 
7bp-10bp G/C homopolymers (see Figure 4.7 panels A-D). This suggests that there are 
enough homopolymers present for these repeat lengths to show the trends of the data. For 
the 11bp and 12bp homopolymers there are so few repeats that there is not enough data 
for a proper analysis (see Figure 4.7 panels E and F). 
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Figure 4.7: Frequencies of variant reads in homopolymers for MSI-H tumours, matched normal tissue, and 
MSS tumours. Only homopolymers with no known polymorphisms were included in this analysis. Panels 
A-F: Variant read frequencies in 7bp-12bp G/C homopolymers. 
The variant read distribution in the MSI-H samples differs from the distributions 
in the control samples, with the homopolymers in the MSI-H samples having a higher 
frequency of variant reads (see Figure 4.7). The results in Figure 4.7 show that, as 
observed with the A/T homopolymers, MSI increases with repeat length for the G/C 
repeats. Interestingly the MSI-H samples have a greater variant read frequency for the 
G/C homopolymers compared to the A/T homopolymers of an equivalent length (see 
Figure 4.6 and Figure 4.7). For example, most of the 9bp G/C homopolymers in the MSI-
H samples have a variant read frequency between 10% and 55%, whereas the 9bp A/T 
homopolymers in the MSI-H samples have a variant read frequency between 5% and 
45%. Also the shape of the curve for the 10bp G/C repeats in the MSI-H samples is more 
reminiscent of the curve for the 11bp or 12bp A/T repeats than the 10bp A/T repeats. The 
frequency of variant reads in the control samples also increase with repeat length (see 
Figure 4.7). These variant reads are presumed to be caused by PCR and sequencing error. 
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The frequency of variant reads for the control sample C/G homopolymers is also higher 
than for the equivalent A/T homopolymer repeat lengths (see Figure 4.6 and Figure 4.7).  
4.2.5. The distributions of indel sizes 
To investigate the size distribution of variant reads in MSI-H tumours, variant 
read lengths were analysed, and results for 7bp - 12bp A/T repeats are shown in Figure 
4.8. The prevalence of deletions is higher than insertions in the MSI-H sample group. 
This suggests that deletions are more indicative of MSI than insertions, and is consistent 
with results seen in gastric cancers (Yoon et al., 2013). As the repeat size increases the 
fraction of the indels that is made up of insertions dwindles until in the 10bp repeats the 
excess of 1bp insertions in the MSI-H tumours compared to the control samples is 
marginal (see Figure 4.8 panel D). In the 11bp and 12bp repeats there is no excess in 
insertions in the MSI-H samples compared to the controls (see Figure 4.8 panel E and F).  
For the 7bp, 8bp and 9bp homopolymers most of the deletions were 1bp in length 
(see Figure 4.8 panels A-C). However, there is an emergence of additional variant 
homopolymer lengths in the larger repeats (see Figure 4.8 panels D-F). In the 10bp and 
11bp repeats there are more 2bp deletions observed in the MSI-H samples compared to 
the controls. For the longer 12bp homopolymers there was a surplus of 1bp, 2bp and 3bp 
deletions in the MSI-H group compared to the controls. The deletions present in the 
controls are at a lower frequency than in the MSI-H samples, and as mentioned before are 
assumed to be derived from PCR artefacts and sequence error. In the control samples 
there are more deletions than insertions present for all repeat sizes (see Figure 4.8). 
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Figure 4.8: The indel distributions observed in the 7bp -12bp A/T homopolymers extracted from whole 
genome sequence data. Repeats were recorded as including an indel size if the indel was observed one or 
more reads. Panel A: The distribution of indels in the 7bp repeats. Panel B: The distribution of indels in the 
8bp repeats. Panel C: The distribution of indels in the 9bp repeats. Panel D: The distribution of indels in 
the 10bp repeats Panel E: The distribution of indels in the 11bp repeats. Panel F: The distribution of indels 
in the 12bp repeats. 
In general, the indels seen in the MSI-H samples are at a higher frequency than in 
the control samples (see Figure 4.9). For Figure 4.9 indel frequencies were deliberately 
but arbitrarily chosen for each repeat length to highlight the differences between MSI-H 
samples and controls. For the 7bp and 8bp A/T repeats there is a large excess of both 1bp 
deletions and 1bp insertions at a frequency ≥10%. As the repeat size increases the fraction 
of high frequency insertions diminishes, while there is an emergence of high frequency 
2bp and 3bp deletions in the MSI-H samples (see Figure 4.9). 
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Figure 4.9: The distributions of high frequency indels observed in the 7bp -12bp A/T homopolymers 
extracted from whole genome sequence data. Cut-offs of different indel frequencies for different repeat 
lengths were deliberately chosen to highlight differences between the MSI-H samples and controls. Panel 
A: The distribution of indels with a frequency ≥10% for the 7bp repeats. Panel B: The distribution of indels 
with a frequency ≥10% for the 8bp repeats. Panel C: The distribution of indels with a frequency ≥15% for 
the 9bp repeats. Panel D: The distribution of indels with a frequency ≥20% for the 10bp repeats. Panel E: 
The distribution of indels with a frequency ≥25% for the 11bp repeats. Panel F: The distribution of indels 
with a frequency ≥30% for the 12bp repeats. 
Because of the small number of 11bp and 12bp G/C homopolymers the indel 
distributions in these have not been analysed. In comparison to the A/T repeats of equal 
size, a greater fraction of the indels observed in the G/C repeats consist of insertions (see 
Figure 4.8 and Figure 4.10). In the G/C repeats, the fraction of indels consisting of 
insertions diminishes with increased repeat length, just as seen in the A/T repeats. The 
distribution of indels in the 7bp-9bp repeats consists of mainly 1bp deletions and 1bp 
insertions, with an excess of these indel sizes in the MSI-H samples compared to controls. 
In the 10bp repeats, there is an excess of 1bp and 2bp deletions in the MSI-H samples 
compared to the control samples (see Figure 4.10 panel D). The 10bp A/T repeats are also 
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the shortest repeats where an excess of 2bp deletions is seen in the MSI-H samples 
compared to controls. 
 
Figure 4.10: The indel distributions observed in the 7bp -10bp G/C homopolymers extracted from whole 
genome sequence data. Panel A: The distribution of indels in the 7bp repeats. Panel B: The distribution of 
indels in the 8bp repeats. Panel C: The distribution of indels in the 9bp repeats. Panel D: The distribution 
of indels in the 10bp repeats. 
For the G/C homopolymers there are also a much greater fraction repeats with 
high frequency indels in the MSI-H samples compared to the controls (see Figure 4.11). 
In the control samples there are more high frequency insertions than deletions in the 7bp-
8bp repeats. There is a larger difference in the number of high frequency deletions 
between the MSI-H samples and the control samples than the difference in number of 
high frequency insertions between the two groups. This suggests that, also for the G/C 
repeats, deletions are more indicative of MSI than insertions. 
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Figure 4.11: The distributions of high frequency indels observed in the 7bp -12bp G/C homopolymers 
extracted from whole genome sequence data. Panel A: The distribution of indels with a frequency ≥10% 
for the 7bp repeats. Panel B: The distribution of indels with a frequency ≥15% for the 8bp repeats. Panel 
C: The distribution of indels with a frequency ≥20% for the 9bp repeats. Panel D: The distribution of indels 
with a frequency ≥30% for the 10bp repeats. 
A file containing the 218181 variable 7-12bp homopolymers that were identified 
in this chapter can be found in the file Homopolymer_SNP_file_mmr7-12bp on the 
supplementary CD. This file also contains minor allele frequency annotations for any 
SNPs within 30bp of the start of each repeat. In the next chapter, this file will be used to 
identify 7bp-10bp homopolymers with a variant read frequency ≥10% in the MSI-H 
samples and no variant reads in the controls, and 11bp-12bp homopolymers with a variant 
read frequency ≥15% in the MSI-H samples and variant allele fraction of ≤5% in the 
controls. These repeats will be identified for further analysis of and possible inclusion in 
a sequence based MSI test.  
  
100 
 
4.3. Discussion 
Because no whole genome studies analysing indels in homopolymers had been 
performed for MSI-H colorectal tumours, in this chapter the indel profiles of 7-12bp 
homopolymers in 12 MSI-H colorectal tumours and controls were investigated. The aims 
of this analysis were to analyse the impact of homopolymer length and repeat unit on 
indel distributions in MSI-H colorectal tumours, and also generate a list of homopolymer 
that were found to be highly variable in MSI-H samples so that some of these repeats 
could be assessed in an independent panel of tumours later. In order to achieve these aims, 
an indel caller, which was appropriate for analysing indels in homopolymers was needed. 
To find a good indel caller three commonly used indel callers, VarScan, Dindel and 
GATK, were evaluated. 
The comparison between indel callers showed that there are differences in indel 
calls between the programs VarScan, Dindel and GATK with only 2 out of the 13 indels 
identified in a small stretch of exome sequence being called by all three programs. 
Because of this, comparisons were made to determine which program would be the most 
appropriate for calling indels in homopolymers using a control exome sequence. GATK 
was chosen as the most appropriate indel caller. This was because GATK had a higher 
ratio of indel calls that passed filter to indel calls that failed filter for homopolymers 
≤15bp compared to Dindel. VarScan was excluded because it had no annotations for 
homopolymer and it would therefore be difficult to single out indels in homopolymers 
using this caller. GATKs HomopolymerRun annotator was used in the initial assessment 
of variant callers, but GATKs TandemRepeatAnnotater was found to be better than the 
HomopolymerRun annotator because the HomopolymerRun annotator failed to annotate 
all homopolymers. The TandemRepeatAnnotater was therefore used for all subsequent 
analyses. Using GATKs UnifiedGenotyper and TandemRepeatAnnotater the distribution 
of variant read frequencies in the MSI-H tumours differed from those of the controls. The 
results from the comparisons between MSI-H samples and controls suggests that an 
appropriate indel caller was chosen. 
Using pooled low depth genome sequences the MSI-H samples were easily 
distinguishable from the controls (see Figure 4.6 and Figure 4.7). The distribution of indel 
frequencies in the matched normal and MSS samples were the same, and therefore the 
difference in the distribution in the MSI-H samples can be attributed to mutations 
accumulated due to failure of the mismatch repair system in the MSI-H tumours. There 
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were more indels in homopolymers in the MSI-H samples compared to the control 
samples and most of the indels in the MSI-H samples were found at a higher frequency 
than the indels in the controls. This suggests that most of the indels caused as a result of 
MSI occur at a higher frequency compared to indels caused by PCR and sequencing error. 
As the repeat length increases so does the frequency of variant reads in the MSI-H 
samples, but so does PCR/sequence error. There is therefore a trade-off between the 
susceptibility of repeats to MSI events and noise with increased repeat length. 
For all repeats, the fraction of high frequency indels consisting of deletions was 
higher than insertions (see Figure 4.9 and Figure 4.11). For both the A/T and the G/C 
homopolymers the fraction of indels consisting of insertions was highest in the 7bp 
homopolymers (see Figure 4.8 and Figure 4.10). This fraction decreases until in the 11bp 
repeats A/T repeats and the 10bp G/C repeats there is no longer more insertions in the 
MSI-H samples compared to the controls. These results suggest that deletions are more 
indicative of MSI than insertions. The distribution of deletion sizes changes with repeat 
length for 7bp-12bp homopolymers. For 7bp-9bp homopolymer MSI presents mostly as 
1bp deletions. In the 10bp and 11bp repeats there were some 2bp deletions as well as the 
1bp deletions. For 12bp homopolymers MSI is present in the form of 1bp, 2bp, and 3bp 
deletions. For the 10bp-11bp there were very few repeats in the control samples that 
contained high frequency 2bp and 3bp deletions (see Figure 4.9 and Figure 4.11). This 
suggests that these repeat sizes may be valuable in an MSI test because high frequency 
deletions ≥2bp in length are very indicative of MSI. 
There were a lot less unstable G/C homopolymers discovered compared to A/T 
homopolymers (216495 A/T homopolymers versus 1686 G/C homopolymers). This is 
consistent with the data reported by Yoon et al. (2013) in gastric cancers. This is expected 
because there are fewer G/C homopolymers in the human genome than A/T 
homopolymers (Dechering et al., 1998). A contributing factor could conceivably be that 
G/C homopolymers are also less susceptible to MSI than A/T homopolymers. However 
the literature gives evidence to the contrary (Ellegren, 2004, Sammalkorpi et al., 2007). 
In the paper Sammalkorpi et al. (2007) the G/C homopolymers investigated showed a 
higher rate of susceptibility to MSI compared to A/T homopolymers. Because of the extra 
hydrogen bond between guanine and cytosine slippage events for these bases should be 
less common during DNA replication. However A/T homopolymers in genomic DNA 
pack in such a way to allow bifurcated hydrogen bonds to form between bases as well as 
the usual hydrogen bonds (Nelson et al., 1987). This gives extra rigidity to the DNA 
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structure of A/T repeats and increases the kinetic energy needed to cause a slippage during 
DNA replication. This could be one of the explanations for why A/T repeats are less 
susceptible to MSI than G/C repeats. 
In concordance with the literature reporting that G/C homopolymers are more 
unstable than A/T homopolymers, my results show that 7bp-10bp G/C homopolymers are 
more unstable than the A/T homopolymers of the same lengths. The MSI-H samples have 
a greater frequency of variant reads in the G/C homopolymers compared to the same read 
length A/T homopolymers (see Figure 4.6 and Figure 4.7). Despite the G/C 
homopolymers having a comparatively higher indel frequency compared to the A/T 
repeats of the same size, the size distribution of deletions is similar for both repeat types. 
For example, the excess in 2bp deletions in the MSI-H samples compared to the controls 
is first seen in the 10bp repeats for both A/T and G/C repeats (see figures Figure 4.8 and 
Figure 4.10). 
4.3.1. Conclusions 
In conclusion, the frequency of variant reads in MSI-H colorectal tumours 
increased with homopolymer length for both A/T and G/C homopolymers. In the MSI-H 
tumours the number of homopolymers containing deletions was higher than the number 
of homopolymers containing insertions for all repeat lengths analysed. The deletions 
caused as a result of MSI occur at a higher frequency compared to the deletions found in 
normal controls, and in the larger repeat sizes deletions of 2bp and 3bp were observed in 
the MSI-H samples. Also 218181 of highly variable homopolymers have been identified 
for further analysis. Many of these are potentially suitable for a sequencing based MSI 
test. 
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Chapter 5. Assessing next generation sequencing of 
short homopolymers identified from whole genome 
sequence data in microsatellite unstable tumours 
5.1. Introduction and aims 
5.1.1. Next generation sequencing of MSI-H tumours in 2013- 2014 
In chapter 4 low depth whole genome sequences consisting of 12 MSI-H tumours, 
12 MSS tumours and matched normal tissue for 11 of the MSI-H tumours were analysed. 
Because of the low coverage of the whole genome data (~3-4 fold sequence coverage) 
variant calls from all tumour in each group were pooled prior to analysis.  A list of indels 
in 7-12bp homopolymers was generated containing the frequencies of variant reads in 
each sample group for all repeats. The list of indels was annotated with all SNPs as of 
dbSNP (version 137, hg19) (Sherry et al., 2001) within 30bp of the start of the repeats. A 
total of 218,181 variable 7-12bp homopolymers were identified. The most variable of 
these are potentially suitable for a next generation sequencing based MSI test. It is not 
clear if the short homopolymers that have been reported in the literature are the best 
markers for an MSI test. There could potentially be more unstable repeats among the 
218,181 repeats identified in chapter 4. In this chapter, the aim is to sequence some of the 
repeat identified in the whole genome analysis in a small panel of tumours enabling the 
most unstable repeats to be selected for a sequencing based MSI test. 
The first paper to illustrate the potential use of next generation sequencing for 
detecting MSI was The Cancer Genome Atlas Network (2012). More papers expanding 
on this work were published after the whole genome analysis in chapter 4 was conducted 
(Lu et al., 2013, Niu et al., 2014, Salipante et al., 2014, Yoon et al., 2013). Yoon et al. 
(2013) analysed MSI in gastric cancers and gastric cancer cell lines using RNA 
sequencing. They also performed whole genome sequencing of 3 MSI-H and 3 MSS 
gastric cancer cell lines. In concordance with results in chapter 4, Yoon et al. (2013) found 
that mutations in mononucleotide repeats that are caused by MSI consist mainly of 
deletions. Yoon et al. (2013) also reported that the susceptibility of mononucleotides to 
MSI is dependent on repeat length with longer repeats being more prone to MSI, which 
is consistent with the results from my whole genome analysis.  
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In their study Yoon et al. (2013) discovered mononucleotide repeats with 
deletions in MSS cell lines and concluded that mismatch repair deficiency may not be the 
only factor that affects the frequency of deletions in mononucleotide repeats in gastric 
cancers (Yoon et al., 2013). 27.2% of the deletions identified in all 3 MSI-H gastric cancer 
cell line whole genome sequences were also seen in MSS gastric cancer cell lines (Yoon 
et al., 2013). A few markers with deletions in stable tumours will therefore most likely 
have to be taken into account when developing a test for colorectal cancers.  
Methods other than using a set panel of short repeats for an MSI test have also 
been suggested (Lu et al., 2013, Niu et al., 2014, Salipante et al., 2014). Using RNA-Seq 
data Lu et al. (2013) found that the proportion of microsatellite insertions over all 
insertions divided by the proportion of microsatellite deletions over all deletions could be 
used to reliably predict the MSI status of MSI-H and MSS tumours. Niu et al. (2014) have 
developed a software tool (MSIsensor) for differentiating between MSI-H and MSS 
tumour samples when given tumour and matched normal whole genome sequences. A 
similar approach has been developed by Salipante et al. (2014). They have developed a 
pipeline (mSINGS) that can determine a sample’s MSI status using exome sequence data 
or sequence data from the capture panels ColoSeq and UW-OncoPlex. The mSINGS 
software analysis uses a panel of mononucleotide repeats specific to each of the three 
sequencing approaches and calls MSI based on the fraction of mononucleotide repeats 
that show the emergence of new variant read lengths. Repeats are classed as unstable if 
the number of variant read lengths exceed the mean number of read lengths + 3x the 
standard deviations measured in control samples. Approaches like this may be used in the 
future if performing whole genome sequencing, exome sequencing or gene panel 
sequencing of all tumours becomes an economically viable and routine method for 
analysing colorectal tumours. However in the near future sequencing a small a panel of 
short repeats will be a more cost effective way of determining the MSI status of cancers. 
The number of markers in such a repeat panel will have to reflect how susceptible to 
microsatellite instability the markers are. One thing to consider will be that a shorter 
microsatellite will produce less PCR error whereas larger microsatellites are more 
susceptible to MSI. 
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5.1.2. Receiver operator characteristics as a method for assessing the ability 
short homopolymers for differentiating between MSI-H and MSS tumours 
Receiver Operator Characteristics (ROC) curves are curves where the true 
positive rate (sensitivity) is plotted against the false positive rate (1-specificity) for a range 
of different threshold values. ROC are used for data that can be classified using binary 
classification as either positive or negative for a trait. In this chapter the trait of interest is 
microsatellite instability. ROC curves can be an important tool for evaluating thresholds 
of diagnostic tests. These curves are used as a visual aid for analysing the sensitivity and 
specificity for different thresholds. Setting thresholds is often a trade off between 
sensitivity and specificity. If a high threshold is chosen there is a risk that some 
individuals with the disease but low test values will be missed. In this case the specificity 
of the test will be high at the expense of sensitivity. On the other hand if thresholds are 
set low there could be a risk of individuals without the disease receiving a positive test 
result. In this case the specificity of the test would be low to facilitate a higher sensitivity.  
For a ROC curve the true positive rate is plotted along the y axis and the false 
positive rate is plotted along the x-axis. Each point along the curve represents the true 
positive and false positive rate at a given threshold. For the work in this chapter the 
frequency of reads containing deletions will be used for the thresholds. Therefore each 
the ROC curves would show the true positive and false positive rate across a range of 
deletion frequency thresholds. The samples would be plotted in order of decreasing 
deletion frequencies. Each MSI-H sample would be plotted as an increase in the true 
positive rate and each MSS sample would be plotted as an increase in the false positive 
rate. An example of a ROC curve can be found in Figure 5.1. 
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Figure 5.1: ROC curve 
The area under the receiver operating characteristic curve (AUC) is a measure of 
how well a test can differentiate between individuals that have a disease and individuals 
that do not have the disease. In this chapter AUC is employed to evaluate the ability of 
individual homopolymers for differentiating between MSI-H and MSS tumours. An AUC 
of 1 would indicate that all MSI-H samples have a higher deletion frequency than the 
MSS samples. On the other hand an AUC value of 0.5 would mean that a repeat has no 
discrimination power because there would be 50-50 chance that any randomly chosen 
MSI-H sample would have a higher deletion frequency than any randomly chosen MSS 
sample. Possible AUC values range between 0 – 1, and any AUC vale of x indicates that 
there is an x ×100 percent chance that any randomly chosen MSI-H sample would have 
a higher deletion frequency than any randomly chosen MSS sample.    
5.1.3. Aims 
In chapter 3 it was established that short mononucleotide repeats (7bp-14bp) are 
susceptible to microsatellite instability and that these short repeats might be used to 
differentiate between MSI-H and MSS samples using next generation sequencing on the 
Illumina MiSeq platform. It was also shown that by using neighbouring SNPs it is 
possible to distinguish between the two alleles for repeats with a neighbouring 
107 
 
heterozygous SNP to determine which allele contains the variant reads. Using this 
technique it will be shown that there may be an allelic bias for variant reads of repeats 
affected by MSI. However, due to the low number of unstable repeats in the chosen panel 
of MSI-H tumours, only 5 examples of repeats with a heterozygous SNP were available 
for study. In chapter 4 whole genome sequence data from MSI-H colorectal cancers were 
mined to identify new homopolymers that are highly variable in MSI-H tumours and have 
closely situated neighbouring SNPs with high minor allele frequencies. In this chapter, 
approximately 100 of the newly discovered repeats are tested to assess their variability in 
a small panel of tumours. This was done to find out if these repeats are unstable in a 
different panel of MSI-H tumours. In this chapter the targets are: 
 Using the list of unstable repeats generated from the whole genome analysis in 
chapter 4, select homopolymers that show a high frequency of variant reads in 
MSI-H tumours for sequencing in a small panel of MSI-H tumours and controls. 
 
 Assess the level of instability in the chosen repeats in the new panel of tumours 
to enable the selection of the most variable repeat for use in a future sequencing 
based MSI test. 
 
 Evaluate the use of SNPs for analysing allelic distribution of MSI in a larger 
panel of repeats. 
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5.2. Results 
5.2.1. Choosing repeats identified in the whole genome analysis for 
investigation in a new panel of MSI-H tumours 
A total of 218,181 variable 7-12bp homopolymers were identified from the whole 
genome analysis in chapter 4. To validate specific repeats for MSI detection, some of the 
most unstable homopolymers identified in the whole genome analysis were selected for 
further analysis. The list of 218,181 variable 7-12bp homopolymers was narrowed down 
by filtering for repeats with a read depth ≥20x in each group (MSI-H, matched normal for 
the MSI-H samples, and MSS samples). Repeats with common polymorphisms (dbSNP 
version 173, hg19) (Sherry et al., 2001) were excluded. 7-10bp repeats were selected if 
they had a variant read fraction of 10% or higher in the MSI high sample group and no 
variant reads in the controls. For the 11-12bp repeats were selected if they had a variant 
read fraction of 15% or higher in the MSI-H samples and a variant read fraction of ≤5% 
in the controls. A variant read fraction of ≤5% in 11-12bp repeats was presumed to be 
caused by sequencing and PCR error. Homopolymers with low indel frequencies in the 
control samples were desired because it would be easier to cope with repeats with a low 
background error rate. It is presumed that variation in background errors could to some 
extent be attributed to sequence context.  
The Perl script AnnotateCloseSNPs.pl was used to annotates SNPs within 30bp 
of the start of repeats (see methods section 2.8.7.4 for further detail). Homopolymers were 
selected to insure the inclusion of SNPs with a high minor allele frequency within 30bp 
were selected. If there were more than one SNP detected within 30bp of a repeat, the 
minor allele frequencies were added together as a quick method to assess the value of the 
SNPs. Repeats were only selected if there were SNPs within 30bp of the repeat with minor 
allele frequencies, which summed up to least a frequency of 0.2. In total 529 A/T 
homopolymers fitted these criteria. Because there were few G/C homopolymers in the 
data set the criteria for including SNPs within 30bp of the repeat was omitted and the 
requirement for a read depth ≥20x in each group was relaxed. This resulted in a data set 
of 33 G/C homopolymers.  A list of all these repeats can be found on the supplementary 
CD (File names: “GC_SNPfile_sorted.xlsx” and “AT_SNPfile_sorted.xlsx”).  
The UCSC Genome browser (Kent et al., 2002) was used to assess the possibility 
of creating primers for the homopolymers that passed the above criteria. Many of the 529 
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A/T homopolymers and 33 G/C homopolymers that met the selection criteria above were 
situated in regions of low complexity such as LINES and SINES, which limited the 
number of repeats where primers could be produced without the risk of miss-priming. 
The 120 most variable repeats for which suitable primers could be produced were selected 
to assess the utility of these specific mononucleotides for sequence based detection of 
MSI repeat length variation. 
The selected 120 unstable mononucleotide repeats (7-12bp) were amplified from 
FFPE tissue and sequenced using the Illumina MiSeq. The FFPE tissues consisted of a 
selection of 6 Lynch Syndrome tumours, matching normal mucosa for 5 of these tumours, 
and 6 MSS tumours (see Table 5.1). Up to 120 repeats were amplified for each sample. 
For the matched normal tissue there was too little material to enable the sequencing of all 
120 repeats so this material was only used for a selection of repeats. For the other samples 
the amount of available DNA was also in a limited supply. ~300bp amplicons were 
produced using the high fidelity Pfu-based Herculase II Fusion DNA polymerase and 35 
PCR cycles. Amplicons were quantified using Qiagen QIAxcel, then pooled at a roughly 
equimolar concentration. Agencourt AMPure XP beads were used for PCR clean-up. 
After PCR clean-up the amplicon pools were diluted to a concentration of 0.2ng/μl before 
Library Prep using the Illumina Nextera XT kit (Illumina, San Diego, CA, United States 
of America). 
Samples  Sample Type  Lynch Syndrome Patients Number 
U029 Tumour  Lynch Syndrome Tumour  U029 
U096 Tumour  Lynch Syndrome Tumour  U096 
U179_H03 Tumour  Lynch Syndrome Tumour  U179 
U179_H12 Tumour  Lynch Syndrome Tumour  U179 
U303 Tumour  Lynch Syndrome Tumour  U303 
U312 Tumour  Lynch Syndrome Tumour  U312 
U029 Normal  Normal Mucosa  U029 
U096 Normal  Normal Mucosa  U096 
U179 Normal  Normal Mucosa  U179 
U312 Normal  Normal Mucosa  U312 
169259  MSS tumour  n/a 
169736  MSS tumour  n/a 
169836  MSS tumour  n/a 
170146  MSS tumour  n/a 
170402  MSS tumour  n/a 
171223  MSS tumour  n/a 
Table 5.1: Tissue samples consisting of Lynch Syndrome tumours, matching normal tissue for the Lynch 
Syndrome tumours and MSS tumours. 
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A list containing the 120 mononucleotide repeats can be found in table Table 5.2. 
Primer design, PCR amplification and the QIAxcel quantification for 75 of the 
homopolymers was carried out by the students Ghanim Alhilal (Institute of Genetic 
Medicine, Newcastle University) and Iona Middleton (Institute of Genetic Medicine, 
Newcastle University) under my supervision. I did primer design, PCR amplification and 
the QIAxcel quantification for the remaining 45 homopolymers. Many of the failed PCRs 
for both students were repeated by me.   
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Repeat Name  Repeat Size   Repeat Position  SNP1   SNP2  SNP3 
GM04  7bp  chr13:92677561  rs9560900       
GM19  7bp  chr11:114704378  rs142833335  rs190597109  rs10502196 
GM24  7bp  chr10:117432196  rs2532728       
GM25  7bp  chr3:110871917  rs74593281  rs6437953  rs188039266 
GM27  7bp  chr11:85762247  rs669813  rs181565251  rs146406522 
GM30  7bp  chr14:53111542  rs12880534       
IM13  7bp  chr2:235497098  rs6721256  rs183025093  rs187312036 
IM14  7bp  chr7:80104530  rs11760281       
IM19  7bp  chr9:82475000  rs72736428  rs186539440  rs4877153 
IM20  7bp  chr13:57644695  rs6561918       
IM22  7bp  chr7:90135495  rs10487118  rs10487117  rs139214151 
IM23  7bp  chr6:72729530  rs557365       
IM26  7bp  chr3:166053586  rs2863375       
IM27  7bp  chr7:35079238  rs4723393  rs112516918    
IM43  7bp  chr21:32873760  rs9981507       
IM55  7bp  chr3:143253844  rs13099818       
IM61  7bp  chr12:73576422  rs34696106       
IM66  7bp  chr17:48433966  rs147847688  rs141474571  rs4794136 
IM67  7bp  chr7:22290894  rs67082587  rs57484333    
IM69  7bp  chr9:92765722  rs1036699       
LR04  7bp  chr1:4677109  rs113646106  rs2411887    
LR06  7bp  chr18:20089449  rs501714       
LR08  7bp  chr11:56546205  rs181578273  rs7117269    
LR13  7bp  chr8:21786971  rs2127206       
LR15  7bp  chr8:92077209  rs56084507       
LR25  7bp  chr16:63209545  rs76192782  rs79880398  rs4949112 
LR45  7bp  chr2:226938121  rs180896305  rs1522818  rs144175764 
LR47  7bp  chr10:20506728  rs11597326  rs12256106    
LR49  7bp  chr15:93619047  rs80323298  rs201097746  rs12903384 
LR50  7bp  chr2:76556320  rs925991  rs144630203    
LR51  7bp  chr10:51026724  rs8474       
GM03  8bp  chr4:120206446  rs17050454  rs10032299    
GM08  8bp  chr21:36575085  rs2834837  rs115025058    
GM09  8bp  chr20:6836976  rs6038623       
GM16  8bp  chr6:100743595  rs7765823       
GM20  8bp  chr7:142597494  rs6961869  rs6961877    
IM15  8bp  chr6:91455181  rs1231482       
IM21  8bp  chr1:215136389  rs181787229  rs1901621  rs1901620 
IM25  8bp  chr12:24568356  rs10771087       
IM39  8bp  chr2:103233866  rs76771828  rs190979688  rs187315716 
IM40  8bp  chr4:84074813  rs10516683       
IM41  8bp  chr6:147948940  rs1944640  rs112075239    
IM57  8bp  chr3:81210016  rs35085583       
IM59  8bp  chr8:108359000  rs10156232       
IM63  8bp  chr3:115816065  rs34764455       
IM68  8bp  chr12:129289692  rs10847692       
LR02  8bp  chr4:134947775  rs189671825  rs192703656  rs1494978 
LR18  8bp  chr1:220493934  rs191265856  rs199830128  rs74940412 
LR19  8bp  chr12:29508668  rs10843391  rs186762840    
LR20  8bp  chr1:64029633  rs146973215  rs191572633  rs217474 
LR27  8bp  chr4:72877514  rs55894427  rs74733006    
LR31  8bp  chr3:62995577  rs183248146  rs2367592    
LR46  8bp  chr20:10660084  rs143884078  rs182346625  rs6040079 
GM05  9bp  chr2:216770762  rs6704859       
GM06  9bp  chr16:77496517  rs6564444  rs143453795  rs145573459 
GM10  9bp  chr1:59891623  rs946576  rs182557762    
GM11  9bp  chr5:166099890  rs347435       
GM15  9bp  chr7:97963736  rs6465672       
GM17  9bp  chr11:95551110  rs666398       
GM21  9bp  chr3:142695338  rs185182       
GM23  9bp  chr5:11345920  rs184237728  rs32123    
GM28  9bp  chr5:29209380  rs4130799       
IM16  9bp  chr18:1108766  rs114923415  rs73367791  rs59912715 
IM17  9bp  chr13:31831504  rs932749       
IM42  9bp  chrX:96502620  rs1409192       
IM44  9bp  chr12:9797065  rs201750704  rs4763716    
LR05  9bp  chr2:10526616  rs111286197  rs13431202    
LR10  9bp  chr1:81591387  rs111814302  rs1768398  rs1768397 
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LR14  9bp  chr17:69328494  rs9895642       
LR21  9bp  chr15:50189464  rs182900605  rs80237898  rs2413976 
LR24  9bp  chr1:153779428  rs192329538  rs1127091    
LR28  9bp  chr12:81229785  rs185642078  rs28576612  rs10862196 
LR34  9bp  chr3:115377097  rs187521190  rs192106258  rs9883515 
LR40  9bp  chr2:13447469  rs6432372       
GM01  10bp  chr11:28894428  rs7951012       
GM22  10bp  chr14:43401009  rs58274313       
GM26  10bp  chr14:49584750  rs187027795  rs11628435    
GM29  10bp  chr3:70905559  rs2687195       
IM07  10bp  chr6:100701947  rs189035042  rs6915780    
IM12  10bp  chr8:23602937  rs389212       
IM33  10bp  chr8:25731926  rs202225742  rs35644463  rs113180202 
IM34  10bp  chr7:83714718  rs1524881       
IM35  10bp  chr11:84425221  rs67283158  rs10792775  rs116387070 
IM37  10bp  chr17:50813569  rs2331498       
LR26  10bp  chr16:80050257  rs4889066  rs187883346    
LR29  10bp  chr6:78198348  rs1778257       
LR30  10bp  chr11:105445091  rs7933640       
LR32  10bp  chr19 :37967219  rs7253091       
LR35  10bp  chr8:130384501  rs4733547       
LR39  10bp  chr17:66449341  rs2302784       
GM02  11bp  chr1:116246109  rs10802173  rs148789685    
GM07  11bp  chr7:93085747  rs2283006       
GM13  11bp  chr12:107492626  rs34040859  rs77265275  rs201488736 
GM14  11bp  chr3:177328817  rs6804861       
IM28  11bp  chr9:5122910  rs10815163       
IM32  11bp  chr18:42045500  rs8087346       
IM45  11bp  chr4:99545419  rs189419054  rs2178216    
IM52  11bp  chr21:22846823  rs74462385  rs9982933  rs2155801 
IM53  11bp  chr9:20662629  rs182630429  rs140426089  rs12352933 
IM54  11bp  chr21:33710014  rs13046776       
IM65  11bp  chr13:25000863  rs7324645  rs9511253    
LR01  11bp  chr13:97387479  rs1924584  rs4771258    
LR11  11bp  chr2:217217870  rs13011054  rs147392736  rs139675841 
LR12  11bp  chr14:47404235  rs187434561  rs144159314    
LR16  11bp  chr3:8522416  rs148171413  rs6770049    
LR17  11bp  chr14:55603030  rs79618905  rs77482253  rs1009977 
LR23  11bp  chr2:142013941  rs434276  rs146141768    
LR33  11bp  chr4:138498649  rs200714826  rs4637454  rs111688169 
LR48  11bp  chr12:77988096  rs11105832       
GM18  12bp  chr10:8269565  rs113251670  rs189036006  rs533236 
IM47  12bp  chr21:22734436  rs2588655  rs149325240  rs232496 
IM49  12bp  chr3:56682065  rs7642389       
IM50  12bp  chr20:37048155  rs1739651  rs145870165    
IM51  12bp  chr5:128096988  rs4836397       
IM64  12bp  chr16:14216095  rs201451896  rs112858435  rs75477279 
LR36  12bp  chr4:98999722  rs182020262  rs17550217    
LR41  12bp  chr4:34074106  rs190518698  rs6852667    
LR43  12bp  chr5:86199060  rs201282399  rs10051666  rs6881561 
LR44  12bp  chr10:99898285  rs78876983  rs7905388  rs7905384 
LR52  12bp  chr16:63861440  rs2434849       
Table 5.2: A list of the 120 mononucleotide repeats sequenced. This list contains the designated repeat 
names, the length and location (genome build hg19) of each mononucleotide repeat, and the rs numbers of 
neighbouring SNPs. The repeat name indicates who performed the primer design and PCR amplification 
(GM= Ghanim Alhilal, IM= Iona Middleton, and LR = Lisa Redford). 
For the MiSeq run a MiSeq Reagent Kit (v3 600-cycles) (Illumina, San Diego, 
CA, United States of America) was used. Sequencing was done on the Illumina MiSeq to 
an average read depth of >10000 paired end reads per amplicon. A cluster density of 1604 
K/mm2 was achieved on the Illumina flow cell and a Q-Score of over 30 was obtained for 
60.6% of the bases sequenced (see Figure 5.2). There was a drop in Q-Score towards the 
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latter cycles (see Figure 5.3). This is believed to be due to reaching the end of some of 
the amplicons being sequenced. A total read depth of 30,107,152 was obtained across all 
samples for this MiSeq run. The sample U179_H12 tumour had the lowest read depth 
with 468,565 reads and the sample 169259 had the highest total read depth of 4,047,041 
reads. 
 
Figure 5.2: The quality score (Q-Score) distribution for the reads generated on the MiSeq. Blue = bases 
with a Q-Score <30, Green = bases with a Q-Score >30. 
 
Figure 5.3: The quality score (Q-Score) distribution for each cycle showing a drop in Q-Score towards the 
later cycles of each read. 
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Variant calling was performed using the variant caller COPReC, run by Dr Mauro 
Santibanez-Koref (Institute of Genetic Medicine, Newcastle University). This is the same 
variant caller that was used in chapter 3 (see methods section 2.8.6.2). Graphs were only 
created for repeats with a minimum of 100 paired end reads spanning the repeat. The 
criteria of a minimum of 100 paired end reads was used to prevent a misrepresentation of 
variant frequencies caused by PCR duplicates which may happen at low read depths. 
5.2.2. Fragment analysis to determine the MSI status of Lynch Syndrome 
tumours 
To confirm the MSI status of the Lynch Syndrome samples used in this chapter a 
standard fragment analysis was carried out on all of these samples using the Promega 
MSI Analysis System Version 1.2 kit (Promega, Madison, WI, United States of America).  
The fragment analysis traces for tumours and matching normal tissue from 
patients U029 and U179 can be found below in Figure 5.4. Two tumours were analysed 
for patient U179. These are two separate tumours, one of which was removed from the 
patient in 2003 and the other in 2012. The U029 tumour and both U179 tumours had 
instability at all five markers confirming the diagnosis as MSI-H (see Figure 5.4). My 
interpretations of the fragment analysis traces was confirmed by Ottie O’Brien (Northern 
Genetics Service, Newcastle Hospitals NHS Foundation Trust). 
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Figure 5.4: Results for the U029 and U179 tumours using a standard fragment analysis test. Panels A and 
B show results for the U029 normal mucosa sample and tumour sample respectively, Panels C and D show 
results for the U179 normal mucosa sample and the U179_H03 tumour sample respectively, Panels E and 
F show results for the U179 normal mucosa sample and the U179_H12 tumour sample respectively. 
The fragment analysis traces for tumours and matching normal tissue from 
patients U312, U303 and U096 can be found in Figure 5.5. The U312 Tumour was 
confirmed as being MSI-H with instability detected at three markers (BAT26, BAT25 
and NR-24) (see Figure 5.5 panels A and B). The U303 tumour was also confirmed as 
being MSI-H with instability detected at all five markers (see Figure 5.5 panels C and D). 
The U096 tumour on the other hand did not show any instability at any of the marker (see 
Figure 5.5 panels E and F). The classification of the three tumours from patients U312, 
U303 and U096 was confirmed by Ottie O’Brien (Northern Genetics Service, Newcastle 
Hospitals NHS Foundation Trust).  
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Figure 5.5: Results for the U312, U303 and U096 tumours using a standard fragment analysis test. Panels 
A and B show results for the U312 normal mucosa sample and tumour sample respectively, Panels C and 
D show results for the U303 normal mucosa sample and tumour sample respectively, Panels E and F show 
results for the U096 normal mucosa sample and tumour sample respectively. 
The documentation for the wax block from which the U096 tumour sample was 
derived (block R06038/03-1C) was rechecked. This revealed that wax block R06038/03-
1C was not a part of the tumour from patient U096, but a piece of the distal resection 
margin. The wrong wax block had been cut and I was provided with the wrong sample. 
This means that sequenced samples consisted of 5 MSI-H tumours, 6 MSS tumours, 
matched normal mucosa for 4 of the MSI-H tumours and normal mucosa from patient 
U096.  
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5.2.3. Read length variation in 7bp - 12bp repeats 
To assess the instability rates of 120 7-12bp repeats these were sequenced in up 
to 5 MSI-H cancers and controls. For the 7bp repeats, variant reads with 1bp deletions 
were observed in the MSI-H samples at a frequency that notably differed from what was 
observed in the control samples (see Figure 5.6).  
 
 
Figure 5.6: Read length variation in 7bp repeats. Panel A: Variant read frequencies in MSI-H tumours and 
controls for seven out of the twenty-seven 7bp mononucleotide repeats sequenced. Panel B: Four repeats 
with 1bp deletions in MSI-H samples. Delta = change in homopolymer length. 
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For the 8bp repeats, variant reads in the MSI-H samples also presented as 1bp 
deletions and these were found at a higher frequency compared to the 1bp deletions 
observed in the 7bp repeats (see Figure 5.7). Interestingly the repeat LR46 showed 
instability in all five of the MSI-H tumours. This might suggest that this 8bp repeat is 
highly susceptible to MSI (see Figure 5.7).  
 
Figure 5.7: Read length variation in 8bp repeats. Panel A: Variant read frequencies in MSI-H tumours and 
controls for seven out of the twenty-two 8bp mononucleotide repeats sequenced. Panel B: Read length 
variation in MSI-H samples for repeats LR20 and LR46. Delta = change in homopolymer length  
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For the 9bp mononucleotide repeats most of the variant reads present in the MSI-
H samples are 1bp deletions but there are some 2bp present in the MSI-H samples for 
example see repeats LR10 sample U029 tumour and IM16 sample U179H03 tumour (see 
Figure 5.8). The repeat LR05 has a high 1bp deletion frequency in both the MSI-H 
samples and controls. This could be a result of LR05 being a G/C mononucleotide repeat 
while all the other 9bp repeats sequenced are A/T repeats. A/T homopolymers in genomic 
DNA pack in such a way to allow bifurcated hydrogen bonds to form between bases as 
well as the usual hydrogen bonds (Nelson et al., 1987). This increases the energy needed 
to cause slippage during DNA replication for A/T repeats and could be a reason for G/C 
repeats having more PCR error compared to A/T repeats of the same length. 
 
Figure 5.8: Read length variation in 9bp repeats. Panel A: Variant read frequencies in MSI-H tumours and 
controls for seven out of the twenty-one 9bp mononucleotide repeats sequenced. Panel B: Two repeats with 
1bp and 2bp deletions in MSI-H samples. Delta = change in homopolymer length 
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For the 10bp repeats both 1bp and 2bp deletions are present in the MSI-H samples 
(see Figure 5.9). Variant reads in the form of 1bp deletions are also present in the control 
samples, but at a lower frequency than seen in the MSI-H samples. The repeats IM37 and 
IM34 also have low levels of 2bp deletions in the controls.   
 
Figure 5.9: Read length variation in 10bp repeats. Panel A: Variant read frequencies in MSI-H tumours and 
controls for seven out of the sixteen 10bp mononucleotide repeats sequenced. Panel B: Repeats with 1bp 
and 2bp deletions. Delta = change in homopolymer length 
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For the 11bp mononucleotide repeats there is a change in the shape of the graphs 
for many of the MSI-H samples compared to the controls with an emergence of new 
variant repeat lengths of 9-10bp (see Figure 5.10). The repeat LR16 is likely to contain a 
polymorphism because there is a roughly equal amount of reference reads and reads with 
1bp deletions for the two tissue biopsies from patient U096. Both tissue biopsies from 
U096 are normal tissue and the biopsies were taken 1 year apart so the reads containing 
1bp deletions are highly unlikely to be mutations. The repeats LR01 and LR32 also 
contain potential polymorphisms (see Figure 5.10 sample 169259 for repeat LR01 and 
sample 169736 for repeat LR23). On the other hand, it is also possible that some of the 
variant reads seen in the MSI-H samples are due to polymorphisms. It can be hard to tell 
the difference between polymorphisms and genuine mutations in cases such as samples 
U303 tumour and U179_H12 tumour for repeats GM14 and IM28 respectively, where no 
normal tissue was available for comparison. 
 
Figure 5.10: Read length variation in 11bp repeats. Panel A: Variant read frequencies in MSI-H tumours 
and controls for seven out of the nineteen 11bp mononucleotide repeats sequenced. Panel B: Repeats with 
potential polymorphisms. Delta = change in homopolymer length 
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For the 12bp repeats there were a lot of variant read lengths observed in the MSI-
H samples which were not present in any of the controls (see Figure 5.11). There were 
more variant reads in the MSI-H samples than reference reads for some of the markers. 
This was never seen in the control samples. Deletions as large as 4bp and even 5bp were 
observed in the MSI-H samples for some of the repeats (see Figure 5.11 repeats LR41 
and LR52). 
 
Figure 5.11: Read length variation in 12bp repeats.This figure shows seven of the 12bp mononucleotide 
repeats sequenced. Panel A: Variant read frequencies in MSI-H tumours and controls for seven out of the 
eleven 12bp mononucleotide repeats sequenced. Panel B: Repeats with 4bp and 5bp deletions in MSI-H 
samples. Delta = change in homopolymer length 
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5.2.4. Deletion frequencies in repeats identified by whole genome sequencing 
The data can also be analysed in a different way, which highlights the trends 
mentioned before. For the patient U096 two separate sets of normal mucosa were 
analysed. For the data analysis in this section results obtained from wax block R06038/03-
1C were used with the exception of repeats IM64 (12bp A/T repeat) and IM67 (7bp G/C 
mononucleotide repeat) which failed to be sequenced from the R06038/03-1C sample. 
Only one of the two U096 samples was used because they were duplicates with little 
difference between the two. A/T and G/C repeats were plotted separately. 
For most 7bp mononucleotide repeats there was a deletion frequency of less than 
1% in the control samples (see Figure 5.12). In only three cases was there a deletion 
frequency of over 2% in the control samples. These cases consisted of the repeat LR49 in 
samples U029 normal mucosa and U179 normal mucosa with deletion frequencies of 3% 
and 2.9% respectively, and the repeat LR51 with a deletion frequency of 3.3% in the 
normal mucosa from patient U096. In the MSI-H samples there were a few repeats which 
had a larger deletion frequency than the rest. Seven repeats had a deletion frequency 
above 4% in the MSI-H samples (see Table 5.3). These consisted of three repeats for the 
U029 tumour sample, one repeat for the U179_H12 tumour sample, one repeat for the 
U303 tumour sample, and two repeats for the U312 tumour sample. 
 
Figure 5.12: Deletion frequencies in all the 7bp mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls.    
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U029T  U179_H12 U303T U312T 
Repeat  DF Repeat  DF Repeat DF Repeat DF 
IM19  8.3%   LR49   10.2%  LR51 9.4%  IM14 15.0% 
IM43  5.4%           LR15 5.1% 
IM55  8.9%             
Table 5.3: 7bp repeats with a deletion frequency ≥4% in the MSI-H samples. T= tumour sample, DF= 
deletion frequency. 
In the 8bp mononucleotide repeats the deletion frequencies were consistently 
below 3% in the controls with the exception of repeat LR19 from the U029 normal 
mucosa where the deletion frequency is 5.8%. In the MSI-H samples there were 12 
repeats with a deletion frequency ≥5% (see Figure 5.13). Sample U029 tumour had five 
repeats with a deletion frequency ≥5%, U179_H03 tumour had two, U179_H12 tumour 
had three, U303 tumour had one, and U312 tumour had one (see Table 5.4).  
 
Figure 5.13: Deletion frequencies in all the 8bp mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls.    
U029T  U179_H03 U179_H12 U303T  U312T
Repeat  DF Repeat  DF Repeat DF Repeat DF  Repeat  DF
GM09  14.9%  LR20  35.6%  IM59 14.2%  LR46 14.3%  LR46  7.2% 
IM41  13.3%  LR46  13.2%  LR19 8.6%         
IM59  5.7%      LR46 18.5%         
LR20  8.6%                
LR46  20.1%                
Table 5.4: 8bp repeats with a deletion frequency ≥5% in the MSI-H samples. T= tumour sample, DF= 
deletion frequency. 
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In the 9bp mononucleotide repeats there were no repeats in the control samples 
with a deletion frequency ≥10%, while four of the five MSI-H samples had repeats with 
a deletion frequency ≥10% (see Figure 5.14). These consisted of samples U029 tumour 
with 7 repeats, U179_H03 tumour with 4 repeats, U303 tumour with 2 repeats, and U312 
tumour with 2 repeats (see Table 5.5). 
 
Figure 5.14: Deletion frequencies in all the 9bp mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls. 
U029T  U179_H03T U303T U312T 
Repeat  DF Repeat  DF Repeat DF Repeat DF 
GM11  22.9%  GM10  17.6%  LR10 13.4%  GM17 11.4% 
GM15  17.1%  GM11  28.0%  LR24 13.9%  LR10 10.7% 
GM17  15.1%  IM16  10.5%     
IM16  26.5%  LR10  24.7%     
LR10  15.9%  LR40  43.4%     
LR24  15.8%         
LR40  14.9%         
Table 5.5: 9bp repeats with a deletion frequency ≥10% in the MSI-H samples. T= tumour sample, DF= 
deletion frequency. 
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For the 10bp repeats there was one repeat with a deletion frequency ≥20% in the 
control samples (see Figure 5.15). This repeat was IM35 in sample 169736 which had a 
deletion frequency of 23.6%. In the MSI-H samples there were several repeats with a 
deletion frequency ≥20% (see Figure 5.15). These consisted of 6 repeats for tumour U029, 
1 repeat for tumour U179_H03, 3 repeats for tumour U179_H12, 2 repeats for tumour 
U303, and 1 repeat for tumour U312 (see Table 5.6). 
 
Figure 5.15: Deletion frequencies in all the 10bp mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls. 
U029T  U179_H03T U179_H12T U303T  U312T
Repeat  DF Repeat  DF Repeat DF Repeat DF  Repeat  DF
IM07  32.4%  LR32  56.2%  IM35 25.7%  LR29 23.4%  LR32  20% 
IM34  25.7%      LR26 21.1%  LR32 31.2%     
LR26  22.4%      LR32 26.6%       
LR29  21.2%             
LR30  27.8%             
LR32  25.7%             
Table 5.6: 10bp repeats with a deletion frequency ≥20% in the MSI-H samples. T= tumour sample, DF= 
deletion frequency. 
 
 
 
127 
 
Most 11bp homopolymers sequenced in the control samples have a deletion 
frequency below 30% (see Figure 5.16). There were four exceptions. The repeat LR01 
had a deletion frequency of 62.8% and 35.4% in the MSS tumour 169259 and the U179 
normal mucosa. The repeat LR23 had a deletion frequency of 46% in the MSS tumour 
169736 and the repeat LR16 had a deletion frequency of 57.3% in the sample from patient 
U096.  In the MSI-H samples there were many repeats that that had a deletion frequency 
≥ 30% (see Figure 5.16). These consisted of 13 repeats for the U029 tumour sample, 5 
repeats for the U179_H03 tumour sample, 5 repeats for the U303 tumour sample, two 
repeats the U179_H12 tumour sample, and only one repeat for the U312 tumour sample 
(see Table 5.7). 
LR01, LR16, LR23 had high deletions frequencies in the control samples and as 
mentioned before this could potentially be due to polymorphisms. The mononucleotide 
repeats used in this study have all been screened for polymorphisms using the dbSNP 
(version 137), but there may still be polymorphism present for some of the repeats which 
have not been registered in this version of dbSNP. It is also possible that the variant reads 
for some of the Lynch Syndrome tumours may be a result of polymorphisms.   
 
Figure 5.16: Deletion frequencies in all the 11bp mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls. 
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U029T  U179_H03T U179_H12T U303T  U312T
Repeat  DF Repeat  DF Repeat DF Repeat DF  Repeat  DF
GM02  38.4%  GM02  32.9%  IM28 38.8%  GM14 35.3%  LR48  36.1% 
GM07  44.0%  GM07  65.3%  LR33 33.3%  IM65 36.3%       
IM28  49.3%  LR16  54.3%     LR17 30.5%       
IM32  30.4%  LR17  42.2%     LR23 46.8%       
IM45  50.4%  LR33  52.8%     LR48 44.8%       
IM52  34.7%                   
IM54  43.2%                   
IM65  42.4%                   
LR12  31.4%                   
LR17  36.5%                   
LR32  31.2%                   
LR33  37.4%                   
LR48  31.5%                   
Table 5.7: 11bp repeats with a deletion frequency ≥30% in the MSI-H samples. T= tumour sample, DF= 
deletion frequency. 
The 12bp mononucleotide repeat IM51 had a deletion frequency above 40% in 
the two of the MSS tumours 169259 and 171223. It is possible that the repeat IM51 
contains a polymorphism for these two samples. Other than this repeat there were no more 
repeats with a deletion frequency ≥ 40% in the control samples (see Figure 5.17). Out of 
the MSI-H tumours there were three which contained repeats with a deletion frequency ≥ 
40% (Figure 5.17). The three samples were the U029 tumour with 5 repeats, the 
U179_H03 tumour with 3 repeats, and the U303 tumour with 4 repeats (see Table 5.8).  
 
Figure 5.17: Deletion frequencies in all the 12bp mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls. 
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U029T  U179_H03T U303T
Repeat  DF Repeat  DF Repeat DF
GM18  67.4%  LR36  61.0%  GM18 55.4% 
IM51  53.7%  LR44  53.4%  LR36 40.6% 
LR36  52.7%  LR52  64.4%  LR41 47.4% 
LR41  49.5%      LR52 48.5% 
LR52  61.8%       
Table 5.8: 11bp repeats with a deletion frequency ≥40% in the MSI-H samples. T= tumour sample, DF= 
deletion frequency. 
With an increase in repeat length there was a higher deletion frequency observed 
in the unstable repeats of the MSI-H samples. There was however also an increase in the 
deletion frequencies of the controls and an increase in the variation of deletion frequencies 
between different repeats of the same size. An increase in repeat length meant an increase 
in the average deletion frequency for both MSI-H tumours and controls (see Figure 5.18). 
There was a larger increase in the average deletion frequency of the MSI-H tumours with 
increased repeat length compared to the controls. 
 
Figure 5.18: Mean deletion frequencies for the A/T mononucleotide repeats. 
For the 7bp-8bp G/C mononucleotide repeats all of the control samples had a low 
background deletion frequency of less than 1% (see Figure 5.19). Both 8bp G/C repeats 
also had a deletion frequency of less than 1% in all the MSI-H samples. The three 7bp 
G/C repeats IM66, IM67 and LR08 had a higher deletion frequency than observed in any 
of the controls for at least one of the MSI-H samples (see Figure 5.19). The repeat IM66 
had a deletion frequency of 16.9% and 14.3% respectively in samples U029 tumour and 
U179_H12 tumour. The repeat IM67 had a deletion frequency of 9% and 2.8% for the 
U179_H12 tumour sample and the U303 tumour sample respectively. The repeat LR08 
had a deletion frequency of 14.7% in the U029 tumour. 
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For the 9bp G/C mononucleotide repeat LR05, the deletion frequency in all of the 
control samples was between 23-33% (see Figure 5.19). This is higher than any of the 
deletion frequencies seen in the controls for the 9bp A/T repeats (see Figure 5.14). Out of 
the five MSI-H samples, two samples had a higher deletion frequency for the repeat LR05 
than was seen in the control samples (see Figure 5.19). These two samples were 
U179_H12 tumour where LR05 had a deletion frequency of 38.1% and sample U303 
tumour where LR05 had a deletion frequency of 44.3%. 
 
Figure 5.19: Deletion frequencies in all the G/C mononucleotide repeats. Panel A shows the deletion 
frequencies in the MSI-H tumours. Panel B shows the deletion frequencies in the controls. 
Despite the existence of variant reads from PCR based error, Figure 5.20 shows 
that use of multiple short repeats can readily identify MSI-H tumours that exhibit limited 
instability as assessed by fragment analysis. 
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Figure 5.20: Comparison between using a standard fragment analysis test and using the short 7-8bp markers 
that were sequenced in both tumour and normal tissue. A: Fragment analysis results for the U312 normal 
mucosa. B: Fragment analysis results for the U312 tumour. C: Sixteen 7-8bp mononucleotide repeats that 
were sequenced in both the U312 tumour and normal mucosa.  
5.2.5. The allelic distribution of MSI in variable repeats identified from whole 
genome sequences data 
All A/T repeats and most of the G/C repeats sequenced had neighbouring SNPs 
with a high minor allele frequency. Homopolymers with these neighbouring SNPs with a 
high minor allele frequency were chosen to enable the study of allelic bias for these 
homopolymers.  
In Figure 5.21 there are some examples of allelic bias in MSI-H tumours. For the 
7bp and 8bp repeats, the reads containing a 1bp deletion are mostly present on one allele 
(see Figure 5.21 panels A-B). For the 11bp repeat IM65 in the U029 tumour sample there 
is an imbalance between the two alleles both for the 1bp deletion (Fisher’s exact test: p-
value <10-100) and for the 3bp deletion (Fisher’s exact test: p-value 3.1×10-72) (see Figure 
5.21 panel D). This suggests this repeat has had two separate replication mistakes, which 
have not been rectified by the compromised mismatch repair system. For the 12bp repeat 
LR36 in the U303 tumour sample there are significantly more reads containing a 2bp 
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deletion on the allele with an A at the SNP site than the allele with a T (Fisher’s exact 
test: p-value 4.22×10-36). 
 
Figure 5.21: Examples of allelic imbalance in different lengths of mononucleotide repeat. Panel A the repeat 
IM14 in tumour U312, Panel B the repeat LR20 in tumour U179_H03, Panel C the repeat IM65 in tumour 
U029, Panel D the repeat LR36 in tumour U303.  
To investigate allelic bias across all samples and all heterozygous repeats the Perl 
scripts FisherTest_AllDeletions.pl and FisherTest_IndividualIndels.pl were written. Both 
scripts use the output files of our in house variant caller COPReC as input files. The Perl 
scrips identify repeats that are heterozygous for a neighbouring SNP and perform a 
Fisher’s exact test to determine if the fraction of variant reads is significantly different 
between the two alleles. Repeats were defined as heterozygous if there were 100 paired 
end reads spanning both SNP and repeat for each allele and one allele did not have less 
than 10% of the total read count. The criteria of a minimum of 100 paired end reads per 
allele was used to prevent a misrepresentation of variant frequencies caused by PCR 
duplicates. The criteria that repeats were not analysed if one allele has less than 10% of 
the total read count was used because such an extreme allele imbalance might indicate 
sample contamination. The Fisher’s exact test calculations were performed using an 
external module integrated into my Perl program. The module was written by Pedersen 
T. (https://metacpan.org/pod/Text::NSP::Measures::2D::Fisher::twotailed). The script 
FisherTest_AllDeletions.pl calculates the fraction of reads that contain a deletion and the 
fraction of reads that do not contain a deletion for each allele and performs a Fisher’s 
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exact test to see if there is a significant difference in deletion distribution between the two 
alleles. The script FisherTest_IndividualIndels.pl calculates the fraction of reads that 
correspond to each individual insertion and deletion size, then calculates if there is a 
significant difference between the two alleles for each separate indel size.   
Figure 5.22 shows the results for the Fisher’s exact test where the significance of 
differences in total deletion frequencies between the two alleles of repeats were 
calculated. The repeats plotted in Figure 5.22 include only repeats where the neighbouring 
SNP was classified as heterozygous. In some cases, a repeat had more than one 
neighbouring heterozygous SNP and in these cases, all heterozygous SNP repeat 
combinations were plotted. This method was chosen because different SNPs would have 
a different number of reads spanned both SNP and repeat. Therefore, different repeat and 
SNP combinations could provide different levels of significance for allelic bias. The 
results of the two-tailed Fisher’s exact test indicate that there is more allelic bias in the 
MSI-H samples compared to the MSS samples (see Figure 5.22). To Bonferroni correct 
a p-value of 0.01, this p-value was divided by the number of heterozygous SNP repeat 
combinations (0.01/519 = 1.9×10-5). A table containing the number of repeats with a 
statistically significant p-value can be found in Table 5.9. There were 52 repeats with a 
statistically significant p-value in the MSI-H samples compared to 12 in the controls. 
There are three mononucleotide repeats in control samples that have an allelic bias with 
a p-value below 10-20 (see Figure 5.22). These include both U096 samples where there is 
a large bias between the alleles for the repeat LR16. As mentioned before the LR16 repeat 
is almost certainly polymorphic in patient U096 and this would explain the level of bias 
in deletion frequency seen between the two alleles of this repeat. The third repeat with a 
p-value below 10-20 is LR23 in the MSS tumour 169736. This is also a potential 
polymorphism.  
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Figure 5.22: Allelic bias in deletion frequency for MSI-H samples and MSS samples measured using the 
p-value of a two tailed Fisher’s exact test. Red = MSI-H samples, Blue = MSS samples. The line 
corresponds to a Bonferroni corrected p-value of 0.01.  
Tumour sample  Sample Type 
Number of repeats with a significant allelic bias 
(p‐value ≤ 1.9×10‐5) 
U029T  MSI‐H Tumour  16 
U179H03T  MSI‐H Tumour  16 
U179H12T  MSI‐H Tumour  4 
U303T  MSI‐H Tumour  8 
U312T  MSI‐H Tumour  8 
U029N  Normal Mucosa  0 
U179N  Normal Mucosa  1 
U312N  Normal Mucosa  1 
U096N
R06038/03‐1C  Normal Mucosa  3 
U096N  Normal Mucosa  2 
169259  MSS Tumour  4 
169736  MSS Tumour  1 
169836  MSS Tumour  0 
170146  MSS Tumour  0 
170402  MSS Tumour  0 
171223  MSS Tumour  0 
Table 5.9: The number of repeat with a Bonferroni corrected p-value of 0.01 (0.01/519 = 1.9×10-5) for each 
tumour sample.  
Repeats with a neighbouring heterozygous SNP were also analysed to determine 
the significance of bias between the two alleles for individual indel sizes using the script 
FisherTest_IndividualIndels.pl. This was done using a two-tailed Fisher’s exact test 
where the frequency of each individual indel size was interrogated (see methods section 
2.9.1). For each allele the reads were classed as containing the indel size under 
investigation or does not contain the indel size under investigation. For each repeat, the 
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indel with the lowest p-value was recorded in Table 5.10. If there were multiple 
heterozygous SNPs neighbouring a repeat then the SNP where the lowest p-value was 
obtained was used.   
The MSI-H samples have the highest number of heterozygous repeats with an 
indel event which is significantly biased between the two alleles. Up to a significance 
level of p-value <10-10 there are a higher number of repeats in the MSI-H samples (see 
Table 5.10). However, the number of repeats sequenced differs between samples and the 
number of heterozygous repeats also differ between samples. For the MSI-H samples the 
fraction of the heterozygous repeats that contain allelic imbalance for individual indel 
sizes is generally higher than seen in the controls. The U179_H03 tumour sample has an 
allelic imbalance at a significance level of p-value <10-10 for 46% of the heterozygous 
repeats, U029 tumour for 45% of the heterozygous repeats, U303 tumour for 21% of the 
heterozygous repeats, U179_H12 tumour for 10% of the heterozygous repeats, and the 
U312 tumour for 11% of the heterozygous repeats. The fraction of the heterozygous 
repeats that contain allelic imbalance for individual indel sizes is also high in the U096 
controls.  For the U096 sample from block R06038/03-1C there is an allelic imbalance at 
a significance level of p-value <10-10 for 10% of the heterozygous repeats and for the 
other U096 sample (CAPP2 wax block label: U096 normal 23.12.02) an allelic imbalance 
in 17% of the repeats.  
The U096 patient sample from block R06038/03-1C had three repeats with an 
allelic bias for 1bp deletions of a significance level of p-value <10-10. These three repeats 
were LR16 (p-value <10-100), LR27 (p-value 2.9x10-17), and LR51 (p-value 2.1×10-18). 
LR16 is suspected to be polymorphic in patient U096. The U096 sample (U096 normal 
23.12.02) shows allelic bias for a 1bp deletion in the repeat LR16 which is believed to be 
a polymorphism. 
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Status  Sample  Repeats with 2 alleles 
p‐value 
<1E‐10 
p‐value 
<1E‐7 
p‐value 
<1E‐5 
p‐value 
<1E‐3 
p‐value 
<0.05 
Lynch Tumour  U029T  42  19  19  19  20  25 
Lynch Tumour  U179T H03  37  17  19  19  20  24 
Lynch Tumour  U179T H12  41  4  6  6  9  13 
Lynch Tumour  U303T  38  8  8  9  10  17 
Lynch Tumour  U312T  45  5  7  9  10  17 
Normal Mucosa  U029N  17  0  0  0  0  3 
Normal Mucosa  U179N  20  0  1  2  4  9 
Normal Mucosa  U312N  18  1  1  1  1  4 
Normal Mucosa  U096N  R06038/03‐1C   29  3  3  3  4  10 
Normal Mucosa  U096N (23.12.02)  6  1  2  2  2  3 
MSS Tumour  169259  49  0  0  1  6  10 
MSS Tumour  169736  39  1  1  1  3  9 
MSS Tumour  169836  16  0  0  0  1  3 
MSS Tumour  170146  19  0  0  0  0  2 
MSS Tumour  170402  33  0  0  0  0  0 
MSS Tumour  171223  37  0  0  0  0  5 
Table 5.10: The number of repeats with allelic bias for individual indels sizes measured using the p-value 
of a two tailed Fisher’s exact test. 
5.2.6. Identifying the most informative homopolymers  
The ability of each repeat to discriminate between the MSI-H samples and the 
MSS samples was assessed using the area under the receiver operating characteristic 
curve (AUC). Dr Mauro Santibanez-Koref (Institute of Genetic Medicine, Newcastle 
University) performed the AUC calculations. Receiver operating characteristic curves are 
a method of measuring true positive and false positive rates. In this case the AUC is a 
measure of how well a given homopolymer can differentiate between the MSI-H and 
MSS samples. 
Using AUC as a measure of a repeat’s ability to discriminate between MSI-H 
samples and controls, it was concluded that the discrimination power increased with the 
length of repeat for the A/T mononucleotide repeats (see Figure 5.23). The 11bp and 12bp 
mononucleotide repeats achieved the best discrimination between MSI-H samples and 
controls with a median AUC of above 0.95 for separating the MSI-H and control samples 
(see Figure 5.23). Because the longer repeats are better able to separate the MSI-H and 
control samples it was decided to include mainly long repeats in the final panel of repeats. 
However some MSI-H samples are easier to identify using the shorter repeats, for 
example the U312 tumour sample analysed in this chapter and the U096 tumour sample 
analysed in chapter 3. The U096 tumour sample in chapter 3 did not show any deletion 
frequencies above what was observed in the controls for the 12bp-15bp mononucleotide 
repeats sequenced, but did have a 1bp deletion frequency above 14% for two 8bp repeats 
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(DEPDC2 and AL359238) and a 1bp deletion consisting of 18.6% of the reads for one 
10bp repeat (AVIL). The U312 tumour sample analysed in this chapter only showed a 
deletion frequency above 1.5x the deletion frequency seen in any of the control samples 
for the 11bp repeats GM07, GM14 and LR48. No 12bp repeats had a deletion frequency 
above 1.5x the deletion frequency seen in any of the control samples for the U312 tumour 
sample. The U312 tumour sample was easier to identify as MSI-H using the shorter 7bp-
10bp repeats (see Figure 5.12 - Figure 5.15). This suggests that it may be beneficial to 
include some of the shorter repeats in a final panel.   
 
Figure 5.23: Box plot showing the ability of different mononucleotide lengths to separate between MSI-H 
samples and MSS samples using the area under the receiver operating characteristic curve (AUC). 
The aim was to select markers with a clear difference between unstable repeats 
and background PCR and sequencing error. The aim was also to select repeats which 
showed instability in as many of the MSI-H samples as possible. To achieve this, markers 
were classed as unstable in the MSI-H samples if a marker had a deletion frequency of 
>5% and at least two times the deletion frequency of any of the control samples for the 
7-9bp repeats. For the 10bp-12bp repeats a marker was classed as unstable in a MSI-H 
sample if it had a deletion frequency of >5% and at least 1.5 times higher than seen in 
any control sample for the same repeat. These thresholds were chosen arbitrarily. The 
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markers that were chosen for further investigation where markers that were classed as 
unstable in at least 60% of the MSI-H samples and also had an AUC of at least 0.9. Marker 
LR11was also chosen, despite having a lower AUC (AUC: 0.82), because the AUC for 
the SNP was higher than 0.9, making this an interesting marker for studying allelic bias. 
The markers that were chosen are highlighted in grey in Table 5.11 and Table 5.12. Most 
of these repeats are long repeats of 10bp or longer, with the exception of the 8bp repeat 
LR46. The repeat LR46 was chosen because it had a deletion frequency in all five MSI-
H tumours of more than 2 times the deletion frequency of any of the control samples. 
None of the G/C repeats analysed in this chapter were chosen as part of the final panel 
because repeats with a higher instability rate and higher AUC for the MSI-H samples 
were available from the A/T repeats sequenced.
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MS size  MS 
MSI‐H  
(>100 
reads) 
MSI >2x largest MSS 
(deletion frequency) 
Fraction of 
MSI‐H detected 
(>100 reads) 
AUC   Bias.AUC SNP  Info 
7bp  IM14 3  1 0.33 0.89  NA 
7bp  IM43 3  1 0.33 0.56  NA 
7bp  IM55 3  1 0.33 0.67  NA 
7bp  LR51 3  1 0.33 0.56  NA 
7bp  IM19 5  1 0.2 0.76  NA 
7bp  LR15 5  1 0.2 0.62  NA 
7bp  LR49 5  1 0.2 0.51  NA 
7bp  GM04 4  0 0 0.53  NA 
7bp  GM19 5  0 0 0.51  NA 
7bp  GM25 4  0 0 0.49  NA 
7bp  GM27 5  0 0 0.66  NA 
7bp  GM30 5  0 0 0.94  NA 
7bp  IM13 2  0 0 0.56  NA 
7bp  IM22 3  0 0 0.67  NA 
7bp  IM23 3  0 0 0.67  NA 
7bp  IM26 3  0 0 0.89  NA 
7bp  IM27 3  0 0 0.44  NA 
7bp  IM61 3  0 0 0.56  NA 
7bp  LR13 5  0 0 0.47  NA 
7bp  LR25 4  0 0 0.41  NA 
7bp  LR45 5  0 0 0.8  NA 
7bp  LR47 5  0 0 0.6  0.73 
7bp  LR50 4  0 0 0.66  0.67 
7bp  GM24 1  0 0 0 NA 
8bp  LR46 5  5 1 1 0.83  chosen
8bp  IM59 3  2 0.67 0.67  NA 
8bp  LR20 4  2 0.5 0.67  1 
8bp  IM41 3  1 0.33 0.89  NA 
8bp  GM09 5  1 0.2 0.9  NA 
8bp  GM03 4  0 0 0.66  NA 
8bp  GM08 5  0 0 0.63  NA 
8bp  GM16 5  0 0 0.46  NA 
8bp  GM20 5  0 0 0.4  NA 
8bp  IM15 3  0 0 0.44  NA 
8bp  IM20 2  0 0 0.56  NA 
8bp  IM21 3  0 0 0.56  NA 
8bp  IM25 3  0 0 0.67  NA 
8bp  IM39 3  0 0 0.78  NA 
8bp  IM40 3  0 0 0.44  NA 
8bp  IM57 5  0 0 0.6  NA 
8bp  IM63 5  0 0 0.64  NA 
8bp  LR18 4  0 0 0.53  NA 
8bp  LR19 5  0 0 0.56  NA 
8bp  LR27 5  0 0 0.56  NA 
8bp  LR31 4  0 0 0.66  NA 
9bp  GM11 5  3 0.6 0.8  NA 
9bp  LR24 5  3 0.6 0.84  NA 
9bp  GM17 5  2 0.4 0.94  NA 
9bp  GM28 5  2 0.4 0.57  NA 
9bp  IM16 5  2 0.4 0.78  NA 
9bp  LR40 5  2 0.4 0.7  NA 
9bp  GM21 4  1 0.25 0.68  NA 
9bp  GM10 5  1 0.2 0.54  NA 
9bp  GM15 5  1 0.2 0.6  1 
9bp  GM23 5  1 0.2 0.8  NA 
9bp  IM17 5  1 0.2 0.59  NA 
9bp  LR10 5  1 0.2 0.96  NA 
9bp  LR14 5  1 0.2 0.38  NA 
9bp  LR21 5  1 0.2 0.8  NA 
9bp  GM05 5  0 0 0.57  0.5 
9bp  GM06 5  0 0 0.66  NA 
9bp  IM42 3  0 0 0.56  NA 
9bp  IM44 3  0 0 1 NA 
9bp  LR28 5  0 0 0.67  1 
9bp  LR34 5  0 0 0.62  NA 
Table 5.11: Table containing information for all the 7bp-9bp A/T repeats sequenced. Repeats were classed 
as unstable if they had a deletion frequency above 5% and >2x higher than any of the control samples. 
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MS 
size  MS 
MSI‐H 
(>100 
reads) 
MSI >1.5x largest 
MSS (deletion 
frequency) 
Fraction of MSI‐
H detected 
(>100 reads) 
AUC   Bias.AUC SNP  Info 
10bp  GM29  5  4  0.8  0.94  NA  chosen 
10bp  LR32  5  4  0.8  1  NA  chosen 
10bp  GM01  5  2  0.4  0.94  NA    
10bp  GM22  5  2  0.4  0.97  0.73    
10bp  GM26  5  2  0.4  0.87  0.89    
10bp  LR29  5  2  0.4  0.68  NA    
10bp  LR39  5  2  0.4  0.74  NA    
10bp  IM07  3  1  0.33  0.78  NA    
10bp  IM33  3  1  0.33  0.56  NA    
10bp  IM34  3  1  0.33  0.67  NA    
10bp  LR30  5  1  0.2  0.42  NA    
10bp  IM12  3  0  0  0.67  NA    
10bp  IM35  3  0  0  0.33  NA    
10bp  IM37  3  0  0  1  NA    
10bp  LR26  5  0  0  0.6  0.65    
10bp  LR35  5  0  0  0.51  NA    
11bp  GM14  5  5  1  1  NA  chosen 
11bp  LR48  5  5  1  1  NA  chosen 
11bp  GM07  5  4  0.8  1  1  chosen 
11bp  GM13  5  4  0.8  0.89  NA    
11bp  LR11  5  4  0.8  0.82  0.92  chosen 
11bp  LR17  5  4  0.8  0.98  NA    
11bp  IM28  3  2  0.67  0.78  NA    
11bp  IM54  3  2  0.67  0.67  NA    
11bp  IM52  5  3  0.6  1  NA    
11bp  IM65  5  3  0.6  0.96  0.72    
11bp  LR33  5  3  0.6  1  NA    
11bp  GM02  5  2  0.4  0.94  NA    
11bp  IM32  3  1  0.33  1  NA    
11bp  IM45  3  1  0.33  0.89  NA    
11bp  IM53  3  1  0.33  1  NA    
11bp  LR12  5  1  0.2  1  NA    
11bp  LR01  1  0  0  0.56  NA  Potential polymorphism 
11bp  LR16  5  0  0  0.66  0.67  Potential polymorphism 
11bp  LR23  5  0  0  0.88  NA  Potential polymorphism 
12bp  LR44  5  4  0.8  1  0.73  chosen 
12bp  IM49  3  2  0.67  1  NA  chosen 
12bp  LR36  5  3  0.6  1  NA  chosen 
12bp  LR43  5  3  0.6  0.98  NA    
12bp  LR52  5  3  0.6  0.88  NA    
12bp  GM18  5  2  0.4  0.97  0.89    
12bp  IM50  5  2  0.4  0.89  NA    
12bp  IM47  3  1  0.33  1  NA    
12bp  IM64  4  1  0.25  0.7  NA    
12bp  LR41  5  1  0.2  0.96  NA    
12bp  IM51  3  0  0  0.44  NA    
Table 5.12: Table containing information for all the 10bp-12bp repeats sequenced. Repeats were classed as 
unstable if they had a deletion frequency above 5% and >1.5x higher than any of the control samples. Only 
samples with > 100 reads were analysed. Repeats that were chosen for further analysis are highlighted in 
grey. 
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MS 
size  MS 
MSI‐H 
(>100 reads) 
MSI >2x largest MSS 
(deletion frequency) 
Fraction of MSI‐H 
detected 
(>100 reads) 
AUC   Bias.AUC SNP 
7bp  IM66  3  2  0.67  0.67  NA 
7bp  LR08  4  1  0.25  0.43  NA 
7bp  IM67  5  1  0.2  0.55  NA 
7bp  LR04  4  0  0  0.62  NA 
7bp  LR06  2  0  0  0.75  NA 
8bp  IM68  3  0  0  0.56  NA 
8bp  LR02  5  0  0  0.73  NA 
9bp  IM69  2  0  0  0.56  NA 
9bp  LR05  5  0  0  0.73  NA 
Table 5.13: Table containing information for all the G/C mononucleotide repeats sequenced. Repeats were 
classed as unstable if they had a deletion frequency above 5% and >2x higher than any of the control 
samples. Only samples with > 100 reads were analysed. 
The repeats in Table 5.14, which were taken from the literature and analysed in 
chapter 3, were also selected as part of the final panel of repeats. Some shorter 8bp and 
9bp repeats were included because shorter repeats may be more unstable in some tumours. 
The U096 tumour in chapter 3 displayed more instability in the shorter repeats than >10bp 
repeats. There was also a tumour in this chapter, U312 tumour, which displayed more 
instability in the shorter 7bp-10bp repeats compared to the 11bp and 12bp repeats (see 
Figure 5.12 - Figure 5.17). 
Repeat Name  Size (bp)  Repeat Base  Number of MSI‐H samples with 
instability in this repeat in chapter 3 
DEPDC2  8  C 1 out of 4
AL359238  8  A 1 out of 4
AL954650  9  C 1 out of 4
AP003532_2  9  A 1 out of 4
TTK 9  A 1 out of 4
AL355154  10  A 2 out of 4
AVIL 10  A 3 out of 4
ASTE1  11  A 3 out of 4
EGFR 13  A 2 out of 4
FBXO46  14  A 3 out of 4
Table 5.14: Repeats taken from the literature and analysed using a panel of 4 MSI-H tumours and controls 
in chapter 3. 
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5.3. Discussion 
To validate specific repeats for MSI detection, 120 of the repeats with the highest 
variant read frequency identified from whole genome sequence data were analysed in a 
small panel of tumours and control tissues using Illumina sequencing. Repeats were 
selected to ensure representation of all repeat lengths (7bp-12bp). In addition, repeats 
linked to a SNP with a high minor allele frequency were chosen to faciliate allele specific 
variant read identification. This chapter has concentrated on deletion frequencies to gauge 
MSI because in previous chapters the conclusion has been that deletions are more 
indicative of MSI than insertions. This is also consistent with results obtained by Yoon et 
al. (2013) who showed that mutations in mononucleotide repeats that are caused by MSI 
in gastric cancers are mainly deletions. One of my aims was to select the most variable of 
the 120 repeats so these could become part of a final panel of repeats for the use as an 
MSI test. Ten repeats from the literature analysed in chapter 3, have already been chosen 
to as part of this final panel of repeats. 
Of the 120 repeats sequenced, MSI was observed as an increase in deletion 
frequency in at least one MSI-H cancer for 63 of the A/T mononucleotide repeats. 40% 
of the short A/T repeats (7bp-9bp) showed MSI, compared to 80% of longer (10bp-11bp) 
A/T repeats (see Table 5.11 and Table 5.12). However, longer repeats showed more 
PCR/Sequencing error derived variability in control tissues. The 7bp and 8bp repeats had 
the lowest instability rates. 7bp -9bp repeats were classed as unstable in a MSI-H tumour 
if there was a deletion frequency above 5% and >2x the deletion frequency observed in 
any of the control samples for that repeat. For the 7bp repeats seven out of the 24 repeats 
sequenced showed instability in at least one MSI-H tumour. For the 8bp repeats only 5 
out of the 21 repeats showed instability in at least one MSI-H tumour. However one of 
the 8bp repeats LR46 was unstable in all five tumours sequenced. This could suggest that 
there is some attribute of the location of this repeat that makes it more susceptible to MSI. 
For this reason LR46 was chosen for further study as part of the final panel of repeats to 
be used on a larger panel of tumours. Fourteen out of the twenty 9bp repeats sequenced 
showed instability in at least one tumour. Comparatively, five out of the six 9bp repeats 
from the literature, and analysed in chapter 3, showed instability in at least one of the 5 
tumours sequenced. This means that a greater fraction of the 9bp repeats in chapter 3 
showed instability in at least one tumour. However, the method used for classifying 
markers as unstable is different in this chapter to the one used in chapter 3. In this chapter 
analysis of the total deletion frequency of repeats in the MSI-H samples has been 
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compared to the total deletion frequency of the same repeat in control samples, while in 
chapter 3 arbitrary cut-offs were defined for individual deletion sizes. 
The longer repeats were better able to discriminate between the MSI-H samples 
and controls (see Figure 5.23). More of these repeats were therefore chosen as part of the 
final panel of repeats to be tested on a larger panel of tumours. The 10bp -12bp repeats 
were classed as unstable in a MSI-H tumour if there was a deletion frequency >1.5x the 
deletion frequency observed in any of the control samples for that repeat. For the 10bp 
repeats, instability was observed in 11 out of the 16 repeats for at least one MSI-H tumour. 
Two of the repeats even showed instability in 4 out of the 5 MSI-H samples analysed. 
These two repeats were therefore chosen to be part of the final panel or repeats. For the 
11bp and 12bp repeats there was instability in 16 out of the 19 repeats analysed and 10 
out of the 11repeats analysed respectively. Many of the 11bp and 12bp repeats showed 
instability in 3-5 of the tumours tested. Four of the 11bp repeats and 3 of the 12bp repeats 
which showed instability in the largest number of tumours were chosen to become part 
of the final panel of repeats. 
Of the 9 G/C mononucleotide repeats sequenced, only 3 (33%) showed instability 
in at least one of the MSI-H tumours sequenced. Because more unstable repeats were 
available from the A/T mononucleotide repeats none of the G/C repeats were chosen for 
the final panel of repeats to be sequenced in a larger panel of tumours.  
Consistently more repeats had higher deletion frequencies in the MSI-H samples 
compared to the controls. However, there were some exceptions with repeats in control 
samples showing a high deletion frequency. In some cases, such as for the 11bp repeats 
LR01, LR16, and LR23 (see Figure 5.16), the reason for a high deletion frequency may 
be due to polymorphisms. For some of the repeats on the other hand the high deletion 
frequencies are unlikely to be caused by polymorphisms. This is the case for the 8bp 
repeat LR19 which has a deletion frequency of 5.8% in the U029 normal mucosa and the 
10bp repeat IM35 which has a deletion frequency of 23.6% in the MSS tumour sample 
169736. Yoon et al. (2013) analysed MSI in gene regions of gastric cancers and gastric 
cancer cell lines and mononucleotide repeats with deletions were also discovered in MSS 
cell lines suggesting that mismatch repair deficiency is not the only cause of deletions in 
mononucleotide repeats. It is likely a few markers with deletions in stable tumours will 
therefore have to be taken into account when developing a test for colorectal cancers. This 
is expected and is also the case for the fragment analysis tests such as the Promega MSI 
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test where instability in one of the five markers does not mean a sample is classed as MSI-
H. 
For patient U179 two separate tumours were analysed, one that was resected in 
2003 (U179_H03) and a second tumour that was resected in 2012 (U179_H12). The 
U179_H03 tumour has instability in many repeats which are stable in the U179_H12 
tumour. For example for the 9bp repeats (see Figure 5.14) there were five repeats with a 
deletion frequency above 10% for the tumour from 2003 (GM10: 17.6%, GM11: 28%, 
IM16: 10.5%, LR10: 24.7%, LR40: 43.4%). All five of these markers were also 
sequenced in the 2012 tumour but none of them had a deletion frequency above 10% 
(GM10: 0.4%, GM11 1.0%, IM16: 2.6%, LR10: 7.4%, LR40: 2.5%). The presence of 
many stable repeats in the U179_H12 tumour which showed instability in the U179_H03 
tumour indicates that the 2012 tumour is likely to be a new primary tumour, or possibly 
a recurrence of the U179_H03 tumour from an earlier clone before the emergence of 
instability in those repeats.  
Mining the whole genome sequences of MSI-H tumours allowed for the selection 
of many repeats that had neighbouring SNPs with a higher minor allele frequency than 
were available for study in chapter 3. This means that there were many more repeats with 
heterozygous SNPs available in the sequenced samples than had been available for the 
samples in chapter 3. An average of 32 heterozygous SNPs were present in each of the 
sequenced samples (see Table 5.10). This allowed a more comprehensive study of the 
allelic bias of deletion frequencies in the MSI-H samples. There were more repeats with 
an allelic bias in the MSI-H samples compared to the controls (Figure 5.22). There were 
two repeats (LR16 and LR23) with a two-tailed Fisher’s exact test p-value below 10-20 in 
three of the control samples (both of the U096 normal mucosa samples and the MSS 
tumour 169736). However the repeats LR16 and LR23 look like they are polymorphic in 
these samples, which would explain the levels of allelic bias. The results for allelic bias 
of deletion frequencies therefore suggest that if no repeats with polymorphisms are used 
then allelic bias can be used to confirm some of the deletions as real MSI events as 
opposed to sequencing and PCR error. In these cases the second allele could be used to 
determine background PCR and sequencing error rate as an internal control which could 
be compared to the allele with a high deletion frequency. For the longer 11bp and 12bp 
repeats it might be better to analyse allelic bias for individual deletion sizes because these 
repeats sometimes accumulate more than one deletion in MSI-H samples. If two deletions 
of different sizes occur on different alleles it would still be possible to detect the allelic 
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bias by looking at individual deletion sizes, while no allelic bias might be detected if total 
deletion frequency was used to measure allelic bias. 
5.3.1. Conclusions 
In conclusion, the selected 120 repeats that were highly variable in MSI-H whole 
genome sequences also showed a high level of instability in the five MSI-H tumours 
sequenced in this chapter. 40% of the short 7bp-9bp A/T repeats, 80% of the longer 10bp-
12bp A/T repeats and 33% of the G/C repeats were unstable in at least one of the MSI-H 
tumours. Many of the sequenced repeats had neighbouring heterozygous SNPs and there 
was an excess of repeats showing an allelic bias of reads with deletions in the MSI-H 
samples compared to the controls.  
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Chapter 6. Clonality in MSI-H tumours 
6.1. Introduction 
6.1.1. Clonality within tumours 
The majority of colorectal tumours are believed to develop from dysplastic crypts, 
progressing  to adenomas and then  to carcinomas before becoming metastatic diseases 
(Fearon, 2011, Fearon and Vogelstein, 1990). The initial driver mutation that starts a cell 
on the pathway to become a colorectal tumour is believed to occur in an intestinal crypt. 
The number of stem cells in an intestinal crypt are small (Barker et al., 2008). Because of 
the small population size of stem cells and the stem cells in each crypt being separate 
populations, crypts become monoclonal through genetic drift (Simons and Clevers, 
2011). New mutations that arise might therefore drift to fixation in stem cell populations 
within individual crypts. A cell with a pathogenic mutation could start the process towards 
the development of a tumour by creating the first dysplastic crypt through this 
mechanism. Mutant cells then start to expand to neighbouring crypts. Theories on the 
mechanism of mutant crypt proliferation include crypt fission, epithelial restitution to heal 
a damaged area, migration of malignant cells across the epithelium down into 
neighbouring crypts, and dispersal of cells through the basement membrane to 
neighbouring crypts (Merlo et al., 2006). Kloor et al. (2012) reported cases of crypt fission 
with MMR deficient crypts showing irregular branching and duplication adding evidence 
to the theory that dysplastic crypts can spread via crypt fission. Thirlwell et al. (2010) 
identified partially dysplastic crypts showing a top down growth pattern and 
histologically normal cells in the base of the crypt. This suggests a spreading of dysplastic 
cells across the epithelium down into previously unaffected crypts. 
There are different hypothesises as to whether the loss of mismatch repair (MMR) 
function is the first step towards the development of an MSI-H tumour in Lynch 
Syndrome patients, or if loss of MMR usually occurs at the adenoma stage (Boland, 
2012). There is evidence to suggest that a knockout of the MMR genes is not the first 
mutation in tumour development with the discovery of adenomas that are MSS and 
adenomas with both MSI-H and MSS regions in Lynch Syndrome patients. A study by 
Giuffre and colleges used laser dissection to analyse different regions of 18 adenomas 
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from Lynch Syndrome patients. These adenomas were tested using both 
immunohistochemistry and MSI fragment analysis and two tumours showed no loss of 
MMR proteins or microsatellite instability while the rest were MSI-H (Giuffre et al., 
2005). For many of the MSI-H tumours, differences in instability in different biopsies 
were observed. Eight of the tumours even had biopsies with MSI-L or MSS results as 
well as biopsies that were MSI-H (Giuffre et al., 2005). These finding would be consistent 
with initially MSS adenomas acquiring a ‘second hit mutation’ of a MMR gene resulting 
in microsatellite instability. If this were the case then the loss of MMR function would 
not be the initial driver mutation which initiated tumorigenesis. 
On the other hand, there is also evidence to suggest that a loss of MMR function 
could be the first mutation which initiates the development of cancers in Lynch Syndrome 
patients. Kloor et al. (2012) analysed crypts in normal mucosa from Lynch Syndrome 
patients and discovered crypts with an absence of MLH1 expression in MLH1 mutation 
carriers, and crypts with an absence of MSH2 expression in MSH2 mutation carriers. In 
total, 27 MMR deficient crypt foci were identified (~1 per cm2) in the normal mucosa of 
Lynch Syndrome carriers, while none were identified in the normal mucosa of controls. 
In the Lynch Syndrome patients, each deficient crypt foci consisted of between 1 to 19 
crypts. Seven out of the 27 MMR deficient crypt foci were MSI tested and all seven were 
found to contain microsatellite instability further confirming that crypt foci were MMR 
deficient. These findings suggest that MMR deficient Lynch Syndrome tumours could 
arise from crypts which have lost MMR function. If this is the case then loss of MMR 
gene function may be the first mutation which initiates the transformation from normal 
mucosa to MSI-H tumour in Lynch Syndrome patents.  
For many of the sporadic MSI-H tumours the pathway to a loss of mismatch repair 
function may be different to what happens in Lynch Syndrome tumours. Many of these 
tumours may originate as adenomas with CIMP hypermethlation, then during later 
tumour development, loss of MLH1 gene expression due to MLH1 hypermethylation 
causes the development of MSI (Fearon, 2011). Loukola et al. (1999) analysed adenomas 
from 378 patients and discovered only six patients with MSI-H adenomas, only one of 
which turned out to not have a germline mutation in one of the MMR genes. This adds 
further evidence to the theory that in sporadic MSI-H tumours the loss of MMR function 
occurs during the development of the tumour and is not the initial driver mutation.  
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Tumour initiation and progression differs for different types of tumour. For 
example lung cancers often develop through a field effect, where the development of 
several separate lung preneoplastic lesions occurs in different locations which can then 
develop into separate tumours (Wistuba, 2007). In other cases, tumours have a single cell 
as their point of origin. As the tumours grow, they accumulate mutations and some 
mutations (driver mutations) give cells an advantage compared to other cells. Different 
cells with different sets of driver and passenger mutations may arise and become prolific 
within the same tumour giving rise to different clones and creating heterogeneous 
tumours. Clones may arise which have a selective advantage allowing them to 
outcompete the other clones in a tumour. This can lead to selective sweeps which will 
return a tumour to a monoclonal state (Greaves and Maley, 2012, Merlo et al., 2006). 
Another possibility is that the number of clones continues to expand as a tumour develops, 
creating tumours that are a mosaic of different clones. Tumours can be thought of as an 
ecosystem consisting of evolving clones competing for the available resources such as 
space and nutrients (Merlo et al., 2006). For some tumours the number of clones detected 
can be an indicator of tumour progression. One example of a type of tumour where this 
is true is the Barrett’s oesophagus tumour. For this tumour one study found that for every 
clone identified in a pre-malignant lesion the relative risk of the lesion developing into a 
adenocarcinoma increased by a factor of 1.43 (Maley et al., 2006). The number of clones 
is also associated with the chance of drug resistance. With more clones, there is a higher 
chance that the tumour will survive chemotherapy. 
Clonality within tumours can be studied by analysing a set of markers over 
different regions of a tumour. Studying the clonality of tumours can give new insight into 
how tumours develop. Theoretically, the order in which different clones in a tumour arose 
can be deduced by analysing the patterns of mutations for different clones (Merlo et al., 
2006). For example, if one clone has a mutation in one marker A and another clone has a 
mutation in both marker A and marker B, then it is likely that the clone which only has a 
mutation in marker A arose first.  Microsatellites have previously been used to assess the 
clonality of tumours. One example is the analysis of tumours in the Tasmanian devil 
(Sarcophilus harrisii), population on Tasmania. Siddle et al. (2007) showed that the 
tumours spreading through the Tasmanian devil population are of the same clonal origin 
by analysing the length of different microsatellites. This use of microsatellites helped 
prove that the tumours are being spread as allografts from devil to devil. 
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6.1.2. Aims 
In this chapter, the aim is to use the sequencing of short mononucleotide repeats 
to investigate the clonal composition of MSI-H tumours. By taking different biopsies 
from different regions of the same tumour, it should be possible to detect whether there 
are differences in the instability of short mononucleotide repeats throughout the tumour. 
Differences in the instability of repeats across a tumour, such as differences in variant 
repeat lengths, would indicate the presence of different sub-clones within a tumour. 
Heterozygous SNPs will also be used to determine the allelic origin of variants. This will 
allow the instability of repeat to be investigated in more detail because variants on 
different alleles can be identified. For variants located in multiple biopsies it will be 
possible to deduce whether a variant is present on the same allele and therefore likely to 
be the result of one mutation, or if a variant is located on different alleles in different 
biopsies and therefore the result of independent mutations. In this chapter, the aim is to: 
 
 Determine whether there is evidence of clonal evolution in MSI-H colorectal 
tumours.  
 
 Determine whether the use of heterozygous SNPs to identify on which allele a 
variant is present provides extra information about the clonality of MSI-H 
tumours.  
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6.2. Results 
6.2.1. The curation of fresh tissue biopsies for the clonality study 
Tumour and tissue samples for the clonality analysis were obtained from the 
Newcastle Hospitals NHS Foundation Trust after ethical review (REC reference 
13/LO/1514). Biopsies were taken from fresh colorectal tumours shortly after resection 
using the hours of a clock face as a reference point. The side of the tumour closest to the 
antimesenteric border was defined as 12 o’clock. In some of the tumours it was 
impractical to use the antimesenteric border as 12 o’clock, for example because the 
tumours had grown across the antimesenteric border. In these cases the proximal 
orientation of the tumour was defined as 12 o’clock. Where possible four scalpel biopsies 
of external tumour tissue were taken from the 3, 6, 9 and 12 o’clock positions round the 
tumour followed by four fine needle aspiration biopsies taken from the 3, 6, 9 and 12 
o’clock positions from deeper within the tumours. If the tumour was too small for this 
sampling technique then not all 8 biopsies were collected. Normal mucosa was sampled 
using a scalpel 7-10cm away from the tumour to ensure the normal mucosa biopsies were 
not contaminated by any tumour tissue (see methods section 2.1.2.4 for more details). A 
total of 13 tumours were biopsied by Dr Stephanie Needham (Pathology department, 
Newcastle Hospitals NHS Foundation Trust). 
6.2.2. MSI fragment analysis testing of tumours to identify MSI-H tumours 
To identify MSI-H tumours, one biopsy from each tumour as well as the matched 
normal mucosa was tested using the Promega MSI Analysis System, Version 1.2 kit 
(Promega, Madison, WI, United States of America). The fragment analysis tests showed 
that for 10 out of the 13 tumours there was no difference in instability between the normal 
mucosa biopsy and the tumour biopsy. The remaining three tumours were unstable at all 
5 markers (see fragment analysis traces Figure 6.1). These three MSI-H tumours were 
used for the subsequent work described in this chapter. 
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Figure 6.1: Fragment analysis traces for the three MSI-H tumours. Panel A tumour PR17848/14, Panel B 
tumour PR51896/13, Panel C tumour PR10654/14.  
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6.2.3. Three MSI-H tumours PR10654/14, PR17848/14 and PR51869/13 
For each of the three MSI-H tumours 8 biopsies were taken using the clock face 
as a reference point. These 8 biopsies consisted of four scalpel biopsies sampling the 
surface of the tumour at each quadrant of the clock face, and 4 fine needle aspiration 
biopsies from deeper within the tumours at each quadrant of the clock face.    
The tumour PR17848/14 was a large carcinoma. This tumour had grown across 
the antimesenteric border and it was therefore easier to orientate biopsies with the 
proximal side of the tumour as 12 o’clock. Normal mucosa was sampled from 10cm away 
from the tumour. A photo of the tumour prior to processing can be found in Figure 6.2.       
 
Figure 6.2: The tumour PR17848/14. Biopsies were taken from this tumour using a clock face as reference. 
The proximal side of the tumour was designated as 12 o’clock.   
The tumour PR51896/13 was located close to the ileocaecal valve. This tumour 
was orientated with the proximal side of the tumour as 12 o’clock for the purpose of 
obtaining biopsies. Normal mucosa was biopsied 10cm from the tumour. For a photo of 
the tumour PR51896/13 see Figure 6.3. This tumour had already been processed in 
formalin fixative prior to being photographed, but all biopsies were taken before the 
processing of the tumour began.  
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Figure 6.3: The tumour PR51895/13. Biopsies were taken from this tumour using a clock face as reference. 
The proximal side of the tumour was designated as 12 o’clock.   
The tumour PR10654/14 was located where the terminal ileum meets the caecum. 
The tumour was removed via a limited right hemicolectomy. This tumour was biopsied 
using the side of the tumour closest to the antimesenteric border as 12 o’clock. Normal 
mucosa was sampled 7.5cm from the tumour. The tumour PR10654/14 was a necrotic 
tumour, and there was a risk that the 9 o’clock needle biopsy contained only necrotic 
tissue. For a photo of the tumour PR10654/14 see Figure 6.4.      
154 
 
 
Figure 6.4: The tumour PR10654/14. Biopsies were taken from this tumour using a clock face as reference. 
The antimesenteric border was designated as 12 o’clock.   
6.2.4. Mutation detection in multiple biopsies from MSI-H tumours 
DNA concentrations were adjusted to ~10ng/µl for the production of amplicons. 
Amplicons were produced using Herculase II Fusion polymerase (Agilent, Santa Clara, 
CA, United States of America) and 28 PCR cycles. The reduction in the number of PCR 
cycles compared to that used previously was possible because the quality of DNA 
obtained from the fresh or frozen tumour tissue was better than DNA obtained from FFPE 
tissue. For each biopsy, 20 mononucleotide repeats were amplified (see Table 6.1 for a 
list of mononucleotide repeats). Amplicons were sequencing on an Illumina MiSeq using 
a MiSeq Reagent Kit v3 (600-cycles) (Illumina, San Diego, CA, United States of 
America) (see methods sections 2.3.2.2 and 2.7.2.2 for more details). The biopsies from 
tumours PR10654/14, PR17848/14 and PR51869/13 were sequenced on the same MiSeq 
run as the samples analysed in chapter 7 of this thesis. 
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Repeat Name Repeat Size Repeat Position SNP1  SNP2  SNP3
LR46  8bp  chr20:10660084  rs143884078  rs182346625  rs6040079 
LR24  9bp  chr1:153779428  rs192329538  rs1127091    
GM01  10bp  chr11:28894428  rs7951012       
GM22  10bp  chr14:43401009  rs58274313       
GM26  10bp  chr14:49584750  rs187027795  rs11628435    
GM29  10bp  chr3:70905559  rs2687195       
LR32  10bp  chr19 :37967219  rs7253091       
AVIL  10bp  chr12:58202497  rs2277326       
GM07  11bp  chr7:93085747  rs2283006       
GM14  11bp  chr3:177328817  rs6804861       
LR11  11bp  chr2:217217870  rs13011054  rs147392736  rs139675841 
LR17  11bp  chr14:55603030  rs79618905  rs77482253  rs1009977 
LR48  11bp  chr12:77988096  rs11105832       
ASTE1  11bp  chr3:130733047          
IM49  12bp  chr3:56682065  rs7642389       
LR36  12bp  chr4:98999722  rs182020262  rs17550217    
LR43  12bp  chr5:86199060  rs201282399  rs10051666  rs6881561 
LR44  12bp  chr10:99898285  rs78876983  rs7905388  rs7905384 
LR52  12bp  chr16:63861440  rs2434849       
FBXO46  14bp  chr19:46214701  rs34505186       
Table 6.1: A list of the 20 mononucleotide repeats sequenced for the multiple biopsies of tumours 
PR10654/14, PR17848/14 and PR51869/13. This list contains the designated repeat names, the length and 
location of each mononucleotide repeat, and the rs numbers of neighbouring SNPs. 
Variant calling was performed using COPReC (see methods section 2.8.6.2). The 
percentage of reads corresponded to each variant repeat length and the percentage of 
reference reads was calculated to enable the analysis of different indel sizes in the 
multiple biopsies for tumours PR10654/14, PR17848/14 and PR51869/13. Repeats were 
only analysed if there were ≥100 paired end reads spanning the repeat. The criteria of a 
minimum read depth was used to prevent a misrepresentation of variant frequencies 
caused by PCR duplicates. Table 6.2 contains the mean paired end read depth per 
mononucleotide repeat for all tumour biopsies. The 6 o’clock needle biopsy for tumour 
PR10654/14 was underrepresented among the reads generated for this MiSeq run. 
   PR51896/13  PR17848/14  PR10654/14 
Normal Mucosa  1135  1464  1707 
3 o’clock Scalpel Biopsy  1344  1928  1713 
6 o’clock Scalpel Biopsy  1100  2570  992 
9 o’clock Scalpel Biopsy  1408  1591  1924 
12 o’clock Scalpel Biopsy  1247  2383  1855 
3 o’clock Needle Biopsy  4733  2347  2363 
6 o’clock Needle Biopsy  986  1024  163 
9 o’clock Needle Biopsy  1362  1343  1719 
12 o’clock Needle Biopsy  1454  1447  1868 
Table 6.2: The mean paired end read depth per mononucleotide repeat for the biopsies of tumours 
PR10654/14, PR17848/14 and PR51869/13.  
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To analyse the deletions on individual alleles the perl script 
AlleleicBias_IndividualIndels.pl was written. This script was used to identify repeats that 
are heterozygous for a neighbouring SNP and calculate the percentage of reads 
corresponding to each variant repeat length and reference repeat length for both alleles. 
(see methods section 2.8.7.5 for more details).  
6.2.5. The clonal composition of tumour PR17848/14  
For 13 out of the 20 homopolymers tested there was a higher deletion frequency 
within the tumour compared to the normal mucosa. A representative selection of 6 of 
these repeats can be found in Figure 6.5, the rest can be found in the appendix Figure 9.1. 
All the unstable repeats with neighbouring heterozygous SNPs showed allelic bias for the 
tumour 17848/14 with the deletion being present mainly on one allele (see Figure 6.5). 
There is instability in all eight tumour biopsies for tumour 17848/14 (see Figure 
6.5). There is a lower deletion frequency in the 6 o’clock and 9 o’clock scalpel biopsies 
compared to the other tumour biopsies. These two biopsies do however show a 
significantly higher 2bp deletion frequency compared to the normal mucosa for 
homopolymer LR11 allele 1 (see Figure 6.5 panels A). LR11 allele 1 has a 2bp deletion 
frequency of 6.3% and 11.4% in the 6 o’clock and 9 o’clock respectively compared to the 
2bp deletion frequency of 0.29% in the normal mucosa (two-tailed Fisher’s exact test p-
values: <0.0000001). This suggests there is some instability within these two biopsies. 
The low levels of instability in the 6 o’clock and 9 o’clock scalpel biopsies may be due 
to contamination by normal tissue.  
The 9 o’clock needle biopsy stands out as different from the other biopsies for the 
homopolymers ASTE1, GM14, LR17 and IM49. For the repeat ASTE1 there is a lack of 
reads with 1bp deletions compared to other biopsies, and reads with a 2bp deletion make 
up 89% of the reads (see Figure 6.5 panels C). This shows that the 9 o’clock needle biopsy 
has a high tumour cell content and that the 2bp deletion is likely to be biallelic for this 
biopsy. The lack of reads with a 1bp mutation suggest that tumour cells with this mutation 
are underrepresented in the 9 o’clock needle biopsy region. For the repeat GM14 the 9 
o’clock biopsy is the only biopsy with a notably different 1bp deletion frequency to the 
normal control (see Figure 6.5 panels D). This suggests that this is a relatively new 
mutation which has developed in this location. The absence of a 1bp repeat in ASTE1 
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and an overrepresentation of a 1bp deletion in GM14 for the 9 o’clock needle biopsy 
suggests that the 1bp deletions in these repeats are located in different groups of cells. A 
difference in levels of contamination by normal tissue cannot account for the low 1bp 
deletion frequency in the other biopsies for GM14, because the level of instability in all 
of these biopsies, with the exception of the 6 o’clock and 9 o’clock scalpel biopsies, are 
high in other markers such as LR52. The repeat LR52 has a combined 2bp and 3bp 
deletion frequency of between 36% and 72% for these biopsies indicating that all of these 
biopsies have a tumour cell content of ~35% or higher (see Figure 6.5 panels G).  
For the repeat LR17 allele 1 there is a notably different level of 2bp deletions in 
the 9 o’clock needle biopsy compared to the normal mucosa (see Figure 6.5 panels E). 
The level of 2bp deletions in the other biopsies could be explained by PCR error. The 2bp 
deletion could be present in the same group of cells with the 1bp deletion in GM14, 
because both of these deletions are only present in the 9 o’clock needle biopsy. Further 
evidence that there may be a difference between the 9 o’clock needle biopsy and other 
biopsies can be seen for the repeat IM49 allele 2. For there is a low frequency of 2bp 
deletions compared to most of the other tumour biopsies despite evidence which suggests 
this biopsy has a very high tumour cell content (see Figure 6.5 panel I). This suggests that 
there is a difference in the composition of tumour cells in this region compared to the rest 
of the tumour. Further evidence of this is the high 1bp deletion frequency in the 9 o’clock 
needle biopsy for IM49. 
The 9 o’clock scalpel biopsy has a deletion distribution that is reminiscent of 9 
o’clock needle biopsy for marker IM49, with no significant difference in 2bp deletion 
frequency compared to the normal mucosa for allele 2 (two-tailed Fisher’s exact test p-
value: 0.67) and a 1bp deletion frequency that is significantly higher than what is observed 
in the normal mucosa (two-tailed Fisher’s exact test p-value: 0.0000098) (see Figure 6.5 
panels I). This is the only instance where the mutation profile of the 9 o’clock scalpel 
biopsy differs from the other scalpel biopsies and the 3 and 6 o’clock needle biopsies.  
The results discussed above indicate that the 9 o’clock needle biopsy contains a 
group of cells with a different mutation profile compared to what is present in the other 
tumour biopsies. This could indicate that there is a distinct sub-clone located in the 9 
o’clock needle biopsy region of this tumour. There may also be a difference in the 
composition tumour cells in the 9 o’clock scalpel biopsy, which shows a lack of the 2bp 
deletion seen in other biopsies for the homopolymer IM49.    
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Figure 6.5: Frequencies of variant reads in 6 repeats showing instability for the tumour PR17848/14. Each 
panel shows the indel frequencies in 8 tumour biopsies and normal mucosa from the same patient. Tumour 
biopsies were taken from the four quadrants of the tumour according to the clock face. Normal = Normal 
Mucosa, S = Scalpel Biopsy (a biopsy from the surface of the tumour), N = Needle biopsy (a biopsy from 
deeper into the tumour tissue). *A total of ≥100 paired end reads for the marker, but less than 100 paired 
end reads for the allele. 
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6.2.6. The clonal composition of tumour PR51896/13 
For the tumour PR51896/13 14 of the 20 homopolymers analysed showed signs 
of instability. A representative selection of 7 of these repeats can be found in Figure 6.6, 
the rest of the repeats can be found in the appendix Figure 9.2 and Figure 9.3. The 9 
o’clock scalpel biopsy has the highest frequency of variant reads for most of the repeats 
sequenced (see Figure 6.6). The 6 o’clock scalpel biopsy on the other hand does not 
notably differ in variant read frequencies from what is present in the normal mucosa. This 
biopsy could therefore be classed as MSS. Whether this is a result of contamination by 
normal tissue or a result of sampling cells that belong to a clone that that arose before the 
knock out of MMR function is unknown. 
For the repeat AVIL the 1bp and 2bp deletions present for this marker are found 
at a roughly equal ratio in all the tumour biopsies except the 6 o’clock scalpel biopsy 
which does not show any signs of instability (see Figure 6.6 panel B). This suggests that 
the 1bp and 2bp deletions are present in the same cells and these cells only became prolific 
after appearance of both variants.  
For the repeat LR46 only the 3 and 9 o’clock scalpel biopsies have a notably 
higher 1bp deletion frequency compared to the normal mucosa (see Figure 6.6 panel A). 
Repeats such as ASTE1, LR52, and FBXO46 have deletion levels in the needle biopsies 
and 12 o’clock scalpel biopsy on an equivalent level to what in seen in the 3 o’clock 
scalpel biopsy for the same repeats (see Figure 6.6 panels C, G and H). This suggests that 
lack of a deletion frequency that differs from the normal mucosa in LR46 is not due to 
normal contamination in the needle biopsies and 12 o’clock scalpel biopsy, but an absence 
of that mutation in the tumour cells in these biopsies. This could indicate that the 1bp 
mutation in LR46 occurred late in tumour development and that the 3 and 9 o’clock 
scalpel biopsies share a clonally distinct population of cells containing this 1bp deletion.   
Another difference between biopsies can be seen for GM14 allele 2 were there is 
a 2bp deletion frequency of 19% in the 12 o’clock needle biopsy (see Figure 6.6 panel E). 
Many of the other biopsies have a low level of 2bp deletions on allele 1, but the 12 o’clock 
needle biopsy is the only biopsy with a 2bp deletion frequency that notably differs from 
the normal mucosa on allele 2. This could suggest that there is a clonally distinct 
population of cell located in the 12 o’clock needle biopsy region of the tumour. 
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The repeat FBXO46 also gives evidence to support the hypothesis that there are 
different sub-clonal populations of tumour cells in tumour PR51896 (see Figure 6.6 panel 
H). The 12 o’clock scalpel biopsy contains a 4bp deletion which is absent in the 3 o’clock 
scalpel biopsy and the 3 o’clock scalpel biopsy contains a 5bp deletion which is absent in 
the 12 o’clock scalpel biopsy. This indicates that there is a population of cells present in 
the 3 o’clock scalpel biopsy region of the tumour that is not present in the 12 o’clock 
scalpel biopsy region of the tumour and vice versa.   
There may also be evidence of different populations of tumour cells spread 
throughout the tumour. For the repeat ASTE1 there is a 2bp deletions frequency above 
10% in all biopsies except the 12 and 6 o’clock scalpel biopsies (see Figure 6.6 panel C). 
The 12 o’clock scalpel biopsy has a 1bp deletion frequency of 44.4%. A 2bp deletion of 
only 4.2% in this biopsy may therefore indicate that the 1 and 2bp deletion are present in 
different groups of cells. The 2bp deletion in ASTE1 is also likely to be present in a 
different group of cells than the ones that contain 1bp deletions in the repeats LR32 and 
GM14 allele2 because these deletions are present at a high frequency in the 12 o’clock 
scalpel biopsy where the 2bp deletion in ASTE1 is present at a low frequency.  
The results above suggests that the tumour PR51896/13 is composed of different sub-
clones with one distinct group cells, characterised by mutations in LR46 which have been 
enriched in the 3 and 9 o’clock scalpel biopsy region of the tumour, while a different 
population, characterised by 2bp mutations in GM14 allele 2 is enriched in the 12 o’clock 
needle biopsy region of the tumour. 
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Figure 6.6: Frequencies of variant reads in 7 repeats showing instability for the tumour PR51896/13. Each 
panel shows the indel frequencies in 8 tumour biopsies and normal mucosa from the same patient. Tumour 
biopsies were taken from the four quadrants of the tumour with positioning according to the clock face. 
Normal = Normal Mucosa, S = Scalpel Biopsy (a biopsy from the surface of the tumour), N = Needle 
biopsy (a biopsy from deeper into the tumour tissue). 
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6.2.7. The clonal composition of tumour PR10654/14 
The tumour PR10654/14 had sixteen out of twenty mononucleotide repeats that 
showed signs of instability for at least one tumour biopsy. A representative selection of 7 
of these repeats can be found in Figure 6.7, the rest of the repeats can be found in the 
appendix Figure 9.4 and Figure 9.5. As mentioned before the 6 o’clock needle biopsy for 
tumour PR10654/14 was sequenced to an average read depth of 163 paired end reads per 
amplicon. As a result, many amplicons had a read depth below 100 paired end reads and 
were not analysed. The criteria of a minimum of 100 paired end reads was used to prevent 
a misrepresentation of variant frequencies caused by PCR duplicates. Other samples that 
were not analysed because of having less than 100 paired end reads were the 12 o’clock 
scalpel and needle biopsies for the repeat IM49.  
For this tumour there is also limited instability seen in the 6 o’clock scalpel biopsy. 
For the repeats ASTE1, LR17 and FBXO46 there might be instability in the 6 o’clock 
scalpel biopsy. The repeat ASTE1 has a 2bp deletion frequency that is over 7 times larger 
in the 6 o’clock scalpel biopsy than in the normal mucosa (see Figure 6.7 panel D). The 
6 o’clock scalpel biopsy has a higher frequency of 2bp deletions than the normal mucosa 
for the repeat LR17 with a 2bp deletion frequency of 3.2% and 0.3% respectively (see 
Figure 6.7 panel E). The 6 o’clock scalpel biopsy also has 4bp deletion present at a 
frequency of 5.8% in the repeat FBXO46 (see Figure 6.7 panel I). Because there are no 
reads in the normal mucosa containing a 4bp deletion for FBXO46 it is highly likely that 
the 4bp deletion in the 6 o’clock scalpel biopsy is caused by MSI. The results from 
ASTE1, LR17 and FBXO46 could indicate that there is some instability present in the 6 
o’clock scalpel biopsy. It is possible that the low mutation frequencies in this biopsy are 
caused by contamination from normal tissue. 
The 3 o’clock scalpel biopsy differs from many of the other biopsies for repeats 
LR32, GM07, GM14 and LR52 (see Figure 6.7). For the repeat LR52 the 3 o’clock scalpel 
biopsy is the only biopsy with a 3bp deletion frequency that notably differs from the 
normal mucosa, and for the repeat GM14 the 3 o’clock scalpel biopsy is the only biopsy 
that has a 2bp deletion frequency which notably differs from the normal mucosa on allele 
2. This suggests that there is a clonally distinct population of cells, which is highly 
overrepresented in the 3 o’clock scalpel biopsy region of the tumour. 
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For the repeat LR32 the 3 o’clock scalpel biopsy and 6 o’clock needle biopsy are 
the only biopsies with a significantly higher 1bp deletion frequency than the normal 
mucosa (two-tailed Fisher’s exact test p-values: <0.0000001). This is the only repeat 
where the 3 o’clock scalpel biopsy and 6 o’clock needle biopsy share a mutation which 
is not present in the other tumour biopsies (see Figure 6.7 panel C). This could suggest 
that that the 1bp deletion in the 3 o’clock scalpel biopsy and 6 o’clock needle biopsy have 
arisen separately as opposed to being present in the same population of cells, or that they 
are present in the same population of cells but these biopsies also contain additional 
populations of cells that are also present in other biopsies.   
For the repeat GM07 allele 2, the 3 o’clock scalpel biopsy and 6 o’clock scalpel 
biopsy are the only biopsies with a significantly higher 1bp deletion frequency compared 
to the normal mucosa (two-tailed Fisher’s exact test p-values: 0.0012 and <0.0000001 
respectively). This could suggest that the cell population that contains the 1bp deletion in 
the 3 o’clock scalpel biopsy also exist in the neighbouring 6 o’clock scalpel biopsy. It is, 
however, difficult to analyse the similarities between the 6 o’clock scalpel biopsy and 
other biopsies because of the low level of instability seen in the 6 o’clock scalpel biopsy.  
For the homopolymer GM07 at least 4 different replication mistakes in different 
groups of cells must have occurred to make the deletion distribution seen in this tumour 
with both 1bp and 2bp deletions present on both alleles in different biopsies (see Figure 
6.7 panels D and E). This repeat has different mutation profiles in different regions of the 
tumour, which could represent the emergence of different tumour sub-clones. As 
mentioned before, the 3 o’clock scalpel biopsy and 6 o’clock scalpel biopsy may contain 
cells from a clonally distinct cell population. Equally, the 9 o’clock biopsies share a 
distinct mutation pattern with a 2bp deletion frequency above 40% on both alleles. This 
may indicate a clonally distinct population of cells in the 9 o’clock region. The 12 o’clock 
biopsies and 3 o’clock needle biopsy share the same mutation profile on both alleles for 
marker GM07, which may indicate a common clonal decent for cells in these regions. 
The repeat FBXO46 appears to be polymorphic with both reference reads and 
reads containing a 1bp deletion being present at a frequency of 33.5% and 52% 
respectively in the normal mucosa (see Figure 6.7 panel I).
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Figure 6.7: Frequencies of variant reads in 7 repeats showing instability for the tumour PR10654/14. Each 
panel shows the indel frequencies in 8 tumour biopsies and normal mucosa from the same patient. Tumour 
biopsies were taken from the four quadrants of the tumour according to the clock face. Normal = Normal 
Mucosa, S = Scalpel Biopsy (a biopsy from the surface of the tumour), N = Needle biopsy (a biopsy from 
deeper into the tumour tissue). * A total of ≥100 paired end reads for the marker, but less than 100 paired 
end reads per allele.
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Based on the results discussed previously in this section I would conclude that the 
tumour PR10654/14 could broadly be divided up into 4 distinct regions of clonally 
different cells (see Figure 6.8). The 6 o’clock scalpel biopsy, which shows limited 
instability in this tumour, has been designated region 1. The 3 o’clock scalpel biopsy, 
which has a different deletion pattern to the other tumour biopsies for markers LR32, 
GM07, GM14 and LR52, has been designated region 2. The 12 o’clock biopsies and the 
3 o’clock needle biopsy have the same deletion compositions on each allele for the repeats 
shown in Figure 6.7. For this reason, the 12 o’clock biopsies and the 3 o’clock needle 
biopsy have been designated region 3. The two 9 o’clock biopsies have assigned region 
4 because these two biopsies were the only biopsies with a 2bp deletion on each allele for 
the repeat GM07 (see Figure 6.7). Otherwise the two 9 o’clock biopsies are very similar 
to the biopsies from region 3. Because of the low read depth obtained for the 6 o’clock 
needle biopsy there were many markers where this biopsy was not analysed. For the 
markers that were analysed the 6 o’clock needle biopsy, it was similar to the 3 o’clock 
scalpel biopsy for marker LR32, and was otherwise similar to the biopsies in region 3. I 
would therefore conclude that the 6 o’clock scalpel biopsy is likely to closely related 
regions 2 and 3.          
 
Figure 6.8: Four possible clonal regions for tumour PR10654/14 highlighted in yellow. The number without 
brackets represent scalpel biopsies and the numbers in brackets represent needle biopsies. The scalpel 
biopsies were taken from the tumour surface while the needle biopsies were used to sample tissue deeper 
within the tumour. 
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6.3. Discussion 
 
The fresh tissue yielded high quantities of DNA even for the fine needle aspiration 
biopsies. For the fresh tissue there were no problems creating amplicons of 300bp, which 
has been a challenge in the FFPE tissue used in previous chapters. Creating amplicons 
from FFPE tissue is a known problem, which arises because preserving tissue in this way 
causes the fragmentation of DNA. Using DNA obtained from FFPE tissue can therefore 
be problematic for many diagnostics tests including the current fragment analysis test 
which is used to diagnose MSI. For this work using DNA from fresh or frozen tissue 
meant that the number of PCR cycles could be reduced from 35 to 28. A reduction in PCR 
cycles should give a reduction in PCR error making it easier to distinguish between real 
mutations and background noise. Using fresh or fresh frozen tissue for the diagnosis of 
MSI would therefore be an advantage, whether the test is a future sequencing based MSI 
test or a current fragment analysis test. If standard practice could be changed so that a 
tissue sample for MSI testing was obtained prior to formalin fixation then MSI diagnosis 
would be easier with a lower failure rate. There was very low read depth obtained for the 
PR10654/14 6 o’clock needle biopsy but this is believed to have occurred during the 
Nextera XT library prep, because all amplicons for this sample were fine when quantified 
on the QIAxcel prior to starting the Nextera XT library prep. 
The needle biopsies consistently showed a high frequency of variant reads for the 
markers that were unstable in each tumour. This suggests that needle biopsies may be a 
good method for sampling tumours for MSI analysis. It should however be noted that 
differences in marker instability across a tumour means that a needle biopsy does not give 
the complete picture of the MSI across the whole tumour. On the other hand a single 
needle could be inserted into several regions of the tumour being sampled. Such a 
technique using needle biopsies could be used as a method for sampling tumour tissue for 
new point of care devices such as the Q-POC being developed by the company 
QuantuMDx which is a possible future platform for a sequencing based MSI test.  
Short 8bp-14bp microsatellites have made a good tool for identifying different 
sub-clones using instability in the three MSI-H tumours PR10654/14, PR17848/14 and 
PR51869/13. Differences between biopsies were observed in all three tumours. 
Differences between biopsies included; instability in a different number of repeats and 
different deletion sizes observed in different biopsies from the same tumour. The results 
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presented here indicated that there is a distinct sub-clone located in the 9 o’clock needle 
biopsy region of tumour PR17848/14. Results for tumour PR51869/13 suggested that 
there might be a clonally distinct group of cells in the 3 and 9 o’clock scalpel biopsy 
region of the tumour and a different clonally distinct group of cells present in the 12 
o’clock needle biopsy region of the tumour. The tumour PR10654/14 had a greater 
number of differences between biopsies than the other two tumours. The results for 
PR10654/14 suggest that this tumour can be divided up into at least 4 regions with distinct 
sub-clones. The results for these three tumours suggest that as the tumours have 
developed they have continued to accumulate mutations. Using short homopolymers to 
identify distinct clonal regions of MSI-H tumours may be useful as it could, for example, 
enable metastasis evolution to be tracked.  
For the tumour PR51896/13 the 6 o’clock scalpel biopsy showed no sign of 
instability in any of the 20 repeats tested. This is despite other biopsies from this tumour 
showing instability in 14 out of the 20 markers tested. There are two possible explanations 
for why this biopsy exhibits no microsatellite instability. One possible reason is that the 
6 o’clock scalpel biopsy contained tumour cells belonging to a clone that arose early in 
tumour development prior to the knock out of mismatch repair function. Evidence 
suggests that sporadic MSI-H tumours most likely develop from MSS adenomas (Fearon, 
2011, Loukola et al., 1999) so this is a possibility. Information on whether the tumour 
PR51896/13 is a sporadic MSI-H tumour or not is not available, but the majority of MSI-
H tumours occur in patients without a germline mutation so there is a high likelihood that 
this tumour is a sporadic MSI-H tumour. The other possibility is that the 6 o’clock scalpel 
biopsy from tumour PR51896/13 has been contaminated by normal tissue. It is peculiar 
that the 6 o’clock scalpel biopsies from all three tumours contained a lower level of 
instability compared to the other biopsies. This could suggest this lower level of MSI is 
something to do with the sampling technique leading to a contamination of normal tissue 
in the form of blood or normal mucosa.   
Using repeats with neighbouring SNPs with a high minor allele frequency proved 
useful because it provided extra information about the number of different mutations that 
have occurred in a repeat throughout the tumour. For example in the tumour PR10654/14, 
being able to see which allele different deletions belonged helped with the analysis of the 
tumour (see Figure 6.7). For the repeats with neighbouring heterozygous SNPs (GM14 
and GM07) there were deletions of the same size on both alleles with frequencies that are 
unlikely to be caused by PCR and sequencing error. This indicates that there have been 
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separate replication mistakes on both alleles that have not been rectified by the 
compromised mismatch repair system in the tumour PR10654/14. It would not have been 
possible to know this without using the heterozygous SNPs. For example, it was only 
clear that there had been at least 4 different deletion events in the mononucleotide repeat 
GM07 for tumour PR10654/14 after analysing the two alleles individually. The extra 
information provided by being able to distinguish between the two alleles for this tumour 
did not just show that there were more deletions than expected in these repeats, but also 
helped identify different sub-clonal regions within the tumour PR10654/14 (see Figure 
6.8).    
Using repeats with neighbouring heterozygous SNPs also has the potential to help 
study other aspects of the clonal development of MSI-H tumours. In the study of familial 
adenomatous polyposis (FAP) a patient with sex chromosome mixoploid mosaicism 
(XO/XY) helped reveal that some FAP tumour are not of monoclonal origin. For 3 out of 
the 55 adenomas analysed by Thirlwell et al. (2010) different groups of tumour cells 
within the same adenoma had the XO and XY genotypes. This showed that the tumour 
could not have originated from just one cell. Using the same principle, heterozygous SNPs 
could be used to study the origin of tumours in mosaic patients to determine if the tumours 
are of monoclonal or polyclonal origin. Identifying SNPs where a minor allele is only 
present in one of the groups of cells in a mosaic patient could be a powerful tool for 
analysing the clonal origin of tumours in mosaic patients. Especially if several SNPs are 
used, some with a minor allele present in one tissue and others with a minor allele present 
in the other tissue. Although the need for mosaic patients would limit the usefulness of 
this technique to only a few individuals it would be a more powerful tool than using X 
chromosome inactivation to determine if tumours are of a monoclonal origin. X 
chromosome inactivation has been widely used for investigating the clonal origin of 
tumours (Leedham and Wright, 2008). In early embryonic development one of the X 
chromosomes in females is inactivated. Which X chromosome is inactivated will differ 
in different cells. Analysing many tumours showing activation of only one X 
chromosome have been used as evidence of monoclonal origin in tumours (Fearon et al., 
1987). However the discovery of a tumour showing activation of genes on both X 
chromosomes would not necessary indicate that a tumour was of a polyclonal origin. This 
is because the reactivation of genes on the inactive X chromosome does occur in tumours 
(Chaligne et al., 2015). Using heterozygous SNPs in mosaic patients would therefore be 
better for proving the polyclonal origin of tumours. 
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6.3.1. Conclusions 
In conclusion, there was evidence to suggest that the three MSI-H tumours where 
multiple biopsies were analysed were all heterogeneous tumours composed of different 
sub-clones. The use of repeats with neighbouring heterozygous SNPs to identify the 
allelic origin of deletions also facilitated a more in-depth analysis of the clonal evolution 
of the three MSI-H tumours. 
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Chapter 7. MSI test validation and investigation of 
QuantuMDx’s Q-POC platform  
7.1. Introduction and aims 
7.1.1. Introduction 
7.1.1.1. Current MSI testing platform  
Recently, it has been reported that current clinical criteria and management 
guidelines used to identify colorectal cancer (CRC) patients for MSI testing (Amsterdam 
II criteria and revised Bethesda Guidelines) fail to identify a significant number of Lynch 
Syndrome patients (Canard et al., 2012, Mills et al., 2014, Perez-Carbonell et al., 2012). 
This has led to suggestions that all CRC tumours should undergo molecular testing (Vasen 
et al., 2013, Canard et al., 2012, Mills et al., 2014, Julie et al., 2008). Screening all 
colorectal cancers for MSI then Lynch Syndrome could be used to detect many of the 
patients and families with Lynch Syndrome that currently go undetected. Also, to enable 
future targeted treatment for both sporadic and germline MSI-H CRCs, MSI testing 
practices should change so that all CRCs are tested for MSI. Because MSI tests are 
expensive it would, with the current methods, be very expensive to test all CRCs in order 
to identify the MSI-H cancers.  
A Sequence based MSI typing using short mononucleotide repeats could be 
advantageous in terms of cost and ease of interpretation through automation. This could 
further lower the cost of an MSI test such that it is more cost effective to test all colorectal 
cancers for MSI and reduce the time it takes to receive a test result. A sequencing based 
MSI test could be introduced as a next generation sequencing assay on a platform such 
the Illumina sequencers or it could be produced even more cheaply on a platform like the 
one currently being developed by the company QuantuMDx. 
7.1.1.2. QuantuMDx’s silicon nanowire platform  
The company QuantuMDx are developing a cheap and fast DNA testing point of 
care (Q-POC) device. This device may ultimately allow the rapid diagnosis of many 
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diseases including MSI testing for colorectal cancer. One of the main aims of this project 
has been to create an MSI assay that is compatible with the technology being developed 
by QuantuMDx. As mentioned before, the markers used in current fragment analysis are 
too long for sequencing because polymerases cannot replicate long homopolymers 
faithfully. Therefore shorter repeats are needed for a QuantuMDx Q-POC assay. As part 
of my PhD project I have developed a panel of short homopolymers for MSI detection 
and also worked on the initial development of some of the components of QuantuMDx’s 
Q-POC device.  
QuantuMDx’s device consists of four main components. The first component will 
be a tissue lysis chamber. This may comprise either of a mechanical lysis device or 
involve chemical lysis using a proteinase k based method. The tissue used can either be 
FFPE tissue or fresh tissue. QuantuMDx plan to use a needle biopsy style approach to 
sample fresh tumour tissue. This means that the amount of tissue used will be small and 
sheared from passing through the needle minimising the time needed to lyse the tissue. 
This is important for a rapid point of care device. Results in chapter 6 showed that using 
a needle biopsy to identify microsatellite instability using fresh tumour tissue works well.  
  The second component is a DNA extraction cassette; this contains a sorbent filter 
(Q-FILTER™) for the adsorption and removal of cellular components such as proteins, 
lipids and low molecular weight compounds while DNA is not absorbed. This means that 
lysed sample and buffer solution can be passed into the filter, and the buffer solution 
containing purified DNA will pass through the filter ready for PCR amplification while 
other cellular material is retained.  
The third component of QuantuMDx’s technology is their micro fluidic PCR 
cassette (Q-AMP™) which relies on the PCR mixture flowing through different 
temperature zones to achieve PCR amplification. For the PCR reaction itself there is the 
possibility of using either a two-step or a three-step continuous flow PCR. A three-step 
PCR has three heating zones; a denaturation zone, an annealing zone, and an extension 
zone. A two-step PCR on the other hand only has the denaturation zone and the annealing 
zone. For the two-step PCR, amplicon extension happens in the brief temperature 
transition between the annealing zone and denaturation zone. This can be achieved 
because Taq polymerase can synthesis a new DNA strand at a rate of 60-100 nucleotides 
per second (Kim et al., 2006). Continuous flow PCR has been shown to produce 
detectable amounts of PCR product in just 8-30 minutes (Kim et al., 2006). This type of 
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PCR therefore allows for the rapid production of PCR amplicons, reducing the overall 
time from sample to detection.  
The last component is a silicon nanowire based detection device. The nanowires 
will be printed with amine terminated DNA or peptide nucleic acid (PNA) probes for each 
region of interest. The amine group allows the DNA/PNA probes to be attached to the 
nanowires through a reaction with aldehyde groups on the nanowire surface. DNA 
features with widths of 100nm can be printed using microarray printing technologies such 
as Dip-Pen Nanolithography (Demers et al., 2002), allowing different nanowires on the 
same chip to be printed with different probes. These probes will capture the PCR product, 
produced by the PCR cassette, and function as primers for a sequencing by synthesis 
reaction that incorporates negatively charged nucleotides. Silicon nanowires are highly 
sensitive to the binding of charged molecules and have the advantage of a linear change 
in conductance with the concentration of charged molecules over a large dynamic range 
(Cui et al., 2001). This could potentially be used to detect what fraction of DNA 
molecules contain the base of a mononucleotide repeat and what fraction of molecules 
contain the base after the repeat enabling the fraction of reads containing an indel as well 
as indel size to be determined. 
QuantuMDx are planning to use proprietary negatively charged nucleotides in 
their sequencing reaction. These nucleotides comprise of a negatively charged reporter 
group attached to a dNTP by a cleavable linker (see Figure 7.1). The modified dNTP 
work as a substrate for polymerases, allowing the negatively charged dNTPs to be added 
to the nascent strand during a sequencing by synthesis reaction. Upon base incorporation, 
the negatively charged reported group will create a change in conductance of a nanowire 
allowing the detection of successful incorporated bases. Using silicon nanowires it is 
possible to detect DNA hybridising to probes in real time (Gao et al., 2007). It should, 
therefore, also be possible to detect the incorporation of bases with negatively charged 
reporter groups in real time. The modified dNTPs also have reversible blocking groups 
which will ensure that only one base is incorporated at a time in the sequencing reaction. 
The reversible blocking group is cleaved before the next base can be incorporated. This 
should allow more accurate sequencing of mononucleotide repeats than is achieved using 
sequencing technologies such as 454 sequencing or IonTorrent where chain termination 
is not used and the number of bases in a mononucleotide repeat is inferred by signal 
intensity (Stranneheim and Lundeberg, 2012, Shendure and Ji, 2008).   
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Figure 7.1: A diagram showing an example of one of QuantuMDx’s negatively charged bases. Each base 
will have a reversible blocking group allowing the incorporation of one base at a time, and a negatively 
charged reporter group which will be detected by the nanowires of QuantuMDx’s detector. RBG = 
reversible blocking group 
7.1.2. Aims 
The initial screen of 120 homopolymers with neighbouring SNPs, identified from 
whole genome data, showed a high level of instability in the five MSI tumours sequenced 
with 40% of the short 7bp-9bp A/T repeats, 80% of the longer 10bp-12bp A/T repeats 
and 33% of the G/C repeats showing instability in at least one tumour (chapter 5). Markers 
were arbitrarily defined as unstable if a marker had a deletion frequency >5% and a 
deletion frequency of at least twice that of any of the control samples for the 7-9bp 
repeats, or 1.5x that of any of the control samples for the 10-12bp repeats. Using 
heterozygous SNPs located within 30bp of the repeats I was also able to show that there 
was an excess of repeats showing allelic bias of reads with deletions in the MSI-H 
samples. 10 markers from whole genome analysis, which were classed as unstable in at 
least 60% of the MSI-H samples and also had an AUC of at least 0.9 were chosen for 
further investigation (chapter 5). The 10 markers taken from the literature, which showed 
instability in chapter 3 were also selected for further analysis. To further refine the 
selected panel of 20 repeats it would be advantageous to look at the sensitivity and 
specificity of the markers at different deletion frequencies to define thresholds for calling 
instability. To obtain enough data to define reasonable thresholds for each marker, the 
markers needed to be sequenced in a larger panel of tumours than analysed to date. This 
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chapter will also outline my contributions towards the hardware development of the 
QuantuMDx Q-POC device which, when complete, can potentially be used as a platform 
for a sequencing based MSI test. The work outlined in this chapter will aim to:   
 Test a larger panel of CRCs to assess the sensitivity and specificity of the chosen 
panel of repeats 
 Perform an analysis to determine suitable thresholds for calling instability by 
analysing the sensitivity and specificity of each marker. 
 Evaluate the allelic bias in the MSI-H tumours to assess if allelic bias can be 
used as an additional tool for differentiating between mutations caused by MSI 
and sequencing and PCR artefacts.   
 Develop the QuantuMDx hardware which can be used as a platform for the MSI 
test.  
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7.2. Results 
7.2.1. Identification and curation of a panel of colorectal tumours 
In previous chapters, the repeat panels have been tested on a small number of 
MSI-H tumours and controls to identify highly informative markers and assess the impact 
of length on information content. For the work in this chapter it was important to obtain 
a large number of tumours to define thresholds for calling instability and determine if the 
chosen panel of repeats is sufficient for differentiating between MSI-H and MSS tumours. 
A total of 92 tumour samples were obtained after ethical review (REC reference 
13/LO/1514). These tumours were supplied by Ottie O’Brien (Northern Genetics Service, 
Newcastle Hospitals NHS Foundation Trust), and Julie Coaker (Institute of Genetic 
Medicine, Newcastle University) in the form of FFPE wax curls and DNA already 
extracted FFPE samples.  
DNA from the 92 tumours was first assessed to identify how many tumours had a 
sufficient quantity and quality of DNA to produce amplicons of ~300bp in length for a 
panel of 20 markers. The size of the panel was chosen because 20 markers should be 
sufficient to differentiate between MSI-H and MSS tumours and there was insufficient 
DNA for many of the tumours to amplify a larger panel. For 3 tumours there was too little 
starting material to be able to amplify 20 repeats. Out of the remaining 89 tumour DNA 
samples it was possible to amplify 58 of the samples using amplicons of ~300bp.  
For 24 tumour samples all the PCR reactions were performed manually. To save 
time, 8 amplicons (DEPDC2, AL359238, AL954650, AP003532_2, TTK, AL355154, 
AVIL, ASTE1, EGFR, FBXO46) for 34 tumours were done robotically by NewGene 
(NewGene Ltd, International Centre for Life, Newcastle Upon Tyne, NE1 4EP, UK). For 
these 34 tumours the remaining 12 amplicons were produced manually. The PCR protocol 
and reagents used by NewGene did not differ from the protocol as outlined in methods 
section 2.3.2.2. The only difference in the protocol for the amplicons produced by 
NewGene was that after PCR amplification post PCR cleanup was performed by 
NewGene using Ampure XP beads. NewGene had a high PCR failure rate. 48 out of a 
total of 272 amplicons produced by NewGene did not produce a sufficient amount of PCR 
product to give visible products on the gels. The PCR for all of the failed amplicons were 
repeated manually. 
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Quantification for all PCR products was done using a Qiagen QIAxcel (Qiagen, 
Limburg, Netherlands) prior to amplicon pooling. After pooling, all amplicon pools were 
processed using Agencourt AMPure XP beads (Beckman Coulter, Pasadena, California, 
United States) to remove residual PCR reagents and Primer dimers. After PCR clean up 
each amplicon pool was quantified using a Qubit 2.0 fluorometer (Life Technologies, 
Carlsbad, CA, United States of America) and each amplicon pool was diluted to achieve 
a DNA concentration of 0.2ng/µl which is the recommended input DNA concentration 
for the Nextera XT library prep. The Illumina Nextera XT library prep was used to 
prepare the amplicons for sequencing on the Illumina MiSeq (Illumina, San Diego, CA, 
United States of America). The sequencing was performed using a MiSeq Reagent Kit v3 
(600-cycles) (Illumina, San Diego, CA, United States of America). A flow cell cluster 
density of 2,068,000mm2 was obtained for this MiSeq run giving a total read depth of 
33,775,992 across all samples. This gave an average read depth of ~10000 paired end 
reads per amplicon. A Q-Score of over 30 was obtained for 56.8% of the bases sequenced 
(see Figure 7.2). There was a drop in Q-Score towards the latter cycles (see Figure 7.3). 
This is believed to be due to reaching the end of some of the amplicons being sequenced. 
 
Figure 7.2: The quality score (Q-Score) distribution for the reads generated on the MiSeq. Blue = bases 
with a Q-Score <30, Green = bases with a Q-Score >30. 
177 
 
 
Figure 7.3: The quality score (Q-Score) distribution for each cycle showing a drop in Q-Score towards the 
later cycles of each read. 
Variant calling was performed using COPReC. This is the same variant caller used 
in chapters 3, 5 and 6 (see methods section 2.8.6.2 for more details).  
7.2.1.1. The ability of individual microsatellite markers for detecting MSI-H tumours 
166 out of the 224 amplicons produced by NewGene failed to be sequenced, 
which is believed to be due to these amplicons having undergone PCR cleanup before 
being quantified using the QIAxcel. This meant that these amplicons were in a solution 
of dH2O whereas the amplicons produced manually had not been cleaned up and were 
therefore in PCR buffer. Due to the amplicons being in different solutions for the 
quantification it appears that they have not been quantified equally on the QIAxcel, and 
as a result, the amplicons produced by NewGene were over diluted. This resulted in the 
amplicons produced by NewGene being under represented in the final library that was 
sequenced on the MiSeq. As a result these amplicons are underrepresented in the 58 
tumours sequenced. Table 7.1 summarises the number of repeats sequenced for each 
tumour.  
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Tumour 
Sample 
MSI 
status 
Number of 8bp‐12bp Repeats 
Sequenced 
Number of 13bp‐14bp Repeats 
Sequenced 
15_S7  MSI‐H  18  2 
19_S9  MSI‐H  17  1 
21_S10  MSI‐H  16  0 
27_S15  MSI‐H  18  1 
3_S2  MSI‐H  15  1 
30_S16  MSI‐H  18  2 
31_S17  MSI‐H  18  0 
33_S18  MSI‐H  15  0 
34_S19  MSI‐H  12  0 
40_S21  MSI‐H  9  0 
41_S22  MSI‐H  15  0 
44_S24  MSI‐H  15  0 
5_S4  MSI‐H  18  1 
52_S29  MSI‐H  16  0 
53_S30  MSI‐H  15  2 
55_S31  MSI‐H  15  0 
80_S43  MSI‐H  12  0 
82_S45  MSI‐H  15  0 
83_S46  MSI‐H  14  0 
84_S47  MSI‐H  16  0 
G103_S54  MSI‐H  18  0 
G135_S55  MSI‐H  18  2 
G160_S56  MSI‐H  18  2 
G196_S57  MSI‐H  18  2 
G21_S51  MSI‐H  18  2 
G229_S58  MSI‐H  18  2 
G56_S52  MSI‐H  18  2 
G73_S53  MSI‐H  18  2 
13_S6  MSS  18  1 
18_S8  MSS  18  0 
2_S1  MSS  18  1 
22_S11  MSS  15  0 
24_S12  MSS  18  0 
25_S13  MSS  14  1 
26_S14  MSS  14  1 
36_S20  MSS  18  1 
4_S3  MSS  18  1 
43_S23  MSS  14  0 
45_S25  MSS  15  0 
49_S26  MSS  15  1 
50_S27  MSS  15  2 
51_S28  MSS  14  0 
59_S32  MSS  15  1 
60_S33  MSS  12  0 
64_S34  MSS  15  0 
65_S35  MSS  15  0 
69_S36  MSS  16  0 
70_S37  MSS  14  0 
71_S38  MSS  14  0 
72_S39  MSS  13  0 
73_S40  MSS  12  0 
74_S41  MSS  14  0 
79_S42  MSS  14  0 
8_S5  MSS  18  1 
81_S44  MSS  15  0 
88_S48  MSS  13  0 
90_S49  MSS  17  0 
91_S50  MSS  16  0 
Table 7.1: MSI status and number of amplicons sequenced for all 58 tumours.  
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The ability of each repeat to discriminate between the MSI-H samples and the 
MSS samples was assessed using the area under the receiver operating characteristic 
curve (AUC). Dr Mauro Santibanez-Koref (Institute of Genetic Medicine, Newcastle 
University) performed the AUC calculations. Receiver operating characteristic curves are 
a method of measuring true positive and false positive rates. In this case the AUC is a 
measure of how well a given homopolymer can differentiate between the MSI-H and 
MSS samples. An AUC of 1 is achieved if all the MSI-H samples have a higher deletion 
frequency than the MSS samples for a given repeat. Any randomly chosen MSI-H sample 
from the data set would in this case have a 100% chance of having a higher deletion 
frequency than any randomly chosen MSS sample from the data set. An AUC value of 
0.5 would mean that a repeat has no discrimination power because there would be 50-50 
chance that any randomly chosen MSI-H sample would have a higher deletion frequency 
than any randomly chosen MSS sample. 
The AUC values for all the homopolymer in the final panel can be found in Table 
7.2. On average, the AUC increases with repeat length up to a repeat length of 12bp. This 
means that the longer repeats, up to a length of 12bp, are better at discriminating between 
the MSI-H samples and MSS samples. This was expected because longer microsatellites 
are more prone to microsatellite instability events than shorter repeats. For the shorter 
repeats there will therefore be more repeats in MSI-H samples that have not been affected 
by a mutation, decreasing the ability of those repeats to discriminate between MSI-H 
samples and MSS samples. The 13bp and 14bp repeat have an AUC of 0.9 and 0.722 
respectively. These are lower AUC values than seen in all the 12bp and all but one of the 
11bp repeats (see Table 7.2). This could indicate that sequencing and PCR error are so 
high in these repeats that using the frequency of all deletions as a measure of instability 
is no longer as good for discriminating between MSI-H and MSS samples as it is for the 
shorter 11bp and 12bp repeats. On the other hand it could be that the chosen 13bp and 
14bp repeat are less prone to MSI due to sequence context and there may be many other 
13bp and 14bp repeat in the genome that are more unstable than these two. For the 14bp 
repeat FBXO46 a low AUC could also be due to the presence of a sequence length 
polymorphism in some of the controls. One of the tumours in chapter 6 had a sequence 
length polymorphism for this repeat which indicates there is a possibility that FBXO46 
could be polymorphic in some samples.     
180 
 
Repeat Name  Size (bp)  Repeat 
Base 
Number of Samples Sequenced  AUC 
DEPDC2  8  C 36 0.645 
LR46  8  A 58 0.825 
AL359238 9  A 53 0.806 
AL954650 9  C 29 0.639 
AP003532_2  9  A 58 0.896 
TTK  9  A 46 0.733 
AL355154 10  A 33 0.915 
AVIL  10  A 39 0.927 
GM29  10  A 57 0.883 
LR32  10  A 57 0.910 
ASTE1  11  A 41 0.957 
GM07  11  A 58 0.968 
GM14  11  A 58 0.873 
LR11  11  A 55 0.919 
LR48  11  A 56 0.988 
IM49  12  A 58 0.958 
LR36  12  A 58 0.919 
LR44  12  A 58 0.994 
EGFR  13  A 12 0.900 
FBXO46  14  A 23 0.722 
Table 7.2: Area under the receiver operating characteristic curve (AUC) for each marker in the final panel 
of repeats. This table shows the length of each repeat, the repeat unit, and the ability of each repeat to 
discriminate between MSI-H and MSS samples expressed as the area under the receiver operating 
characteristic curve. 
In the previous chapter I showed that PCR and sequencing error is dependent to 
some degree on the length of the homopolymer. Therefore different thresholds for calling 
instability will be needed for different homopolymer lengths. Thresholds for calling a 
marker unstable can be determined for each repeat length by assessing the sensitivity and 
specificity of each of the individual markers. Sensitivity and specificity are used to 
measure test accuracy. Sensitivity is measured as the fraction of patients who have a 
condition and have a positive test result for it. Specificity is the fraction of patients who 
don’t have a condition and have a negative for that condition. Therefore sensitivity and 
specificity can be summarised as: 
Sensitivity = True Positives / (True Positives + False Negatives) 
Specificity = True Negatives / (True Negatives + False Positives) 
For this work a tumour was defined as MSI-H if it had previously been classed as 
MSI-H using a standard Promega MSI test (MSI Analysis System, Version 1.2: Promega, 
Madison, WI, United States of America). Tumours were classed as MSS if no instability 
had been detected in any of the five markers from the Promega MSI test. The Promega 
MSI tests for all tumours were performed by the Northern Genetics service. For each of 
the short mononucleotide repeats sequenced sensitivity and specificity curves were 
produced. Each of the sensitivity and specificity curves has the frequency of reads 
containing deletions on the x-axis. The y-axis of each sensitivity curve is the fraction of 
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MSI-H samples. The sensitivity curve shows the fraction of MSI-H samples (y-axis) that 
have a deletion frequency of or below the deletion frequency shown on the x-axis, which 
is the sensitivity at each given deletion frequency. The y-axis of the specificity curve is 
the fraction of MSS samples. The specificity curve shows the fraction of MSS samples 
(y-axis) that have a deletion frequency of or above the frequency shown on the x-axis 
which is the specificity at each given deletion frequency. 
The sensitivity and specificity curves for the 8bp-9bp repeats can be found in 
Figure 7.4. Of the 8bp repeats, LR46 (extracted from the whole genome analysis) has a 
higher sensitivity than DEPDC2 (taken from the literature) for deletion frequencies up to 
40%. Both repeats have a 100% specificity or no false positives at a deletion frequency 
of 4.1%. At this deletion frequency LR46 has a sensitivity of 42.9% with 12 out of the 28 
MSI-H samples detected, and DEPDC2 has a sensitivity of 26.1% with 6 out of the 23 
sequenced MSI-H samples detected.   
All of the 9bp repeats have 100% specificity for a 5.5% deletion frequency and 
above. At a deletion frequency of 5.5% the two repeats AP003532_2 and TTK have the 
highest sensitivity with 57.1% and 43.5% respectively. The two repeats AL954650 and 
AL359238 have a sensitivity of 42.1% and 21.7% at this deletion frequency.    
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Figure 7.4: Sensitivity and Specificity curves for the 8bp and 9bp homopolymers used in the final panel of 
repeats. DEPDC2 and LR46 are 8bp repeats while AL359238, AL954650, AP003532_2 and TTK are 9bp 
repeats. Value = fraction of samples, Freq = deletion frequency 
All of the 10bp repeats have a 100% specificity at a deletion frequency of ≥14.2%. 
For a deletion frequency of 14.2% the repeat LR32 has a sensitivity of 82.1%, which is 
the highest for any of the 10bp repeats at this deletion frequency. The other 10bp repeats 
AVIL, AL3551554, GM29 have a sensitivity of 71.4%, 35.3% and 25.9% respectively.    
For the 11bp repeats, the repeat ASTE1 had the highest frequency of deletions in 
the control samples with a deletion frequencies ranging between 11.9% - 19.75%. All of 
the 11bp repeats have a 100% specificity at a deletion frequency of ≥19.8%.  
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Figure 7.5: Sensitivity and Specificity curves for the 10bp and 11bp homopolymers used in the final panel 
of repeats. AL355154, AVIL, GM29, and LR32 are 10bp repeats. ASTE1, GM07, GM14, LR11, and LR48 
are 11bp repeats. Value = fraction of samples, Freq = deletion frequency 
All of the 12bp repeats have a 100% specificity at a deletion frequency of ≥19.4%. 
At a deletion frequency of 19.4% the repeats LR44, LR36 and IM49 have a specificity of 
92.9%, 75% and 64.3% respectively.   
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The 13bp marker EGFR had a high dropout rate within the sequence data and was 
only sequenced in 12 of the 58 tumours. Only two out of the 12 tumours that this marker 
was sequenced in were MSS tumours. EGFR has a 100% specificity at a deletion 
frequency of ≥24%, but as this is only based on data from 2 MSS samples it is not very 
dependable.  
The 14bp homopolymer FBXO46 was only sequenced in 23 tumours. One of the 
MSS tumours (26_S14) had a deletion frequency of 88.49% for this tumour. This was the 
highest deletion frequency seen in any of the tumours, which means that at the point 
where there is a 100% specificity for this marker there is a 0% sensitivity (see Figure 7.6 
panel E). In chapter 6 the repeat FBXO46 was found to have a polymorphism for the 
patient from which the tumour PR10654/14 was extracted with 52% of the reads in the 
normal mucosa having a repeat length that was 1bp shorter than the reference sequence. 
It is possible that the tumour 26_S14 has such a high deletion frequency because it is 
homozygous for the same polymorphism. Because there is no matching normal tissue for 
the tumour 26_S14 it is not possible to determine if there is a polymorphism in this patent 
for the marker FBXO46. The presence of a polymorphism in the tumour PR10654/14 
means that this marker is not suitable for the use in an MSI test because the marker being 
potentially polymorphic means that a high deletion frequency is not necessarily an 
indication of MSI. Unfortunately the tumour PR10654/14 was sequenced in the same run 
as the samples discussed in this chapter so I was not aware of the polymorphism prior to 
the sequencing of the samples discussed here.   
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Figure 7.6: Sensitivity and Specificity curves for the 12bp, 13bp, and 14bp homopolymers used in the final 
panel of repeats. IM49, LR36, and LR44 are 10bp repeats. EGFR and FBXO46 are 13bp and 14bp repeats 
respectively. Value = fraction of samples, Freq = deletion frequency 
7.2.1.2. Optimisation of thresholds for differentiating tumours by MSI status 
To assess the performance of the repeats for differentiating between MSI-H 
tumours and MSS tumours the panel of repeats was evaluated using different deletion 
frequencies as cut-offs. Two repeats were excluded from this analysis: EGFR because it 
was only successfully sequenced in two of the MSS samples and there was therefore very 
little information about the background PCR and sequencing error rates for this repeat. 
FBXO46 was excluded because this repeat may be polymorphic in some samples. Using 
a repeat with a repeat length polymorphism is problematic when the deletion frequency 
of the repeats is being used to classify samples as MSS or MSI-H. This means that the 
panel of repeats used in the subsequent analysis consist of eighteen 8bp-12bp 
mononucleotide repeats. Different thresholds were set for each repeat size.  
186 
 
First, thresholds were set so that each group of repeats of the same length had the 
minimum number of incorrectly classified repeats. If the minimum number of incorrectly 
classified repeats could be obtained at more than one deletion frequency, then the lowest 
of these deletion frequencies was used as the threshold. The deletion frequency for each 
repeat length in which this minimum error rate was achieved can be found in Table 7.3. 
Assigning thresholds in this way means that there are many instances where a repeat has 
a deletion frequency above the threshold in the MSS samples, which gives a high false 
positive rate. For the 8bp repeats (LR46 and DEPDC2) there is a false positive rate of 
0.256. This means that for these two repeats the MSS samples have a deletion frequency 
that meets the threshold for calling instability 25.6% of the time. For the 8bp repeats 
(LR46 and DEPDC2) there is a false negative rate of 0.235, which means that 23.5% of 
the time the MSI-H samples have a deletion frequency below the threshold used to call 
instability. For the false positive and false negative rates for the other repeat sizes see 
Table 7.3.   
Chromosome instability is the most common cause of colon cancer accounting for 
approximately 85% of CRCs while the other approximately 15% of CRCs have mismatch 
repair gene defects and are characterized by microsatellite instability (Grady, 2004, 
Sinicrope and Sargent, 2012). Using this information it is possible to predict how many 
errors there would be for each repeat size given a panel of tumours which conform to 
division of MSI-H and MSS tumours that would be expected if all colorectal tumours 
were tested for MSI. This is done by multiplying the false positive rate by 85 to obtain 
the percentage of false positive errors and multiplying the false negative rate by 15 to 
obtain the percentage of false negative errors for a panel of tumours consisting of 85% 
MSS tumours and 15% MSI-H tumours. False positive and false negative error rates for 
each repeat size assuming a panel of tumours consisting of 85% MSS tumours and 15% 
MSI-H tumours can be found in Table 7.3. 
In the next section, an analysis of repeats based on repeat length by setting 
thresholds for each repeat length individually and calculating the false positive and false 
negative error rates for these thresholds is presented. Using these false positive and false 
negative error rates, the error rates for a panel of tumours consisting of 15% MSI-H 
tumours and 85% MSS are calculated. The number of unstable repeats for each tumour 
in the sequenced panel of 58 tumours is also assessed. The equations for calculating false 
positive and negative error rates can be found in method section 2.9.3. Finally, an 
evaluation of how allelic bias could be used to augment an MSI test is discussed. 
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Repeat 
Length 
Deletion 
Frequency 
Threshold 
Minimum 
Number of 
Errors  FPR  FNR 
% False 
Positive 
Errors 
(assuming 
85% MSS) 
% False 
Negative Errors 
(assuming 15% 
MSI‐H) 
8bp  0.016  23  0.256  0.235  21.7  3.5 
9bp  0.041  50  0.011  0.527  0.9  7.9 
10bp  0.142  42  0.000  0.452  0.0  6.8 
11bp  0.121  40  0.130  0.169  11.1  2.5 
12bp  0.164  18  0.033  0.179  2.8  2.7 
Table 7.3: Thresholds for each repeat size that minimise the number of misclassified repeats. This table 
shows the deletion frequency thresholds that give a minimum number of errors for each repeat size. For 
each threshold the table shows the number of errors, the false positive error rate, the false negative rate, and 
the percentage of errors for a panel of tumours consisting of 85% MSS tumours and 15% MSI-H tumours. 
FPR = false positive error rate, FNR = false negative error rate. 
Using the deletion frequency thresholds shown in Table 7.3 the number of repeats 
passing the threshold for each tumour was plotted using a bar chart (see Figure 7.7). Using 
these thresholds, every MSI-H tumour had five or more repeats that met the threshold for 
calling instability. For the MSS samples there were up to three repeats which met the 
threshold for calling instability. Using these thresholds it is therefore possible to separate 
the MSI-H tumour and MSS tumours because the panel of 18 repeats is able to correctly 
classify every MSS and MSI-H cancer using a cut-off of 4 or 5 unstable repeats to classify 
a sample as MSI-H. 
 
Figure 7.7: Number of 8bp-12bp repeats classed as unstable in each tumour using thresholds for each repeat 
size that minimise the number of misclassified repeats.  
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The sensitivity of the marker panel could easily be adjusted by adding more 
repeats. The specificity is more important because false positives can accumulate. 
Individual repeats being classed as unstable in MSS samples is therefore more of a 
problem than individual repeats being classed as stable in MSI-H samples. In fact because 
replication errors in MSI-H samples occur randomly it is expected that some of the repeats 
in MSI-H samples will not be affected by replication errors and will therefore remain 
stable. To better reflect this, different weighting can be placed on false positive and false 
negative errors. Different weightings of errors were assessed to see how they would affect 
the false positive and false negative error rates for the sequenced panel of tumours, and 
the number of unstable repeats in MSI-H and MSS tumour samples.   
 The weighting of different errors was adjusted so that a false positive error is 1.5x 
worse than a false negative error and the deletion frequency thresholds for calling a repeat 
unstable were adjusted to reflect this different cost of the two types of errors. The deletion 
frequency thresholds were set so that the cost of errors was minimised. This changed the 
thresholds for the 11bp and 12bp repeats reducing the false positive error rates for these 
repeats (see Table 7.4).  
Repeat 
Length 
Deletion 
Frequency 
Threshold 
FPR  FNR 
% False Positive 
Errors 
(assuming 85% 
MSS) 
% False Negative 
Errors (assuming 
15% MSI‐H) 
8bp  0.016  0.256  0.235  21.7  3.5 
9bp  0.041  0.011  0.527  0.9  7.9 
10bp  0.142  0.000  0.452  0.0  6.8 
11bp  0.174  0.051  0.277  4.3  4.2 
12bp  0.194  0.000  0.226  0.0  3.4 
Table 7.4: Thresholds for each repeat size that minimise the cost of misclassified repeats given that a false 
positive error is 1.5x worse than a false negative error. This table shows the deletion frequency thresholds 
that give a minimum cost of errors for each repeat size. For each threshold the table shows the false positive 
error rate, the false negative rate, and the percentage of errors for a panel of tumours consisting of 85% 
MSS tumours and 15% MSI-H tumours. FPR = false positive error rate, FNR = false negative error rate. 
The new deletion frequency thresholds (see Table 7.4) were then used to calculate 
how many repeats passed the thresholds for each tumour sample. Using the new 
thresholds all the MSI-H tumours still have 5 or more repeats that are classified as 
unstable while none of the MSS tumours have more than 2 unstable repeats. The panel of 
18 repeats is therefore able to classify every MSS and MSI-H cancer correctly using a 
cut-off of 3 - 5 unstable repeats to classify a sample as MSI-H (see Figure 7.8). By 
weighting false positive errors as 1.5 times more costly than false negative errors the 
panel of 18 repeats is better able to differentiate between the MSI-H and MSS samples. 
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Figure 7.8: Number of 8bp-12bp repeats classed as unstable in each tumour using thresholds for each repeat 
size where a misclassified repeat in a MSS sample is 1.5x as bad as a misclassified repeat in a MSI-H 
sample. 
The weighting of different errors was adjusted further so that a false positive error 
is two times worse than a false negative error. The deletion frequency thresholds were 
adjusted so that cost of errors was minimised. As a result the thresholds for calling a 
repeat unstable were increased for both the 8bp and 11bp repeats (see Table 7.5). For the 
10bp -12bp repeats there are no false positive errors using the current deletion frequency 
thresholds (see Table 7.5). 
Repeat 
Length 
Deletion 
Frequency 
Threshold 
FPR  FNR 
% False 
Positive Errors 
(assuming 85% 
MSS) 
% False 
Negative Errors 
(assuming 15% 
MSI‐H) 
8bp  0.037  0.023  0.608  2.0  9.1 
9bp  0.041  0.011  0.527  0.9  7.9 
10bp  0.142  0.000  0.452  0.0  6.8 
11bp  0.198  0.000  0.369  0.0  5.5 
12bp  0.194  0.000  0.226  0.0  3.4 
Table 7.5: Thresholds for each repeat size that minimise the cost of misclassified repeats given that a false 
positive error is 2x worse than a false negative error. This table shows the deletion frequency thresholds 
that give a minimum cost of errors for each repeat size. For each threshold the table shows the false positive 
error rate, the false negative rate, and the percentage of errors for a panel of tumours consisting of 85% 
MSS tumours and 15% MSI-H tumours. FPR = false positive error rate, FNR = false negative error rate. 
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The new deletion frequency thresholds found in Table 7.5 were used to analyse 
the panel of tumours. Using these thresholds has reduced the number of repeats classed 
as unstable in the MSS tumours to two repeats (see Figure 7.9). One repeat for the tumour 
22_S11 and one repeat for the tumour 64_S34. All of the MSI-H tumours have 2 or more 
repeats which are classed as unstable (see Figure 7.9). The panel of 18 repeats is therefore 
able to correctly classify all MSS and MSI-H tumours if a cut-off of 2 unstable repeats is 
used to classify a sample as MSI-H. 
 
Figure 7.9: Number of 8bp-12bp repeats classed as unstable in each tumour using thresholds for each repeat 
size where a misclassified repeat in a MSS sample is 2x as bad as a misclassified repeat in a MSI-H sample. 
If the weighting of different errors is adjusted so that a false positive error is more 
than 5 times worse than a false negative error, then the resulting thresholds result in no 
false positive errors for any repeat size (see Table 7.6). At these thresholds the false 
negative error rate for the MSI-H samples is between 22.6% for the 12bp repeats and 
64.7% for the 8bp repeats. For a panel of tumours which conform to division of 15% 
MSI-H tumours and 85% MSS tumours the error rate would be between 3.4% and 9.7% 
for each marker size. All of these errors are false negative errors. Because all 18 markers 
would be used together for classifying samples as MSI-H the false negative error rate for 
the full panel of repeats will be much lower than the false negative rate for individual 
repeat sizes.  
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Repeat 
Length 
Deletion 
Frequency 
Threshold 
FPR  FNR 
% False Positive 
Errors 
(assuming 85% 
MSS) 
% False 
Negative Errors 
(assuming 15% 
MSI‐H) 
8bp  0.041  0.000  0.647  0.0  9.7 
9bp  0.055  0.000  0.581  0.0  8.7 
10bp  0.142  0.000  0.452  0.0  6.8 
11bp  0.198  0.000  0.369  0.0  5.5 
12bp  0.194  0.000  0.226  0.0  3.4 
Table 7.6: Thresholds for each repeat size that minimise the cost of misclassified repeats given that a false 
positive error is >5x worse than a false negative error. This table shows the deletion frequency thresholds 
that give a minimum cost of errors for each repeat size. For each threshold the table shows the false positive 
error rate, the false negative rate, and the percentage of errors for a panel of tumours consisting of 85% 
MSS tumours and 15% MSI-H tumours. FPR = false positive error rate, FNR = false negative error rate.  
When the panel of 28 MSI-H tumours and 30 MSS tumours is analysed using the 
deletion frequency thresholds found in Table 7.6, there are 2 or more repeats classed as 
unstable in all of the MSI-H tumours. Because the thresholds for each repeat length have 
been set so that there are no false positive errors the panel of 18 repeats is able to correctly 
classify all MSS and MSI-H tumours if a cut-off of 1-2 unstable repeats is used to classify 
a sample as MSI-H. 
 
Figure 7.10: Number of 8bp-12bp repeats classed as unstable in each tumour using thresholds for each 
repeat size where a misclassified repeat in a MSS sample is >5x as bad as a misclassified repeat in a MSI-
H sample.  
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7.2.1.3. Allelic bias in MSI-H tumours  
Most of the chosen panel of repeats had neighbouring SNPs with a high minor 
allele frequency. This was to allow the allelic bias to be analysed in repeats with a 
heterozygous SNP. Repeats were defined as heterozygous if there were 100 reads 
spanning both SNP and repeat for each allele and one allele did not have less than 10% 
of the number of reads compared to the other allele. Heterozygous repeats were identified 
and a two-tailed Fisher’s exact test was performed to determine if there was a bias in 
deletion frequency between the two alleles using my script FisherTest_AllDeletions.pl 
(See methods section 2.9.1). A Fisher’s exact test was performed for every heterozygous 
SNP, therefore if there were more than one heterozygous SNP in close proximity to a 
homopolymer that homopolymer would be analysed using all SNPs, and the data plotted. 
This method was chosen because different SNPs would have a different number of reads 
spanning both SNP and repeat. Therefore different repeat and SNP combinations could 
provide different levels of significance for allelic bias 
The results of the two-tailed Fisher’s exact test showed an excess of allelic bias in 
the MSI-H samples compared to the MSS samples (see Figure 7.11). The allelic bias can 
therefore potentially be used to differentiate between genuine mutations and sequencing 
artefacts, because low levels of indels caused by sequencing/PCR error tend to affect both 
alleles equally. There are four of the MSS tumours showing examples statistically 
significant amount of allelic bias at a Bonferroni corrected p-value of 0.01 (0.01/335= 
0.00002). These four MSS tumours consist of 45_S25, 65_S35, 26_S14 and 71_S38. The 
MSS tumour 45_S25 has allelic imbalance in the repeat LR36. This was measured at two 
SNPs with a p-value of 1.3×10-37 and 7.9×10-16 for SNP1 and SNP2 respectively. The 
MSS tumour 65_S35 shows a significant allelic imbalance for the repeat AL954650 p-
value of 2.8×10-16. Tumours 26_S14 and 71_S38 have allelic imbalances for one repeat 
each at a p-value of 2.1×10-6 and 3.0×10-5 respectively. 
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Figure 7.11: Allelic bias in deletion frequency for MSI-H samples and MSS samples measured using the 
p-value of a two tailed Fisher’s exact test. Red = MSI-H samples, Blue = MSS samples. The line 
corresponds to a Bonferroni corrected p-value of 0.01. 
Because an excess of allelic bias is seen in MSI-H tumours compared to MSS 
tumours it could also be incorporated into an MSI test. This was done by allocating 1 
point for each repeat passing the deletion frequency thresholds shown in Table 7.6, and 
1.5 points for each repeat that both passes the deletion frequency thresholds and has a 
statistically significant amount of allelic bias using Bonferroni corrected p-value of 0.01. 
Using this system of point allocation, each MSI-H tumour has at least two points whereas 
no points are allocated any of the MSS tumours. A threshold of 1-2 points could therefore 
be used to classify a tumour as MSI-H. The MSI-H tumour 27_S15, which only has two 
unstable repeats, is homozygote for SNPs neighbouring both unstable repeats. Adding 
extra points for allelic bias therefore does not increase the measurable difference between 
MSI-H tumours and MSS tumours compared to using the same deletion frequency 
thresholds without extra points for allelic bias.    
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Figure 7.12: Point based MSI assay, with 1 point for each repeat passing a deletion frequency threshold, 
and 1.5 points for repeats that both pass the deletion frequency threshold and have a statistically significant 
amount of allelic bias. The thresholds used for each repeat size can be found in Table 7.6 and allelic bias 
was considered significant at a Bonferroni corrected p-value of 0.01.    
7.2.2. Optimization of DNA extraction and amplification using QuantuMDx’s 
microfluidic platform 
The company QuantuMDx (QuantuMDx Group Ltd, Times QuantuMDx Square, 
Newcastle upon Tyne, UK) are producing a point of care device for DNA analysis. My 
PhD work has been performed in collaboration with this company with the aim that the 
MSI test I have been working on will be part of a cancer diagnosis assay. As part of my 
PhD work I have contributed to the development of the QuantuMDx hardware. This work 
was conducted in 2011-2012 when QMDx's technology was in its infancy. The work I 
have conducted with QuantuMDx has allowed me to become familiar with the 
QuantuMDx hardware and how the final MSI assay will work on QuantuMDx’s device 
as well as contribute to the development of the hardware itself. This development work 
will be described in the next sections of this chapter. 
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7.2.2.1. DNA extractions from whole blood using the QuantuMDx DNA extraction 
cassette 
DNA extractions from lysed whole blood were performed on QuantuMDx’s 2012 
prototype DNA extraction cassettes. These extractions from blood were performed as a 
proof of principle test to establish that the DNA extraction cassette worked, and assess its 
performance before moving on to attempting DNA extractions of tissue samples. A photo 
showing the layout of the DNA extraction cassette can be found in Figure 7.13.  
 
Figure 7.13: QuantuMDx’s 2012 prototype DNA extraction cassette. 
Prior to DNA extraction, the sample channel was loaded with 200µl of whole 
blood and the buffer channel was filled with a proprietary buffer. The cassette is then 
loaded onto QuantuMDx’s prototype machine (the MiniChemLab) (see  
Figure 7.14). First, the buffer is pushed through the DNA extraction cassette using 
the syringes of QuantuMDx’s prototype machine at a flow rate of 100μl/min for 300 
seconds. Once the filter has been soaked through with buffer there is a five minute 
incubation period while buffer activates the filter. Next the blood is pushed into the filter 
at a flow rate of 100μl/min for 120 seconds. It is optimal to load ~190µl of the blood into 
the filter. Leaving some blood behind in the sample channel helps prevent bubbles from 
entering the filter and creating a channel through the filter by displacing filter particles. 
Once the blood has been loaded onto the filter buffer from the buffer channel is flowed 
through the cassette at a flow rate of 50μl/minute, with a pause every 80 seconds to allow 
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elute to be collected from the collection channel. Due to the limited size of the buffer 
channel, the buffer channel needs topping up with buffer during this procedure. This is 
done during one of the pauses when the amount of buffer is low. The buffer pushes the 
sample through the filter. The filter is meant to retain the cellular components that are 
passed through it, with the exception of DNA, which is passed out through the collection 
channel together with the buffer. Each extraction was split into a number of elute fractions 
of 10-80μl volume each. PCR amplification was then performed to confirm the presence 
of DNA in each elute and to confirm that the DNA was of a suitable purity to achieve 
PCR amplification. The PCR products were then visualised on an agarose gel. The gel 
image in Figure 7.15 shows DNA extracted from blood for two different DNA extraction 
cassettes. The results showed that QuantuMDx’s prototype DNA extraction cassette was 
able to produce DNA of a sufficient quality to obtain a decent amount of PCR product 
(see Figure 7.15).  
 
Figure 7.14: The QuantuMDx prototype (The MiniChemLab) with the cassette manifold (right corner) and 
the syringe pumps (left corner) which are attached to the cassette manifold via plastic tubing. 
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Figure 7.15: Gel image of the PCR results from the blood DNA extraction. DNA was extracted from blood 
using the DNA extraction cassette. This DNA was collected in elute fractions. To confirm the presence of 
high quality DNA in the elute fractions BAT26 primers were used to amplify the DNA. The ladder used in 
this experiment is a Quick-Load 2-log DNA ladder (New England Biolabs). 
7.2.2.2. DNA extractions from FFPE tissues using the QuantuMDx DNA extraction 
cassette 
As a control for the DNA extraction of FFPE tissues, use of the Promega 
ReliaPrep™ FFPE gDNA Miniprep System kit (Promega, Madison, WI, United States of 
America) was chosen.  This kit is a commonly used kit and considered one of the gold 
standards for the extraction of DNA from FFPE tissues. Prior to performing the 
experiment using the DNA extraction cassette an experiment was performed to see 
whether wax curls of a similar size would produce roughly the same amount of DNA. 
This was done to determine if one could extract DNA from different wax curls of the 
same size using the DNA extraction cassette and ReliaPrep™ kit and be able to compare 
the results between the two extraction methods. 
Two wax curls of roughly similar size (wax curl 867 and wax curl 902) were 
extracted using the Promega ReliaPrep™ FFPE gDNA Miniprep System kit. 
Quantification of the DNA concentration using Quant-iT™ PicoGreen dsDNA Assay 
(Life Technologies, Carlsbad, CA, United States of America) on an Fluoroskan Ascent 
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FL (Thermo Scientific, Waltham, Massachusetts, USA) showed that wax curl 867 
contained almost 6 times the amount of DNA compared to wax curl 902. Table 7.7 
contains the absorbance data and DNA concentrations obtained for this experiment. 
Figure 7.16 shows the standard curve for the PicoGreen assay. 
 
Figure 7.16: Standard curve for the PicoGreen assay used to measure the DNA concentration obtained from 
the DNA extractions of wax curls 867 and 902. 
Sample  Average 
absorbance 
Concentration on 
plate (ng/ml) 
Dilution 
factor 
Concentration of 
sample (ng/ml) 
Initial 
Volume 
(μl) 
Total 
yield 
(ng) 
Wax curl 
867 DNA 
3.53 183  33.3x 6094 30  183
Wax curl 
902 DNA 
0.673 33  33.3x 1099 30  33
Table 7.7: PicoGreen absorbance readings at 520 nm for wax curls 867 and 902 and the corresponding 
DNA concentrations. 
6.1ng/μl of DNA was obtained from wax curl 867 and 1.1ng/μl of DNA was 
obtained from wax curl 902. This means that it will not be possible to use wax curls of a 
similar size to compare yields from different extraction methods. A better method for 
comparing different DNA extraction methods may be to split the lysate from one wax 
curl, then extract DNA from the lysate using the DNA extraction cassette and the 
ReliaPrep™  kit. 
Attempts were also made to amplify the DNA obtained from the wax curls 867 
and 902. The BAT26 Primers failed to amplify the DNA extracted from the wax curls. 
One explanation for this may be that the DNA obtained from the wax curls was too 
fragmented to amplify a 395bp long amplicon. Bioanalyser (Agilent, Santa Clara, CA, 
United States of America) results confirmed that this may be a possibility. Most of the 
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DNA obtained from wax curl 867 consisted of 200-1000bp fragments (see Figure 7.17) 
showing that the genomic DNA obtained from the wax curl is very sheared and the larger 
the PCR amplicon the less template there will be to start the PCR.  
 
 
Figure 7.17: Bioanalyser results from the DNA extract obtained from wax curl 867.  
Primers for a 150bp amplicon were used to successfully amplify DNA from the 
wax curl DNA extracts (see Figure 7.18). These results are consistent with the theory that 
the DNA obtained from the wax curls is very fragmented.  
 
Figure 7.18: PCR amplification of the DNA extract obtained from wax curls 867 and 902. DNA obtained 
from a blood sample was used as a positive control. The PCR amplification was performed using the 
CYP2C9 primers which generate a 154bp product. 
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After the success of extracting DNA from two wax curls using the Promega 
ReliaPrep™ FFPE gDNA Miniprep System kit, the next steps included determining if 
DNA could be extracted using the DNA extraction cassette and analysing how these two 
methods compared to each other. A large wax curl (wax curl number 878) was lysed using 
the lysis method from the ReliaPrep™ FFPE gDNA Miniprep System kit. 100μl of the 
lysate was processed using the ReliaPrep™ FFPE gDNA Miniprep System kit and the 
other 100μl of the lysate was processed using QuantuMDx’s DNA extraction cassette 
(see Figure 7.19). The end product was 40μl of DNA extract from the ReliaPrep™ FFPE 
gDNA Miniprep System kit and ten 40-50μl fractions from the DNA extraction cassette.  
 
Figure 7.19: Schematic diagram of the DNA extraction of wax curl 878.  
The DNA extract obtained both from the Promega spin column and the DNA 
extraction cassette were analysed using a Quant-iT™ PicoGreen dsDNA Assay on a 
Fluoroskan Ascent FL. The absorbance readings for these samples can be found in Table 
7.8 and the standard curve can be found in Figure 7.20.  
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Figure 7.20: Standard curve for the PicoGeen assay showing the correlation between absorbance readings 
obtained from the Fluoroskan Ascent FL and DNA concentration. 
Sample  Average 
absorbance 
Concentration 
on plate 
(ng/ml) 
Dilution 
factor 
Concentration 
of sample 
(ng/ml) 
Initial 
Volume 
(μl) 
Total 
yield 
(ng) 
Promega sample 
10x dilution 
1.27  66.6 333x
 
22.19 40  887.6
Cassette  elute1  0.05  0.2 16.6x 0.00 48.4  0.2
Cassette elute 2  0.24  10.6 16.6x 0.18 48.8  8.6
Cassette elute 3  5.98  323.9 16.6x 5.38 49.8  267.7
Cassette elute 4  3.05  163.8 16.6x 2.72 44  119.7
Cassette elute 5  1.23  64.7 16.6x 1.07 43.6  46.8
Cassette elute 6  0.60  30.5 16.6x 0.51 51.6  26.1
Cassette elute 7  0.36  17.1 16.6x 0.28 43.6  12.4
Cassette elute 8  0.23  10.0 16.6x 0.17 47.6  7.9
Cassette elute 9  0.21  9.0 16.6x 0.15 44  6.5
Cassette elute 10 0.16  6.1 16.6x 0.10 43  4.3
Table 7.8: Absorbance values and amount of DNA for the cassette extraction and Promega extraction of 
wax curl 878. The absorbance values highlighted in red are above the standard curve so any calculations 
using these are estimates. 
After the concentration of DNA had been calculated for each of the elutes from 
the DNA extraction cassette the amount of DNA in each sample was calculated (see Table 
7.8). The DNA recovery rate for the DNA extraction cassette compared to the Promega 
kit can be found in Table 7.9.  
Total amount of DNA from the 
cassette (ng)  
Recovery rate compared to the Promega 
kit (%) 
500.2  56.4
Table 7.9: A comparison of the efficiency of the DNA extraction cassette compared to the Promega kit. 
A graphical representation of the DNA output of the DNA extraction cassette can 
be found in Figure 7.21. This figure shows that most of the DNA exits the cassette in the 
third elute fraction. The first ~100μl contain very little DNA.   
202 
 
 
Figure 7.21: The DNA output of the DNA extraction cassette for wax curl number 878. 
7.2.2.3. Optimising the QuantuMDx PCR cassette 
Before this work was started on optimising the first prototype of QuantuMDx’s 
PCR cassette, PCR amplification had yet to be achieved by QuantuMDx using this 
cassette. Figure 7.22 shows the PCR cassette and heater layout.  PCR experiments were 
performed on several PCR cassettes in an attempt to optimise the first generation of PCR 
cassettes. These experiments included changing some of the reagents in the mastermix, 
the volume of the mastermix to avoid the effects of evaporation, and adding surfactants. 
The addition of surfactants such as PVP was examined to prevent molecules like Taq 
polymerase from sticking to the hydrophobic surface of the PCR channels in the 
QuantuMDx PCR cassette (Kim et al., 2006). BlueJuice tests, which consisted of running 
1x BlueJuice (Invitrogen) through the cassettes, were also performed to test the durability 
of cassettes under different conditions. In the original PCR program the cassettes were 
pressurised to help maintain a smooth flow of liquid through the PCR cassette and to 
minimise bubbles. This part of the program needed to be removed to stop the cassettes 
leaking. The flow rate was shown to still be smooth if the PCR mixture was not too 
viscous. There was, however, a lot of bubble formation disrupting the liquid column in 
the PCR tubes. This resulted in lots of small PCR reactions instead of one large PCR 
reaction. The PCR setup used on the cassette remained a two-step setup throughout all 
the experiments. Listed below is a short summary of all the cassette experiments 
performed and the outcome of these experiments (see Table 7.10). Each run on a cassette 
consisted of 30 PCR cycles. 
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Figure 7.22: PCR Cassette. Panel A: The prototype QuantuMDx PCR cassette. Panel B: Simplified diagram 
showing how the PCR cassette works when it is placed on the heaters of QuantuMDx’s prototype. The PCR 
channel in one of QuantuMDx’s cassettes gives 30 PCR cycles. 
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Date  Run  Pump 
rate 
μl/min 
Mastermix 
Reagents 
 Input  
 DNA 
Surfactant  Pressure   Temp 
oC 
Result 
17/2/12  1  10  100μl Mastermix,
10U Taq, 
BAT26 Primers 
gDNA No
Surfactant 
Yes  56 oC 
And 
90 oC 
FAIL 
/leaked 
17/2/12  2  10  50μl Mastermix,
5U Taq, 
BAT26 Primers 
gDNA No
Surfactant 
Yes  56 oC 
And 
90 oC 
FAIL 
/leaked 
17/2/12  3  10  50μl Mastermix,
5U Taq, 
BAT26 Primers 
gDNA No
Surfactant 
Yes  56 oC 
And 
90 oC 
FAIL 
/leaked 
17/2/12  4  10  50μl Mastermix,
5U Taq, 
BAT26 Primers 
gDNA No
Surfactant 
Yes  56 oC 
And 
90 oC 
No Product
20/3/12  5  5  BlueJuice Test No DNA No
Surfactant 
Yes  56 oC 
90 oC 
FAIL 
/leaked 
20/3/12  6  5  BlueJuice Test No DNA No
Surfactant 
Yes  56 oC 
90 oC 
Trial 
Successful 
21/3/12  7  5  50μl Mastermix,
2.5% PVP, 5U Taq, 
CYP2C9 Primers 
H2O
 
2.5% PVP 
0.1mg/ml BSA, 
10 min Soak 
Yes  56 oC 
And 
90 oC 
FAIL 
/leaked 
21/3/12  8  5  50μl Mastermix,
2.5% PVP, 5U Taq, 
CYP2C9 Primers 
DNA
 
2.5% PVP 
0.1mg/ml BSA, 
20 min Soak 
Yes  56 oC 
And 
90 oC 
FAIL 
/leaked 
21/3/12  9  Manual 
 
50μl Mastermix,
2.5% PVP, 5U Taq, 
CYP2C9 Primers 
DNA
 
2.5% PVP 
0.1mg/ml BSA, 
10 min Soak 
Yes  56 oC 
And 
90 oC 
No Product
23/3/12  10  5  BlueJuice Test No DNA No
Surfactant 
No  56 oC 
90 oC 
Trial 
Successful 
23/3/12  11  5  BlueJuice Test No DNA No
Surfactant 
No  56 oC 
90 oC 
Trial 
Successful 
23/3/12  12  5  60μl Mastermix,
2.5% PVP, 6U Taq, 
CYP2C9 Primers 
DNA
 
2.5% PVP 
0.1mg/ml BSA, 
10 min Soak 
No  56 oC 
And 
90 oC 
No Product
23/3/12  13  5  60μl Mastermix,
2.5% PVP, 6U Taq, 
CYP2C9 Primers 
DNA
 
2.5% PVP 
0.1mg/ml BSA, 
10 min Soak 
No  56 oC 
And 
95 oC 
No Product 
after 2 runs 
through 
cassette 
23/3/12  14  5  60μl Mastermix,
2.5% PVP, 6U Taq, 
CYP2C9 Primers 
DNA
 
No
Surfactant 
No  56 oC 
And 
95 oC 
No Product 
28/3/12  15      2.5% PVP   Leaked 
28/3/12  16  5  100μl Mastermix,
2.5% PVP, 10U 
Taq, 
CYP2C9 Primers 
DNA 2.5% PVP
10 min Soak 
No  56 oC 
And 
95 oC 
No Product
28/3/12  17  5  100μl Mastermix,
2.5% PVP, 10U 
Taq, 
CYP2C9 Primers 
5μl 
Product 
from run 
16 
Same cassette as 
run 16. No new 
surfactant was 
added 
No  56 oC 
And 
95 oC 
No Product
28/3/12  18  5  100μl Mastermix,
2.5% PVP, 10U 
Taq, 
CYP2C9 Primers 
5μl 
Product 
from run 
17 
Same cassette as 
run 16 and 17. No 
new surfactant 
was added 
No  56 oC 
And 
95 oC 
No 
Product. 
Lots of 
primer 
dimers  
29/3/12  19  5  100μl Mastermix,
1% PVP, 12.5U 
Taq, 
CYP2C9 Primers 
1μl 100:1 
Amplicon 
solution 
0.1mg/ml BSA,
3 hour Soak 
No  56 oC 
And 
92 oC 
Good 
product 
29/3/12  20  5  100μl Mastermix,
1% PVP, 12.5U 
Taq, 
CYP2C9 Primers 
5μl 
Product 
from run 
19 
Same cassette as 
run 19. No further 
surfactant was 
added 
No  56 oC 
And 
92 oC 
Product + 
Lots of 
primer 
dimers 
29/3/12  21  5  100μl Mastermix,
1% PVP, 12.5U 
Taq, 
CYP2C9 Primers 
5μl 
Product 
from run 
20 
Same cassette as 
run 19 and 20. No 
new surfactant 
was added 
No  56 oC 
And 
92 oC 
Product + 
Lots of 
primer 
dimers 
Table 7.10: List of PCR cassette optimisation experiments that have been performed. 
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The purpose of these PCR cassette experiments was to show that DNA 
amplification is achievable on the prototype PCR cassettes. The protocol used to amplify 
DNA using the PCR cassette is listed in methods section 2.3.1. The result of PCR cassette 
runs 19, 20 and 21 are shown in Figure 7.23. Lane 2 contains 20μl of the amplicon 
solution which was used as the input DNA in this experiment and lane 3 shows this 
amplicon solution diluted to the concentration present in the mastermix. Lane 6 contains 
the PCR product obtained after one pass through the PCR cassette. Although the band in 
this lane is dim compared to the positive control in lane 4 it shows that DNA amplification 
in the microfluidic channels has been achieved. Subsequent passes through the cassette 
using the PCR product from the previous experiment as template DNA favoured the 
amplification of primer dimers over the PCR product (see lanes 8 and 10, Figure 7.23). 
The results of these experiments show that it is possible to achieve PCR amplification 
using QuantuMDx’s prototype cassette. However the fact that detectable PCR 
amplification was only achieved using diluted PCR product as a template highlighted that 
a lot more optimisation work was needed before the PCR cassette was preforming well 
enough to be integrated into a point of care device. 
 
Figure 7.23: Gel image from the PCR cassette experiment. Lane 2 contains 20μl of the amplicon solution 
of which 1μl was used as the input DNA for run 19. Lane 3 contains the amplicon solution diluted to the 
same concentration of DNA as was present in the mastermix for run 19 prior to PCR amplification on the 
PCR cassette. Run 20 used 5μl of product from run 19 as input DNA. Run 21 used 5μl of product from run 
20 as input DNA. Both run 20 and 21were performed on the same PCR cassette as run 19. 
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7.3. Discussion 
7.3.1. The feasibility of a sequencing based MSI test using short repeats  
Using the panel of homopolymers sequenced in this chapter it was possible to 
define thresholds that separated all MSI-H and MSS tumours. This panel, therefore, 
shows good potential for the use as an MSI test for differentiating between MSI-H and 
MSS tumours. Different thresholds were assessed for their ability to distinguish between 
MSI-H tumours and MSS tumours. In the first instance, deletion frequency thresholds 
were set which minimised the number of misclassified homopolymers for each 
homopolymer length. A homopolymer was defined as misclassified if it was defined as 
stable in an MSI-H tumour (a false negative error) or unstable in an MSS tumour (a false 
positive error). The results of this were thresholds where there were a maximum of 3 
repeats classed as unstable in any MSS tumour and at least 5 unstable repeats in all the 
MSI-H samples. For an MSI test, these thresholds could be used with a cut-off of 4 or 5 
unstable repeats to call a tumour unstable. This would allow correct classification of all 
MSI-H and MSS tumours sequenced for this chapter. However, a larger difference 
between the number of repeats classed as unstable in the MSI-H samples and the MSS 
samples was achieved when thresholds were adjusted to accommodate a false positive 
error being 1.5x more costly than a false negative error. With these adjusted thresholds, 
the maximum number of repeats classed as unstable in a MSS tumour was two, while 
there was still a minimum of 5 unstable repeats for every MSI-H tumour. For an MSI test, 
these new thresholds could be used with a cut-off of 3, 4 or 5 unstable repeats to call a 
tumour unstable. In this case it might be best to go for a cut-off of 4 unstable repeats. This 
cut-off would allow for more variation in the number of repeats being classified as 
unstable in both MSI-H tumours and MSS tumours than seen in this chapter before a 
tumour was misclassified. 28 MSI-H tumours and 30 MSS tumours is a small samples 
size for testing a panel of repeats. Having a cut-off that allows for more variation in both 
MSS and MSI-H tumours would be beneficial if the panel is to be used in other tumours, 
for example, as a routine MSI test. 
It may however be better to increase the thresholds so that there are few or no 
repeats being classed as unstable in the MSS samples. If thresholds are set so that unstable 
repeats are expected in the MSS samples then there is the risk that in some tumours the 
numbers of repeats classed as unstable can accumulate without MSI necessarily being the 
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reason for a large number of repeats being classed as unstable. The sensitivity of the panel 
of repeats could always be increased by adding more repeats to the panel. It is therefore 
unnecessary to increase sensitivity by using low thresholds and risk losing specificity. 
Individual repeats being classed as unstable in MSS tumours is, therefore, more of a 
problem than individual repeats being classed as stable in MSI-H tumours. The thresholds 
for calling a repeat unstable can be adjusted so that false positive errors are >5x more 
costly than a false negative error which means that no repeats are classified as unstable in 
any of the MSS samples and there are still at least two unstable repeats in any MSI-H 
tumour. For an MSI test, these thresholds could be used with a cut-off of 1or 2 unstable 
repeats to call a tumour unstable. It might however be best to use a cut-off of 2 unstable 
repeats rather than 1 because a low level of microsatellite instability can occur in MSS 
tumours. For example Yoon et al. (2013) found that mononucleotide repeats with 
deletions occurred MSS gastric cancer cell lines, but at a lower frequency than in MSI-H 
sample. Allowing for the odd unstable repeat in a MSS sample would, therefore, be 
sensible.  
It could be beneficial to add more markers to the panel or exchanging some of the 
shorter markers for longer more unstable ones because for repeat sizes of 8bp-12bp the 
number of unstable samples detected by each marker generally increased with repeat 
length. This would allow a cut-off of more than two unstable markers to be used for 
calling MSI-H. With thresholds set so that no repeats are classed as unstable in the MSS 
tumours and using two unstable markers as a cut-off for calling instability there is a large 
risk that the panel of repeats will not be able to cope well with MSI-low samples. 
Increasing the cut-off to three or more unstable repeats for calling MSI-H tumours cannot 
be done with the current panel without miss classifying two of the 28 tumours MSI-H 
tumours giving a false negative rate of 7% for the set of tumours used in this chapter.    
There was an excess of homopolymers showing significant allelic bias among 
MSI-H samples compared to MSS samples. Allelic bias could therefore be used as an 
indication of whether a variant is a real mutation or the result of sequencing and PCR 
error. Incorporating allelic bias into the MSI assay was attempted by adding extra points 
for any unstable repeat with a statistically significant allelic bias. An extra 0.5 points for 
a significant level of allelic bias was chosen because this gives extra value to an unstable 
repeat with allelic bias, but one polymorphic repeat would not be enough to misclassify 
a tumour if a cut-off of 2 points was used to classify a tumour as MSI-H. All 18 markers 
have no registered polymorphisms as of dbSNP build 173 and therefore should, in theory, 
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be monomorphic, but there is always the possibility of polymorphisms which have yet to 
be discovered. For repeats with allelic bias there is also the potential of using the allele 
without the deletion as an internal control to determine the background PCR and 
sequencing error for the homopolymer. The usefulness of allelic bias is however limited 
to repeats with a neighbouring heterozygous SNP. If the SNP is homozygous it is not 
possible to distinguish the two alleles.    
7.3.2. The prospects for QuantuMDx’s DNA extraction cassette  
QuantuMDx’s microfluidic DNA extraction cassette was initially tested on human 
blood to get an idea of the efficiency of the cassette and to gain experience using the DNA 
extraction cassette and the MiniChemLab, which was QuantuMDx’s prototype. The 
results from this test were encouraging so the DNA extraction cassette was used to extract 
DNA from paraffin wax embedded tumour tissue. DNA extraction from paraffin wax 
embedded tumour tissue was successfully achieved using the lysis method taken from 
Promega ReliaPrep™ FFPE gDNA Miniprep System kit and DNA extraction using the 
DNA extraction cassette. The DNA recovery rate for the DNA extraction cassette 
compared to the Promega ReliaPrep™ FFPE gDNA Miniprep System kit was 56%. The 
DNA obtained using this extraction method was of a high enough quality for PCR 
amplification. This is quite good considering that the method of tissue lysis has not been 
optimised for the DNA extraction cassette and the current filter in the cassette was 
optimised for blood, not tissue. These experiments indicated that the DNA recovery rate 
for this cassette could be further improved. However this was only the result of one 
experiment with no replications. Ideally several replications of this experiment should 
have been performed, but at the time the DNA extraction and PCR cassette experiments 
were being performed, QuantuMDx experienced cassette supply problems which  limited 
this aspect of the thesis preparation.  
The preliminary results show that the DNA extraction method used by 
QuantuMDx can be adapted for using FFPE tissues as an input material. Being able to 
extract DNA from FFPE tissues is of importance for validating a MSI test the 
QuantuMDx device, because archived FFPE material of known MSI status would be 
relatively easily available for test validation purposes. QuantuMDx’s plan is that the first 
MSI diagnostic device available on the market will be designed to use FFPE tissues as 
the input material. This is to allow the MSI test on the Q-POC to easily fit in with the 
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current practice of fixing tumours just after they have been removed from a patient. After 
the Q-POC MSI test has become well established, the next step will be to provide a Q-
POC MSI test as part of a larger cancer test that can be used in the operating theatre on 
fresh tissue. A test like this would provide immediate information on MSI status as well 
as other cancer markers during the operation itself. This could give clinicians information 
on the importance of polyp resection during endoscopy or help assess a tumour’s 
aggressiveness during surgery. It would also be possible to test resection margins, 
avoiding either the necessity for further surgery or the inclusion of a large operative 
margin.  
7.3.3. The prospects QuantuMDx’s PCR cassette  
The initial optimisation of the first generation PCR cassette was successful but 
further optimisation was indicated. It took quite a while to achieve PCR amplification 
using the cassettes. Some of these problems were due to a manufacturing fault which 
resulted in the cassettes being prone to leakage. The other main reason making it difficult 
to obtain a PCR product from the PCR cassettes was due to problems with coating the 
cassettes with surfactants. The polycarbonate surface of the cassettes attracts the Taq 
polymerase enzyme to the hydrophobic surface of the cassette where it is liable to stick 
and no longer be able to catalyse the PCR reaction (Kim et al., 2006). Using BSA as a 
surfactant reduces some of this problem, but a better solution was needed. Otherwise the 
PCR conditions such as temperature and amount of time spent in the two different 
temperature zones needed to be optimised. In my experiments, a cassette PCR took 
33minutes.  This was too long for a point of care setting and led to a further and ultimately 
successful design programme by other colleagues.  
Since 2012 when my attachment to the Q-POC team ended, major improvements 
to their cassette PCR have made multiplex assays feasible, using gDNA as the input. Due 
to the improvements QuantuMDx have made to their hardware since my contributions, 
the QuantuMDx Q-POC platform is now starting to look like a promising platform for 
the MSI test developed in this PhD project.  
Future work will aim to reduce the cost of a sequencing based MSI test. 
Multiplexing will be needed to reduce the cost and effort needed to produce the amplicons 
for an MSI test. In the future the aim will be to produce primers which will allow for 
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multiplexing so many or all the repeats can be produced in a single PCR reaction. 
Multiplexing will be needed whether the final platform consists of using Illumina 
sequencing or the test is being carried out on QuantuMDx’s Q-POC device.  
For the Illumina system library preparation is also costly. To reduce this cost our 
group are currently producing primers with adapter overhangs which will allow Illumina 
sequencing primers and indexes to be added using a few cycles of PCR on a standard 
thermocycler. For the QuantuMDx Q-POC platform, library prep is unnecessary as each 
tumour will be analysed separately. The rapid turn around time of the Q-POC will still 
allow several tumours to be analysed on the same device over the course of a working 
day. The aim is that the Q-POC will be able to do testing from sample to result in as little 
as 15min (Burn, 2013). As well as testing for MSI, other cancer biomarkers such as K-
RAS and BRAF will be investigated at the same time. Using QuantuMDx’s Q-POC 
platform the price of an MSI and cancer biomarker test could plummet as low as $20 
(Burn, 2013). 
7.3.4. Conclusions 
A comparison between Quantumdx’s DNA extraction cassette and one of the gold 
standard kits available on the market, the Promega ReliaPrep™ FFPE gDNA Miniprep 
System kit, showed that the DNA recovery rate of the DNA extraction cassette compared to 
the Promega kit was 56%.  
Experimentation with different surfactants to avoid DNA denaturation on the PCR 
channel surface highlighted some of the challenges of microfluidics based PCR and data 
indicating a possible solution was obtained. This project enabled the first QuantuMDx 
PCR cassettes to function, thus showing that the PCR system was viable. 
It was possible to distinguish between the 28 MSI-H tumours and the 30 MSS 
tumours using the final panel of 18 homopolymers. This suggests that this panel or an 
extended version of this panel of repeats could be used as sequencing based test for 
diagnosing MSI. Allelic bias analysis will be a useful adjunct in a next generation 
sequencing based MSI assay to help differentiate between genuine mutations and 
sequencing artefacts. 
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Chapter 8. General discussion and future work 
8.1. General discussion 
Identifying patients with Lynch Syndrome is important because early intervention 
can save lives. The use of traditional family history based guidelines for identifying 
patients with Lynch Syndrome results in many being missed. Molecular testing for all 
colorectal and endometrial cancers is therefore being recommended (Vasen et al., 2013, 
Canard et al., 2012, Mills et al., 2014, Julie et al., 2008). MSI testing all colorectal cancers 
would also be advantageous because new treatments which target MSI-H tumours are 
being discovered. For example pembrolizumab which blocks the cells’ Programmed 
Death 1 (PD-1) pathway increasing the immune response against cancer cells has been 
shown to be effective in MSI-H tumours but not MSS tumours (Le et al., 2015). 90% of 
the patients with a MSI-H colorectal cancer who were given the pembrolizumab 
monoclonal anti-PD-1 antibody treatment responded to this treatment in this landmark 
study. To cope with the increase in tumours being MSI tested if a “test all approach” is 
adopted, it would be advantageous to consider high throughput screening approaches to 
test for MSI. In the work presented here, next generation sequence typing of short 
mononucleotide has been developed as a method to identify microsatellite unstable 
tumours.  
In the first results chapter, it has been demonstrated that MSI could be detected 
using short mononucleotide repeats and an amplicon sequencing approach with the 
Illumina MiSeq as a sequencing platform. For the mononucleotide repeat lengths 
investigated, data showed that susceptibility to MSI increases with repeat length, but so 
does sequencing and PCR error. This is consistent with what has previously been reported 
in the literature (Fazekas et al., 2010, Flores-Renteria and Whipple, 2011). The longer 
10bp-12bp were found to be unstable in more tumours than the shorter repeats. However, 
in chapters 3 and 5 there were two tumours where the shorter 7bp-10bp repeats were more 
unstable than the longer 11bp-12bp repeats (U096 tumour in chapter 3, and U312 tumour 
in chapter 5). This suggested that a panel of repeats consisting of a range of repeat lengths 
from 7bp-12bp might be the best approach for identifying MSI-H tumours, because it is 
not known how all MSI-H tumours behave in respect to instability in different repeat 
lengths. A broad approach with a range of different repeat sizes was considered 
preferable. 
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To identify a large number of potential markers for distinguishing between MSI-
H and MSS tumours, whole genome sequences were mined for highly unstable 7bp-12bp 
mononucleotide repeats. This is to our knowledge the first study to analyse whole genome 
sequences to identify highly variable repeats for panel based MSI identification. The indel 
frequencies in 7bp-12bp mononucleotide repeats in whole genome sequences of MSI-H 
CRCs were analysed using matched normal tissue and MSS stable CRC whole genome 
sequences as controls. One of the limitations of this analysis was the low read depth of 
the genome sequences available for analysis. For this reason, the reads for each group 
(MSI-H, matched normal for the MSI-H samples, and MSS samples) were pooled and 
only repeats with ≥20 reads in each group were analysed. Despite the low read depth of 
the whole genome sequences used, it was immediately apparent that the MSI-H tumours 
had a different indel distribution in 7bp-12bp mononucleotide repeats compared to 
controls. The normal tissue samples and MSS tumours showed the same indel 
distributions, which suggests that the differences seen in the MSI-H tumours were caused 
by microsatellite instability. There was a greater excess of deletions in the MSI-H CRCs 
compared to insertions. This suggested that deletions are more indicative of mismatch 
repair deficiencies in CRC than insertions for 7bp-12bp mononucleotide repeats. 
In chapter 7, the number of mononucleotide repeats was refined down to a panel 
of eighteen 8bp-12bp repeats consisting of repeats taken from the literature and repeats 
identified through the whole genome analysis. This panel of repeats was sufficient to 
distinguish between MSI-H and MMS tumours with a 100% sensitivity and specificity in 
a sample of 58 tumours (28 MSI-H tumours and 30 MSS tumours) using a range of 
different deletion frequencies as thresholds and different numbers of unstable repeats to 
classify tumours as unstable, demonstrating the robustness of the marker panel. The most 
practical set of thresholds were the ones that allowed no false positive markers in the MSS 
tumour group. The reason for this is that if thresholds are set so that unstable repeats are 
expected in the MSS samples then there is the risk that in some tumours the numbers of 
repeats classed as unstable can accumulate. Using these thresholds there were 2-17 
unstable repeats in each of the MSI-H tumours. For an MSI test, a cut-off of 2 unstable 
repeats to call a tumour MSI-H should be used with this system because the odd unstable 
repeat can be found in MSS tumours (Yoon et al., 2013). 
There were no polymorphisms as of dbSNP build 173 for the 18 markers of the 
final MSI testing panel, and no repeats showed potential polymorphism in the MSS 
tumours used to test these repeats. All repeats should therefore be monomorphic, which 
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means that the panel of repeats can be used without the need for a comparison between 
tumour and normal tissue. However, it is possible that polymorphisms in some of these 
repeats may be discovered in the future. This is another reason why a cut-off of 2 unstable 
repeats for calling a tumour MSI-H would be wise. It is however conceivable that it may 
not be possible to define a clear cut-off for identifying all MSI-H tumours because at the 
lower end of the spectrum there may be a continuum of instability levels between MSI-
H, MSI-L and MSS tumours.  
Another advantage of the MSI test described in this thesis is that the test can be 
automated, reducing the need to use valuable staff time to determine the MSI status of 
tumours. The monomolecular nature of next generation sequencing provides a 
quantitative approach to measuring deletion frequencies allowing automation. The 
approach of using deletion frequencies as thresholds for calling unstable markers lends 
itself well to automation, in contrast to the current Promega MSI test where fragment 
analysis traces are subjectively analysed.  
Recently, there have been a couple of next generation sequencing panel based 
MSI test approaches published. These tests are the first next generation sequencing MSI 
tests to use a small panel of repeats and amplicon sequencing, which is also the strategy 
used in this thesis. This highlights the current relevance and importance of the work.  
Gan et al. (2015) used a series of 5 long mononucleotide and dinucleotide markers 
(BAT25, BAT26, BAT34c4, D18S55, D5S346) in their next generation sequencing based 
MSI test. Tumours were defined as MSI-H if the repeat length with the most reads had a 
deviation of ≥2bp and ≥4bp for mononucleotide and dinucleotide repeats respectively 
compared to the repeat length with the most reads in matching normal tissue. This method 
does have the disadvantage that matching normal tissue is needed. This assay may also 
have a reduced sensitivity compared to the currently popular Promega fragment analysis 
assay for tumours such as the U312 tumour analysed in chapter 5. The Promega pentaplex 
assay identified this tumour as MSI-H because of extra stutter peaks, but the highest peak 
was the same in the normal and tumour tissue for all 5 markers. In this thesis, short 7bp-
12bp repeats were sensitive enough to identify MSI in this tumour, which could indicate 
that the methodology used in this thesis would have a higher sensitivity than the method 
proposed by Gan et al. (2015). 
A paper by Hempelmann et al. (2015) has suggested a similar approach to MSI 
testing as the one devised in this work. This showed that it can be cost effective to use 
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amplicon sequencing on a platform such as the Illumina MiSeq to identify MSI-H 
tumours. However, Hempelmann et al. (2015) used 11 mononucleotide repeats of 12bp-
28bp in length as their MSI marker panel, rather than the short (7-12bp repeats) analysed 
here. The MSI test they have developed (MSIplus) is performed using the software 
mSINGS developed by Salipante et al. (2014). This software required the input of a set 
of MSS reference samples to establish baseline values for the run. Samples are 
subsequently classed as MSI-H if the number of variant read lengths exceed the mean 
number of read lengths + 3x the standard deviation as calculated using the set of reference 
samples. Hempelmann et al. (2015) analysed a total of 81 tumours using MSIplus. 
Interpretable results were obtained for 96% of the tumours leaving 3 tumours which could 
not be typed. For the tumours with interpretable results a 97.1% sensitivity and 100% 
specificity was achieved. This assay has the advantages that the PCR reactions are 
performed in multiplex and Illumina adapters are added using a second PCR reaction 
priming off the amplicon specific primers. This helps reduce the cost of the assay. Other 
advantages include; that primers for mutations in KRAS, NRAS, and BRAF are included 
in the assay, so these can be typed using the same MiSeq run, and mSINGS operates 
without the need for matched normal tissue. Disadvantages include the use of long 
microsatellites (12bp-28bp), which means high levels of PCR and sequencing error, and 
as a result the assay requires the establishment of assay specific baseline values for each 
sequencing run. 
Advantages of the MSI assay presented in this thesis compared to MSIplus is the 
use of shorter repeats which means less sequencing and PCR error, and sequencing error 
is further reduced through paired end read sequencing and the use of an indel caller that 
only analyses concordant paired end reads. For the panel of repeats devised in this thesis 
the aim will be to use the same threshold values for calling instability for different runs, 
assuming the same methodology is used. In the assay presented in this thesis it was also 
possible to differentiate between all MSI-H and MSS tumours; in contrast some of the 
tumours could not be typed by MSIplus and one tumour was misclassified. On the other 
hand, a larger panel of tumours was analysed using MSIplus compared to the numbers 
analysed in this thesis. This work has been limited by the availability of MSI-H tumour 
samples. Challenges have included obtaining tumour samples and obtaining DNA of 
usable quality from tumours preserved by formalin fixing and paraffin embedding. 
Short mononucleotide repeats could also be used to investigate the clonal 
evolution of MSI-H tumours. In chapter 5 short repeats were used to show that the latter 
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of two tumours derived from patient U179 was unlikely to be a reoccurrence of the first 
tumour. This is because several repeats found to be unstable in the tumour extracted in 
2003 were stable in the tumour extracted in 2012. In chapter 6 I used twenty 8bp-14bp 
repeats to evaluate the clonal composition of three MSI-H tumours. There was evidence 
of different sub-clones in all three MSI-H tumours analysed. For each tumour 8 different 
biopsies were analysed using a biopsy of normal mucosa from the same patient as a 
reference point. For the tumour PR17848/14 there was evidence from three separate 
repeats to support the existence of a clonally distinct group of cells in the 9 o’clock needle 
biopsy region of the tumour. Results for tumour PR51869/13 suggested that there might 
be a clonally distinct group of cells in the 3 and 9 o’clock scalpel biopsy region of the 
tumour and a different clonally distinct group of cells present in the 12 o’clock needle 
biopsy region of the tumour. In contrast with the results from tumour PR17848/14 the 
evidence for each of the different clonally distinct group of cells identified was only 
substantiated by one repeat. Results from several different repeats for the third tumour, 
PR10654/14, suggested there were distinct sub clones in at least 4 regions of the tumour. 
It is possible that more variation could have been detected in this tumour if a greater 
number of biopsies had been used. Plans have been made to study these three tumours 
further by using immunohistochemistry to identify different morphological regions which 
can be biopsied and sequenced.     
We believe this is the first time that short mononucleotide repeats have been used 
to assess the clonal evolution of MSI-H tumours. The addition of neighbouring SNPs 
allowed individual alleles to be analysed separately. The added information provided by 
being able to distinguish between the two alleles of repeats meant it was often easier to 
identify multiple deletion events in repeats with a heterozygous SNP, making 
neighbouring SNP a valuable asset. 
8.2. Future work 
The panel of repeats outlined here has subsequently been expanded upon. This 
work has including calculating threshold values for the new repeats. The hope is that this 
will increase the minimum number of unstable markers detected in MSI-H samples and 
result in larger difference between MSI-H and MSS samples. Future work consists of 
validating the improved marker panel and on a larger number of tumours. The extended 
marker panel is currently being tested on a cohort of 220 colorectal tumours of which 
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roughly 140 are MSI-H. This work will enable the validation of markers and thresholds 
devised in this thesis to be assessed and refined if necessary.  
Instead of the costly Nextera XT library prep, a two stage PCR approach is being 
used where amplicon specific primers are used to amplify the targets of interest. 
Overhangs consisting of partial Illumina sequencing adaptors are attached to the amplicon 
specific primers allowing the Illumina sequencing adaptors from the Nextera XT index 
kit to be added in a second PCR reaction. All amplicons for each individual tumour will 
be pooled prior to performing the second PCR amplification step, saving further time and 
cost. Using this sample prep method, a cost of ~£26 pounds per sample can be achieved 
for a MiSeq run containing 96 samples (see Appendix Table 9.4 for a breakdown of costs). 
Because the need for the Nextera XT kit has been eliminated 300bp amplicons are no 
longer necessary and amplicons have been redesigned to a length of ~100bp. This has 
allowed better amplification from FFPE tissue. Further refinement to this system will 
include optimising a multiplex PCR so that each mononucleotide repeat need not be 
amplified separately. This will make the assay more cost effective and reduce the 
turnaround time from sample receipt to sequencing. A further reduction in the cost per 
sample can be achieved by increasing the number of samples per MiSeq run once the 
required read depth per amplicon has been established for this new library prep method.  
Once the assay has been optimised using the 220 tumours described above, the 
sequencing based MSI assay will be run in parallel with MSI testing performed by the 
Northern Genetics Service. This will enable the new method to be trialled before being 
put into routine practice.  
The MSI test will be developed and trialled using Illumina as a sequencing 
platform. This is one possible platform for the MSI test, but another possibility is the 
QuantuMDx Q-POC platform. The assay has been designed so it is compatible with 
QuantuMDx’s technology, and a future aim is to transfer the assay to the QuantuMDx 
platform after the development of this platform is complete. If the QuantuMDx device 
lives up to expectations, the MSI assay can potentially be performed on a chip with other 
cancer biomarkers at a cost under £20 (Burn, 2013). It has also been estimated that the 
QuantuMDx device may cost as little as £500 and the turnaround time for assays may be 
as little as 15min (Burn, 2013). This could enable the test to be performed in the operating 
theatre, giving information about prognosis during operations. This could allow surgeons 
to make decisions regarding the operation based on the tumour’s genetic profile. Lymph 
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nodes and resection margins could also be tested during surgery enabling the removal of 
more tissue if necessary and eliminating the need for another surgery, which is often 
needed if resection margins test positive for tumour content. 
Running the MSI marker panel in parallel with other tumour markers in the same 
MiSeq run, or on the same QuantuMDx chip, would eliminate the need for many separate 
diagnostic tests and reduce testing costs. In the future the MSI test will also be automated 
eliminating the subjective analysis currently needed to analyse MSI test fragment analysis 
traces. This will save man-hours and cost. The reduced cost could potentially allow the 
screening of all colorectal cancers in countries that currently rely on the Amsterdam II 
Criteria and revised Bethesda Guidelines to identify patient with Lynch Syndrome. The 
revised Bethesda guidelines and Amsterdam II Criteria fail to identify a significant 
number of Lynch Syndrome patents (Canard et al., 2012, Mills et al., 2014, Perez-
Carbonell et al., 2012). Screening of all colorectal cancers for Lynch Syndrome will save 
lives, ensuring appropriate surveillance and identifying relatives who have also inherited 
a mismatch repair mutation so they can be monitored. Gene carriers can be offered 
prophylactic medication (like aspirin) to reduce Lynch Syndrome tumour rates. 
Molecular testing for mismatch repair defect in all colorectal and endometrial tumours 
for the identification of Lynch Syndrome patients is supported by the literature (Vasen et 
al., 2013, Canard et al., 2012, Mills et al., 2014, Julie et al., 2008).  
Another reason for MSI testing all colorectal cancer would be to enable the future 
use of specific treatments targeted at MSI-H tumours. The landmark study of Le et al 
(2015) is likely to result in a major shift towards identification of MSI high tumours in 
order to deploy PD1 blockade as a primary intervention. Hopefully the work described in 
this thesis will help bring the promise of these new agents to early fruition. 
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Chapter 9. Appendix 
 
Figure 9.1: Repeats for tumour PR17848/14 which were not included in chapter 6. Repeats were only 
analysed if there were ≥100 paired end reads spanning the repeat. 
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Figure 9.2: 9bp-11bp repeats for tumour PR51896/13 which were not included in chapter 6. Repeats were 
only analysed if there were ≥100 paired end reads spanning the repeat. 
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Figure 9.3: 12bp repeats for tumour PR51896/13 which were not included in chapter 6. Repeats were only 
analysed if there were ≥100 paired end reads spanning the repeat. 
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Figure 9.4: 9bp-11bp repeats for tumour PR10654 which were not included in chapter 6. Repeats were only 
analysed if there were ≥100 paired end reads spanning the repeat. * A total of ≥100 paired end reads for the 
marker, but less than 100 paired end reads per allele. 
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Figure 9.5: 12bp repeats for tumour PR10654 which were not included in chapter 6. Repeats were only 
analysed if there were ≥100 paired end reads spanning the repeat. 
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Amplicon 
Name 
Repeat 
length 
(bp) 
Repeat 
Unit   Amplicon position  Forward Primer   Reverse Primer  SNP1  SNP2  SNP3 
CYP2C9  N/A  N/A  chr10:96740990‐96741143  TGCATGCAAGACAGGAGCC  GGAGAAACAAACTTACCTTGGGAA          
BAT26  26  A  chr2:47641351‐47641743  CTTTAGAACTGGATCCAGTGG  AAAAAGTGGAGTGGAGGAGG          
Axin2  7  C  chr17:63532406‐63532719  AACCCAGTTTCTTTCCTTCTG  GCCTCAACCTAGGACCCTTC  rs35415678       
AL590078  8  A  chr9:26468834‐26469145  TCACCACTGGGGACTTTTTC  TGAGCACACCAAGTCATTCTG  rs10967352       
MX1  8  C  chr21:42825925‐42826244  TAGAGGCAGCAGGCTCTCAG  ACCCCACAAACCATGAAATC  rs35138081       
HPS1  8  C  chr10:100186775‐100187078  CACAGCCCATTCCTGGAC  GCCATTGCTTACATCTCATGG  rs12571249   rs12571245    
IL1R2  8  C  chr2:102626258‐102626576  AGGACTCTGGCACCTACGTC  TCGCAAGGAAACTACAGCAG  rs2282747       
DEPDC2  8  C  chr8:68926559‐68926888  TCTGGGAAAAAGCCCATAAC  ACAACACCCTCTCACCCAAC  rs4610727       
APBB2  8  C  chr4:41034386‐41034688  TGACTATGACAGGAGCTTAAAACTG  CCCACACCACATTGTATGTAGAC  rs4861359       
SLC4A3  8  C  chr2:220493959‐220494271  GGCACACCAGGAGAAAGAGG  GCCCCGACCTACCATACAG  rs597306       
AC079893  9  A  chr7:109669372‐109669697  CGTTTTTGTGGAAGCATACG  CCAAATGGCAAATAAAAGAAGG  rs4591959       
AL390295  9  A  chr13:35354677‐35355008  CATGATATGCCCATGTAGGG  ATTGGTGAAGGAACCAGCAG  rs9572382       
AL359238  9  A  chr14:83421969‐83422285  CAGCTGAAACCGAAGTGAAG  TTGATGATCCTTTTGACACCAC  rs72703572       
AP003532_2  9  A  chr11:127624900‐127625216  CCCTTTACACCACATCAATGC  GCAGGGCCCATCATACAG  rs10893736       
TTK  9  A  chr6:80751710‐80752026  TTCCCAACTGTAAGAACAAGAGAG  CACTTCAGAGTGATGTTGTCTTCA  rs17254634       
C4orf6  9  A  chr4:5526980‐5527306  TCTTCCTTATGACAACCCACAC  GAGCACCTTCCGACTCACTC   rs886532  rs113971480    
AL954650  9  C  chr1:191926696‐191927019  TGCCAATATTTCAATTTTTCTCC  AGACTATGCCTTGCCCAGAG  rs77489859       
AL355154  10  A  chr13:82018382‐82018682  TGCCAATATTTCAATTTTTCTCC  AGACTATGCCTTGCCCAGAG  rs9545694       
AVIL  10  A  chr12:58202332‐58202663  CTGCAGAGCCACCCATTC  AGATGAACCAAGCCAGAAGC  rs2277326       
ASTE1  11  A  chr3:130732912‐130733215  TGGAGGCCTCACTATGTTCC  CTGGTGCACGGACTATGC          
MRPL2  12  C  chr6:43021823‐43022132  GTGGGGACAGACCCAGTG  GGGCAAGAGGCCTAACAGTG  rs58470539       
EGFR  13  A  chr7:55273419‐55273760  CACAGACTGGTTTTGCAACG  CTTGTGCTCCTTGCTCACAG          
FBXO46  14  A  chr19:46214532‐46214834  CTCCAGCGAGAAAGAATTGG  ATTGATCCCTCACCGGAAC  rs34505186           
FTO  15  A  chr16:54147638‐54147956  TTTGTTATATCCCATTAGGTGCC  ATCACGAGGTTGAGATCGAG  rs77984007  rs11348169    
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GM01  10  A  chr11:28894282‐28894553  TCAAGGCCAGGCAATTAATCAG  ACTTGCTGAATGTCCAAGGTG  rs7951012       
GM02  11  A  chr1:116245990‐116246244  GTGCTACATGAGATAGCTGGGA  CTCTTCTGGCCAGTTCTATGTGT  rs10802173  rs148789685    
GM03  8  A  chr4:120206298‐120206557  TGGAGTAAGACCCTTTAGGCAG  AGACTCTGGAAGCAAATGGCA  rs17050454  rs10032299    
GM04  7  A  chr13:92677409‐92677684  CCTTTTGGCCAGAATATGCC  GGCATGAGGAAGTGAAGGGA  rs9560900       
GM05  9  A  chr2:216770642‐216770900  AGGTGTCAAGCAAGGACTCAG  AGGCGTTTTCACGTTGGAGG  rs6704859       
GM06  9  A  chr16:77496387‐77496667  AGAGGCAGAATGTGGAAAAGTC  GCATTCTCCCACAGCACAAT  rs6564444  rs143453795  rs145573459 
GM07  11  A  chr7:93085548‐93085828  GGAGGGACATGTGTTTCCAAAT  CACAATGAGCCAAGTCTCACA  rs2283006       
GM08  8  A  chr21:36574923‐36575189  AGCAACCTCTTAAATCCAGTACT  TGGGCTTTCTTGACTTTGGA  rs2834837  rs115025058    
GM09  8  A  chr20:6836843‐6837099  TTTCTCAGGACAAAGAGCAAGGT  CTGGGTTCCATCTTGTGGGG  rs6038623       
GM10  9  A  chr1:59891529‐59891795  ATCAGCTGACTCCTTACCCT  TGGGGTGAGAGATGGACATG  rs946576  rs182557762    
GM11  9  A  chr5:166099809‐166100081  CTCATGGTTAATACAATTAGGCACA  ACATGGTGTGCTACCTTTCA  rs347435       
GM13  11  A  chr12:107492450‐107492711  TTCTTCAGGGCCCATTATTGT  TGAGGAATGTGCAGTTGACAC  rs34040859  rs77265275  rs201488736 
GM14  11  A  chr3:177328721‐177329014  AGCTTGGCCATATTTGTGCA  ACTTGATAGGGTTAAATGTCCGT  rs6804861       
GM15  9  A  chr7:97963570‐97963830  TGCCTTCGAGTTTAAATGCCT  GCCTCGTTATTTTGTGTGCC  rs6465672       
GM16  8  A  chr6:100743524‐100743782  GCCACACTGACTTTGAACCTT  ACAGCTTCTTCCTCACTCTACT  rs7765823       
GM17  9  A  chr11:95550977‐95551231  TCCCTAGAAAGAGAACGACAACA  AAATGCCCACCAAGATTGTAAAA  rs666398       
GM18  12  A  chr10:8269462‐8269727  GGGGAGAAGACGGTTGAACT  ACTGGTTCACTGGCCTTTTG  rs113251670  rs189036006  rs533236 
GM19  7  A  chr11:114704247‐114704523  AGGTAAAGTCAGACACAATCCCA  ACCCTCATGTTTCCCACCTCA  rs142833335  rs190597109  rs10502196 
GM20  8  A  chr7:142597420‐142597679  GCAATCACATTTGCATTGGTTTT  TGACTATGAGCTCCACAAACGTA  rs6961869  rs6961877    
GM21  9  A  chr3:142695286‐142695560  TTCTCCATTGGAAGTATTTGGGA  TGTGTATTCAGGGTCCAGGG  rs185182       
GM22  10  A  chr14:43400950‐43401207  TCATAACCAAGAGCACCACCT  TGTGATAGGGAAACACACGGA  rs58274313       
GM23  9  A  chr5:11345800‐11346075  CAGCATAAATCCAATGGCTATG  TCAGATTGCAAAGGGGTACA  rs184237728  rs32123    
GM24  7  A  chr10:117432031‐117432299  AAACATTTCGACTGGTGCAA  TTCTTCTTTCCCCCAAATGA  rs2532728       
GM25  7  A  chr3:110871894‐110872161  TGGGATTAGGGAAGGGAGAG  GGCCCTCCCCAACTAAAAT  rs74593281  rs6437953  rs188039266 
GM26  10  A  chr14:49584656‐49584913  CCTTCCTTTGATCCGCAAGC  CTGCCACCTAGGAACTGGAG  rs187027795  rs11628435    
GM27  7  A  chr11:85762061‐85762349  TTTTTGTTGCCCATTTCCTC  AGGGTACTGACCCTAGCTCCA  rs669813  rs181565251  rs146406522 
GM28  9  A  chr5:29209275‐29209526  CTCAGACAAAGACATACGAAGCC  TTGGTTCTACAGTAATTGTGCTTCT  rs4130799       
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GM29  10  A  chr3:70905468‐70905731  CCCTCCCAAATGTCAAGTGT  CCCACCCACACTCTTTTGTT  rs2687195       
GM30  7  A  chr14:53111446‐53111710  TCAATGCTATTGGCCTATAAAGAGT  ATGCATTTCCTTCTGGCCTA  rs12880534       
IM07  10  A  chr6:100701756‐100702050  TCACCATCATCACCATGCTT  TCTGGCAAACTCTTCACTGG  rs189035042  rs6915780    
IM12  10  A  chr8:23602751‐23603036  AGTGGAGAAAACGGTTGTGG  GAAGGCAGACAAGGGATTCA  rs389212       
IM13  7  A  chr2:235496873‐235497180  GTGACCGCACAAAGTCACAC  TCCAACAATCACAGTCCATGA  rs6721256  rs183025093  rs187312036 
IM14  7  A  chr7:80104285‐80104624  TCAAGACTCAGCCATTTCCA  GGAAGCTGAGAGCAGGTTTTT  rs11760281       
IM15  8  A  chr6:91455016‐91455307  TCGTCAGGCTCTGCAACTAC  CGATGGGATTGAATTTGGAT  rs1231482       
IM16  9  A  chr18:1108609‐1108894  AGGACCTCGAGCTTCTCTTT  TTCTTTTGCTTCCGTGTGTG  rs114923415  rs73367791  rs59912715 
IM17  9  A  chr13:31831349‐31831705  TGCAACCAGAGGTTTTAATCG  CTCAATTCAGCAACAGGTCA  rs932749       
IM19  7  A  chr9:82474924‐82475277  CAACCACAGTTTGCCAGCTA  TCCTTGCTATCATTTGGAGAGA  rs72736428  rs186539440  rs4877153 
IM20  7  A  chr13:57644542‐57644833  CCAGTTTCACATTTCGCTTGT  TGGCAACAAAACAGTAACAGGA  rs6561918       
IM21  8  A  chr1:215136329‐215136605  AGTGAATGGGCTTTGGACTG  AACTGGAGTGGGTGAACCTG  rs181787229  rs1901621  rs1901620 
IM22  7  A  chr7:90135380‐90135698  CACCAGCTTTTCTCCCTTCA  TGGCACTCAATACCAAACTGG  rs10487118  rs10487117  rs139214151 
IM23  7  A  chr6:72729441‐72729714  GGTTTCTGTGCTGAATCTTGG  AACCCCAGTTTTCTGCCTCT  rs557365       
IM25  8  A  chr12:24568297‐24568575  CCATGGTACCACTGTGGAGT  TAGAGGGGGCTTGAATGTTG  rs10771087       
IM26  7  A  chr3:166053374‐166053712  GGGCTCGACTTGATTTACGA  GGGAAGCAATCTCATGGCTA  rs2863375       
IM27  7  A  chr7:35079029‐35079302  ACGCATGGAAAAAGAGGTTC  CAAGGCTGGTATGGGTCAAT  rs4723393  rs112516918    
IM28  11  A  chr9:5122829‐5123102  TGTGGAATCCCTCCTGAAAT  CCGCTGGTGGACTTTTACTC  rs10815163       
IM32  11  A  chr18:42045361‐42045640  GCCAAAATGCCTAACTCCAA  GGACTCGGATGGAAGACAAA  rs8087346       
IM33  10  A  chr8:25731833‐25732120  AGGGTATGATTTGGGGGTGT  GTGGACCAAAGGAGCAGAAG  rs202225742  rs35644463  rs113180202 
IM34  10  A  chr7:83714549‐83714816  TGAGGGTGGATGCTTCATTT  CAGGATATTCCTCAGTTCAGTTCC  rs1524881       
IM35  10  A  chr11:84425027‐84425322  TCAAATGCAGACTCAACATGA  AGCAGAGGAGCCATCAATTC  rs67283158  rs10792775  rs116387070 
IM37  10  A  chr17:50813421‐50813720  CAGGCACACACACTTTCGTT  TTCTCATGCAGTCAACCATTG  rs2331498       
IM39  8  A  chr2:103233602‐103233932  AGACGTCCAAAGGTCGCTAA  CCCTCACTGCCTGTAAACCT  rs76771828  rs190979688  rs187315716 
IM40  8  A  chr4:84074695‐84074985  ATCACAAAAACAGGGGCCTA  CCTTGTCTGGCTCAATCACC  rs10516683       
IM41  8  A  chr6:147948700‐147949027  CTGCTCCACATTCCCATTCT  TGGCAGGAAACATCTGTTCA  rs1944640  rs112075239    
IM42  9  A  chrX:96502491‐96502781  TGGCTGAGTAAAATGGTGACA  GCTTGGGGGAATTTCTTGAT  rs1409192       
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IM43  7  A  chr21:32873526‐32873866  CAGAAGGTCAGGACCACACA  ATTTGGTGGGTTCCAGTGAG  rs9981507       
IM44  9  A  chr12:9796844‐9797182  CCTCCTAGCATTCCATAGCAC  TGCAACCTCGTAAGCTCATTT  rs201750704  rs4763716    
IM45  11  A  chr4:99545274‐99545564  GCCACATTTGCTGGTATTCA  TTTTTCCTCTGGGAAACCAT  rs189419054  rs2178216    
IM47  12  A  chr21:22734257‐22734517  TGGTTCAGACATACACGTACAGG  ATAACAGGCACAAGGGTGGA  rs2588655  rs149325240  rs232496 
IM49  12  A  chr3:56681883‐56682149  CCTGGCAAATGATGCTTTAGA  CCTCCCTCCTAGGCTCAAGT  rs7642389       
IM50  12  A  chr20:37047920‐37048224  CGAGGCGGGTATTTACTTGA  GGAGTTGGGGCAAAAATCAC  rs1739651  rs145870165    
IM51  12  A  chr5:128096936‐128097255  CAAACCCCCGAGACACAC  AACGTGGCTCTTTATCCCATT  rs4836397       
IM52  11  A  chr21:22846659‐22846944  GATGGAGGGCCCTTTAATTT  CGATGAAGTGGTTGATGTGAG  rs74462385  rs9982933  rs2155801 
IM53  11  A  chr9:20662482‐20662766  GACAACTCCGAAGGGCAATA  AGTTTGGGTTGCAAGACGTT  rs182630429  rs140426089  rs12352933 
IM54  11  A  chr21:33709922‐33710213  GCAACATTGAAATGCTGGAA  TAACATTTGGGAGGGGGAAT  rs13046776       
IM55  7  A  chr3:143253627‐143253930  GCTGAATAGCGGGATCAAAA  GGAATTAGGTACCAGATCTCCTTT  rs13099818       
IM57  8  A  chr3:81209863‐81210156  GATTATCAGCCCAGGGAGGT  ATGGCAGCACTGGGAAATTA  rs35085583       
IM59  8  A  chr8:108358809‐108359137  TATGGCTGCAGCATTACCAG  GCCAGAGTCCACAGACTCAA  rs10156232       
IM61  7  A  chr12:73576301‐73576606  GAGCAAGGCATTTGAATCTG  ATATGAGGCGCTCTCTCTCG  rs34696106       
IM63  8  A  chr3:115815913‐115816216  TGCCTTTGGTTGTACCTTTG  TCAAGTGAGCCTTGTGGAAA  rs34764455       
IM64  12  A  chr16:14215981‐14216240  CCTTCCCCGTTCTTTCTCTT  AAGGTAGGTGACCGGCTGAT  rs201451896  rs112858435  rs75477279 
IM65  11  A  chr13:25000797‐25001149  GCATCTCAAACTGTGCCTGT  CACGGGTCTAACTGTCCTCA  rs7324645  rs9511253    
IM66  7  C  chr17:48433883‐48434148  CCACTCCAGCAAGTCTCCAG    CAAGGGCCTGCTGTATGTCA    rs147847688  rs141474571  rs4794136 
IM67  7  C  chr7:22290637‐22290990  AGCCCATGTTTTCCACAGAA  TACCAGGTGCCCTAAACAGG  rs67082587  rs57484333    
IM68  8  C  chr12:129289515‐129289789  TTCTAGACACAGACGCACACG  GGGACTGCCACTAGTAGCTCA  rs10847692       
IM69  7  C  chr9:92765658‐92765989  TGGGGGCAGTTTCTATTCTG  ATCAGTTTTCGATGGGGAGA  rs1036699       
LR01  11  A  chr13:97387292‐97387567  TTGGATGCTGGATTTTGACA  CTCATATCCCCCTCCCAGAA  rs1924584  rs4771258    
LR02  8  C  chr4:134947615‐134947875  TATTGGCCAGGAATTTTTGC  GGAGCTCACGCTAATGACCT  rs189671825  rs192703656  rs1494978 
LR04  7  C  chr1:4676948‐4677234  CCCCAAGCTGTTTCCTCCAT  GCTGGGGCAAGAAATTCAGC  rs113646106  rs2411887    
LR05  9  C  chr2:10526489‐10526814  GAGCTGCCTACTCGCTGACT  GCCACTGATGACAACCTCCT  rs111286197  rs13431202    
LR06  7  C  chr18:20089314‐20089588  CATCTAGCATTCTCTCATTTCAGC  TGCCAAAACCAAAGACAAGG  rs501714       
LR08  7  C  chr11:56546008‐56546315  GGCTGCTTAAGGGAAAGTGC  CGTGTTTTGGTCAAAGTTGTG  rs181578273  rs7117269    
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LR10  9  A  chr1:81591297‐81591555  ATGTTTGGTGCATGAAATCTG  TGAGTTCCACATGGCTCTTG  rs111814302  rs1768398  rs1768397 
LR11  11  A  chr2:217217726‐217218005  TATTCCCCTTGTGTGGGAGA  CAAAGAGAATGGGTGGGAGT  rs13011054  rs147392736  rs139675841 
LR12  11  A  chr14:47404086‐47404346  GGTGAGGAAAGCACAAGGTC  CCGTGGAATTTCTTCTGCAC  rs187434561  rs144159314    
LR13  7  A  chr8:21786845‐21787107  TCCTCGTCCTCTCAGATGTGT  TCAGGACTTAGCACCAGGAAA  rs2127206       
LR14  9  A  chr17:69328365‐69328640  CCCGTTTTCAGACCAAGTGT  TTGGAACAGGATGGGTGAAT  rs9895642       
LR15  7  A  chr8:92077118‐92077383  TGATTCGGGCTTGGACTTAG  GTCAATCACTTTGCCTGCTC  rs56084507       
LR16  11  A  chr3:8522305‐8522590  GTTTGATCTCTGGCCCTGTC  GCCTCCTTAATCTCCTCCATC  rs148171413  rs6770049    
LR17  11  A  chr14:55602913‐55603194  AGACCACCCCTTAGGCAAAC  AGTGCAGCAAGGCAGATGAG  rs79618905  rs77482253  rs1009977 
LR18  8  A  chr1:220493800‐220494106  TGGGGAGGGAACCTCATTAC  CAGTGCCTGTTGAGTAGAACC  rs191265856  rs199830128  rs74940412 
LR19  8  A  chr12:29508532‐29508843  TGAGTGCTGCTCATATTTTTCC  GGGGCTTCAGTCTCAGGATAG  rs10843391  rs186762840    
LR20  8  A  chr1:64029521‐64029836  TCAGCCTATGAAGATCCTCTG  AAGGAAGACGGGGAAGACTG  rs146973215  rs191572633  rs217474 
LR21  9  A  chr15:50189339‐50189607  TGGGTACAAAGCTCAAGTCAAC  TCTCCAAAGGCTTCTCCTTG  rs182900605  rs80237898  rs2413976 
LR23  11  A  chr2:142013847‐142014151  TGTAGCCTAGGTAAAGAGGACAA  CATTTAGCATTTTGCCATTCC  rs434276  rs146141768    
LR24  9  A  chr1:153779290‐153779565  TATGCCTTCTGGAGGAGTGG  TGGAATAGCGGTAAGGCTTG  rs192329538  rs1127091    
LR25  7  A  chr16:63209414‐63209676  TTAACCTGCCAGCTCAGTTC  GCTTCCACTCATTTGCATTG  rs76192782  rs79880398  rs4949112 
LR26  10  A  chr16:80050164‐80050433  TGCATAGGCAGACCTCAAAAC  GAAAGCCTGATGTTTGACACC  rs4889066  rs187883346    
LR27  8  A  chr4:72877320‐72877604  TTTGGTCATTGCTGTCATGG  CAACAAGGAATTGAATGATGC  rs55894427  rs74733006    
LR28  9  A  chr12:81229619‐81229925  TGAGTCCCTTTTGAAATGTTG  GCCAACCAATGGAGTTTTAAG  rs185642078  rs28576612  rs10862196 
LR29  10  A  chr6:78198189‐78198498  CAATGTTTGATTAACCATGACG  GCACTTTTCTCACACAATTTGG  rs1778257       
LR30  10  A  chr11:105444906‐105445201  GCAGGAATTCATTCTGAAGC  AACGCAGTGAGGAACAAAGG  rs7933640       
LR31  8  A  chr3:62995387‐62995657  TGGATTTGCATCTGTGAATTG  TTTTGATGGCTTTTACTTTTCC  rs183248146  rs2367592    
LR32  10  A  chr19:37967035‐37967313  CTGCCTATGCCAAACAAATG  AGCACAAGCCTTTTGTCAGC  rs7253091       
LR33  11  A  chr4:138498516‐138498782  GAATAGCGGGAAGAACTGGA  TGCATTCGAATCAGGAATGA  rs200714826  rs4637454  rs111688169 
LR34  9  A  chr3:115376990‐115377261  CCCATCCTTAGACCCCAGAC  GAAAATGAGACGCGAAAAGG  rs187521190  rs192106258  rs9883515 
LR35  10  A  chr8:130384312‐130384584  AAAGCTTGTGGGTGATGGAG  TGCTTGGAATAGGATGCTTTG  rs4733547       
LR36  12  A  chr4:98999555‐98999845  TCCCCAGGACCCTAGTCTTC  GGTGGCAAGCACTTTTGTAAG  rs182020262  rs17550217    
LR39  10  A  chr17:66449171‐66449485  AGCATGGGAATAACGACAGG  TCGTTGTGTTGGAGGTAGAGC  rs2302784       
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LR40  9  A  chr2:13447304‐13447570  AAATGAACACTATGCATGTCAGG  TTGCCTCTTGCAACTGATTG  rs6432372       
LR41  12  A  chr4:34073929‐34074197  CATGGACCGCTGATCTCTG  GGAGGGATCTAGCCACCAC  rs190518698  rs6852667    
LR43  12  A  chr5:86198899‐86199207  GGCAACAGCCTCATAACTGC  GCTGTCTCCTGGCTCTAACC  rs201282399  rs10051666  rs6881561 
LR44  12  A  chr10:99898182‐99898454  TTTGGCTGGGCCTGGTAG  CAGAGTGCACCTCAGTGACC  rs78876983  rs7905388  rs7905384 
LR45  7  A  chr2:226937965‐226938246  TGCAGAGAAGAGATACAGAAAGC  TGCAAAAATCCCAGATTGAAG  rs180896305  rs1522818  rs144175764 
LR46  8  A  chr20:10659968‐10660261  GAGTGTGGGAGAAGTCCTACG  TTCAGGAGATGAAAAGGCTTG  rs143884078  rs182346625  rs6040079 
LR47  7  A  chr10:20506574‐20506830  TCCCTGAAGGAAGGAAAAATC  GTGATTGTGAAGTTGGATTTGC  rs11597326  rs12256106    
LR48  11  A  chr12:77988002‐77988288  ATTACCCATGGGGGATGTTG  AGTTGGGGAACATTCCTTCC  rs11105832       
LR49  7  A  chr15:93618885‐93619163  ATCTGTAAGGATCGGGCTGA  CAACACAACGCCATACTGCT  rs80323298  rs201097746  rs12903384 
LR50  7  A  chr2:76556173‐76556470  TTCCCCATTTGATGATCCTG  AGAGTTTTCCCCACTCAGCA  rs925991  rs144630203    
LR51  7  A  chr10:51026570‐51026831  TGAATATGCCTCAAGCACCA  AATGCAAACCTCCTAGGTTAAAA  rs8474       
LR52  12  A  chr16:63861273‐63861586  GTGCTCTGCATCTCATACGC  CCTCCTTGGCTAACTTGCTC  rs2434849       
Table 9.1: List containing amplicon/repeat name, amplicon position (genome build hg19), primers, and SNP rs numbers for SNPs in close proximity to mononucleotide repeats. 
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CAPP patient 
Number 
Gene containing 
germline 
mutation 
Tissue Type  Tumour Block Number 
Chapters where the 
samples were used 
U029  MSH2  Tumour  H10/7014 A18  5 
U096  MLH1  Tumour  R06038/03‐1E  3 
U096  MLH1  Normal Mucosa*  R0603F/03‐1C  5 
U179  MLH1  Tumour  H03‐19031‐1 B42  3 and 5 
U179  MLH1  Tumour  H12/4786 A6  5 
U184  MLH1  Tumour  8.9.05 6cFT  3 
U303  MLH1  Tumour  07/1615‐1B  3 and 5 
U312  MSH2  Tumour  07/3480‐1C  3 
U312  MSH2  Tumour  07/3480‐1B  5 
Table 9.2: CAPP Lynch Syndrome patient tumour samples used in the work described in this thesis. * Block 
containing the distal resection margin which was erroneously supplied instead of tumour tissue. 
patient  Tissue Type 
SRA 
Sample 
Accession 
Number  Sample Id  Analysis Id 
TCGA‐AA‐3516  MSI‐H Tumour  SRS130750  TCGA‐AA‐3516‐01A‐02D‐1167‐02  69e9e641‐fa2e‐4bd9‐848e‐be5f507660a2 
TCGA‐AA‐3672  MSI‐H Tumour  SRS097008  TCGA‐AA‐3672‐01A‐01D‐0957‐02  9b01e1d4‐2cca‐49ef‐9672‐e8692ae621be 
TCGA‐AA‐3715  MSI‐H Tumour  SRS097080  TCGA‐AA‐3715‐01A‐01D‐0957‐02  23acfb6f‐8071‐47cf‐9c62‐67c22c63e0ec 
TCGA‐AA‐3966  MSI‐H Tumour  SRS130791  TCGA‐AA‐3966‐01A‐01D‐1109‐02  4b50f9fa‐0fb6‐4293‐afc5‐adc0350f4ed2 
TCGA‐AA‐A00R  MSI‐H Tumour  SRS153954  TCGA‐AA‐A00R‐01A‐01D‐A077‐02  300eea0f‐bc14‐4253‐a544‐fbc53243ecce 
TCGA‐AA‐A01P  MSI‐H Tumour  SRS130846  TCGA‐AA‐A01P‐01A‐21D‐A079‐02  60b884be‐5009‐495f‐aec8‐bd3be4bf7597 
TCGA‐AA‐A01Q  MSI‐H Tumour     TCGA‐AA‐A01Q‐01A‐01D‐A077‐02  d8e8f805‐00c6‐467e‐a8fc‐a2674f1ac38e 
TCGA‐AA‐A02R  MSI‐H Tumour  SRS154223  TCGA‐AA‐A02R‐01A‐01D‐A077‐02  1d75d53d‐94a2‐497e‐9c4e‐f45cf27912d9 
TCGA‐AZ‐4313  MSI‐H Tumour  SRS157354  TCGA‐AZ‐4313‐01A‐01D‐1405‐02  a0a2a333‐708c‐46dd‐ab19‐c6e7e033d724 
TCGA‐AZ‐4615  MSI‐H Tumour  SRS157387  TCGA‐AZ‐4615‐01A‐01D‐1405‐02  ae769553‐f8cb‐407b‐b41a‐524adb07282d 
TCGA‐CK‐4951  MSI‐H Tumour  SRS159294  TCGA‐CK‐4951‐01A‐01D‐1405‐02  ef054dd4‐e5ed‐4143‐80ef‐08beffa04d1b 
TCGA‐CM‐4746  MSI‐H Tumour  SRS159316  TCGA‐CM‐4746‐01A‐01D‐1405‐02  1878a6ba‐0f5c‐40b4‐a018‐7508c8fa3dc2 
TCGA‐AA‐3516  Matched Normal  SRS130751  TCGA‐AA‐3516‐10A‐01D‐1167‐02  e1dbd1cc‐89ad‐4f93‐97f1‐982b4ac7f7f3 
TCGA‐AA‐3672  Matched Normal  SRS097012  TCGA‐AA‐3672‐10A‐01D‐0957‐02  99a5462d‐3cb8‐464b‐98c6‐cec13491994c 
TCGA‐AA‐3715  Matched Normal  SRS097084  TCGA‐AA‐3715‐10A‐01D‐0957‐02  6c0543fd‐e91d‐4cf1‐a64b‐89ad9e63cf71 
TCGA‐AA‐3966  Matched Normal  SRS130801  TCGA‐AA‐3966‐10A‐01D‐1109‐02  078906fa‐6e88‐4626‐b01f‐9b529b969460 
TCGA‐AA‐A01P  Matched Normal  SRS130854  TCGA‐AA‐A01P‐11A‐11D‐A079‐02  74847765‐b70c‐47c8‐9eb4‐d5eae2e4c704 
TCGA‐AA‐A01Q  Matched Normal     TCGA‐AA‐A01Q‐10A‐01D‐A078‐02  0e3b9a0b‐8fd8‐4726‐bcd8‐d5b8563bb630 
TCGA‐AA‐A02R  Matched Normal     TCGA‐AA‐A02R‐10A‐01D‐A078‐02  0f21aa03‐df30‐4b29‐b908‐daf9584088d6 
TCGA‐AZ‐4313  Matched Normal  SRS157361  TCGA‐AZ‐4313‐10A‐01D‐1405‐02  7c0a3b4d‐0fc0‐4b9a‐b4c4‐d075b8117f42 
TCGA‐AZ‐4615  Matched Normal  SRS157394  TCGA‐AZ‐4615‐10A‐01D‐1405‐02  af33c9f9‐02a6‐4e4a‐9f1d‐52f04bfa6116 
TCGA‐CK‐4951  Matched Normal  SRS159301  TCGA‐CK‐4951‐10A‐01D‐1405‐02  5ac4252e‐6cb6‐4226‐a8cd‐489a9986c61e 
TCGA‐CM‐4746  Matched Normal  SRS159323  TCGA‐CM‐4746‐10A‐01D‐1405‐02  a9540af8‐5f10‐4d06‐a31d‐1e25a69e31bd 
TCGA‐AA‐3509  MSS Tumour  SRS156892  TCGA‐AA‐3509‐01A‐01D‐1405‐02  4e552949‐246f‐4788‐a760‐9b6a23d89bf3 
TCGA‐AA‐3555  MSS Tumour  SRS196934  TCGA‐AA‐3555‐01A‐01D‐1637‐02  875b31fd‐9e8a‐49d2‐89b4‐d8256f89ef5a 
TCGA‐AA‐3558  MSS Tumour  SRS130763  TCGA‐AA‐3558‐01A‐01D‐1167‐02  1b21ee51‐605f‐478b‐8a82‐e25a3fa9b678 
TCGA‐AA‐3685  MSS Tumour  SRS130776  TCGA‐AA‐3685‐01A‐02D‐1167‐02  25f4344f‐ea46‐48ac‐b2a9‐74f9222fb8aa 
TCGA‐AA‐3693  MSS Tumour  SRS097064  TCGA‐AA‐3693‐01A‐01D‐0957‐02  3a9f1142‐0d5b‐4583‐a570‐4da8e1455e0c 
TCGA‐AA‐3968  MSS Tumour  SRS130808  TCGA‐AA‐3968‐01A‐01D‐1167‐02  3f6440b7‐1298‐4892‐a133‐3d48eb885eda 
TCGA‐AA‐3970  MSS Tumour  SRS130814  TCGA‐AA‐3970‐01A‐01D‐1109‐02  d67dcadf‐7893‐42fd‐afd7‐e2ed9a1aa33d 
TCGA‐AA‐A00U  MSS Tumour  SRS153966  TCGA‐AA‐A00U‐01A‐01D‐A077‐02  285ce8fc‐dc1b‐4188‐bb8e‐723573a9545a 
TCGA‐AY‐4070  MSS Tumour  SRS133582  TCGA‐AY‐4070‐01A‐01D‐1109‐02  acec5f0d‐3fa8‐45ca‐bdda‐3058c14bbcc0 
TCGA‐AY‐4071  MSS Tumour  SRS133599  TCGA‐AY‐4071‐01A‐01D‐1109‐02  1b3451c6‐b020‐4a04‐b454‐018ceb86da2f 
TCGA‐CA‐5256  MSS Tumour  SRS159111  TCGA‐CA‐5256‐01A‐01D‐1405‐02  1cad444d‐0ed8‐437d‐8f26‐66e103379160 
TCGA‐CM‐4748  MSS Tumour  SRS159338  TCGA‐CM‐4748‐01A‐01D‐1405‐02  bc5d8cfa‐f666‐4b3a‐9117‐5b60f92d480e 
Table 9.3: Sample identifiers for whole genome sequences obtained from The Cancer Genome Atlas 
(TCGA) group. 
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Reagent  Total cost (£) 
Number of 
reactions per 
sample 
Estimated number of 
samples the product 
can be used for 
Cost per 
sample (£) 
Amplicon specific primer with Illumina 
overhang adapters 
18 primer pairs (Synthesis scale 0.04μmol)   291.60  18  400  0.73 
Nextera® XT Index Kit (96 Indices, 384 
Samples)  662.00  1  384  1.72 
Herculase II Fusion DNA Polymerase 400Rxn 
(800 reactions with a PCR volume of 25μl)  273.00  19  42  6.48 
AMPure XP ‐ 60ml 
(45μl per sample for each cleanup)  721.02  2  660  1.09 
QIAxcel DNA Screening Kit (2400)  517.00  18  130  3.98 
Qubit® dsDNA HS Assay Kit (500 assays kit)  161.20  2  250  0.64 
MiSeq Reagent Kit v3 (600 cycles)  1100.00  1  96  11.46 
Table 9.4: The estimated cost per sample for a sequencing based MSI assay composed of 18 markers. The 
costs are estimated for a sample prep where amplicon specific primers with Illumina overhang adaptor 
sequences are used, enabling Illumina sequencing primers to be added in a second PCR reaction. The 
second PCR reaction will be performed after all 18 amplicons have been pooled at an equal concentration. 
Sequencing 96 samples per MiSeq run gives an average read depth of ~10000 paired end reads per amplicon 
if a read depth comparable to what was obtained for the MiSeq run in chapter 7 is achieved.  
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